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Abstract 
 
Metabolic dependencies of breast cancer cell lines under normoxia and hypoxia 
 
Cellular metabolism is one of the core processes for cell growth and proliferation. This 
process is altered in cancer cells as most solid tumours exhibit increased glucose uptake 
and lactate secretion, a feature known as the Warburg effect. These metabolic changes 
are the consequence of oncogene activation, loss of tumour suppressor function and/or 
mutations in metabolic enzymes. However, cancer cell metabolism is not limited to the 
Warburg effect and the exact role the metabolic machinery plays in facilitating 
proliferation and cell survival in different cancer types is still poorly understood and 
requires further study. 
 
Breast cancer is a complex and heterogeneous disease at the molecular level. In addition, 
the PI3K/AKT signalling pathway is frequently activated in breast cancers due to loss 
of the PTEN tumour suppressor, oncogenic activation of PIK3CA or overexpression of 
certain growth factor receptors. 
 
This study aimed to investigate whether the metabolic requirements of breast cancer cell 
lines are determined by their molecular alterations. By using RNA interference (siRNA), 
the expression of 231 metabolic enzymes, transporters and metabolic regulators of the 
cellular glucose and lipid metabolism were ablated in a panel of 14 breast cancer cell 
lines and 3 non-malignant breast cell lines with distinct molecular characteristics.  
Solid breast tumours are known to have regions of high/low delivery of nutrients and 
oxygen that facilitate changes in the metabolic dependencies of cancer cells that reside 
within these areas. Moreover, these solid tumours that contain regions of poor oxygen 
delivery are associated with cancers refractive to treatment and that have poorer overall 
survival. Thus, to examine the metabolic dependencies of cells that reside in these 
regions, an environment of low oxygen was recapitulated and the effect of silencing of 
metabolic genes on cell survival was assessed. Crucially, this approach has led to the 
identification of previously known and novel metabolic genes that are essential for 
survival of breast cancer cells for each of the defined breast cancer subgroups. 
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In addition, the characterisation of the metabolic requirements and processes revealed 
that each subgroup displays a distinct metabolic phenotype that might provide potential 
novel molecular targets that could be exploited therapeutically.  
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1 Introduction 
1.1 Cancer 
Cancer is defined as not one but an array of diseases with more than 200 different types 
depending on the cell and tissue of origin. The latest research studies show that the 
incidence rates for cancer are increasing and that by 2040 one in four people aged over 
65 in the United Kingdom will be cancer survivors (Maddams et al., 2012), making 
cancer one of the most significant causes of mortality not only in the UK, but 
throughout the developed world. This underlines the importance of continuing the 
efforts to get a better understanding of the complexity of cancer and to discover novel 
therapeutic strategies. 
 
The progression from a normal cell to a cancerous cell is a multistep process that 
reflects the accumulation of genetic and epigenetic alterations within a cell’s genome. In 
general, high-frequency mutations in cancer are mainly found in proto-oncogenes and 
tumour suppressor genes. Gain-of-function (GOF) mutations in proto-oncogenes result 
in hyperactive forms, termed oncogenes that can promote cell transformation. 
Conversely, loss-of-function (LOF) mutations in tumour suppressor genes, expression 
of which usually restricts cell transformation, result in a hypoactive or inactive state of 
the respective gene. Complex alterations occur during the process of transformation and 
some cancer cells become dependent on the continued activation of a single 
gene/pathway. This dependence is termed ‘oncogene addiction’ (Weinstein and Joe, 
2008). In addition to high-frequency mutations, recent sequencing studies show that 
cancer cells harbour a large number of low-frequency aberrations (Kan et al., 2010; 
Shah et al., 2012).  
 
The common phenotypes that contribute to the transformation process from a normal 
cell to a cancerous cell have been described as the 12 hallmarks of cancer (Hanahan and 
Weinberg, 2011). These hallmarks are depicted in Figure 1.1. One of these hallmarks is 
the independency from external proliferative signals due to upregulation of growth 
factor receptors, or mutations in growth factor signalling cascades. Moreover, cancer 
cells resist inhibitory signals that would normally halt proliferation and cell growth. 
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Furthermore, cancer cells have the ability to evade stimuli that lead to the induction of 
apoptosis. Another hallmark of cancer is the ability to overcome the limited number of 
replication cycles that normal cells are restricted to, giving cancer cells unlimited 
replicative potential. 
 
Another important hallmark of cancer is the activation of cell migration and invasion 
that is a prerequisite of metastasis formation. Cancer cells lose the expression of certain 
cell/cell and cell/matrix adhesion molecules and become able to invade into local blood 
or lymph vessels and disseminate to distant tissues (Hanahan and Weinberg, 2011). The 
proliferation and growth advantage of cancer cells is often associated with the 
deregulation of metabolic processes. The metabolic reprogramming of cancer cells 
allows them to not only survive but also grow under conditions of stress, such as 
nutrient and oxygen starvation, which contributes to tumorigenic potential. In addition, 
the deprivation of oxygen is a common feature of the tumour microenvironment and 
leads to the induction of new blood vessels, a process termed ‘tumour angiogenesis’. 
Tumour angiogenesis supports the supply of oxygen and nutrients to the growing 
tumour and facilitates invasion and metastasis. 
 
 
Figure 1-1 The hallmarks of cancer 
This schematic overview is adapted from (Hanahan and Weinberg, 2011) and illustrates the hallmarks of 
cancer. These hallmarks are defined by intracellular processes (e.g. genome instability), intercellular 
signalling between tumour cells and/or other cell types (e.g. cancer-associated fibroblasts, immune cells) 
and extracellular interactions between tumour cells and the microenvironment. 
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1.2 Breast Cancer 
1.2.1 Incidence 
Breast cancer is the most common type of cancer occurring in women of the developed 
and developing world, comprising 16 % of all mortality cases in cancer. In 2010, 49,961 
new breast cancer cases and 11,633 breast cancer-related deaths were reported in the 
United Kingdom alone (source Office of National Statistics http://www.ons.gov.uk).  
In recent years, despite the increase in breast cancer incidence, mortality rates have 
decreased. This has been attributed to screening programmes and earlier detection of the 
disease, the advances in the understanding of the biology of breast cancer, and the 
development of novel therapeutic strategies for the treatment of patients with this 
disease (www.cancerresearchuk.org/cancerinfo/cancerstats/types/breast/incidence). 
Most cases of breast cancer occur sporadically. However, approximately 5-10% of all 
breast cancers are hereditary and develop in individuals who have a breast cancer 
predisposition due to germline gene mutations (Scheuner et al., 2010; Slattery and 
Kerber, 1993). The genes most frequently linked to hereditary breast cancer are breast 
cancer type 1 (BRCA1) and breast cancer type 2 (BRCA2) susceptibility proteins, 
which together account for approximately 2% of all breast cancers (Malone et al., 2006; 
Papelard et al., 2000).  
Historically, breast cancer was defined as a single disease, but it is now appreciated that 
breast cancer is a heterogeneous and complex disease and in fact encompasses multiple 
diseases in the same anatomical site.  
 
1.2.2 Breast cancer treatment 
 
Successful cancer treatment requires the complete eradication of tumour cells to prevent 
recurrence, which is the main cause of mortality. The current standard of care for 
patients with primary breast cancer is local management, including surgery and 
radiotherapy, and adjuvant systemic treatment (i.e. endocrine therapy and/or 
chemotherapy and/or molecularly targeted therapies) to reduce the risk of disease 
relapse. Treatment decisions are based on a number of clinical parameters, including 
age of the patient, tumour size, regional and lymph node metastasis, and histological 
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parameters, including histological grade and expression of hormone receptors (estrogen 
receptor (ER) and progesterone receptor (PR)) and the Human Epidermal Growth 
Factor Receptor 2 (HER2). 
 
Patients with ER-positive/HER2-negative breast cancers tend to have a better prognosis 
and outcome than patients with ER-negative/HER2-negative or HER2-amplified breast 
cancers (Fan et al., 2006). As ER-positive/HER2-negative tumours are dependent on 
estrogen for proliferation, therapeutic intervention with selective ER modulators 
(SERMs) have been proven successful in the clinic. Approaches to target ER signalling 
in ER-positive breast cancers include anti-estrogens (such as Tamoxifen and 
Fulvestrant), which bind to the ER and inhibit its function, and aromatase inhibitors, 
which block estrogen synthesis thereby depriving the tumour of this important growth-
promoting signal (Johnston, 2010). 
 
HER2-positive breast cancer cells depend on the activation of the HER2 onco-protein, 
and multiple strategies to inhibit this molecular target have been developed. To date, the 
most successful strategy produced the humanised monoclonal antibody Trastuzumab 
(also known as Herceptin), which binds to the extracellular domain of HER2 and 
inhibits its function as an activator of intracellular signalling pathways that drive 
proliferation (Hudis, 2007). Trastuzumab has been shown to improve overall survival 
(OS) by 33-35% of breast cancer patients with HER2-positive tumours in combination 
with chemotherapeutic drugs such as paclitaxel (Perez et al., 2008; Romond et al., 
2005). An alternative approach to treat HER2-positive tumours is to inhibit HER2 
activity by targeting the intracellular tyrosine kinase domain. The most established 
small molecule inhibitor targeting HER2 is Lapatinib, an orally administered dual 
inhibitor that blocks the activity of HER2 and epidermal growth factor receptor (EGFR) 
through reversible binding (Burris, 2004). Lapatinib is currently approved for the 
treatment of patients with metastatic breast cancer (Opdam et al., 2012).  
 
Breast tumours that do not express hormone receptors or HER2, i.e. the ER-
negative/HER2-negative cancers, do not benefit from the endocrine and anti-HER2 
therapies mentioned above and are treated using conventional cytotoxic and/or spindle-
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poison agents (e.g. paclitaxel, docetaxel, capecitabine, gemcitabine) (Foulkes et al., 
2010). 
 
The genetic heterogeneity of breast cancer is an ongoing challenge for clinicians as 
patients that have breast cancer with identical clinicopathological characteristics may 
have markedly distinct outcomes. There is therefore a clear need to identify additional 
markers to help selecting those patients that may benefit from a certain type of therapy.  
1.2.3 Breast cancer classification 
To account for the heterogeneity and reduce the complexity of breast cancer, different 
classification systems have been introduced. These include a) a histological 
classification (Lakhani et al., 2012), b) a clinical classification system based on the 
expression of hormone receptors and HER2, the predictive markers and targets of 
endocrine and anti-HER2 treatments, and c) a molecular classification system based on 
gene expression profiling.  
Recent sequencing studies analysing the entire genome or exome (only the coding 
regions of the genome) of breast tumours, as well as comparative genomic hybridization 
(CGH) that detect gene copy number and changes using single nucleotide 
polymorphism (SNPs), revealed that breast cancers can also be classified depending on 
their repertoire of genetic aberrations (CancerGenomeAtlasNetwork, 2012; Curtis et al., 
2012; Shah et al., 2012). The genetic landscape of breast cancer is discussed in section 
1.2.4. 
1.2.3.1 Molecular classification 
 
The molecular classification of breast cancer is based on gene expression profiling by 
using complementary DNA (cDNA) microarrays (DeRisi et al., 1996). Such profiling 
has unravelled breast cancer as a disease with multiple transcriptional subtypes. Using 
so called ‘intrinsic gene lists’ and hierarchical clustering analyses, it has been found that 
ER-positive and ER-negative breast cancers differed significantly at the transcriptional 
level (Perou et al., 2000; Sorlie et al., 2001). Within the ER-positive and ER-negative 
subgroups at least five molecular subtypes have been identified: Two ER-positive 
subtypes termed luminal A and luminal B, and three ER-negative subtypes termed 
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basal-like, ERBB2-enriched and normal-like breast cancers (Cheang et al., 2008; Hu et 
al., 2006; Parker et al., 2009; Reis-Filho and Pusztai, 2011; Sorlie et al., 2003). 
Importantly, these molecular subtypes have been shown to be associated with distinct 
outcomes. Women with luminal A breast cancers have the best prognosis while patients 
with a basal-like or ERBB2-enriched breast cancer have the worst outcome (Hu et al., 
2006; Parker et al., 2009). However, this molecular classification system is still 
evolving as additional ER-negative molecular subtypes have been identified, including 
the molecular apocrine subtype (Doane et al., 2006; Farmer et al., 2005; Guedj et al., 
2012) and claudin-low breast cancers (Prat et al., 2010). 
1.2.3.2 Clinical classification 
 
The clinical classification of breast cancer is based on the expression of the hormone 
receptors, which predict response to endocrine therapy, and growth factor receptor 
HER2, which is the molecular target of Trastuzumab and is used as a predictive marker 
for the response to this drug. 
1.2.3.2.1 Estrogen receptor-positive, HER2-negative breast cancer 
The majority of breast cancers (approximately 70%) express estrogen receptor α (ERα) 
and are sensitive to estrogen. Estrogen diffuses through the plasma membrane and binds 
to the ER within the cytoplasm. This complex then translocates to the nucleus where it 
binds to estrogen responsive element (ERE) sequences in the promoter regions of its 
target genes. In addition, estrogen can also bind to ER molecules that are located in or 
close to the plasma membrane. ERα and ERβ are the two main forms of ER and are 
encoded by different genes: ESR1 and ESR2, respectively. These receptors display some 
differences in their tissue specific expression pattern, but can also be co-expressed 
within the same tissue (Deroo and Korach, 2006).  
1.2.3.2.2 HER2-amplified/HER2-positive breast cancer  
HER2-amplified breast cancers are characterised by the amplification of the ERBB2 
gene locus on chromosome 17q12-q21, which codes for the receptor tyrosine kinase 
HER2 (Arriola et al., 2008). Amplification or overexpression of HER2 is observed in 
15-20% of all breast cancer cases. This subtype is a more aggressive form of breast 
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cancer and leads to a worse outcome compared to ER-positive breast cancers (Slamon et 
al., 1987).  
HER2-positive breast cancers can be further classified by the expression of ER 
(Marchio et al., 2008). HER2-positive breast cancers positive for ER expression belong 
to the luminal B gene expression subtype, whereas HER2-positive breast cancers with 
less than 1% ER expression belong to the ERBB2-enriched gene expression subtype.  
1.2.3.2.3 ER-negative, HER2-negative breast cancer 
Breast tumours that lack expression of ER, PR and HER2 belong to the subtype of ER-
negative/HER2-negative breast cancer. This group has also been termed triple negative 
breast cancer (TNBC) and accounts for approximately 15-20% of all breast cancer cases 
(Foulkes et al., 2010). The clinical definition suggests that this cancer type cannot be 
treated with Trastuzumab or endocrine therapy given that it is not driven by, and that 
lacks the expression of, the respective molecular markers HER2 and ER/PR. The TNBC 
subtype is a heterogeneous subtype and is comprised of different subgroups such as 
basal-like breast cancer (75%) with minor groups including claudin-low breast cancers 
(Foulkes et al., 2010; Lehmann et al., 2011). TNBCs display the worst OS with very 
limited treatment options (Foulkes et al., 2010; Perou, 2011). 
1.2.4 Genetic landscape of breast cancer 
The genetic alterations in breast cancer are defined by only a few highly recurrent 
mutations. These mutations mostly affect well-established oncogenes and tumour 
suppressors including TP53, PIK3CA, and PTEN. Recent studies investigated the 
genetic composition of thousands of breast tumours by sequencing, CGH, and gene 
expression profiling (Curtis et al., 2012; Marcotte et al., 2012) and revealed numerous 
additional mutations that are rare and affect less than 3% of breast cancer patients (i.e. 
non-recurrent mutations). Interestingly, 50% of these mutations affect the JUN 
signalling cascade (Hartmaier et al., 2012). 
1.2.4.1 The PI3K pathway 
 
The most prevalent genetic alterations in breast cancer affect the phosphatidylinositol-3-
kinase (PI3K) signalling pathway. This signalling pathway consists of a family of 
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proteins regulating multiple cellular processes such as cell growth, cell motility, cell 
differentiation and cell survival (Baselga, 2011). The PI3K pathway can be activated in 
breast cancer through several mechanisms: constitutive signalling by growth factor 
receptors such as HER2 (overexpressed in 15-20%) (Slamon et al., 1987) or EGFR 
(overexpressed in 6-36%) (Bhargava et al., 2005; Harris et al., 1989; Walker and 
Dearing, 1999), activating mutations in PIK3CA (30%) or loss of function of PTEN 
(16%) (source: catalogue of somatic mutations in cancer (COSMIC)). 
1.2.4.2 HER2 
 
The receptor tyrosine kinase HER2 (ERBB2) is one of four members of the epidermal 
growth factor (EGF) receptor family (Yarden and Pines, 2012). Members of this family 
are expressed in multiple tissues. HER2 and EGFR (ERBB1) have been implicated in 
tumorigenesis (Hynes and Stern, 1994; Moscatello et al., 1995; Slamon et al., 1989; 
Sunpaweravong et al., 2005). HER2 signalling is activated by homodimer formation or 
by heterodimerisation with other members of the HER family (e.g. HER3 (ERBB3) and 
EGFR) in a ligand-dependent or ligand-independent manner. Overexpression of HER2 
can result in ligand-independent activation of HER2 signalling due to the close 
proximity of receptors (Graus-Porta et al., 1997). Ligand-dependent activation results in 
various combinations of HER dimerisation through binding of certain ligands (e.g. EGF, 
neuregulin) (Olayioye et al., 2000). The extracellular domain of HER2 shows low 
affinity towards these ligands (Alroy and Yarden, 2000). 
Activated HER2 promotes the activity of two main downstream signalling cascades; the 
mitogen activated protein kinase (MAPK) pathway and the PI3K pathway (Yarden and 
Sliwkowski, 2001). Interestingly, the activation of the ER can also activate ERBB 
signalling through stimulation of matrix metalloproteinases (MMP) to release EGF 
(Razandi et al., 2003). 
1.2.4.3  PI3Ks 
 
All enzymes of the PI3K family are heterodimers that consists of a catalytic and a 
regulatory subunit. They catalyse the phosphorylation of the 3’-hydroxyl group of 
different phosphatidylinositol phosphates (PIPs) or phosphatidylinositol (PI). Class IA 
PI3Ks selectively phosphorylate phosphatidylinositol-4,5-bisphosphate (PIP2) to 
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generate phosphatidylinositol-3,4,5-trisphosphate (PIP3). PIP3 acts as a second 
messenger and is important for the activation of specific signalling cascades. Under 
resting conditions, cellular PIP3 levels are very low due to the negative regulation of the 
PI3K pathway by the phosphatase and tensin homolog on chromosome 10 (PTEN), a 
lipid phosphatase that removes the 3’-phosphate group from PIP3 (Vanhaesebroeck et 
al., 2010).  
Class I PI3Ks are mostly activated in response to growth factor receptor signalling 
(Katso et al., 2001). Class IA consists of three isoforms of the catalytic subunit p110 (α, 
β and δ) and three isoforms of the regularly subunit p85 (α, β and δ). The proto-
oncogene p110α is encoded by the PIK3CA gene and is frequently mutated in human 
cancer. In common tumour types including breast cancer, 80% of these gain of function 
mutations occur in exons 9 and 20, in particular in two hot spots within the catalytic 
domain of p110α (E545 and H1047) (Samuels et al., 2004). One of the downstream 
targets of class I PI3Ks is the threonine/serine kinase AKT, which regulates numerous 
cellular processes including cell growth, motility, proliferation and cell survival 
(Engelman et al., 2006; Vanhaesebroeck et al., 2010). 
1.2.4.4 Tumour suppressor PTEN  
 
PTEN was first identified as a potential tumour suppressor in 1997 when deletions of 
the gene were found in brain, breast and prostate cancer (Li et al., 1997). PTEN is now 
established as one of the most frequently mutated tumour suppressor genes in sporadic 
cancer. Germline mutations of PTEN have been found in patients with Cowden disease, 
a genetic disorder that leads to a higher risk of cancer (Sansal and Sellers, 2004).  
PTEN is both a lipid and a protein phosphatase. PTEN acting as a lipid phosphatase de-
phosphorylates the 3’ position on PIP3, thereby negatively regulating the downstream 
effectors of PI3K, including PDK1 and AKT. The protein phosphatase activity of PTEN 
has been shown to regulate cyclin D and the family members of the family of SRC 
kinases (Hollander et al., 2011). Loss of PTEN activity results in hyperactive 
PI3K/AKT signalling and can contribute to tumour development and progression. 
According to the COSMIC database, PTEN is mutated in only 6% of all breast cancers. 
However, approximately 40% of all breast cancer tissue samples show loss of PTEN 
expression (Perez-Tenorio et al., 2007). This is due to mechanisms (such as microRNA 
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targeting of PTEN mRNA or protein degradation pathways) that result in 
downregulation of PTEN expression. Of note, mutations in PTEN and PIK3CA are 
generally mutually exclusive in breast cancer (Saal et al., 2005). 
1.2.4.5 TP53 
 
The TP53 gene encodes the transcription factor, which is activated in response to 
various cellular stresses, including hypoxia and DNA damage (Vogelstein, 2000). 
Under non-stressed conditions, p53 is expressed at low levels due to its relatively short 
protein half-life of about 30 minutes (Maltzman and Czyzyk, 1984). Stress signals 
activate p53 mostly by translational or posttranslational modifications that lead to 
stabilisation and nuclear accumulation of the protein. A major regulator of p53 stability 
is the ubiquitin ligase MDM2, which inhibits p53 by mediating its ubiquitination and 
proteasomal degradation (Michael and Oren, 2003). Activated p53 controls the 
transcription of numerous targets genes that regulate cell cycle arrest (e.g. p21) and 
apoptotic cell death pathways (e.g. BAX, NOXA, PUMA) (Riley et al., 2008).  
Functional p53 can suppress cell proliferation and induce cell death in response to anti-
proliferative stimuli. Loss of p53 promotes uncontrolled proliferation of cancer cells 
and promotes genetic instability. p53 is one of the most important tumour suppressors 
and is mutated in up to 50% of sporadic human cancers (Soussi and Lozano, 2005). The 
rate of p53 mutations in breast cancer is 50%-74% (Forbes et al., 2011; Kan et al., 
2010). Moreover, p53 status in breast cancer can influence the clinical response to 
chemotherapy (Jackson et al., 2012). 
1.2.4.6 Additional mutations in breast cancer  
 
Recent studies by the Cancer Genome Atlas Network (CancerGenomeAtlasNetwork, 
2012), the Cancer Genome Project (Nik-Zainal et al., 2012a; Nik-Zainal et al., 2012b; 
Stephens et al., 2012) and the groups of Caldas and Aparicio (Curtis et al., 2012; Shah 
et al., 2012) analysed between 21 and 2000 primary breast cancer by using next-
generation sequencing. These studies provide a comprehensive overview of the 
mutational landscape of breast cancer, identifying previously unrecognised mutations, 
describing novel drivers of tumour development and resulting in the classification of 
additional clinical subtypes. These studies also confirmed the existence of multiple sub-
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clones of cells within a tumour population (intra-tumoural heterogeneity). Furthermore, 
these studies confirmed that mutations in TP53, PIK3CA and PTEN were the most 
prevalent mutations found in breast cancer. TP53 mutations occurred most frequently in 
TNBC. PIK3CA mutations were prevalent in the ERBB2-enriched and luminal A type, 
whereas PTEN mutations were enriched in the luminal B and basal-like subgroups. The 
basal-like subtype displayed the highest rate of genome instability, as determined by 
their CGH profiles. In addition, mutations in ERBB2 were found in TNBC. 
1.2.5 Tumour microenvironment 
In addition to the genetic alterations in cancer cells, environmental factors provided by 
the tissue context also contribute to disease development. In particular, interactions with 
the microenvironment play an important role in determining how oncogenes and tumour 
suppressors regulate cell transformation in a tissue-specific context (Bissell et al., 2002). 
The microenvironment consists of different cell types such as fibroblasts, macrophages 
and other immune cells, extracellular matrix (ECM) components, such as collagen and 
fibronectin fibres, and small molecules including nutrients, ions and oxygen (discussed 
in more detail in 1.3.10). The 3-dimensional (3D) tissue architecture is mainly 
determined by cell-cell and cell-ECM interactions. During early tumorigenesis, tissue 
architecture remains intact. However, even occult tumour cells influence the ECM by 
secreting enzymes, growth factors and cytokines. These factors affect the behaviour of 
stromal cells and contribute to the generation of cancer-associated fibroblasts (CAF) 
from normal fibroblasts. The altered phenotype of CAFs influences the structure of the 
ECM and contributes to tumour progression and metastasis formation (Bissell et al., 
2002; Xing et al., 2010).  
 
It has been suggested that breast cancers can be classified into four different groups 
according to their ECM composition. The ECM type 1 is characterised by high 
expression of metallopeptidases and integrins and has the least favourable outcome. In 
contrast, ECM type 4, characterised by overexpression of serpin family members, 
shows a good prognosis (Bergamaschi et al., 2008).  
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Over the last couple of years, the importance of tumour-stroma interactions has received 
increasing interest. It has emerged that in addition to the important role that the tumour 
microenvironment plays during tumour formation and tumour progression; it can also 
determine the clinical response to cancer therapeutics. Straussman and colleagues 
investigated the sensitivities of 45 different cancer cell lines towards multiple drugs 
when co-cultured with 23 different stromal cell lines (Straussman et al., 2012). This 
study demonstrated that stromal-mediated resistance is common, particularly towards 
targeted agents. Moreover, a recent study in a xenograft breast cancer mouse model 
revealed that the chemokines CXCL1 and CXCL2 are highly expressed in tumours that 
have developed resistance to chemotherapy. This study showed that myeloid cells 
secrete inflammatory proteins that upregulated CXCL1 and CXCL2 in tumour cells 
(Acharyya et al., 2012). Taken together, these studies underline the importance of 
understanding the communication between tumour and stromal cells to improve the 
design of suitable therapeutic strategies.  
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1.3 Metabolism 
1.3.1 Metabolism of quiescent and normal proliferating cells 
The metabolic requirements of non-transformed (normal) cells depend on their 
differentiation state. Quiescent cells are metabolically active to fulfil their physiological 
function and to maintain their structural integrity as well as redox and energy balance. 
Proliferating normal cells require molecular building blocks in the form of amino acids, 
fatty acids and nucleotides to generate macromolecules for cell growth and division 
(Thompson et al., 2005; Vander Heiden et al., 2011). All cellular processes, including 
metabolic reactions, are tightly regulated through control systems that ensure normal 
cell function and maintain cell and tissue integrity. These control systems are mediated 
by cellular signalling processes. These signalling networks contain many of the proto-
oncogenes and tumour suppressors that are also involved in cell transformation and 
tumour development. Any abnormal signalling cues transmitted intra- or intercellular, 
may result in cell cycle arrest and/or programmed cell death.  
Normal cells in resting tissue are in close proximity to blood vessels that usually 
provide sufficient nutrients and oxygen levels for normal cell function. Cells utilise 
sugars, fatty acids and amino acids that are present within their environment. These 
nutrients have to be transported across the plasma membrane by specialised transporters 
and can be catabolised to provide cellular energy in the form of adenosine triphosphate 
(ATP). Most normal cells generate ATP through their mitochondrial metabolism, which 
generates NADH to drive the electron transport chain (ETC) and oxidative 
phosphorylation (Fig 1.2). In contrast, proliferating cells rely on glycolysis for a 
significant proportion of their ATP demand (Vander Heiden et al., 2009). Proliferating 
cells also use some nutrients directly for anabolic reactions to synthesise 
macromolecules. Mitochondrial respiration in normal cells recycles NADH to NAD+ 
thereby coupling energy production with cofactor supply. However, in proliferating 
normal cells, the regeneration of NAD+ can be achieved through both mitochondrial 
respiration and lactate production (Fig 1.2). 
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Figure 1-2 Overview of metabolic activity in quiescent and proliferating cells 
Schematic representation of the metabolism in quiescent cells, proliferating normal cells and proliferating 
cancer cells. Quiescent cells rely mainly on mitochondrial respiration for ATP production. Proliferating cells 
use glucose for the conversion to pyruvate-derived lactate. They also divert carbons from glycolysis to 
accumulate building blocks for macromolecule biosynthesis and to maintain their redox potential. Non-
malignant cells are embedded in and environment that provides sufficient nutrients and oxygen for normal 
cell function. In contrast, cancer cells may be exposed to nutrient and oxygen withdrawal during same 
stages of tumorigenesis.  
 
1.3.2 Rewiring of cellular metabolism in cancer  
Historically, the field of cancer metabolism has been dominated by the discoveries by 
the German biochemist Otto Warburg in the 1920s. He and his colleagues observed that 
malignant rodent liver cells use glycolysis for ATP production even in the presence of 
oxygen (Warburg, 1956; Warburg et al., 1927). This increase in glycolytic activity was 
accompanied by enhanced lactate secretion and was termed aerobic glycolysis, also 
known as the ‘Warburg effect’. These findings led to Warburg’s hypothesis that 
inhibition of mitochondrial respiration is the cause of cancer development, a theory that 
was proven wrong when the genetic contribution to cancer development was established 
in the 1960s.  
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However, the question as to why cancer cells favour the much less efficient process of 
aerobic glycolysis over oxidative phosphorylation remained open. One explanation for 
this phenomenon is that many important metabolic processes required for 
macromolecule biosynthesis depend on intermediates of the glycolytic pathway. Recent 
work in the field of cancer metabolism has demonstrated that increased glycolytic flux 
in cancer cells is the consequence of activation of proto-oncogenes and loss of tumour 
suppressors, and not impaired mitochondrial function. Cancer cells may also favour 
aerobic glycolysis over mitochondrial respiration to minimise the generation of reactive 
oxygen species (ROS). The metabolic re-programming in cancer is essential for redox 
balance and the synthesis of fatty acids, amino acids and nucleotides to generate 
macromolecules for cell growth (Fantin et al., 2006; Lunt and Vander Heiden, 2011; 
Moreno-Sanchez et al., 2007).  
 
Cancer cells also influence the metabolite composition of the immediate tumour 
environment. The increased nutrient influx into cancer cells and their enhanced 
metabolic rate also leads to an increase in metabolic by-products that are secreted into 
the surrounding tissue. Therefore, tumour cells also need to secure mechanisms that can 
remove any toxic by-products in order to stabilise their intracellular as well as their 
extracellular environment. The following chapter will discuss core processes of 
metabolism in the context of the genetic and non-genetic factors that contribute to 
metabolic reprogramming in cancer. 
1.3.2.1 Glycolysis 
Glycolysis is the a metabolic process that converts 1 mole of glucose into 2 moles of 
pyruvate, resulting in a net gain of two moles of ATP and two moles of NADH. The 
fate of glucose-derived pyruvate depends on the cell type and on environmental 
conditions. In well-oxygenated, differentiated tissue, pyruvate enters the mitochondria 
and is completely oxidised to CO2, a process that generates approximately 36 moles of 
ATP per mole of glucose. Under oxygen deprivation, pyruvate is converted to lactic 
acid. This reaction is catalysed by lactate dehydrogenase (LDH) and facilitates the 
conversion of NADH to NAD+, which is a necessary cofactor for the glycolytic flux 
(Fig 1.3). In proliferating tissue, pyruvate is mainly converted to lactate regardless of 
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the oxygen concentration. Lactate produced by muscle during anaerobic exercise is 
converted back to pyruvate and glucose by the liver, a process of metabolic coupling 
known as the Cori Cycle (Cori, 1981). Pyruvate can also be converted to alanine by 
alanine transaminase, which connects glycolysis with amino acid metabolism (Berg et 
al., 2002). It is evident that pyruvate occupies a central position within the cellular 
energy metabolism. The different fates of pyruvate are determined by the relative needs 
of the cells for ATP generation and the requirement of anabolic processes for cell 
growth. 
Many glycolytic enzymes have been shown to be upregulated during tumorigenesis. 
The increased glucose uptake in cancer cells is due to the upregulation of glucose 
transporters. There are five glucose transporters (GLUTs) in the mammalian system. 
GLUT1 and GLUT3 are expressed in most tissues whereas GLUT2, GLUT4 and 
GLUT5 show tissue specific expression patterns. GLUT1 and GLUT3 are 
overexpressed in many different cancer types (Yamamoto et al., 1990) and GLUT1 
expression in primary tumours has been correlated to poor clinical outcome (Macheda 
et al., 2005). The irreversible conversion of glucose to glucose 6-phosphate (G-6-P) is 
catalysed by hexokinase. There are four isoforms of hexokinase (HK1-3 and GCK). 
Hexokinase 2 (HK2) is upregulated in many cancers and its ablation in U87, a 
glioblastoma cell line, decreased cell viability (Wolf et al., 2011). HK1 and HK2 can be 
found in close proximity to the mitochondria and have been implicated in the 
prevention of intrinsic apoptotic cell death (Gottlob et al., 2001; Majewski et al., 2004).   
A rate-limiting step in glycolysis is the conversion of fructose-6-phosphate (F-6-P) to 
fructose-1,6-bisphosphate (F-1,6-BP) regulated by phosphofructokinase1 (PFK1). The 
activity of PFK1 is tightly regulated through several allosteric mechanisms. High levels 
of ATP or citrate inhibit the activity of PFK1 and block the generation of F-1,6-BP. 
This results in an accumulation of upstream intermediates that can be used for other 
biosynthetic pathways, such as the pentose phosphate pathway (PPP) (see 1.3.2.4). 
Another allosteric regulator of PFK1 is fructose-2,6-bisphosphate (F-2,6-BP). This 
metabolite is generated from F-6-P by the activity of 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatases (PFK2/FBPases). F-2,6-BP is an allosteric activator 
of PFK1 and high levels of this metabolite overcome the ATP-mediated inhibition of 
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PFK1 (Telang et al., 2006). The mammalian genome encodes four PFK2 isoforms 
(PFKFB1-4) and two of these, PFKFB3 and PFKFB4, have been implicated in cancer 
(Bando et al., 2005; Minchenko et al., 2002). PFKFB3 is required for anchorage-
independent growth of RAS-transformed cells (Telang et al., 2006), and its inhibition 
impaired glycolytic flux and reduced viability of cancer cells (Clem et al., 2008). 
PFKFB4 has been shown to be important for the survival of metastatic prostate cancer 
cells. In this context, it mainly functioned as FBPases and balanced the glycolytic flux 
with the production of NADPH by the PPP thereby maintaining cellular redox balance 
(Ros et al., 2012). PFKFB4 is also overexpressed in primary human glioblastomas and 
is associated with a poor clinical outcome. The ablation of PFKFB4 in brain cancer 
stem-like cells in-vitro caused reduction in cell number (Goidts et al., 2012). A recent 
finding underlined the importance of the regulation of PFK1 activity by post-
translational modification. High levels of PFK1 glycosylation were observed in cancer 
cell lines and tumour tissues. PFK1 glycosylation was mainly mediated by O-linked β-
N-acetylglucosamine (O-GlcNAc) transferase and resulted in reduced PFK1 activity. 
This decreased the glycolytic flux and redirected the flux of glucose to the PPP, thereby 
providing a selective growth advantage to cancer cells (Yi et al., 2012). 
A recent study by Muller and colleagues found that a passenger mutation in enolase 1 
(ENO1) renders glioblastoma cells vulnerable to ablation of enolase 2 (ENO2) and 
caused enhanced sensitivity towards enolase inhibition. This finding illustrates the 
importance of isoform compensation. Importantly, this study demonstrated that 
passenger mutations in non-essential genes cause cancer specific therapeutic 
vulnerabilities (Muller et al., 2012). 
Another key player in glycolysis is pyruvate kinase (PK), which coordinates the 
conversion of phosphoenolpyruvate (PEP) to pyruvate. In mammals, two genes encode 
PK isoforms (PKM and PKLR) and the PKM gene can give rise to two isoforms, PKM1 
and PKM2, through alternative splicing. PKM2 can adapt its activity in response to 
extracellular stimuli, thereby influencing the glycolytic flux. PKM2 can assemble into 
two different catalytically active complexes: a less active homo-dimer with low affinity 
to PEP and a homo-tetramer with high affinity to PEP resulting in high enzymatic 
activity. The conversion from a tetramer to the dimeric form is induced by binding of 
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PKM2 to viral oncoproteins (Zwerschke et al., 1999), the presence of phosphotyrosine-
containing peptides (Christofk et al., 2008b), phosphorylation (Hitosugi et al., 2009) 
and the presence of ROS (Anastasiou et al., 2011). Expression of the PKM2 isoform 
enables cells to accumulate glycolytic intermediates upstream of PEP for biosynthetic 
processes. The conformational switch of PKM2 also allows cells to regulate their 
glycolytic flux depending on the energy demand of the cell. The expression of PKM2 is 
upregulated in proliferating and cancer cells (Christofk et al., 2008a). Importantly, 
expression of the PKM2 isoform supports tumour formation (Christofk et al., 2008a). 
Some cancers, including lung and breast cancer, show a high expression of lactate 
dehydrogenase A (LDHA), and abrogation of LDHA compromises the proliferation of 
tumour cells under hypoxic conditions (Fantin et al., 2006). Furthermore, inhibition of 
LDHA results in a switch from aerobic glycolysis to oxidative phosphorylation and is 
accompanied by increased ATP production. Interestingly, the inhibition of LDHA 
reduces tumour formation (Fantin et al., 2006), suggesting that LDHA function is 
crucial for cancer cells. Recently, another isoform of LDH, LDHB, has been shown to 
be important for ER-negative/HER2-negative breast cancers. The ablation of LDHB 
impaired cell proliferation in-vitro and caused tumour regression in-vivo (McCleland et 
al., 2012). 
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Figure 1-3 Overview of glycolysis 
Schematic overview of the metabolic reactions that are required to convert glucose into pyruvate as part of 
glycolysis. Many glycolytic intermediates are precursors for other metabolic processes such as fatty acid 
and amino acid synthesis. Under resting conditions, glucose is catabolised to CO2 by mitochondrial 
processes resulting in the production of ATP. Cancer cells use aerobic glycolysis, where approximately 
90% of all glucose-derived carbons are converted to lactate. Lactate is then secreted out of the cell. 
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1.3.2.2 Glutaminolysis 
Glutaminolysis is defined as a metabolic process where glutamine is converted to α-
ketoglutarate via glutamate (Fig 1.4). Glutamine is an important source for cellular 
carbon and nitrogen and is required for the biosynthesis of macromolecules and the 
regulation of the cellular redox potential. Glutamine is the most abundant amino acid in 
human serum (Stein and Moore, 1954). Glutamine-derived carbons are not only used 
for amino acid and nucleotide synthesis but also to replenish metabolites of the 
tricarboxylic acid (TCA) cycle, a process termed anaplerosis (DeBerardinis et al., 
2007). Glutamine can also generate lactate via oxidative carboxylation of malate to 
pyruvate thereby supporting NADPH production. Recent studies have shown that 
glutaminolysis is regulated by the proto-oncogene c-MYC, which is overexpressed or 
amplified in multiple cancers (Dang, 2012). MYC overexpressing cells strongly depend 
on glutamine, which is known as ‘glutamine addiction’ (Dang, 2009). Glutamine-
addicted cells alter their transcriptional programme to upregulate the expression of 
glutamine transporters and enzymes within the glutaminolysis pathway (Wise et al., 
2008). The depletion of glutamine prevents the replenishment of TCA cycle metabolites 
and induces cells to undergo MYC-dependent apoptosis (Yuneva et al., 2007).  
Glutamine metabolism also substantially contributes to lipogenesis (DeBerardinis et al., 
2007; Mullen et al., 2012). Flux studies with isotope-labelled glucose and glutamine 
have revealed that hypoxic cancer cells, or clear cell renal carcinoma (ccRCC) cells 
harbouring deletions in the Von Hippel-Lindau gene (VHL), use reductive glutamine 
metabolism to generate cytosolic citrate for lipid synthesis (Metallo et al., 2012; Wise et 
al., 2008). Moreover, cancer cells with dysfunctional mitochondria also use reductive 
decarboxylation of glutamine to compensate for the lack of mitochondrial metabolism 
(Mullen et al., 2012). 
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Figure 1-4 Overview of Glutaminolysis 
Schematic overview of glutaminolysis. Glutamine addiction is observed in many cancer cells that use 
glutamine as a substrate for anaplerosis of the TCA cycle, as well as nucleotide and hexosamine 
synthesis. However, in cancer cells with dysfunctional mitochondria, glutamine-derived carbons are used 
for lipid synthesis. 
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1.3.2.3 Amino acid synthesis 
Amino acids are the building blocks for proteins and can be mostly provided by the cell 
environment (essential amino acids). However, some amino acids are synthesised by 
intracellular reactions (non-essential amino acids). The major pathways involved in 
amino acid synthesis are glycolysis, the TCA cycle and glutaminolysis (Fig 1.5).  
Recently, the synthesis of the amino acid serine via the serine pathway has been 
demonstrated to be important in cancer. The serine synthesis pathway diverts from the 
glycolytic intermediate 3-phosphoglycerate, and all three metabolic enzymes of this 
pathway are often overexpressed in cancer. The first step of the serine biosynthesis 
pathway is catalysed by the enzyme 3-phosphoglycerate dehydrogenase (PHGDH) and 
amplifications of the PHGDH gene have been found in melanoma and breast cancer 
(Locasale et al., 2011; Possemato et al., 2011). Furthermore, ablation of PHGDH 
expression with shRNA leads to decreased cancer cell survival and flux analysis studies 
showed that serine biosynthesis is tightly coupled to glutaminolysis and that the serine 
synthesis pathway contributes up to 50% of the glutamate to α-ketoglutarate conversion 
(Possemato et al., 2011).  
Not only is serine important for the cell, but it can also be converted to the amino acids 
cysteine and glycine. Together with glutamine, these two amino acids are required for 
the synthesis of glutathione, an important antioxidant system that counteracts the effect 
of ROS. Several antioxidant systems ensure the removal of hydrogen peroxide (H2O2) 
and other free radicals from cells. These include catalases, peroxiredoxins and 
glutathione peroxidases (GPX). GPX proteins become oxidised by H2O2 followed by a 
recycling reaction that requires the reduced form of glutathione (GSH). The removal of 
ROS by the glutathione system protects cell from oxidative damage (Sena and Chandel, 
2012). 
Glutaminolysis is also important for amino acid synthesis. Glutamine can be used to 
generate the amino acids arginine and proline. In addition to their function as precursors 
for protein synthesis, arginine is involved in nitric oxide signalling (Cendan et al., 1996; 
Lala and Chakraborty, 2001), and proline can also act as an antioxidant (Phang et al., 
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2012). Moreover, glutamine shuttling across the plasma membrane is necessary for the 
import of essential amino acids such as phenylalanine (Nicklin et al., 2009).  
 
Figure 1-5 Overview of amino acid synthesis 
Schematic overview of metabolites that are precursors for the biosynthesis of non-essential amino acids. 
Glutamine plays an important role in amino acid synthesis as a precursor to arginine, proline and the 
serine biosynthesis pathway as well as being involved in the import of essential amino acids. 
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1.3.2.4 Fatty acid synthesis 
Fatty acids are carboxylic acids containing a long hydrocarbon chain and are the 
precursors of phospholipids, cholesterol-esters and triacylglycerides. Most cells in the 
adult body rely on lipids to be provided by their environment. In contrast, tumour cells 
re-activate de-novo lipogenesis. Indeed, early experiments using 14C-labelled glucose 
showed that neoplastic tissue slices synthesise lipids regardless of abundant 
extracellular lipids (Medes et al., 1953).  While the role of de-novo lipogenesis in 
cancer cells is not fully understood, several potential benefits for cancer cells have been 
proposed (Menendez and Lupu, 2007). Importantly, the increased rate of fatty acid 
synthesis supports cell growth in multiple ways: it provides lipids for membrane 
biogenesis, it provides cancer cells with fuel that can be mobilised in times of nutrient 
deprivation through fatty acid oxidation and lipid synthesis precursors and these 
products can also function as second messengers and signalling molecules.  
The primary source for fatty acid biosynthesis is citrate, which is synthesised in the 
mitochondria in a two-step process: decarboxylation of pyruvate to form acetyl-CoA, 
followed by the condensation of the acetyl-group with oxaloacetate to form citrate. 
Fatty acid biosynthesis is a cytosolic process and therefore citrate needs to be 
transported from the mitochondria to the cytoplasm. Mitochondrial citrate transporters 
such as SLC25A1 have been shown to be important for citrate efflux from the 
mitochondria, especially in prostate tissue (Mycielska et al., 2009).  
The first step of fatty acid biosynthesis involves the transfer of an acetyl-group from 
citrate to form acetyl-CoA and oxaloacetate by ATP citrate lyase (ACLY) in the 
cytoplasm. The metabolite oxaloacetate can re-enter the mitochondria or be converted 
into pyruvate and NADPH by malic enzyme. Acetyl-CoA, which can also be 
synthesised in the cytoplasm by acetyl-CoA synthetase (ACSS2) (Yoshii et al., 2009), is 
further converted to fatty acids and/or cholesterol. The first step in fatty acid synthesis 
is the carboxylation of acetyl-CoA to malonyl-CoA by acetyl-CoA carboxylase (ACC). 
This highly regulated enzyme has two isoforms, which differ in their ability to become 
allosterically activated by citrate (Locke et al., 2008). Malonyl-CoA is converted to 
palmitate, a saturated fatty acid of 16-carbons, by fatty acid synthase (FASN) via 
repeated condensation reactions of acyl-groups. This saturated fatty acid is the origin of 
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many saturated and unsaturated fatty acids containing more than 16-carbons. The 
desaturation process is catalysed by stearoyl-CoA desaturase (SCD) (Ntambi and 
Miyazaki, 2004) (Fig 1.6). 
As mentioned above, acetyl-CoA can also be used to generate cholesterol, an important 
building block for steroid synthesis and membranes. The condensation of acetyl-CoA 
with acetoacyl-CoA generates 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA), a 
reaction that is catalysed by HMG-CoA synthase (HMGCS). HMG-CoA is further 
converted to mevalonate by HMG-CoA reductase (Goldstein et al., 2006). 
Not only is lipogenesis a process that generates different intermediates for biosynthetic 
processes, it also requires intermediates from other metabolic processes to maintain the 
generation of lipids (e.g. glycolysis, PPP) (Fig 1.6). Increased expression of metabolic 
enzymes involved in lipogenesis such as ACLY, ACC and FASN have been reported 
across different malignancies (e.g. breast and hepatocellular cancer) (Menendez and 
Lupu, 2007; Yahagi et al., 2005; Yoon et al., 2007). The inhibition or ablation of these 
enzymes leads to decreased proliferation and tumour growth and is accompanied by 
increased cell death (Hatzivassiliou et al., 2005; Lupu and Menendez, 2006).  
Important regulators of lipogenesis are the transcription factors of the sterol regulatory 
element binding protein (SREBP) family. SREBPs induce the transcription of multiple 
genes involved in fatty acid and sterol synthesis. The regulation of the activity of 
SREBP involves sensing of intracellular sterol concentrations. Low sterol levels result 
in the induction of the transcription of SREBP target genes. In contrast, high sterol 
levels prevent SREBP processing and inhibit SREBP mediated transcription 
(Bengoechea-Alonso and Ericsson, 2007). It has been demonstrated that SREBP1 is 
also a downstream target of the mammalian target of rapamycin complex 1 (mTORC1) 
(Porstmann et al., 2008). Dysregulation of mTORC1 by oncogenic signalling or loss of 
tumour suppressors during tumorigenesis can therefore enhance de-novo lipogenesis. 
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Figure 1-6 Overview of fatty acid synthesis 
Schematic overview of lipid biosynthesis. Glucose-derived pyruvate or glutamine-derived α-Ketoglutarate 
is used for the production of citrate. Citrate is converted to acetyl-CoA, which either acts as substrate for 
fatty acid synthesis via malonyl-CoA or is used as precursor for cholesterol biosynthesis. Lipogenic 
enzymes such as FASN, ACC and ACLY have been found to be overexpressed in cancer. 
  
Chapter 1 Introduction 
 44 
1.3.2.5 Pentose phosphate pathway 
The pentose phosphate pathway (PPP) is a metabolic pathway that uses glucose-derived 
and glutamine-derived molecules for purine and pyrimidine biosynthesis. The PPP, is 
also a major source of NADPH. NADPH is required for the production of antioxidants, 
which are important to counteract ROS. The PPP is branched into an oxidative and non-
oxidative pathway. The oxidative pathway is important for the synthesis of NADPH and 
produces the 5-carbon sugar, ribulose-5-phosphate (R-5-P). R-5-P is a precursor for 
nucleic acid synthesis by the oxidative pathway (Fig 1.7). Moreover, R-5-P can be 
converted to the glycolytic intermediates F-6-P and glyceraldehyde-3-phosphate via the 
activity of transketolases and transaldolases of the non-oxidative pathway. This allows 
cells to adapt their metabolism according to the relative demands for NADPH, riboses 
and ATP (Berg et al., 2002). 
 
Figure 1-7 Overview of the pentose phosphate pathway 
Schematic overview of the oxidative and non-oxidative PPP. Glucose and glutamine contribute to the 
production of important macromolecules via PPP. NADPH generation is necessary for redox balance and 
ribose-5-phosphate is an important intermediate for other metabolic synthesis processes (e.g. nucleotides, 
amino acids and lipid synthesis) 
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1.3.2.6 NADH and NADPH production 
Besides generating macromolecules for cell growth and proliferation, cancer cells also 
require sufficient amounts of the cofactors nicotinamide adenine dinucleotide (NADH) 
and nicotinamide adenine dinucleotide phosphate (NADPH) for energy transduction 
and biosynthetic processes. The relative abundance of the oxidised and reduced forms 
of these cofactors is also an important regulator of metabolic activity (Feron, 2009). 
NAD+/NADH ratios are important for the catabolism of glucose and fatty acids as well 
as energy production (Chiarugi et al., 2012). Moreover, the relative NAD+/NADH 
levels regulate the activity of many metabolic enzymes. Highly glycolytic cells display 
increased NADH levels relative to NAD+ levels. This leads to a constraint in their 
metabolic activity and cancer cells need to regenerate NAD+ to maintain a balanced 
NAD+/NADH ratio. Cells possess different mechanisms to regenerate NAD+. One 
mechanism is the conversion of pyruvate to lactate by LDH. In oxidative cells, the 
electron transport chain accepts electrons from NADH to regenerate NAD+. NADH 
generated by glycolysis has to be transferred to the mitochondria by the malate-
aspartate shuttle. However, this process is slower than the conversion of pyruvate into 
lactate. (Canto et al., 2009; Canto et al., 2012). 
The other cofactor important for biosynthetic processes and redox regulation is 
NADPH. It has been suggested that the production of NADPH is a rate-limiting factor 
in cancer metabolism (Vander Heiden et al., 2009). This can be partially explained by 
the high demand of NADPH for lipogenesis (14 molecules NADPH are needed per 
molecule palmitoyl-CoA) (Vander Heiden et al., 2009). NADPH can be generated 
through three different metabolic processes: the oxidative arm of the PPP via glucose-6-
phosphate dehydrogenase (G6PD); the conversion of malate to pyruvate by the 
cytosolic isoform of malic enzyme (ME1); and the conversion of isocitrate to α-
ketoglutarate by the cytosolic isoform of isocitrate dehydrogenase (IDH1). Depending 
on the context, cells may prefer one mechanism of NADPH production over another. 
Glutamine-dependent cells have been suggested to produce NADPH by converting 
glutamine-derived malate to pyruvate by ME1 (DeBerardinis et al., 2007). However, 
cancer cells with a less pronounced glutamine addiction or those that use glutamine for 
reductive decarboxylation to form citrate might show a stronger dependence on the PPP 
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enzyme G6PD for NADPH production. However, it should be noted that inherited 
mutations in G6PD, that result in reduced activity of this enzyme, have not yet been 
linked to reduced cancer risk.  
A recent study has provided evidence that the AMP-activated protein kinase (AMPK) 
regulates NADPH levels during metabolic stress situations in cancer cells. Under 
metabolic stress situations, such as nutrient deprivation, energy-consuming processes, 
such as lipid biosynthesis, need to be inhibited while energy production through 
glycolysis and oxidative phosphorylation are activated. Since cells also need to 
counteract ROS, AMPK maintains NADPH levels via inhibition of lipid biosynthesis 
through phosphorylation of acetyl carboxylases 1 and 2 (Jeon et al., 2012).  
In conclusion, NADPH is an important cofactor for biosynthetic processes and also 
essential to maintain redox balance in proliferating and cancer cells. 
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1.3.3 Mutations in metabolic genes regulate cancer metabolism 
Recent discoveries have shown that metabolic genes themselves can harbour LOF or 
GOF mutations. The metabolic phenotype of cancer cells with these genetic alterations 
in metabolic genes can accumulate metabolites resulting in their selective dependency 
on additional metabolic pathways and enzymes. This ‘non-oncogene addiction’ can be 
found in cells harbouring mutations in the mitochondrial enzymes fumarate hydratase 
(FH) and succinate dehydrogenase (SDH), which are part of the tricarboxylic acid cycle 
(Frezza et al., 2010).  
LOF mutations in SDH and FH lead to an accumulation of their substrates, fumarate 
and succinate (Fig 1.8). These metabolites can act as onco-metabolites by inducing 
specific changes to cellular signalling that promote tumorigenesis. Tumours deficient in 
FH exhibit a strong hypoxic gene expression signature due to activation of HIF1α and 
induction of HIF1α target genes (Ashrafian et al., 2010). Increased succinate levels 
inhibit the activity of prolyl hydroxylases (PHDs) that negatively regulate HIF1α (Selak 
et al., 2005). A similar mechanism was found for FH-deficient tumours (Isaacs et al., 
2005; Pollard et al., 2005). Cells that lack functional FH or SDH elicit glycolytic 
phenotypes. Moreover, it has been suggested that FH-deficient cells rely on the urea 
cycle (Frezza et al., 2011).  
A genome wide screen by Parsons and colleagues initially demonstrated the occurrence 
of mutations in the cytoplasmic form of isocitrate dehydrogenase (IDH1) (Parsons et al., 
2008). This was supported by other studies identifying IDH1 as well as IDH2 mutations 
in acute myeloid leukaemia (AML) and glioblastomas (Marcucci et al., 2010; Yan et al., 
2009). The mutation always resulted in a single amino acid change within the active 
centre of the enzyme (arginine 132 in IDH1 and arginine 172 in IDH2). There are three 
isoforms of IDH (IDH1, IDH2 and IDH3). IDH1 and IDH2 are NADP+-dependent 
enzymes whereas IDH3 is NAD+-dependent. These enzymes differ in their localisation 
within the cell. The isoforms IDH2 and IDH3 are part of the mitochondrial metabolism 
whereas IDH1 is localised in the cytoplasm. Metabolite analyses in glioblastomas and 
AML has revealed that mutant forms of IDH1 or IDH2 acquire a neomorphic activity 
and generate the metabolite 2-hydroxyglutarate (2-HG) from α-ketoglutarate (Dang et 
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al., 2009). Increased levels of 2-HG influence histone modifications via the DNA and 
histone demethylase TET2 (Xu et al., 2011), and the jumonji domain containing protein 
2A (JMJD2A) (Chowdhury et al., 2011); thereby linking cellular metabolism to 
epigenetic regulation (Fig 1.8).  
Other genetic alterations of metabolic enzymes in cancer mainly affect gene copy 
number or expression levels. Overexpression of metabolic enzymes has been observed 
in melanoma, prostate and breast cancers. The FASN gene locus is amplified in prostate 
cancer (Migita et al., 2009). Moreover, the metabolite sarcosine is enriched in 
metastatic prostate cancer (Sreekumar et al., 2009). ER-negative/HER2-negative breast 
cancer and melanoma depend on increased flux through the serine/glycine pathway due 
to amplifications in the phosphoglycerate dehydrogenase (PHGDH) gene (Locasale et 
al., 2011; Possemato et al., 2011).  
Together these studies demonstrate that the metabolic adaptations of cancer cells are not 
only the consequence of oncogenic signalling events but can be causally involved in the 
transformation process. It appears that selective pressure can not only alter the activity 
of metabolic enzymes to optimise the survival of cancer cells, but can even lead to the 
production of onco-metabolites that may drive tumorigenesis. Metabolic enzymes are 
important to support proliferation and survival of transformed cells and promote tumour 
growth. The dependency of cancer cells on these metabolic activities and enzymatic 
functions leads to non-oncogene addiction and can be explored therapeutically. It is 
likely that further studies exploring other cancer types might uncover additional 
metabolic oncogenes and onco-metabolites. 
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Figure 1-8 Oncometabolites in cancer cells 
Schematic overview of oncometabolites in cancer cells. Oncometabolites accumulate due to genetic 
alterations in IDH, SDH and FH that regulate a specific reaction. Succinate and fumarate, both 
mitochondrial metabolites, inhibit PHDs, resulting in a pseudo-hypoxic state mediated by 
HIFα stabilisation. 2-HG, generated through mutated IDH, affects DNA methylation.  
  
Chapter 1 Introduction 
 50 
1.3.4 Regulation of metabolism by tumour suppressors and oncogenes  
1.3.4.1 p53 
p53 has also been identified as a key player in the regulation of cellular metabolism and 
reactive oxygen species (Vousden and Ryan, 2009). p53 promotes mitochondrial 
respiration through inducing the expression of an assembly factor of cytochrome c 
oxidase (SCO2). SCO2 is an important regulator of the mitochondrial complex IV, 
which is part of the respiratory chain and required for oxidative phosphorylation 
(Matoba et al., 2006). p53 has also been shown to dampen glycolytic flux though 
several mechanisms. The expression of GLUT1 and GLUT4 are decreased by p53 
(Schwartzenberg-Bar-Yoseph et al., 2004) and p53 downregulates the expression of the 
glycolytic enzyme phosphoglycerate mutase (PGM) (Kondoh et al., 2005). In addition, 
p53 directly increases the expression of the glycolytic regulator TIGAR (TP53-induced 
glycolysis and apoptosis regulator). TIGAR displays sequence homology to FBPases 
and reduces glycolytic activity by lowering F-2,6-BP levels (Bensaad et al., 2006). This 
results in increased entry of G-6-P into the PPP and increases the synthesis of riboses 
and NADPH for nucleotide biosynthesis. However, p53 can also act as a negative 
regulator of the PPP by direct inhibition of G6PD, leading to a decrease in the 
generation of NADPH (Jiang et al., 2011). This can affect overall cellular ROS levels 
due to the antioxidant role of NADPH. ROS levels are balancing many cellular 
processes, such as apoptosis and autophagy. TIGAR also has a p53-independent 
function; being involved in the control of autophagy (Bensaad et al., 2009).  
Another direct p53 target is glutaminase 2 (GLS2). GLS2 is a mitochondrial 
glutaminase that produces glutamate from glutamine. Glutamine can then be converted 
into α-ketoglutarate for mitochondrial respiration. This enzyme promotes an antioxidant 
defence mechanism by increasing reduced glutathione (GSH) and blocking ROS 
accumulation (Hu et al., 2010). These studies underline the importance of p53 in the 
regulation of metabolic processes. Loss of p53 supports the glycolytic phenotype by 
reducing mitochondrial respiration. Moreover, loss of p53 results in increased ROS 
levels that can promote genomic instability and cellular stress. Another mechanism for 
the modulation of energy production by p53 is via the nuclear factor-kappaB (NFκB) 
pathway. p53 expression inhibits the activity of IκB kinases (IKK) that are required for 
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NFκB activation. NFκB increases the expression of GLUT3 and thereby increases 
glucose uptake and glycolysis (Kawauchi et al., 2008).   
p53 also communicates with other tumour suppressors such as AMPK and PTEN to 
coordinate the response of cell growth and proliferation during stress situations such as 
nutrient and oxygen deprivation. p53 has been demonstrated to be essential for AMPK-
mediated fatty acid catabolism (β-oxidation). In a study by Buzzai and colleagues, 
treatment of p53-deficient tumours with metformin, an indirect activator of AMPK, 
resulted in tumour regression. Loss of p53 sensitised cancer cells to metformin by 
preventing the degradation of fatty acids for energy production via autophagy (Buzzai et 
al., 2007). Intriguingly, p53 is also involved in the regulation of lipogenesis. Freed-
Pastor and colleagues showed that cancer-specific mutant forms of p53, which have lost 
their ability to bind to DNA, control the activity of the mevalonate pathway (cholesterol 
biosynthesis) in breast cancer cells. Ablation of mutant p53 led to repression of genes 
such as DHCR7, HMGCR and MVD. The altered expression of these genes resulted in 
morphological changes in the breast cancer cell lines MDA-MB-231 and MDA-MB-
468 cultured in a 3D matrix (matrigel). The cells adopted a more acinar architecture 
usually found in 3D-cultures of non-malignant MCF10A cells. This suggests a potential 
mechanism of how mutant p53 contributes to cell transformation through metabolic 
rewiring (Freed-Pastor et al., 2012). 
1.3.4.2 PI3K/AKT pathway 
One important signalling pathway in the regulation of metabolic processes is the 
PI3K/AKT pathway. This pathway is activated in cancer cells through aberrant 
activation of receptor tyrosine kinases (Moasser, 2007; Sauter et al., 1996), loss of 
PTEN or by activating mutations in PIK3CA (Zhao et al., 2005), AKT (Carpten et al., 
2007) or RAS (Pylayeva-Gupta et al., 2011). Activation of the PI3K/AKT pathway can 
drive metabolic reprogramming in cancer cells. AKT has been suggested to be the 
‘Warburg kinase’ due to its critical role in promoting glycolysis in cancer cells (Robey 
and Hay, 2009). 
AKT stimulates glycolytic flux through upregulation of multiple glycolytic enzymes. 
Activated AKT promotes glucose uptake via GLUT1 (Barthel et al., 2001) and GLUT4 
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(Kohn et al., 1998) and promotes localisation of HK2 to the mitochondrial membrane 
for the conversion of glucose to G-6-P (Robey and Hay, 2006). Glycolysis is further 
influenced by another downstream effector of AKT, forkhead box O1 (FOXO1), which 
is directly phosphorylated by AKT resulting in the suppression of enzymes involved in 
gluconeogenesis (Nakae et al., 2001). Fatty acid synthesis is stimulated by AKT via 
phosphorylation of ACLY, which catalyses the production of acetyl-CoA from citrate in 
the cytoplasm (Berwick et al., 2002) and by induction of expression of genes within the 
lipid biosynthesis pathway (Porstmann et al., 2005).  
However, the most prominent role of AKT is the regulation of cell growth by activating 
mTORC1 signalling. The inhibition of the tuberous sclerosis complex proteins 1 and 2 
(TSC1/2), negative regulators of mTORC1, via AKT-mediated phosphorylation 
activates mTORC1. This enables cells to induce the synthesis of lipids and proteins 
(Inoki et al., 2002). In addition, AKT can also directly phosphorylate Pro-rich AKT 
substrate (PRAS40), a component of mTORC1. This prevents PRAS40 from inhibiting 
mTORC1 (Kovacina et al., 2003). Moreover glycogen synthase kinase 3β (GSK3β), 
which is negatively regulated by AKT (Cross et al., 1995), can also inhibit mTORC1 
activity by phosphorylating TSC2 (Inoki et al., 2006). mTORC1 can also induce 
activation of other important players in tumorigenesis, such as HIF, SREBP (Duvel et 
al., 2010; Porstmann et al., 2008) and c-Myc. mTORC1 has been shown to play a 
dominant role during nutrient stress and oxygen withdrawal. S6 kinase (S6K), a 
downstream target of mTORC1, can elicit a negative feedback response to control for 
aberrant mTORC1 activity. S6K thereby dampens AKT activity through the insulin 
receptor substrate 1 (IRS1) (Nakae et al., 2001).  
1.3.4.3 PTEN 
The tumour suppressor PTEN, a negative regulator of PI3K/AKT signalling, regulates 
cellular homeostasis by controlling processes involved in cell growth, proliferation and 
survival. Many cancers including breast cancer, endometrial cancer, prostate cancer, 
melanoma, and glioblastoma harbour inactivating mutations in PTEN, which highlights 
the importance of this gene in cellular signalling processes (Salmena et al., 2008).  
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Overexpression of PTEN in a transgenic mouse models leads to a decrease in body size 
caused by a reduction of cell number. Mouse embryo fibroblasts (MEFs) isolated from 
PTEN overexpressing mice (referred as Super-PTEN) are resistant to oncogenic 
transformation and Super-PTEN mice show reduced tumour formation after treatment 
with a chemical carcinogen (Garcia-Cao et al., 2012). The effects of PTEN 
overexpression on metabolism included a reduction in body fat accumulation without 
affecting expression of key enzymes of the fatty acid metabolism. The contribution of 
glucose-derived carbons to fatty acids was significantly decreased, pointing to 
decreased glucose uptake. This study further showed that overexpression of PTEN leads 
to an increase in mitochondrial respiration for energy production and an increased 
number of mitochondria. This creates a metabolic state that is not favourable for tumour 
formation by negatively regulating glucose and glutamine consumption, which are 
necessary for anabolic processes (Garcia-Cao et al., 2012). However, the mechanism by 
which PTEN modulates metabolic enzymes independently of PI3K/AKT still needs to 
be investigated. 
1.3.4.4 AMPK 
AMPK is a sensor for nutrient and oxygen deprivation (Hardie, 2011). It consists of a 
hetero-trimeric protein complex formed by three subunits (α, β and γ). The γ-subunit is 
the sensor for the detection of energy stress and binds to AMP and ADP. In non-
stressed situations where nutrients and oxygen are abundant, AMP levels are low. 
During nutrient and energy stress, AMP levels are increased as two moles of ADP are 
converted into one mole of ATP and one mole of AMP to provide energy. AMP binds 
to the γ-subunit and induces a conformational change in the AMPK complex. This 
exposes the catalytic domain located on the α-subunit, which is phosphorylated on 
threonine 172 by AMPK-kinases (LKB1, STRAD and MO25). 
AMPK is a regulator of glucose and lipid metabolism. It activates glucose transporter 
and induces glycolytic flux by phosphorylating PFKFB3 (Mendoza et al., 2012). The 
lipid metabolism enzymes ACC, PLD1, HMGCR are direct downstream targets of 
AMPK and become inactivated during nutrient stress and oxygen deprivation 
(Mihaylova and Shaw, 2011). AMPK influences not only metabolic enzymes but also 
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signalling components that are important for cell growth. One of its downstream targets, 
the TSC1/2 complex, a negative regulator of mTORC1, is phosphorylated to minimise 
energy-consuming and growth-promoting processes such as protein and lipid synthesis 
(Shackelford et al., 2009). AMPK can also phosphorylate and inhibit RAPTOR, one of 
the components of mTORC1 (Gwinn et al., 2008). AMPK also influences the activity of 
several transcription factors. AMPK phosphorylates SREBP and thereby prevents its 
cleavage and nuclear localisation (Li et al., 2011). The crosstalk between p53 and 
AMPK was mentioned earlier (see 1.3.4.1). A recent study has also linked AMPK to the 
regulation of NADPH (Jeon et al., 2012). 
1.3.5 Regulation of metabolic processes by the microenvironment 
Tumour growth is not only characterised by uncontrolled proliferation but also by 
changes in the microenvironment of the cancer cells. Moreover, the tumour 
microenvironment itself can impact tumour metabolism and affect the metabolic 
activity of cancer cells. Interestingly, cancers with the same genetic aberrations exhibit 
different metabolic signatures depending on the tissues they arise in (Yuneva et al., 
2012).  
 
As a tumour increases in size, cancer cells face an increasing challenge to ensure their 
supply of nutrients and oxygen, provided by the vasculature, are obtained. This 
challenge exists because the tumour starts to outgrow the diffusion limit of these 
metabolites (100-200µm distance from blood vessel). These microenvironmental 
conditions, in combination with the genetic instability of cancer cells, can give rise to 
heterogeneous cell populations within the tumour. Some specific challenges of the 
tumour microenvironment that cancer cells have to overcome to sustain growth and cell 
proliferation are discussed below. 
1.3.5.1 Hypoxia 
 
Hypoxia is defined as a reduction in the partial pressure of oxygen and can cause cell or 
tissue damage if the oxygen deprivation is severe or prolonged. The architecture of 
normal tissues consists of ordered structures, which are usually well vascularized. When 
solid tumours arise from a particular tissue (such as breast epithelium), the rapid 
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proliferation of transformed cells disrupts the normal tissue architecture. The 
developing tumour demands increasing amounts of nutrients and oxygen in an 
environment where the ability to deliver these is decreasing. To survive in this 
unfavourable environment, hypoxic tumour cells need to undergo genetic and metabolic 
reprogramming. Recent research has shown that the degree of intra-tumour hypoxia has 
become an important predictor for the OS of cancer patients in the clinic (Horsman et 
al., 2012). Interestingly, cells that occupy hypoxic niches are known to be resistant to 
radiotherapy and chemotherapy, due to inefficient drug delivery. The cells within 
hypoxic niches can also show increased invasive and metastatic potential and develop 
genetic instability (Wilson and Hay, 2011). 
1.3.5.1.1 Hypoxia inducible factors (HIF) and its regulation 
HIF was first described as the transcriptional regulator of the erythropoietin gene (EPO) 
in renal fibroblasts. HIF activation resulted in increased EPO production when the 
oxygen concentration was low (Wang and Semenza, 1995). A large number of 
transcriptional targets of HIF have now been described. These include many genes 
involved in the regulation of angiogenesis and metabolism (Keith et al., 2012; Semenza, 
2010a). At the molecular level, HIF consists of a heterodimeric complex that contains 
an oxygen sensitive α-subunit and an oxygen-insensitive β-subunit. The latter is the aryl 
hydrocarbon receptor nuclear translocator (ARNT), which is ubiquitously expressed. 
There are three genes that encode α-subunits of HIF in mammals: HIF1α, HIF2α and 
HIF3α. Historically, most research has been focussed on HIF1α  but, more recently the 
specific targets and roles of HIF2α have become well understood. HIF1α is expressed 
in most tissues, whereas HIF2α expression is mainly restricted to the vascular 
endothelium, renal cells, liver parenchyma and lung type II pneumocytes. HIF3α is 
much less well characterised. However, HIF3α seems to act as negative regulator to 
HIF1α− and HIF2α-induced gene transcription and is found in the corneal epithelium 
of the eye, the thymus and cerebellum (Majmundar et al., 2010). 
 
HIFα subunits can sense oxygen through an oxygen-dependent degradation domain 
(ODD) that consists of a region of 200 amino acids. In oxygen-rich tissues (2-9% O2), 
HIFα is targeted for degradation by the VHL ubiquitin ligase. Binding of VHL to the 
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ODD requires the hydroxylation of two proline residues (P402 and P564) by one of 
three prolyl hydroxylases (PHD1-3). These modifications are then recognised by the 
VHL-elongin complex that acts as an E3 ubiquitin ligase and marks HIFα for 
ubiquitination. The ubiquitinated HIF α-subunit is then recognised by the 26S 
proteasome, resulting in its degradation (Jaakkola et al., 2001). Another regulatory 
modification of HIFα is the hydroxylation of the asparagine residue N803 by the factor 
inhibiting HIF (FIH). This modification influences HIFα activity rather than stability by 
interrupting its interaction with the co-activator p300/CREB (Mahon et al., 2001).   
 
Several studies have shown that HIFα is also regulated by acetylation. Park and 
colleagues have shown that a member of NAD+ dependent histone deacetylases termed 
Sirtuin 1 (SIRT1) can bind to HIFα. This leads to the deacetylation of lysine residue 
674 and the inactivation of HIFα transcriptional activity. In contrast, acetylation of 
HIFα by the acetyltransferase p300/CREB associated factor (PCAF) promotes HIF1α 
activity (Lim et al., 2010). 
 
In oxygen-deprived tissue (below 2% O2), HIF α-subunits become stabilised or 
activated due to the diminished activity of PHDs and FIH, as well as decreased levels of 
NAD+ and hetero-dimerise with ARNT. These heterodimers recognise and bind to 
specific genomic sequences, termed hypoxia response elements (HRE) (5'-[AG]CGTG-
3'), that lie within target gene promoters. This leads to changes in the transcription of 
genes that are necessary to overcome oxygen deprivation. 
The stability and activity of HIFα can also be affected by other mechanisms. ROS, 
metabolic intermediates such as succinate, fumarate and α-ketoglutarate, and genetic 
alterations of upstream regulators, including the proto-oncogenes RAS, PI3K and 
HER2/ERBB2 and the PTEN tumour suppressor, have been shown to influence the 
activity and/or stability of HIFα (Bardos and Ashcroft, 2004). 
1.3.5.1.2 Hypoxia and HIF function in tumour progression 
Numerous studies have investigated the role of hypoxia during tumour initiation and 
progression (Semenza, 2010a). Many of these studies have focussed on HIF1α. 
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However, it is now clear that only a small subset of genes are regulated by both HIF1α 
and HIF2α, suggesting that they regulate specific transcriptional programmes that 
influence the cellular phenotype in a differential manner (Keith et al., 2012). The 
distinct roles of HIF1α- and HIF2α-specific target genes in tumour progression are 
emerging as a key area of study in the hypoxia field. For example, the opposing effects 
of HIF1α and HIF2α on the activity of c-Myc have been investigated (Keith et al., 2012). 
Furthermore, there is evidence that HIF1α is more important for metabolic regulation in 
cancer cells, while HIF2α  is thought to mainly act on the regulation of angiogenic and 
metastatic processes (Qing and Simon, 2009).  
1.3.5.1.3 HIF regulates metabolic processes 
HIF directly regulates glycolysis by inducing the expression of glucose transporters 
(GLUT1 and GLUT3) thereby increasing the efficiency of glucose uptake (Chen et al., 
2001; Mimura et al., 2012). HIF1α also increases the expression of glycolytic enzymes, 
including enolase 1 and aldolase, which are essential for the conversion of glucose to 
pyruvate (Marin-Hernandez et al., 2009). Moreover, HIF1α activation leads to 
increased expression of PFKFB3, which controls the levels of F-2,6-BP. PFKFB3 acts 
as an allosteric activator of PFK1 thereby contributing to the increased glycolytic flux 
in malignant cells (Minchenko et al., 2002). 
 
HIF1α is also an important inducer of an overall shift in energy production by reducing 
mitochondrial respiration and increasing glycolysis. This is mediated by upregulation of 
pyruvate dehydrogenase kinase 1 (PDHK1, also known as PDK1), which 
phosphorylates and inhibits pyruvate dehydrogenase (PDH), the enzyme that converts 
pyruvate into acetyl-CoA (Kim et al., 2006). As a result, pyruvate is mainly converted 
to lactate by the HIF1α dependent induction of lactate dehydrogenase A (LDHA). In 
addition, HIF1α reduces mitochondrial biogenesis by inhibiting c-Myc (Zhang et al., 
2007a). 
 
HIF1α induces regulators of cellular pH control, including transporters such as 
monocarboxylate transporter 4 (MCT4) and carbonic anhydrase 9 (CAIX). These 
factors enable hypoxic tumour cells to maintain an alkaline intracellular pH and to 
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survive and proliferate under the acidic conditions imposed by oxygen deprivation 
(discussed in more detail in 1.3.5.2). The secretion of lactate leads to increased 
acidification of the extracellular environment, which can promote tumour cell invasion 
and metastasis. Conversion of pyruvate to lactate and its removal by lactate transporters 
allows the cancer cells to regenerate NAD+ and maintain glycolytic flux in hypoxia 
(Feron, 2009). 
 
The metabolic reprogramming by HIFs enables cancer cells to survive in hypoxic 
conditions. However, these cancer cells might become dependent on HIF signalling for 
survival and are potentially more sensitive towards metabolic perturbations.  
1.3.5.1.4 Clinical relevance of HIF and hypoxia 
The molecular findings of how hypoxia and HIF influence cellular and metabolic 
signalling pathways have been also visualised by studying numerous human tissue 
biopsies. Tumours exhibit heterogeneity due to highly proliferative cancer cells growing 
into surrounding healthy tissue accompanied by limited access to the vascular system 
for certain areas of the tumour. This also leads to heterogeneity in hypoxic regions. 
These hypoxic regions correlate with increased HIF1α and HIF2α levels and have been 
associated with a poor OS signature in malignancies of breast, brain, pancreas, colon 
and many others (Semenza, 2010a).  
 
HIF stabilisation and activity have also been described in context of certain genetic 
alterations, such as loss of VHL in ccRCC and mutations in the WNT/β-catenin 
signalling in colon cancer (Majmundar et al., 2010). Genes regulated by HIF are also 
involved in other aspects of cancer biology, such as proliferation (c-MYC, p53), genetic 
instability (GADD45a), apoptosis (BNIP3), evasion of the immune response, 
angiogenesis (VEGFA), invasion and metastasis (CXCR4, MMP1, LOX) as well as 
resistance to radiotherapy. Collectively, these observations show a crucial role of 
hypoxia and HIF in tumour growth and progression. This has led to the development of 
numerous drugs and compounds targeting HIF stabilisation and HIF target genes 
(Semenza, 2010a). However, in some cancers, HIF1α expression correlates with a 
lower mortality rate. This has been shown for several cancer types including non-small-
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cell lung cancer, colorectal cancer and head and neck squamous cell carcinoma. In these 
cancer types, HIF2α expression is believed to be more relevant (Keith et al., 2012; 
Yoshimura et al., 2004). Surprisingly, both HIF1α and HIF2α may therefore have 
tumour suppressor function in certain cancer types and HIF1α has been identified as a 
tumour suppressor in clear cell renal carcinoma (Keith et al., 2012).  
 
Bevacizumab, a monoclonal antibody targeting VEGFA, and Sorafenib, an inhibitor of 
VEGFA receptor tyrosine kinase, have shown some promising effects in certain cancers 
such as metastatic colorectal cancer and renal cancer. However, in other cancers such as 
breast cancer the promised benefits were disappointing (Rapisarda and Melillo, 2012). 
Only in combination with chemotherapeutics was an OS effect observed. It has been 
demonstrated that hypoxic breast tumours predominantly show poorer clinical outcome. 
Also, hypoxic tumours do no respond well to established therapeutics (as compared to 
well oxygenated ER positive tumours), so identifying novel targets within these 
tumours is a worthwhile endeavour. 
1.3.5.2 pH regulation 
 
One hallmark of the tumour microenvironment is extracellular acidosis. In contrast to 
quiescent cells with an intracellular pH (pHi) of ~7.2 and an extracellular pH (pHe) of 
~7.4, tumour cells exhibit altered pH levels (pHi≥7.4 and pHe~6.7-7.1). It is astonishing 
that these cancer cells display a reversed pH gradient compared to quiescent cells 
(Vaupel et al., 1989). This can be explained by increased secretion of protons (H+) and 
acidic metabolites (e.g. lactate) from the cancer cells. The different pH regulation 
systems display tissue specificity and might also compensate for each other.  
Some proton transporters are overexpressed in certain cancer, for example, the 
sodium/hydrogen exchanger NHE1 (SLC9A1), carbonic anhydrase 9 and 12 (CAIX, 
CAXII) and monocarboxylate transporter 1-4 (MCT1-4) (Fig 1.9) These transporters 
have been implicated in cancer progression, cancer cell invasion and metastasis 
formation. The acidic conditions influence the ECM resulting in degradation of certain 
components by matrix metalloproteinases (such as MMP9) (Wolf and Friedl, 2009). 
Cellular pH regulation also influences the activity of lyosomal proteins such as 
cathepsins (Rafn et al., 2012; Rozhin et al., 1994), and activates hyaluronidase 
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(Jacobetz et al., 2012) and the hyaluronan receptor CD44 (Montgomery et al., 2012). 
These degradation systems restructure the ECM leading to a environment that is more 
permissive for cancer cell invasion (Borsi et al., 1996).  
 
The regulation of pH is essential in order to prevent the disruption of metabolic 
processes that are regulated by pH sensitive enzymes. Any perturbations in pH 
homeostasis can affect many cellular processes (metabolism, protein synthesis, 
proliferation and apoptosis). A number of the pH regulation systems are modulated in 
response to hypoxia. For example, NHE1, which extrudes H+ ions in exchange for the 
cation Na+, is induced by hypoxia (Shimoda et al., 2006). Its abrogation caused drastic 
tumour shrinkage, thereby underlining the importance of pH regulation in tumour cells 
(Lagarde et al., 1988).  
 
Carbonic anhydrases catalyse the hydration of CO2 to HCO3- and H+. This reaction is 
reversible and depends on the substrate/product equilibrium. This family consists of 16 
members in the mammalian system, and the isoforms differ in their tissue specific 
expression and subcellular localisation. The expression of CAIX and CAXII, which are 
plasma membrane-bound transporters, is regulated by oxygen levels and it is not 
surprising that CAIX is a downstream target of HIF. In contrast, the transcriptional 
regulation of CAXII is still unclear. In-vivo ablation of these two carbonic anhydrases 
results in intracellular acidosis and reduced tumour growth (Chiche et al., 2009; Lock et 
al., 2012). Other studies have also demonstrated CAIX’s role in the pH regulation of 
cancer cells (Chiche et al., 2010b; Swietach et al., 2010). 
 
Another important pH regulating system involves four members of the 
monocarboxylate transporter family. MCT1-4 facilitate the transport of lactate, pyruvate, 
and other monocarboxylates linked with H+ exchange across membranes. Intriguingly, 
MCT1 and MCT4 are overexpressed in breast, prostate, colorectal and ovarian cancers 
(Pinheiro et al., 2010a; Pinheiro et al., 2008a; Pinheiro et al., 2008b). The effect of 
inhibiting MCT1 was tested in lung and colorectal tumour models. Ablation of MCT1 
induced tumour regression and caused an increase in mitochondrial respiration 
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(Sonveaux et al., 2008). Despite their potential role in tumorigenesis, the specific 
functions of individual MCTs in different tissues have not been fully characterised. 
 
Figure 1-9 pH regulation in non-malignant and cancer cells 
Schematic overview of pH regulation in normal and cancer cells. Normal cells exhibit a lower intracellular 
pH (pHi) than their extracellular pH (pHe) of the microenvironment. However in cancer cells the pH gradient 
is reversed with a higher pHi. This is caused by overexpression of different pH regulation systems (e.g. 
NHE1, MCT and CA).  
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1.4 Targeting altered cellular metabolism in cancer 
In recent years it has become clear that the altered metabolism in transformed cells 
could be used to develop new therapeutic approaches to increase the OS of cancer 
patients. The increased biosynthetic activity of rapidly proliferating cancer cells 
provides an ‘Achilles heel’, as cells depend on the biosynthesis of macromolecules, 
such as nucleotides, amino acids and fatty acids. However, the subtle difference 
between the metabolism of proliferating normal cells and cancer cells presents the 
significant challenge of developing such therapeutics that only target cancer cells. 
Different therapeutic options for the targeting of cancer metabolism have been 
discussed (Dang et al., 2011; Jones and Schulze, 2012; Tennant et al., 2010; Vander 
Heiden, 2010, 2011). 
Targeting glucose metabolism 
Many tumours show a high level of glucose uptake, which can be visualised by 
fluorodeoxyglucose positron emission tomography (FDG-PET). An inhibitor of glucose 
metabolism called 2-deoxy-d-glucose (2-DG) was developed in the 1950s (Ely, 1954). 
This component repressed the activity of HK2 and initially showed promising effects 
in-vitro and in-vivo studies. Cells exposed to sufficient amounts of 2-DG showed 
impaired cell growth by undergoing cell cycle arrest or cell death. Despite these 
promising results, treatment with glycolytic inhibitors (e.g. Lonidamine, 2-DG) alone 
was not efficient enough for therapeutic benefit (Maschek et al., 2004; Papaldo et al., 
2003). Clinical trials are currently evaluating the impact of 2-DG on prolonged survival 
in breast, ovarian and lung cancer in combination with different chemotherapeutic 
drugs. Another inhibitor of HK2, 3-bromopyruvate has also been shown to cause a 
reduction in cell viability in multiple studies (Pedersen, 2012) but has only been used in 
pre-clinical studies to date. 
Targeting nucleotide metabolism 
Cytotoxic agents such as 5-fluroucil and gemcitabine belong to the class of 
antimetabolite chemotherapeutics targeting nucleotide biosynthesis (Ewald et al., 2008). 
They are used across many different cancer types and cause improved survival. 
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However, these agents do not display tumour specificity and target all highly 
proliferative cells. This explains the frequently observed side effects of nausea and hair 
loss, which are due to their effects in proliferating normal cells. However, these agents 
may be highly useful as a proof-of-principle for targeting nucleotide biosynthesis 
(Tennant et al., 2010).  
Targeting lactate metabolism 
Increased lactate secretion is another typical characteristic of cancer cell metabolism 
and drug development efforts have focussed on targeting lactate transporters (MCTs). 
Blocking lactate transport should cause intracellular acidosis due to lactate and proton 
accumulation. Inhibition of lactate transport could also prevent metabolic coupling of 
cancer cells, a mechanism by which cells within hypoxic tumour areas secrete lactate, 
which is then used for energy production by better oxygenated cancer cells. This 
metabolic coupling of glycolytic and oxidative cells has been shown in-vitro and in-vivo 
(Sonveaux et al., 2008). Another approach is to target LDH, the enzyme that converts 
pyruvate into lactate. In-vitro studies demonstrated a reduction in cell viability after 
ablation of LDHA (Fantin et al., 2006). This isoform is specifically upregulated in 
cancer cells compared to normal proliferating cells and compounds targeting LDHA 
could be taken forward to clinical trials. 
Targeting mutated enzymes 
Some cancers harbour specific GOF or LOF mutations in metabolic enzymes (IDH1, 
IDH2, FH and SDH discussed above). These mutations lead to specific alterations in 
cancer metabolism and cancer cells can become highly dependent on these alterations. 
2-HG is a metabolite that is generated by mutant forms of IDH1 and IDH2 and has been 
shown to promote tumorigenesis (Dang et al., 2010). Detection of 2-HG can also be 
used for diagnostic purposes. The metabolic dependencies of cancers harbouring 
specific mutations could be used to develop inhibitors that should be highly selective 
for cancer cells and not affect normal proliferating cells. 
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Targeting mitochondrial metabolism 
Metformin is an approved drug for the treatment of diabetes and has been considered 
for use in cancer. It is an inhibitor of complex I of the respiratory chain, and reduces 
circulating glucose levels in the blood by activating AMPK. (Gallagher and LeRoith, 
2011). Trials in diabetic breast cancer patients that were treated either with neoadjuvant 
chemotherapy alone or received a combination of metformin and neoadjuvant 
chemotherapy, demonstrated that patients on combination therapies showed increased 
pathological complete response compared to the diabetic breast cancer patients with 
only neoadjuvant treatment (Guppy et al., 2011; Jiralerspong et al., 2009) 
A small molecule inhibitor termed Dichloroacetate (DCA) has been used for treatment 
of lactic acidosis in patients with inborn defects of mitochondrial metabolism 
(Stacpoole et al., 2003). DCA inhibits PDHK, which is overexpressed in many cancer 
cells because of its induction by HIF. PDHK supports the glycolytic phenotype by 
inhibiting PDH, which catalyses the oxidative decarboxylation of pyruvate to 
mitochondrial acetyl-CoA. Treatment of cancer cells with DCA causes a shift from a 
glycolytic phenotype to mitochondrial respiration, resulting in increased oxidative stress 
and cell death (Michelakis et al., 2008). This study sets the president that differences in 
metabolism between tumour cells and normal proliferating cells can be therapeutically 
targeted.  
Targeting lipogenesis 
The observation that cancer cells depend on de-novo lipogenesis suggests that enzymes 
of the fatty acid synthesis pathway might be suitable therapeutic targets. Endogenous 
fatty acid synthesis is driven by cytosolic citrate that is secreted from the mitochondria. 
The conversion of citrate to acetyl-CoA is mediated by ACLY. Pre-clinical data 
suggests that ablation of ACLY results in decreased survival of cancer cells 
(Hatzivassiliou et al., 2005). Another lipogenic enzyme, FASN, is overexpressed in 
many cancers (Kuhajda, 2000) and treatment with FASN inhibitors (orlistat, cerulenin 
and C75) reduced cancer cell survival. However, FASN inhibitors have shown dramatic 
effects on whole body metabolism causing substantial weight loss in mice (Loftus et al., 
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2000). It is therefore unclear whether inhibition of lipogenesis will be suitable as anti-
cancer therapy.  
Targeting the tumour microenvironment  
The altered metabolic flux in cancer cells also leads to intra- and intercellular changes. 
The growing tumour mass depends on the diffusion of oxygen and nutrients for cell 
survival. One of the most studied antibodies to inhibit VEGFA-mediated angiogenesis 
is currently part of different clinical trials. Previous studies with bevacizumab alone 
have shown no OS benefits for breast cancer patients (Kerbel, 2009). However in other 
types of cancer, bevacizumab shows promising results. Current studies are investigating 
bevacizumab in combination with other chemotherapeutics to observe increased 
recurrence free and overall survival benefits. 
To investigate the contribution of altered pH regulation in cancer cells to tumour 
development, Robey and colleagues explored the effect of systemic treatment with 
bicarbonate. Treatment with administered orally bicarbonate has counteracted acidosis 
in a mouse model and reduced metastasis formation of orthotopically injected MDA-
MB-231 cells. However, the primary tumour showed no response to bicarbonate 
treatment (Robey et al., 2009). Recent studies have also investigated the inhibition of 
regulators of intracellular pH. Cariporide, an inhibitor of NHE1, has been shown to 
decrease viability in HeLa cells (Lin et al., 2011) as well as in combination with another 
inhibitor in glioma cell lines (Harley et al., 2010). These studies are all restricted to pre-
clinical work in-vitro, but phase II/III clinical trials for carbonic anhydrases inhibitors 
are underway (Tennant et al., 2010).  
In summary these different approaches provide evidence that targeting cancer 
metabolism is a promising therapeutic strategy. However, current clinical trials might 
not yield significant increase in overall survival due to non-specific patient selection. It 
has been recently acknowledged that pre-selection of patients in clinical trials should be 
based on the tumour genotype. Moreover, targeting cancer metabolism might be more 
effective when used in combination with other drugs. Identifying cohorts of patients 
that are likely to benefit from these treatments is of great importance. Suitable screens 
or genetic tests (e.g. detection of IDH mutations or FASN overexpression) have to be 
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employed to identify patients that are more likely to show a response in targeted clinical 
trials.  
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1.5 Aim of thesis 
The aim of this thesis was to investigate the importance of metabolic enzymes, 
metabolite transporters and metabolic regulators for the survival of genetically diverse 
breast cancer cell lines. Not only is it important to identify the metabolic dependencies 
of each breast epithelial cell line but it is also important to identify their potential 
‘Achilles heel’. The following chapters will outline efforts to address the following 
aims of this thesis. These aims were: 
 
• To characterise the metabolic phenotype of different breast cancer subtypes in a 
panel of genetically diverse breast epithelial cell lines. 
 
• To identify metabolic enzymes, metabolite transporters and metabolic regulators 
that are selectively important for the survival of specific subsets of breast cancer cell 
lines by using a functional genetics approach. 
 
• To analyse the mechanism by which these enzymes support the growth and survival 
of specific subtypes of breast cancer cell lines in-vitro and in-vivo. 
 
• To explore mechanisms of deregulation of these enzymes in different subtypes of 
breast cancer. 
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2 Materials & Methods 
2.1 Reagents and chemicals 
2.1.1 Enzymes 
Enzymes were used according to the manufacturer’s instructions. 
- Reverse transcriptase “Superscript II” (Invitrogen; Carlsbad, CA, USA). 
- Restriction enzymes (New England Biolabs Inc, Ipswich, MA, USA) 
- PfuUltra high-fidelity DNA polymerase (Agilent, Wokingham, UK) 
 
2.1.2 Buffers and solutions 
The use of commercially available as well as common solutions and buffers are 
mentioned below. Buffers and solutions for specific experiments are mentioned in the 
relevant sections. Solutions and buffers were prepared with ddH2O and HCl or NaOH 
was used to adjust the pH.  
 
2.1.3 Molecular weight marker 
- 100 bp DNA ladder (New England Biolabs Inc) 
- 1Kbp DNA ladder (New England Biolabs Inc) 
- Full-range Rainbow molecular marker (RPN800E) (GE Healthcare, Chalfont, 
UK) 
 
2.1.4 Bacterial strains 
Escherichia coli (E.coli) strain DH5α (ThermoFisher Scientific, Loughborough, 
UK) 
The E.coli strain DH5α strain is commonly used for cloning and propagating plasmid 
DNA. Genotype: F-, φ80dlacZΔM15, Δ(lacZYA-argF)U169, deoR, recA1, endA1, 
hsdR17(rk-, mk+), phoA, supE44, λ-, thi-1, gyrA96, relA1.  
 
Ultracompetent XL-10 Gold (Agilent) 
This strain is commonly used for cloning and propagating large plasmid DNA 
Genotype: TetrD(mcrA)183, D(mcrCB-hsdSMR-mrr)173, endA1, supE44, thi-1, 
recA1, gyrA96, relA1, lac Hte [F´ proAB lacIqZDM15 Tn10 (Tetr) Amy Camr]. 
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2.1.5 Plasmids 
pCl-neo human monocarboxylate transporter 4 (hSLC16A3)  
The pCl-neo hSLC16A3 construct was kindly provided by Prof. Andrew Halestrap 
(University of Bristol). The genomic DNA sequence of SLC16A3 was subcloned into 
the pCl-neo vector via the EcoRI restriction site. The vector contains two selectable 
markers, a puromycin resistance gene for selection of transduced mammalian cells and 
an ampicillin resistance gene for selection of transformed E. coli. The construct was 
digested with EcoRI to separate the hSLC16A3 insert from the pCl-neo backbone.  
 
pWZL-neo-ecotropic retroviral receptor (EcoR) 
The pWZL-neo-EcoR construct was kindly provided by the Signal Transduction 
Laboratory, Cancer Research UK (CR UK). The construct is a retroviral expression 
vector coding for an ecotropic retroviral receptor. It contains two selectable markers, a 
neomycin resistance gene for selection of transduced mammalian cells and an 
ampicillin resistance gene for selection of transformed E. coli 
 
pBABE puro3 
The pBABE puro3 vector was kindly provided by Prof. Hartmut Land (Morgenstern 
and Land, 1990). This vector is a retroviral expression vector and it contains two 
selectable markers, a puromycin resistance gene for selection of transduced mammalian 
cells and an ampicillin resistance gene for selection of transformed E. coli. 
 
pBABE puro3 hSLC16A3 
The pBABE puro3 hSLC16A3 construct was generated by cloning the hSLC16A3 
sequence of the pCl-neo hSLC16A3 into a pBABE puro3 vector for rescue experiments. 
 
Tet-pLKO-puro 
The Tet-pLKO-puro construct was purchased from Addgene (Cambridge, MA, USA). 
This is a lentiviral expression vector containing two selectable markers: puromycin and 
ampicillin (Wiederschain et al., 2009). This construct also allows inducible expression 
of a gene of interest by the Tet repressor protein (TetR) cassette. In the absence of a 
tetracycline (e.g. doxycycline), the TetR is repressed, whereas in the presence of a 
tetracycline TetR and the gene of interest are expressed. 
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2.1.6 Cell lines 
293T: 
The 293T cell line is a derivative of the human embryonic kidney (HEK) 293 cells. 
293T cells constitutively express the SV40 large T-antigen and are commonly used for 
generation of retroviral and lentiviral particles following transfection of the cells with 
retroviral and lentiviral plasmid constructs (Pear et al., 1993). 
 
Phoenix cell line (amphotropic and ecotropic): 
These cell lines are a derivative of the 293T cells and contain packaging genes gag-pol 
and envelope gene VSV-G. Phoenix ampho cells were used as amphotropically for 
gene delivery of the EcoR to all dividing cells. Phoenix Eco cells were used for gene 
delivery of pBABE puro3 SLC16A3 constructs to all dividing cells containing an Eco 
receptor to allow virus production.  
 
Breast cell line panel 
The breast cell lines were obtained from American Type Culture Collection (ATCC) and 
CR UK Cell Services. 
Table 2-1 Breast epithelial cell lines used in this study. 
Cell line Source 
184B5 ATCC 
AU-565 ATCC 
BT-20  CR UK cell services   
BT-549 CR UK cell services  
HCC38 ATCC 
HCC1806 ATCC 
HCC1954 ATCC 
HS-578T ATCC 
MCF7 CR UK cell services   
MCF10A ATCC 
MCF12A ATCC 
MDA-MB-231 CR UK cell services   
MDA-MB-436 ATCC 
MDA-MB-468 CR UK cell services   
SK-BR-3 CR UK cell services  
T-47D CR UK cell services   
ZR-75-1 ATCC 
 
2.1.7 Xenograft experiment  
Immunodeficient 8-week old female mice (nu/nu) were injected orthotopically into the 
mammary fat pad with 1.5x106 MDA-MB-468 cells that were stably transduced with 
TET-pLKO-SLC16A3 #88. After initial tumour formation (day 10), mice were divided 
into two cohorts, a cohort on a standard diet and the other cohort on a doxycycline diet. 
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The doxycycline containing food (0.2g/kg food pellets, TD.98186, Harlan Laboratories, 
Indianapolis, Indiana, USA) induced depletion of SLC16A3 and mice were monitored. 
Tumour measurements was carried out two times a week and tumour volume was 
determined by use of the ellipsoidal volume formula: ½ x length x (width)2. All animal 
experiments were carried out according to the UK Home Office guidelines. 
 
2.1.8 Antibiotics, inhibitors and other chemicals used in this study 
All inhibitors were were solubilised in dimethyl sulfoxide (DMSO), double distilled 
water (ddH2O) or ethanol (EtOH) and stored at 4ºC or -20ºC. 
Table 2-2 Dilutions of antibiotics used: 
Reagent Supplier Solvent Stock solution Final concentration Type 
 
Ampicillin 
Sigma-Aldrich 
 (St. Louis, MO, USA)  
 
ddH2O 
 
1M 
 
100µg/ml 
Cell membrane 
synthesis inhibitor  
 
Doxycycline 
BD Biosciences  
(San Jose, CA, USA) 
 
EtOH 
 
1mg/ml  
 
1µg/ml 
Protein synthesis 
inhibitor  
Geneticin 
(G418) 
 
Invitrogen  
 
ddH2O 
  
100mg/ml 
  
100µg/ml 
Protein synthesis 
inhibitor  
 
Oligomycin Sigma-Aldrich DMSO 5mg/ml 0.05µg/ ml 
Mitochondrial ATP 
synthase inhibitor  
 
Puromycin  
  
Sigma-Aldrich 
 
ddH2O 
 
1mM  
 
2µg/ ml 
Protein synthesis 
inhibitor  
 
Table 2-3 Dilutions of inhibitors and activators used: 
Reagent Supplier Solvent Stock solution Final concentration Type 
2-deoxy-D 
-glucose (2-DG) Sigma-Aldrich ddH2O 2mM  2M 
Inhibitor of 
glycolysis 
 
AZD3965 
AstraZeneca 
(London, UK) 
 
DMSO 
  
10mM 
  
0.1µM-10µM 
Monocarboxylate 
transporter 1inihibitor 
Complete, Mini 
(EDTA free) 
Roche (Basel, 
Switzerland) 
 
DMSO 
 
1mM  
 
1µM 
Protease inhibitor 
cocktail  
Dichloroacetate 
(DCA) 
 
Sigma-Aldrich 
 
DMSO 
 
0.4M 
 
0.4mM 
Inhibitor of pyruvate 
dehydrogenase kinase 
 
Etoposide 
 
Sigma-Aldrich 
 
ddH2O 
 
10mM  
 
2µM 
Topoisomerase II 
inhibitor 
Lapatinib 
Provided by Dr. 
Eric Sahai DMSO 200µM 1µM 
Dual inhibitor of EGFR 
and HER2 
 
PhosSTOP 
 
Roche 
  
- 
 
20 tablets 
 
1 tablet per 10ml 
Phosphatase 
inhibitor  
RNaseOUT Invitrogen  -  200 units  1 unit 
Recombinant 
Ribonuclease inhibitor 
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Table 2-4 Chemicals used: 
Reagent Supplier Solvent Stock solution Final concentration Type 
Albumin from 
Bovine serum 
(BSA) Sigma-Aldrich ddH2O 30% 3% 
Blocking 
reagent 
Ammonium 
carbonate Sigma-Aldrich ddH2O 75mM 75mM 
Washing 
buffer 
Caspase-3 substrate 
IX 
Merck Millipore 
(Darmstadt, Germany) DMSO 1mg/ml 1µg/ml 
Fluorogenic 
salt 
CellTiter Blue 
Promega (Fitchburg, 
WI, USA) ddH2O 100% 10% 
Fluorescent 
dye 
 
Cholera toxin (CT) Sigma-Aldrich  ddH2O 1mg/ml 100ng/ml Growth factor 
 
Crystal Violet  Sigma-Aldrich ddH2O 100% 0.10% Dye 
Deoxynucleotide 
(dNTP) mix Invitrogen ddH2O 100mM 25mM dNTP 
 
EGF, murine Merck Millipore ddH2O 50µg/ml 20ng/ml Growth factor 
 
FCCP Sigma-Aldrich DMSO 20mM 2µM 
Uncoupling 
agent 
 
Formaldehyde Sigma-Aldrich ddH2O 37% 3.70% 
Fixation 
reagent 
 
Formic acid  Sigma-Aldrich ddH2O 98% n.a. Buffer 
 
Goat serum Sigma-Aldrich TBST  100%  3% Blocking agent 
Hydrocortisone 
(HC) Sigma-Aldrich EtOH 10mg/ml 5µg/ml Growth factor 
Dithiothreitol (DTT) 
 
Invitrogen ddH2O 1M 1mM Redox agent 
 
Insulin, bovine Sigma-Aldrich ddH2O  10mg/ml 10µg/ml Growth factor 
N-Acetyl-L-cysteine 
(NAC) Sigma-Aldrich ddH2O 100mM 5-20µM Anti-oxidant 
Orange G sodium 
salt Sigma-Aldrich Sucrose 30% 0.18% 
tracking dye 
for nucleic 
acids 
 
Protein assay 
Bio-Rad  
(Hercules, CA, USA) ddH2O 100% 20% Protein dye 
 
Sodium L-Lactate 
 
Sigma-Aldrich ddH2O 10M 10mM Metabolite 
4-hydroxy-2,2,6,6-
tetramethylpiperidin
e-N-oxyl(Tempol) 
 
 
Sigma-Aldrich ddH2O 10mM 1-2µM Antioxidant 
 
Tween 20 ThermoFisher Scientific ddH2O 100% 0.1% Detergent  
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2.1.9 Media 
Medium for culturing E. coli DH5α (ThermoFisher Scientific) and XL-10 Gold 
(Agilent): 
The medium preparation and sterilisation process was performed by CR UK Cell 
Services. 
 
Medium for in vitro culture of breast cancer cell lines: 
Table 2-5 Media composition for breast cancer cell lines. 
Media Components Amount 
D-MEM/F-12 (1:1) (Invitrogen) 500ml 
Penicillin/Streptomycin (Gibco, Carlsbad, CA, USA) 1% 
L-Glutamine stock solution (Invitrogen) 100units/ml 
FBS (Gibco) 10% 
 
Medium for in vitro culture of non-malignant breast cell lines: 
Table 2-6 Media composition for non-malignant breast cell lines. 
Media Components Amount 
D-MEM/F-12 (1:1) (Invitrogen) 500ml 
Penicillin/Streptomycin (Gibco) 1% 
L-Glutamine stock solution (Invitrogen) 100units/ml 
Horse Serum (Gibco) 5% 
Insulin (Sigma-Aldrich) 10µg/ml  
Cholera toxin (Sigma-Aldrich) 100ng/ml   
Epidermal growth factor (Merck Millipore) 20ng/ml   
Hydrocortisone (Sigma) 5µg/ml   
 
2.1.10 Antibodies 
Antibodies for immunoblotting were stored and used according to manufacturer’s 
instructions. Briefly, primary antibodies were diluted 1:1000 in 3% BSA/Tris buffered 
saline Tween 20 (TBST) blocking solution, except beta-actin-horse radish peroxidase 
(HRP) (1:10000) and HIF2α (1:500) in 5% milk/TBST. Phospho-specific primary 
antibodies were diluted in 3% BSA/TBST due to interference by milk as blocking 
solution. Secondary antibodies were diluted 1:2000 in 5% milk/TBST.  
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Table 2-7 Primary antibodies used in this study 
Primary Antibody Host Clonality Clone Manufacturer Catalog number 
Acetyl CoA Carboxylase 
(ACC) Rabbit Polyclonal   
Cell Signaling (Boston, 
MA, USA) 3662 
 
AKT Rabbit Polyclonal   Cell Signaling 9272 
 
Aldolase A Mouse Monoclonal 3D9-6F3 
Novus Biologicals 
(Littleton, CO, USA) H00000226-M01 
 
AMPKα  Rabbit Polyclonal   Cell Signaling 2532 
Anti-β-Actin 
 HRP Mouse Monoclonal AC-15 Sigma-Aldrich A3854 
ATP- Citrate  
Lyase (ACLY) Rabbit Polyclonal   Cell Signaling  4332 
 
CD147 (Q370) Rabbit Polyclonal   Novus Biologicals NBP1-19677 
Cleaved Caspase-3 
(Asp175) Rabbit Polyclonal   Cell Signaling 9661 
 
HIF1α Mouse Monoclonal 54/HIF1α BD Biosciences 610959 
 
HIF2α Rabbit Polyclonal   Novus Biologicals NB100-122 
 
MCT1 Rabbit Polyclonal   Merck Millipore AB3538P 
 
MCT4 Rabbit Polyclonal   
Santa Cruz (Santa Cruz, 
CA, USA) sc-50329 
 
Malic enzyme 1 Mouse Monoclonal 3H5 Novus Biologicals H00004199-M03 
 
Malic enzyme 2 Rabbit Polyclonal   Novus Biologicals NBP1-82434 
 
PARP Rabbit Polyclonal   Cell Signaling 9542 
Phospho-
AMPKα (Thr172) Rabbit Polyclonal   Cell Signaling 2531 
Phospho- 
ACC (Ser79) Rabbit Polyclonal   Cell Signaling 3661 
Phospho-  
ACLY(Ser454) Rabbit Polyclonal   Cell Signaling 4331 
Phospho- 
AKT (Ser473) Rabbit Polyclonal   Cell Signaling 9271 
Phospho- 
AKT (Thr308) Rabbit Polyclonal   Cell Signaling 9275 
Phospho- 
EGFR(Tyr992) Rabbit Polyclonal   Cell Signaling 2235 
 
EGFR Rabbit Polyclonal   Cell Signaling 2232 
Phospho- p44/42 MAPK 
(Thr202/Tyr204) Mouse Monoclonal E10 Cell Signaling 9106 
 
p44/42 MAPK Rabbit Polyclonal   Cell Signaling 9102 
 
Fatty Acid Synthase Mouse Monoclonal 23 BD Biosciences 610963 
 
p53  Mouse Monoclonal DO-7 
Dako 
(Cambridgeshire,UK) 610984 
 
p21 (C-19) Rabbit Polyclonal   Santa Cruz sc-397 
 
PTEN Rabbit Polyclonal   Cell Signaling 9552 
 
HER2/ErbB2 Rabbit Polyclonal   Cell Signaling 2242 
 
TKTL1 Mouse Monoclonal JFC12T10 
R-Biopharm 
(Darmstadt, Germany) T-001 
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Table 2-8 Secondary antitbodies used in this study. 
Secondary Antibody Host Clonality Clone Manufacturer Catalog number 
 
ECL Anti-rabbit IgG HRP Donkey Polyclonal    GE Healthcare NA934V  
 
ECL Anti-mouse IgG HRP Sheep Polyclonal    GE Healthcare NA931V  
 
2.1.11 Transfection reagents 
Different transfection reagents were purchased to test and optimise the transfection 
efficiency for each of the breast cell lines used. The test amount was 0.1µl and 0.3µl of 
each reagent  
Table 2-9 Transfection reagents used in this study 
Transfection Reagent Manufacturer 
CodeBreaker™ Promega 
DharmaFect 1 ThermoFisher Scientific  
DharmaFect 2 ThermoFisher Scientific  
DharmaFect 3 ThermoFisher Scientific  
DharmaFect 4 ThermoFisher Scientific  
DreamFect Gold Oz Biosciences (Marseille, France) 
FuGENE® Promega 
GeneEraser™ Agilent 
GeneSilencer® Genlantis (San Diego, CA, USA) 
HiPerFect® Qiagen (Germantwon, MD, USA) 
INTERFERin® Polyplus (Illkirch, France) 
Lipofectamine Invitrogen 
Lipofectamine™ 2000 Invitrogen 
Lipofectamine™ RNAiMAX Invitrogen 
Lullaby® Oz Biosciences 
METAFECTENE® Cambio (Cambridge, UK) 
N-TER™ Nanoparticle Sigma-Aldrich 
Oligofectamine™ Invitrogen 
RiboJuice™ Merck Millipore 
siIMPORTER™ Merck Millipore 
siPORT™ Amine Ambion 
siPORT™ NeoFX™ Ambion 
TransIT-siQUEST® Mirusbio (Madison, Wi, USA) 
TransIT-TKO® Mirusbio 
TransPass R1 New England Biolabs, Inc. 
Plus Reagent Invitrogen 
 
2.1.12 RNA interference (RNAi) oligonucleotides 
The small interference RNA (siRNA) oligonucleotides used for the small screen siRNA 
library and siRNA upgrades for deconvolution studies and follow up studies were 
purchased from ThermoFisher Scientific (siGenome series). Further information can be 
found in Appendix table 2. 
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2.1.13 Primers 
Primers were ordered as desalted oligonucleotides and used for DNA sequencing and 
PCR amplification. Primer information is mentioned in the relevant method section. 
Table 2-10 Sequencing and mutagenesis primers used in this study. 
Gene  Nucleotides Sequence 5’-3’ Orientation Purpose 
SLC16A3_oligo 
3F 40 
GCTGCTGGGCAAACTTCTTTTGGATTAGGAA
GAAGCCCAAA forward 
site directed 
mutagenesis 
SLC16A3_oligo 
3R 40 
TTTGGGCTTCTTCCTAATCCAAAAGAAGTTG
CCCAGCAGC reverse 
site directed 
mutagenesis 
SLC16A3_oligo 
4F 34 
CTCCTGGATGCGACGCACGTGTACATGTACG
TGTT forward 
site directed 
mutagenesis 
SLC16A3_oligo 
4R 34 
AACACGTACATGTACACGTGCGTCGCATCCA
GGAG reverse 
site directed 
mutagenesis 
SLC16A3_oligo 
5F 35 
GCGTCGCTGGGCATGGTAGCAGCATCCTTTT
GCCG forward 
site directed 
mutagenesis 
SLC16A3_oligo 
5R 35 
CGGCAAAAGGATGCTGCTACCATGCCCAGCG
ACGC reverse 
site directed 
mutagenesis 
SLC16A3_oligo 
6F 35 
CGAGGTTGCTCACCTCGTCGCTGATTTTGCTG
CTG forward 
site directed 
mutagenesis 
SLC16A3_oligo 
6R 35 
CAGCAGCAAAATCAGCGACGAGGTGAGCAC
CTCG reverse 
site directed 
mutagenesis 
SLC16A3_221-
239F 20 ACAGGTCCGCTCTGCAGTGT forward sequencing 
SLC16A3_396-
415R  20 GGTTCAGCATGATGAGCGAG reverse sequencing 
SLC16A3_1061-
1080F  20 GTGCCATTGGCCTGGTGCTG forward sequencing 
SLC16A3 1290-
1309R  20 CCGAGTCTGCAGGAGGCTTG reverse sequencing 
pBABE_ 
F 27 CCTCTTTCGACCCCGCCTCAATCCTCC forward sequencing 
pBABE_ 
R 30 CCTGTGGAATGTGTGTCAGTTAGGGTGTGG reverse sequencing 
 
2.2 Experimental procedures 
2.2.1 Mammalian cell culture manipulations 
2.2.1.1 Cell culture  
184B5, AU-565, HCC38, HCC1806, HCC1954, HS-578T, MCF10A, MCF12A, MDA-
MB-436 and ZR-75-1 were kindly provided from Dr. Britta Weigelt (CR UK, LRI), 
who obtained them from ATCC. BT-20, BT-549, MDA-MB-231, MDA-MB-468, 
MCF7, SK-BR-3 and T-47D were obtained from the CR UK Cell Services facility. The 
293T cell line was obtained from the Signal Transduction Lab (CR UK, LRI). Phoenix 
cells were obtained from ATCC. All cell lines were grown in a monolayer and 
maintained in D-MEM/F-12 (1:1) (breast cell line panel) or DMEM (293T and Phoenix 
cells) media supplemented with 2mM L-glutamine and 100units/ml penicillin/ 
100µg/ml streptomycin. The breast cancer cell lines, 293T and Phoenix cells were 
cultured in 10% foetal bovine serum (FBS). The three non-malignant cell lines 
MCF10A, MCF12A and 184B5 were maintained in 5% horse serum (HS), EGF, insulin, 
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hydrocortisone and cholera toxin. Cells were kept in a 5% CO2 atmosphere at 37ºC and 
passaged approximately every 2-3 days when confluent according to ATCC’s 
instructions. Briefly, the supernatant was aspirated, cell were rinsed once with PBS and 
then incubated with a 1:3 mix of trypsin/ versene at 37ºC until the cells detached. Next, 
the cells were resuspended in their designated media to neutralise trypsin. The non-
malignant cells were centrifuged at 650 x g for 5 minutes (min) to remove remaining 
trypsin, the supernatant was aspirated and cells were resuspended in fresh media. For 
experimental purposes, the cells were counted and then seeded. 
Table 2-11 Culturing overview of cell lines used in this study. 
Cell line Split ratio Comments 
184B5  1/3 spin after trypsin 
AU-565  1/3   
BT-20   1/2-1/3   
BT-549  1/4-1/5   
HCC38  1/3   
HCC1806  1/6   
HCC1954  1/3-1/4   
HS-578T  1/3-1/4   
MCF7  1/5   
MCF10A  1/9 spin after trypsin 
MCF12A  1/9 spin after trypsin 
MDA-MB-231  1/5   
MDA-MB-436  1/2 no trypsin 
MDA-MB-468  1/4   
SK-BR-3  1/2 
 T-47D  1/4 
 ZR-75-1  1/3 
 
2.2.1.2 Culture of cell lines under hypoxic conditions 
For cell culture of breast cell lines under hypoxic conditions, cells were placed into a 
hypoxia chamber (Ruskinn Invivo2 500, Bridgend, UK). All breast cell lines were 
cultured under ≤0.5% oxygen conditions. For siRNA transfection experiments cells 
were transferred directly after seeding to the hypoxic chamber for 96 hours (h), whereas 
for protein and RNA extraction experiments cells were seeded 24 h prior to hypoxic 
exposure of 24 h. 
2.2.1.3 Cryopreservation cells of cell lines 
Exponentially growing cells were collected and pelleted as described above. Cells were 
then resuspended in freezing media (40% culture media, 50% FCS and 10% DMSO) 
and 1.5ml aliquots were gradually frozen in cryo vials (Nunc, ThermoFisher Scientific) 
and stored in a freezing container (Nalgene, ThermoFisher Scientific) at -80ºC for at 
least 24 h before being transferred to a liquid nitrogen tank for long term storage. 
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2.2.1.4 Recovery of cryopreserved cell lines 
Frozen vials of cells were quickly thawed in a 37°C water bath. The thawed cell 
suspension of 1.5ml was added to 3ml pre-warmed culture medium in a 15ml falcon 
tube. The cells were then centrifuged for 5 min at 650 x g. The cell pellet was 
resuspended in 6ml fresh media and transferred to 25cm3 culture dish for standard cell 
culture. Cells were incubated overnight before fresh media was added. Experiments 
with freshly thawed cells were set up after at least two passages. 
2.2.1.5 Determination of cell number with Countess automated cell counter 
The cells were counted using the Cell Countess (Invitrogen). Briefly, 10µl of a single 
cell suspension was mixed with 10µl trypan blue stain (0.4%). Next, 10 µl of the 
cell/trypan blue mix was pipetted into a disposable Countess chamber slide. Then, the 
Countess chamber slide was inserted into the instrument and the counting program was 
started. The principle of the Countess is similar to that of a hemacytometer, but it gives 
additional information such as average cell size of live, dead and total cells as well as 
the proportion of single cells versus multiple cells. 
2.2.1.6 Reverse siRNA transfection of breast cell lines using Lullaby reagent 
siRNA oligonucleotides of genes to be targeted were obtained from ThermoFisher 
Scientific. The lyophilized siRNA siGenome upgrades (2nmoles) were dissolved in 
100µl 1x siRNA-buffer (Ambion). The silencing experiments were performed using a 
reverse transfection protocol with 37.5nM siRNA per well of a 96-well plate. Briefly, 
for a 96-well format 3,75µl of siRNA (1µM) were mixed with 6,25µl OptiMEM 
(Invitrogen) and incubated for 5 min. Meanwhile, 0,1µl of Lullaby transfection reagent 
(TF) from Oz Biosciences was mixed with 9,9µl of OptiMEM and then added to the 
siRNA/OptiMEM and incubated for 20 min. In parallel, cells were trypsinised and 
counted and then the optimised concentration of cells (see 2.2.17) was resuspended in a 
total of 80µl media. The 20µl transfection mixes were transferred to each well of a 96-
well plate and the cell suspension was added on top to yield a final volume of 100µl. 
The plates were either incubated at a 20% or 0.5% oxygen atmosphere at 37ºC. The 
media was topped up to 200µl 24 h post transfection. Cells were analysed 96 h post 
transfection. 
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2.2.1.7 siRNA screening in breast cell panel 
For each cell line, a transfection protocol was established during the optimization 
process. 
Table 2-12 Overview of cell plating densities for transfections. 
Cell line Cells plated per well TF reagent  
184B5 5000 per 80µl 0.1µl 
AU-565 7500 per 80µl 0.1µl 
BT-20 6000 per 80µl 0.1µl 
BT-549 3500 per 80µl 0.1µl 
HCC1806 3000 per 80µl 0.1µl 
HCC1954 5000 per 80µl 0.2µl 
HCC38 8500 per 80µl 0.1µl 
HS-578T 4000 per 80µl 0.1µl 
MCF10A 4000 per 80µl 0.1µl 
MCF12A 6000 per 80µl 0.1µl 
MCF7 4000 per 80µl 0.1µl 
MDA-MB-231 4000 per 80µl 0.1µl 
MDA-MB-436 8500 per 80µl 0.1µl 
MDA-MB-468 5000 per 80µl 0.1µl 
SK-BR-3 7500 per 80µl 0.1µl 
T-47D 7000 per 80µl 0.1µl 
ZR-75-1 10000 per 80µl 0.1µl 
 
2.2.1.8 Primary siRNA screen 
Three days prior to screen: 
All eighteen cell lines used for the siRNA screen were passaged under standard tissue 
culture such that they would be 90-95% confluent on the day of the experiment (e.g. 
screen day).  
One day prior to screen: 
Medium of all cell lines was refreshed 24 h prior to the experiment. 
Screen day: 
The aliquoted siRNA library containing 10µl of 375nM siRNA/Hank’s Buffer Salt 
Solution (HBSS) mix were thawed for 20 min at room temperature (RT) and 
centrifuged for 1 min at 3000 x g. Next, 10µl of the transfection reagent mix 
(Lullaby/HBSS) was added to each well of each plate using an 8-channel multichannel 
pipette. The 20µl siRNA/Lullaby/HBSS mixes were left to incubate for 20 min at RT. 
Meanwhile the cells were rinsed with PBS once before trypsination. The cells were 
counted with the Cell Countess and for each cell line the optimised number of cells 
Chapter 2 Materials and Methods 
 
 80 
were resuspended in 200ml freshly prepared media. A cell suspension of 80µl was then 
added to each well of the eighteen 96-well plates (9 plates each for normoxic and 
hypoxic culturing) per cell line by using the WellMate 8-channel microplate dispenser 
(ThermoFisher Scientific). This led to a total volume of 100µl per well with a final 
siRNA concentration of 37.5nM. The plates were then stacked into 2 groups (3 plates 
each of siRNA library plates 1,2 and 3 per oxygen condition). The plates for hypoxia 
were wrapped with aluminium foil to prevent evaporation before being placed into the 
hypoxic chamber (Ruskinn Invivo2 500), whereas the normoxic plates were placed in a 
standard incubator with 5% CO2 atmosphere. Media for the hypoxic plates were 
prepared and incubated overnight to equilibrate in the hypoxic chamber to diminish as 
much oxygen possible within the media. 
Day 1: 
After 24 h, 100µl of the media was added to each plate. The cells were then incubated 
for a further 72 h. 
Day 4: 
The plates were processed in two batches of 9 plates (first normoxia, then hypoxia). The 
WellMate 8-channel microplate dispenser was programmed to remove the media first, 
and then the cells were fixed by adding 100µl of 80% ice-cold EtOH to each well. The 
plates were sealed with foil and stored at 4ºC until the next day. 
Day 5: 
The DAPI solution (1µg/ml) was prepared before the plates were de-sealed. The 
WellMate 8-channel microplate dispenser aspirated the EtOH, washed the fixed cells 
three times with 100µl PBS before adding 30µl of DAPI (1:5000 in PBS) was added for 
1 h before aspirating the solution and adding 100µl of PBS. The plates were then sealed 
and read by the Acumen X3 (TTP Labtech, Hertfordshire, UK), a laser scanning 
imaging cytometer to determine DAPI staining intensity as a readout for cell number. 
2.2.1.9 Fixation and cell number quantification of cells 
Cells were fixed in 80% EtOH (-20ºC) and stored for a minimum of 3 h at -20ºC, then 
fixed cells were washed three times with PBS before staining with 1µg/ml DAPI 
(Roche Diagnostics GmBH) to visualise stained cell nuclei, the Acumen X3 (TTP 
Labtech) was used. 
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2.2.1.10 Viability assays 
Trypan blue staining: 
This is a standard method in cell culture to easily discriminate viable cells from non-
viable cells. Briefly, 10µl of 0.4 % trypan blue solution (Invitrogen) was applied to 
10µl of cell suspension and mixed carefully by pipetting up and down. After an 
incubation of 2 min, cells were counted using a Cell Countess (Invitrogen). Living cells 
appeared unstained due to their intact cell membrane, whereas dead cells were stained a 
blue colour. 
 
Cell Titer blue: 
This assay is based on a fluorescent method to monitor cell viability. Viable cells are 
able to convert the redox dye called resazurin into resofurin, a reaction which features 
auto fluorescence. Non-viable cells are not capable of generating this fluorescent end 
product given that these cells have lost the metabolic capacity to convert resazurin. The 
Cell Titer blue solution (Promega) is applied directly to cells cultured in serum-
supplemented media and incubated for 1-3 h depending on the metabolic activity of 
each cell line (according to the manufacturers). This assay was used for assessing the 
viability of 3D cultures by adding 50µl Cell titer blue to 800µl media in each well of a 
24-well plate. The fluorescent signal was measured with an EnVision fluorescence plate 
reader (PerkinElmer). 
 
2.2.1.11 Generation of stably transfected cell lines expressing different SLC16A3 
constructs using retroviral transduction 
The pWZL construct containing EcoReceptor (5µg) was transfected into Phoenix 
amphotropic packaging cells using LipofectamineTM PLUSTM (Invitrogen). Supernatant 
containing pseudotyped retroviruses were collected 72 h after transfection, filtered 
through a 0.45µm sterile filter (Merck Millipore) and used for transduction. Breast 
cancer cell lines were cultured 12 h prior to transduction in 100mm- dishes to obtain 
25-35% confluent cells. Transduction was carried out with 100% retroviral supernatant 
plus hexadimethrine bromide (polybrene - at a final concentration 8µg/ml) (Abe et al., 
1998). Cells were then incubated for 6 h after which virus-containing supernatant was 
replaced with fresh media after 6 h. The selection for infected cells started 36 h later 
with media supplemented with 0.5µg/ml G418 (Invitrogen). After a two-week selection 
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process, these cells were then infected with ecotropic retroviruses carrying pBABE 
puro3, pBABE puro3 hSLC16A3 wildtype and the different pBABE-puro3 hSLC16A3 
constructs that have been mutated by site directed mutagenesis (see 2.2.2.6). After 24 h 
post infection, the cells were exposed to media supplemented with puromycin (1µg/ml) 
for selection of cells containing the pBABE puro3 constructs. 
 
2.2.1.12 Generation of stably transfected cell lines expressing Tet-pLKO-shRNA 
constructs using lentiviral transduction 
Cells stably expressing inducible short hairpin RNA (shRNA) targeting malic enzyme 1 
(ME1), monocarboxylate transporter 4 (MCT4) and a non-targeting control (scrambled) 
were generated according to the Tet-pLKO-on manual found on the Addgene website 
(http://www.addgene.org/21915/). The shRNA sequences were obtained from the 
Mission system (Sigma-Aldrich) and cloned into the empty Tet-pLKO-puro vector. 
HEK-293-TLA cells were seeded at 4x106 cells in 100mm dishes to reach confluency 
the following day. The transfection of HEK-293-TLA cells was achieved by co-
transfecting 10µg plasmid DNA containing the shRNA sequence, 7.5µg of the gag-
polyprotein encoding vector pCMVΔR8.91 and 2.5µg of the envelope encoding vector 
VSV-G using Lipofectamine2000TM. Briefly, 80µl of Lipofectamine2000TM was added 
to 520µl OptiMEM and incubated for 5 min. Meanwhile, the different plasmids DNAs 
(vsv-g, pCMVDR8.91 and shRNA containing plasmid DNA) were diluted together in a 
total of 600µl OptiMEM. Next, the Transfection reagent mix was added to the DNA 
mix and incubated for 30 min at RT. The HEK-293-TLA cells were carefully washed 
twice with OptiMEM before adding 4ml OptiMEM to the cells. The transfection 
reagent/ DNA mix was then drop wise added to the cells and left overnight. The 
following morning, the breast epithelial cells to be infected were then seeded to reach 
40% confluency the next day. In parallel, 5ml media with 10% heat-inactivated serum 
was added to the HEK-293-TLA cells and incubated for another 24- 36 h. The next day, 
the lentivirus-containing supernatant from the HEK-293-TLA cells was collected, spun 
at 650 x g for 5 min and filtered through a 0.45µm sterile filter. The breast epithelial 
cells were washed once with D-MEM/F-12 (1:1) media before adding 5ml of a 1:1 
lentivirus/media mix supplemented with 8µg/ml polybrene. The cells were incubated 
overnight before adding fresh media. The selection process with puromycin was started 
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36 h post-transfection and was stopped when the control cells were dead. Once the 
selection was complete, the cells were maintained puromycin free. Doxycycline was 
used at a final concentration of 1µg/ml to induce the expression of the shRNA and due 
to the half-life of doxycycline, it was re-added every 48 h. For RNA extraction, 
doxycycline was applied for 72 h. For protein analysis, doxycycline was added for 5 
days and 9 days for cell viability/ clonogenic assays. 
Table 2-13 shRNA sequences used in this study. 
Gene symbol 
 
Sequence Orientation 
Sh 
Scrambled CCGGCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG forward 
Sh 
Scrambled AATTCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG reverse 
SLC16A3 
CCGGCGTCTACATGTACGTGTTCATCTCGAGATGAACACGTACATGTAGACGTT
TTTG forward 
SLC16A3 
AATTCAAAAACGTCTACATGTACGTGTTCATCTCGAGATGAACACGTACATGTA
GACG reverse 
SLC16A3 
CCGGGCTCATACAGGAGTTTGGGATCTCGAGATCCCAAACTCCTGTATGAGCTT
TTTG forward 
SLC16A3 
AATTCAAAAAGCTCATACAGGAGTTTGGGATCTCGAGATCCCAAACTCCTGTAT
GAGC  reverse 
SLC16A3 
CCGGCGTCTACATGTACGTGTTCATCTCGAGATGAACACGTACATGTAGACGTT
TTTG forward 
SLC16A3 
AATTCAAAAACGTCTACATGTACGTGTTCATCTCGAGATGAACACGTACATGTA
GACG reverse 
SLC16A3 
CCGGGCTCATCATGCTGAACCGCTACTCGAGTAGCGGTTCAGCATGATGAGCTT
TTTG forward 
SLC16A3 
AATTCAAAAAGCTCATCATGCTGAACCGCTACTCGAGTAGCGGTTCAGCATGAT
GAGC reverse 
ME1 
CCGGGCCTTCAATGAACGGCCTATTCTCGAGAATAGGCCGTTCATTGAAGGCTT
TTTG forward 
ME1 
AATTCAAAAAGCCTTCAATGAACGGCCTATTCTCGAGAATAGGCCGTTCATTGA
AGGC reverse 
ME1 
CCGGGCTGAGGTTATAGCTCAGCAACTCGAGTTGCTGAGCTATAACCTCAGCTT
TTTG forward 
ME1 
AATTCAAAAAGCTGAGGTTATAGCTCAGCAACTCGAGTTGCTGAGCTATAACCT
CAGC reverse 
ME1 
CCGGGCTTCCTTAACACAAGAGAAACTCGAGTTTCTCTTGTGTTAAGGAAGCTT
TTTG  forward 
ME1 
AATTCAAAAAGCTTCCTTAACACAAGAGAAACTCGAGTTTCTCTTGTGTTAAGG
AAGC reverse 
ME1 
CCGGCCTGTGGGTAAATTGGCTCTACTCGAGTAGAGCCAATTTACCCACAGGTT
TTTG forward 
ME1 
AATTCAAAAACCTGTGGGTAAATTGGCTCTACTCGAGTAGAGCCAATTTACCCA
CAGG reverse 
 
2.2.1.13 Clonogenic assay 
To determine the effect of specific shRNAs on cell viability, shRNA expressing cells 
were plated in the presence or absence of doxycycline in 12-well plates in duplicates at 
a density of 10,000 cells per well. After 12 h, doxycycline (1µg/ml) or EtOH as control 
was added to the assigned wells. After 8 days, cells were washed twice in PBS before 
fixation with 4% paraformaldehyde (PFA) for 15 min at RT. Then, cells were stained 
with 0.05% crystal violet for 30 min on a rocker before being washed with distilled 
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water. Plates were dried overnight at RT. After 12 h, the dye was extracted by adding 
0.5ml methanol per well and the OD was measured at 560 nm to determine relative 
proliferation.  
2.2.1.14 Three-dimensional (3D) matrigel cultures and spheroids 
For 3D cultures, the on-top matrigel assay was performed (Lee et al., 2007). Cells were 
reverse transfected with the siRNA of interest and seeded as a monolayer (2D culture) 
for 24 h. The next day, matrigel (BD Biosciences, phenol-red-free, growth-factor 
reduced) was thawed on ice and 200µl were used to coat one well of a 24-well plate, 
and incubated for at least 20 min at 37ºC to allow the matrigel to solidify. The 
transfected cells were detached with trypsin to generate a single-cell suspension and the 
cell number was determined by the Cell Countess System (Invitrogen).  
Table 2-14 Cell suspensions used for three- dimensional growth studies: 
Cell line 
Cell number for on-top matrigel  
(24-well plate) 
Number of cells plated for spheroid formation 
assay (96-well plate) 
MCF10A 20,000 - 
MDA-MB-231 20,000 2000 
MDA-MB-468 30,000 1000 
HCC1954 20,000 2000 
 
The number of cells for 3D matrigel cultures used for seeding was diluted to a total 
volume of 600µl and put on ice for 5-10 min. Next, 35µl matrigel was added to the cells, 
mixed and carefully transferred on top of the solified matrigel in the plates. 
 
For spheroid formation, the optimised cell number for each cell line tested was diluted 
in 100µl media. Prior to plating in a 96-well format, cells were incubated on ice for 5-10 
min. Next, 2% matrigel was added before the cells were seeded in a 96-well plate and 
centrifuged for 10 min at 650 x g at RT. 
2.2.1.15 Fluorescence-activated cell sorting (FACS) analysis for cell cycle 
Flow cytometry was used to analyse cell cycle, reactive oxygen species (ROS) and 
intracellular pH. All cells used were reverse transfected with the siRNA duplexes of 
interest for 72 h. The labelled cells were transferred to polystyrene tubes (BD Falcon) 
and analysed by laser emission in the mentioned flow cytometer (BD Bioscience).  
 
Cell cycle analysis 
Cells were washed once in PBS (1x) before being harvested and fixed with ice-cold 
70% EtOH and stored at 4ºC for at least two hours or up to a month. Then cells were 
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washed twice in ice-cold PBS. To ensure that only DNA was stained, cells were treated 
with 50µl ribonuclease (100µg/ml) for 5 min. After the digestion step, 200µl of 
propidium iodide (50µg/ml) were added and samples were immediately analysed on the 
flow cytometer. 
 
Reactive oxygen species (ROS) detection 
An h prior to starting the experimental analysis, 1µM H2O2 was added to the assigned 
positive control well. Then, cells were incubated with 5µM 6-carboxy-2',7'-
dichlorodihydrofluorescein diacetate, a chemically reduced, acetylated form of 
fluorescein that is used as an indication of the presence of reactive oxygen species 
(ROS) (Carboxy-H2DCFDA, Molecular Probes) for 30 min at 37ºC. Excess H2DCFDA 
was removed and the labelled cells were then trypsinised, cells were suspended in PBS, 
centrifuged at 650 x g for 5 min and rinsed twice with ice cold PBS and resuspended in 
400µl PBS. The cell suspension was immediately analysed on the LSRIIb flow 
cytometer.  
 
pH detection 
Intracellular pH was determined with 10µM SNARF-4F 5-(and-6)-Carboxylic Acid 
(Molecular probes). Briefly, cells were harvested and washed once in PBS, before being 
incubated with SNARF-4F for 30 min at RT. Excess dye was removed by centrifugation 
and two washing steps with ice cold PBS. Cells were resuspended in 400µl PBS and 
measured on the Fortessa cytometer (BD Biosciences) 
2.2.1.16 Measurement of rate of glycolysis with tritiated glucose 
The uptake of radioactively labelled glucose and the rate of glycolysis was measured by 
monitoring the conversion of 5-3H-glucose to 3H2O. Briefly, cells were washed once in 
PBS prior to incubating them in 0.5ml of glucose free DMEM media (CR UK Cell 
Services) for 30 min at 37°C. Cells were then exposed to DMEM media containing 
glucose (10mM) spiked with 10µCi of 5-3H-glucose. Following incubation for 1 h at 
37°C, triplicates of 50µl aliquots in DMEM media were transferred to uncapped PCR 
tubes containing 50µl of 0.2N hydrogen chloride (HCl), and the PCR tube was carefully 
transferred to a scintillation vial containing 0.5ml of H2O. The scintillation vial was 
then sealed and incubated for 24 h at RT to enable diffusion of the contents of the PCR 
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tube into the H2O. The amounts of diffused and un-diffused 3H were then determined by 
scintillation counting. 3H-glucose-only and 3H2O-only controls were included in each 
experiment to enable the calculation of 3H2O per sample, as well as the rate of 
glycolysis. 
2.2.1.17 Detection of cleaved caspase 3/7 activity 
Apoptotic cell death was determined using the Apo-ONE assay based on that from 
Promega, which allows fluorometric measurement of the activity of caspases 3 and 7. 
Cells were cultured in a 96-well format for allocated times in a total volume of 100µl. 
For each well, 100µl of the buffer mix containing the light sensitive pro-fluorescent 
caspases 3/7 substrate (Z-DEVD-R110) were prepared and added for 1.5 h incubation in 
the dark at RT. Samples with active caspase 3/7 allowed cleavage of the c-terminal part 
of the DEVD substrate, and the resulting R110 (Rhodamine 110) fluorescence was 
measured at a wavelength of 485 nm using an EnVision Mulitlabel plate reader (Perkin 
Elmer). The amount of fluorescence generated is representative of the amount of 
cleaved caspases 3/7 in each sample. To normalise each value to the total protein 
content of the cells, a sulforhodamine B assay was performed afterwards. 
Table 2-15 Apo-One buffer pH7.3 
Components Concentrations 
HEPES 25mM 
EDTA 1mM 
NaCl 10mM 
DTT 5mM 
CHAPS 0.10% 
Z-DEVD R110 substrate 0.01mg/ml 
 
2.2.2 Nucleic acid manipulations 
2.2.2.1 Extraction of total RNA 
Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen) according to 
the manufacturer's instructions for extraction of animal tissues. Briefly, cells were 
disrupted with RLT buffer and the mixture was transferred to shredder columns 
(QIAshredder, Qiagen). The additional step with DNAse was also performed. The RNA 
was eluted in 20-40µl of nuclease-free water (Ambion) depending on the input of cells 
used for RNA extraction. The RNA concentration was measured using the NanoDrop 
spectrophotometer (ThermoFisher Scientific). The RNA was stored at -80ºC. 
Chapter 2 Materials and Methods 
 
 87 
2.2.2.2 Complementary DNA synthesis 
Total RNA was used to generate its complementary DNA (cDNA) with SuperScript II 
reverse transcriptase, Oligo dT12-18 and RNaseOUT (Invitrogen). Reverse transcription 
was performed according to the first-strand cDNA synthesis protocol (Invitrogen). 
Briefly, 1µg RNA was mixed with 1µl of 10mM dNTPs and 1µl Oligo dT12-18 primer 
(500µg/ml) up to a total volume of 12µl and the mix was heated for 5 min at 65ºC. 
Then, the samples were cooled for 5 min on ice before adding 8µl SuperScript II mix to 
each sample (5x first strand buffer, 0.1M DTT, 1µl RNAseOUT (40units/µl), 1µl 
SuperScript II reverse transcriptase (200units/µl). The RNA/ SuperScript mixes were 
incubated for 90 min at 42ºC to generate cDNA. 
2.2.2.3 Nucleic acid quantification 
RNA and DNA concentrations were quantified using the NanoDrop spectro-photometer 
(ThermoFisher Scientific). Briefly, 2µl of nucleic acid solution was used for each 
measurement. The RNA and DNA were always eluted in nuclease free water and 
nuclease free water was used as blank. 
2.2.2.4 Quantitative real time PCR (RT-PCR) 
Quantitative RT-PCR is based on a PCR, where the amplified product is measured after 
each cycle by a fluorescence detector for amplification (7900HT Fast Real-Time PCR 
System, Applied Biosystems). Here, the SYBR Green I dye (Platinum® SYBR® Green 
qPCR SuperMix-UDG with ROX, Invitrogen) was used as the fluorescent dye, which 
binds to double-stranded DNA during the elongation phase (Ponchel et al., 2003). The 
disadvantage of this method is that each double-stranded product, whether specific or 
non-specific, emits a signal. To confirm the presence of a single double-stranded PCR-
product, and confirming the specificity of the RT-PCR performed, a dissociation curve 
was created using the standard melting-curve program (90ºC-65ºC) of SDS2.3 software. 
For every single PCR product, the ratio of fluorescence intensity and temperature is 
displayed via a peak. The more identical products are present in the PCR reaction, the 
higher is the peak of the melting curve. Therefore a melting curve can be used as 
internal quality control that provides information on how many double-stranded 
products are in a given sample and if primer dimers are present and influenced the cycle 
threshold (CT) obtained for a sample.  
Each reaction included 12.5µl Platinum® SYBR® Green qPCR SuperMix-UDG with 
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ROX, 2.5µl QuantiTect Primer (10pmol/µl) and 100ng cDNA. Negative controls such 
as non-template controls were always included in each run. 
The analysis of the quantitative RT-PCR is based on the number of PCR cycles where 
a certain level of fluorescence needs to be present. The CT value is fixed at the 
exponential phase of the PCR curve. The CT is proportional to the logarithm of initial 
amount of the mRNA/cDNA of the gene of interest in a sample. To compare the 
relative concentration of a gene of interest among different samples, the control gene β-
actin was determined in each sample to reflect the difference in cycle number (ΔCT) for 
normalisation of the samples (Livak and Schmittgen, 2001).  
Table 2-16 RT-PCR conditions. 
Temperature Time Cycle(s) 
50ºC 2 min 1x 
95°C  5 min 1x 
95°C  15 sec 40x 
60°C  1 min   
 
Table 2-17 Qiagen QuantiTect Primer used in this study. 
Gene symbol Gene Catalog number 
ACTB  β-Actin QT01680476 
ALDOA Aldolase A QT00082460 
ALDOB Aldolase B QT00094038 
ALDOC Aldolase C QT00996786 
BSG Basigin QT00074564 
 
CAD Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, dihydroorotase 
 
QT00057603 
CHPT1 Choline phosphotransferase 1 QT00038549 
EPAS1 Endothelial PAS domain-containing protein 1  QT00069587 
G6PD Glucose-6-phosphate dehydrogenase QT00071596 
HIF1α Hypoxia inducible factor 1 alpha QT00083664 
HK2 Hexokinase 2  QT00013209 
LDHA Lactate dehydrogenase A  QT00001687 
LDHB Lactate dehydrogenase B  QT00071512 
ME1 Malic enzyme 1 QT00005943 
ME2 Malic enzyme 2 QT00031962  
OXCT2 3-oxoacid CoA transferase  QT02318729 
PPAP2A Phosphatidic acid phosphatase type 2A  QT00067193 
PPAP2B Phosphatidic acid phosphatase type 2B  QT00052836 
PPAP2C Phosphatidic acid phosphatase type 2C  QT00064372 
SLC16A1 Monocarboxylate transporter 1 QT00012838 
SLC16A3 Monocarboxylate transporter 4 QT00085855 
SLC2A1 Glucose transporter 1  QT00068957 
TKTL1 Transketolase 1 QT00017402 
VEGFA Vascular endothelial growth factor A  QT01682072 
 
2.2.2.5 DNA restriction digestions 
To confirm that plasmid DNA contains the expected insert or to insert a sequence into a 
plasmid, the DNA was digested. For this, 1-5µg DNA per reaction were used for 
digestion with 1µl of each restriction enzyme, 2µl restriction enzyme buffer (10x), 0.2µl 
BSA (100x) in a total volume of 20µl using ddH2O. The mix was incubated for either 2 
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h or overnight at 37ºC. All restriction enzymes and buffers were purchased from New 
England Biolabs. A sample of the reaction product was used for analysis by agarose gel 
electrophoresis (see 2.2.8). 
2.2.2.6 PCR based site directed mutagenesis 
The mutagenesis of the complementary sequence of the hSLC16A3 plasmid that can be 
targeted by the SLC16A3 siRNAs has been carried out according to the QuikChange site 
directed mutagenesis protocol (Agilent).  
2.2.2.7 DNA sequencing 
To determine a DNA sequence, Sanger sequencing was performed using specific 
primers and the ABI PRISM® dGTP BigDye® Terminator v3.0 mix (Applied 
Biosystems). The reaction mix consisted of 200-500ng plasmid DNA, 8µl BigDye 
Terminator (BDT) mix and 5pmol primer containing nuclease free water (Ambion) to a 
total volume of 20µl. After the sequencing PCR, the samples were purified with the 
DyeEx 2.0 spin kit (Qiagen) according to manufacturer’s instruction to remove 
unincorporated dye. The centrifugation steps were carried out at 750 x g for 3 minutes. 
David Philips, a member of the CR UK LRI equipment park, carried out the sequencing 
experiments. The sequence analysis was performed by using SeqMan Pro 8.1.5 
(Lasergene). 
Table 2-18 Sequencing PCR condition. 
Temperature Time Cycle(s) 
96ºC 10 sec   
55°C  5 sec 25x 
60°C  4 min   
12°C  ∞ 1x 
 
2.2.2.8 Agarose gel electrophoresis 
To confirm the digestion of plasmids and insertion of sequences, UltraPureTM Agarose 
(Invitrogen) for a 1-2% gel (depending on size of DNA fragments) prepared with 1x 
TAE buffer to separate DNA samples were run for 1 h at 120 V. Ethidium bromide was 
added to the gel and to the TAE running buffer at a final concentration of 0.5µg/ml to 
visualise DNA under UV light. DNA samples were mixed with 6x DNA loading dye to 
load them into the wells of the agarose gel. The size of the DNA fragment(s) was 
established by using 100bp or 1Kbp DNA ladder on the same gel.  
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2.2.2.9 Purification of DNA fragments from agarose gel 
To extract and purify a given DNA sample from an agarose gel, the designated band 
was extracted with a scalpel under longwave UV light and transferred into a 1.7 ml 
reaction tube. Next, the DNA was eluted using the QIAquick Gel Extraction kit 
protocol (Qiagen) according to the instructions. The elution step was carried out with 
40µl ddH2O rather than buffer EB. 
2.2.2.10 Transformation of E.coli DH5α  with plasmids 
An aliquot of chemically competent E.coli DH5α was thawed slowly on ice. 100-
500ng of plasmid DNA was added to 50µl competent E.coli DH5α cells gently mixed 
and incubated for 30 min on ice. The mixture was then incubated at 42°C for 45 
seconds (sec) and immediately after the heat-shock placed on ice for 5 min. Then, 
900µl of pre-warmed liquid LB media without antibiotics was added and the bacterial 
suspension was incubated at 37°C at shaking at 225 rpm for 60 min in a shaking 
incubator. 100µl of bacteria suspension was plated on solid LB media agar plates 
containing ampicillin, incubated for 10 min at RT followed by an overnight incubation 
at 37°C. Transformed colonies were picked and grown for isolation of plasmids by 
Mini and/or Maxi-prep kits (Qiagen). 
2.2.2.11 Transformation of XL10-Gold with ligation reactions 
The protocol for transforming XL-10-Gold bacteria with Tet-pLKO-puro constructs 
was followed according to the Agilent’s instruction. Briefly, an aliquot of chemically 
ultracompetent XL10-Gold was thawed slowly on ice. Next, 4µl β- mercaptoethanol 
was added to 100µl competent cells and incubated for 10 min prior to adding 4µl of 
ligation mixture and, gently mixed and incubated for 30 min on ice. The mixture was 
then incubated at 42°C for 30 sec and immediately after the heat-shock placed on ice 
for 2 min. Then, 900µl of pre-warmed liquid LB media (42ºC) without antibiotics was 
added and the bacterial suspension was incubated at 37°C shaking at 225 rpm for 60 
min in a shaking incubator. A bacterial suspension of 100µl was plated onto solid LB 
media agar plates containing 75µg/ml ampicillin, incubated for 10 min at RT followed 
by an overnight incubation at 37°C. Transformed colonies were grown and picked for 
isolation of plasmids by Mini and/or Maxi-preparation (Qiagen). 
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2.2.2.12 Preparation of plasmid DNA  
To isolate plasmid DNA from E.coli DH5α or XL-10-Gold colonies, multiple clones 
were picked from the LB-agarose plates and cultured in a total volume of 6ml LB 
medium. After 12-16 h, mini-cultures were used for plasmid DNA extraction or if 
larger quantities were required, the mini culture was used to inoculate 400ml of LB 
medium supplemented with ampicillin (50µg/ml) and incubated overnight at 37°C. The 
isolation of the plasmid DNA was carried out by using the Qiagen Mini/ Maxiprep Kit 
(Qiagen) according to the manufacturer’s instructions. The air- dried DNA pellets were 
dissolved in ddH2O and the purity was measured by spectrometry (Abs 280/260). 
 
2.2.3 Protein manipulations 
2.2.3.1 Preparation of cell lysates for immunoblots 
The following procedure was used to extract proteins from adherent cells. Briefly, the 
medium was aspirated and cells were washed with 1x cold PBS prior to lysis with cold 
TNET buffer supplemented with protease (Complete, EDTA free) and phosphatase 
(PhosStop, Roche) inhibitors and DTT. After incubation on ice for 10 min, a cell 
scraper (Sarstedt; Newton, NC USA) was used to collect cell lysates. The cell/protein 
lysates were transferred to 1.7ml reaction tubes and centrifuged at maximum speed for 
10 min at 4°C. The supernatants were then carefully transferred into new 1.7ml tubes. 
Protein lysates were stored at -80°C until further use. 
Table 2-19 TNET lysis buffer 
Components Concentrations 
NP-40 1% 
Tris-HCL (pH8.0) 20mM 
NaCl 137mM 
Glycerol 10% 
EDTA 2mM 
DTT 1mM 
Sodium orthovanadate  
2.2.3.2 Protein quantification using Bradford assay 
In order to load equal amounts of protein samples on SDS- polyacrylamide gels, the 
protein concentration was determined using Bradford reagent (Bio-Rad Protein Assay). 
BSA was used to generate a standard curve. The procedure was performed according to 
the manufacturer’s protocol in a 96-well plate. After 5 min incubation period of each 
sample at RT, the absorbance at 595nm was determined on a SpectraMax 190 plate 
reader using the SoftMax Pro software (Molecular devices).  
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Table 2-20 Dilution of BSA to generate standard curve 
µg/µ l BSA µ l BSA (0.025µg/µ l)  Bradford reagent (µ l) 
0 0 250 
0.4 2 250 
0.8 4 250 
1.2 6 250 
1.6 8 250 
2.0 10 250 
2.4 12 250 
2.8 14 250 
 
NuPage loading dye (4x) was added to 15-20µg protein lysates to denature the proteins. 
TNET buffer was used to equalise total volumes of cell lysates used for separation on 
sodium dodecyl sulphate (SDS)-gels. The mixture was vortexed followed by a 10 min 
incubation period at 70°C. For this study only 4-12% gradient gels were used to 
separate the proteins (see 2.2.3.3). 
Table 2-21 Recipe for 4x NuPage Loading Dye 
Components Concentrations 
SDS 8% 
Tris Base 200mM 
Glycerol  40% 
Bromphenol Blue 0.01g/L 
β-mercaptoethanol 2% 
 
2.2.3.3 Sodium dodecyl sulphate-page 
SDS-page is a common method used to analyse proteins as this technique allows the 
separation of proteins based on molecular weight (Laemmli, 1970). The detergent SDS 
is not only used to denature the proteins into subunits but also imparts a uniform charge 
to them. Therefore, proteins will separate solely based on size and not charge. The 15-
30 µg of protein lysates of interest were loaded in the pockets of a pre-cast 4-12% 
Novex®- NuPage TRIS-glycine SDS-page gels (Invitrogen). The MOPS SDS running 
buffer was purchased from Invitrogen. Pre-stained protein markers RPN800E full-
range (Amersham) were used as a molecular size standard to determine the 
approximate size of the proteins in the protein lysates. The protein lysates loaded on 
the gel were separated at 150 V for 60-90 min. 
Table 2-22 Recipe for NuPAGE® MOPS SDS Running Buffer pH7.7 (20X) (500ml) 
Components Concentrations 
MOPS 50mM 
TRIS base 50mM 
SDS 0.10% 
EDTA 1mM 
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2.2.3.4 Immunoblotting procedure 
Immunoblotting is a commonly used method to transfer proteins separated by 
denaturing gel electrophoresis onto a membrane. To transfer the proteins from a 4-12% 
gradient gel onto a Immobilon-P membrane (Merck Millipore) an electrophoretic 
transfer cell (Bio-RAD) was used according to the manufacturer’s instructions. Briefly, 
the PVDF membrane was prepared by activating it for 15 sec in methanol followed by 
a quick wash with transfer buffer. All other components for the blot were equilibrated 
in transfer buffer. The SDS-gel was gently removed from the plastic and rinsed in 
transfer buffer for 1 min. Then the gel was loaded onto the membrane and the transfer 
was carried out at 250 mA for 120 min. To prevent unspecific binding of the antibodies 
to the membrane, membranes were then blocked in 5% milk or 3% BSA for 1 h at RT. 
A primary antibody against a specific protein of interest on the membrane was diluted 
according to the manufacturer’s instructions and incubated overnight at 4°C on a 
shaker (see Table 2.7). The following day the antibody solution was removed and 
washing steps were carried out by rinsing the membrane twice and washing the 
membrane for 2 x 5 min with 5% milk/TBST and 4 x 5 min in 0.1% TBST on a shaker. 
After the washing steps, a secondary antibody conjugated to horseradish-peroxidase 
(HRP) were used to visualise the primary antibody bound to the protein of interest on 
the membrane (see Table 2.8). The secondary antibody was diluted 1:2000 in 5% 
milk/TBST and incubated for 45 min at RT on a platform shaker. The secondary 
antibody was then visualised by chemiluminescence using the Amersham ECL 
detection kit (GE Healthcare) and detected by Medical X-ray film (Hyperfilm, GE 
Healthcare). The film was developed with an automatic X-ray film processor (JP-33, 
JPI Healthcare Solutions, Planview, NY, USA) after different exposure times 
depending on the signal intensity. 
 
Table 2-23 Transfer buffer 
Components Concentrations 
Glycine 250mM 
Tris Base 25mM 
Methanol  10% 
 
Table 2-24 Tris-buffered saline (TBS) pH7.4 
Components Concentrations 
NaCL 137mM 
Tris Base 25mM 
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Table 2-25 Blocking solution 
Components Concentrations 
Milk powder or BSA 5% 
TBS 500ml  
Tween 20 0.10% 
 
Table 2-26 TBST- washing buffer 
Components Concentrations 
TBS 500ml  
Tween 20 0.10% 
2.2.3.5 Sulforhodamine B assay 
To determine the protein content of cell lines used for metabolic and cleaved caspase 
activity assays, a sulforhodamine B staining was performed. This method was adapted 
from (Vichai and Kirtikara, 2006). Supernatant/ media was aspirated from the cells, 
which were then fixed with cold 10% tri-chloro-acetic acid (TCA) in PBS and 
incubated for 1 h at 4ºC. Next the cells were washed twice with 100µl/well ddH2O and 
air-dried at RT overnight. The following day, 50µl/well of a 0.4% Sulforhodamine B in 
1% acetic acid solution was added and incubated on a rocking platform for 30 min at 
RT. The stained and fixed cells were then washed twice in 1% acetic acid. Cells were 
dried for 1 h before adding 100µl/well 10mM TRIS pH8 to re-solubilise the 
Sulforhodamine B dye for 5 min on a rocking platform at RT. For quantification of the 
protein content, a colorimetric measurement was performed at three different 
wavelengths 530, 565 and 690nm using a SpectraMax 190 plate reader (Molecular 
Devices, Sunnyvale, CA, USA) and analysis was determined by SoftMax Pro software. 
2.2.3.6 Immunofluorescence 
Glass coverslips were placed in 12-well plates and cells were directly seeded onto these 
coverslips (13mm, ThermoFisher Scientific). Three days post-seeding, cells were fixed 
with 3.7% PFA for 15 min at RT followed by two wash steps with PBS. Then, the cells 
were permeabilised using 0.1%Triton- X 100 for 15 min at RT. Cells were blocked for 
1 h in 3% normal goat serum (NGS) before adding anti-MCT4 antibody (see 2.1.9) 
diluted in 3% NGS (1:300) for 2 h at room temperature. After exposure to the primary 
antibody, coverslips were washed twice with PBS. Then the secondary antibody Alexa 
Fluor 633-conjugated anti-rabbit (Molecular probes) diluted in 3% BSA (1:500) was 
added to the cells for 1 h. Cells were then washed with PBS and nuclei were stained 
with DAPI (1µg/ml) for 30 min. Following two washes with PBS, the coverslips were 
mounted on a microscope slide (ThermoFisher Scientific) with 40µl Mowiol 
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(Calbiochem) and dried overnight. The image acquisation was obtained by using a LSM 
710 Upright Confocal microscope (Carl Zeiss) with a 63x Plan APOCHROMAT 1.4 
Oil immersion objective (Carl Zeiss) at RT. Image capture was achieved with the 
ZEN2009 software. All images were processed according to the LRI image processing 
guidelines. 
2.2.3.7 Immunohistochemistry 
All immunohistochemical staining was performed by the LRI Experimental 
Histopathology Laboratory (Prof. Gordon Stamp and Dr Bradley Spencer-Dene). 
Tissue microarray (TMA) slides BR1503 were purchased from US Biomax, Inc. 
(Rockville, MD, USA). Each contained cores in duplicates of three normal breast tissue, 
three fibrocystic adenomas, two cystosarcoma phyllodes, seven intraductal carcinomas 
and sixty invasive ductal carcinomas. All tissues were neutral buffered formalin (NBF) 
fixed and paraffin embedded. The thickness of each section was 5µM. To remove 
paraffin from the TMA, slides were incubated for 2 x 3 min in xylene, then for 2 x 3 
min in 100% industrial methylated spirit (IMS) and rehydrated in 70% IMS and 
distilled water. For antigen retrieval, slides were microwaved in 0.01M sodium citrate 
(pH6) for 15 min (900W oven, on medium setting), and then cooled for 20 min. To 
block endogenous peroxidase activity slides were incubated for 10 min in 1.6% 
H202/PBS. After brief washes in distilled water and PBS, slides were blocked in 10% 
normal goat or horse serum in 1% BSA/PBS for 30 min before the primary antibody 
was applied. Primary antibodies were all diluted in 1% BSA/PBS and incubated for 1 h 
at RT in a humid chamber (dilutions are shown in table 2.26). After primary incubation 
slides were washed 3 x 2 min in PBS and incubated in biotinylated goat anti rabbit IgG 
(1/250 in 1%BSA/PBS) or biotinylated horse anti mouse IgG (1/400 in 1%BSA/PBS) 
for 45 min at RT. After 3 x 2 min PBS washes slides were incubated in Avidin-Biotin-
Complex (Vector Labs) for 30 min washed again in PBS then developed with 
Diaminobenzidine (DAB). After washing in distilled water, slides were counterstained 
with haematoxylin, washed in tap water, dehydrated, cleared and finally mounted in 
DPX mountant. As positive controls, different tissues were the protein of interest is 
expressed, were used. Moreover, secondary antibody only stain as negative control was 
performed on some tissue samples to check for unspecific binding.  
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For immunohistochemical staining of spheroids grown in vitro, spheroids were 
collected with a cut 200ml pipette tip and fixed in 3.7% PFA for 16h at 4ºC. The 
spheroids were then centrifuged and washed with 70% EtOH for short-term storage. To 
facilitate handling and sectioning, spheroids were rehydrated in distilled water and 
transferred into liquid molten 2% agarose in a petri dish and then, when cooled, a small 
block of agarose containing the spheroids was isolated and paraffin processed. After 
embedding, serial 4µm sections were cut onto positively charged slides and dried 
overnight at 37oC. Each set of spheroids was processed in a serial and stained 
histologically for haematoxylin and eosin. For immunohistochemical staining the same 
protocol used for the TMA sections was followed.  
Table 2-27 Primary antibodies used in this study: 
Primary Antibody Dilution 
MCT4 1/300 
cleaved caspase 3 1/900 
Hydroxyprobe 1 1/100 
 
2.2.4 Metabolic Manipulations  
2.2.4.1 Oxygen measurement 
Measurements of cellular oxygen consumption rates were determined with the BD 
Oxygen Biosensor system (BD Biosciences). This system is based on oxygen sensitive 
fluorophore (tris 4,7 diphenyl- 1,10-phenanthroline ruthenium (II) chloride), which is 
quenched when oxygen is present (Rolo et al., 2009). 96-well plates coated with this 
fluorophore embedded into a silicone rubber matrix were used. Empty plates were 
measured on the EnVision™ Multilabel Plate Reader (excitation=485nm, 
emission=630nm) prior to use to compare levels of autofluorescence. Cells to be 
analysed for oxygen consumption were harvested after trypsination and counted. Then, 
1x106 cells were plated in a total volume of 200µl of media per well in these 96-well 
plates. Three independent measurements were performed for each cell line. Standard 
cell culture medium was used to determine the basal oxygen consumption rate of the 
cells analysed, and addition of the uncoupling agent carbonyl cyanide p- 
(trifluoromethoxy) phenylhydrazone (FCCP) (Sigma-Aldrich) to the media at a final 
concentration of 2µM was used to establish the maximal oxygen capacity. The ATP 
synthase inhibitor oligomycin (Sigma-Aldrich) inhibits respiration and was added to the 
media at a final concentration of 0.05µg/ml. The plates were sealed prior to the 
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measurements. After an incubation time of 15 min, the plates were scanned and 
measurements taken every 2 min for 2 h on the EnVision™ Multilabel Plate Reader 
(excitation= 485nm, emission= 630nm). The time profile was then analysed with Excel 
software, where the values were normalised to measurements from wells containing 
medium only. The slope of the fluorescence signal was calculated within the dynamic 
range of the measurements to compare it to the oxygen consumption profile of other cell 
lines. As a positive control, the oxygen scavenger agent sodium sulphite was used. 
2.2.4.2 Cell proliferation assay 
Cell lines were plated in 96-well plates using the cell number established for the siRNA 
screens (see Table 2.12). After 24 h, cells were washed once in PBS before adding 
complete culture media consisting of DMEM supplemented with 10% dialysed FCS, 
either in the presence or absence of glucose and/or glutamine. DMEM was used here, 
because DMEM/F12 was not available without glucose and glutamine. Cells were fixed 
in 80% EtOH 72 h later and cell number was determined with Acumen X3. 
2.2.4.3 Measurement of intracellular lactate 
Intracellular lactate concentrations of the breast cell lines MCF10A, HCC1954, MDA-
MB-231 and MDA-MB-468 were measured. Briefly, cells were washed in PBS twice 
before being harvested. The cells were then collected after the centrifugation step, 
resuspended in ice cold PBS and counted. Next, 0.5x106 cells were centrifuged, and 
then lysed with 200µl dH2O using a 21G syringe. After 20 min incubation on ice, the 
cell suspension was centrifuged for 5 min at 650 x g. The analysis of the lactate levels 
was carried out with the lactate kit from BioVision (Milpitas, CA, USA), according to 
the manufacturer’s instruction. 
2.2.4.4 Measurement of utilised glucose 
Glucose uptake of breast cell lines were measured after 1 h starvation in glucose- and 
glutamine-free DMEM before adding complete culture media for 1 h. The glucose 
changes after addition of complete media were measured with the Glucose kit 
(BioVision) according to the manufacturer‘s instructions and the values were 
normalised to cell mass. To be within the linear range of glucose levels determined by 
the glucose standard curve, 10 µl of the supernatant were diluted 1:10 in glucose assay 
buffer and then 5µl of this dilution were used for establishing the glucose amount 
utilised. 
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2.2.4.5 Measurement of secreted lactate 
Lactate secretion of breast cell lines were measured after 1 h starvation in glucose and 
glutamine free DMEM before adding complete culture media for a further hour. The 
amount of secreted lactate after addition of complete media was measured with a 
BioVision kit according to the manufacturer ‘s instructions and the values were 
normalised to cell mass (see 2.2.3.5). For this, 10 µl of the supernatant of the incubated 
complete media was diluted 1:10 in lactate assay buffer and then 10µl of this dilution 
were used for establishing the secreted amount of lactate. The amount of diluted 
supernatant was determined to make sure to be within the linear range of the lactate 
standard curve. 
2.2.4.6 Measurement of NAD+/NADH ratio 
To determine the redox-potential of chosen breast epithelial cell lines, cells were reverse 
transfected with siRNA duplexes of interest and cultured for 72 h. Next, cells were 
trypsinised, counted and 2x105 cells were used for the experiment. The NAD+/NADH 
kit (Biovision) was used and the protocol was followed according to the manufacturer’s 
instruction. 
2.2.4.7 Measurements of extracellular flux 
To determine cellular bioenergetics of the two main metabolic processes: mitochondrial 
respiration (OCR) and extracellular acidification (ECAR) simultaneously in breast 
epithelial cell lines, a XF96e Extracellular Flux Analyser (Seahorse Biosciences, North 
Billerica, MA, USA) for 96-well plates was used. Real-time measurements of the OCR 
and ECAR were directly measured over a period of time after injection of different 
metabolites such as glucose, L-glutamine, Sodium L-lactate and methyl-pyruvate. A 
flux analyser kit consisted of a dual-analyte sensor XFe96 cartridge plate and a XFe96-
well microplate. Briefly, cells were plated in a volume of 80µl per well of a XFe96-well 
microplate in their normal medium conditions 24 h prior to the experiment. The XFe96 
flux cartridge plate includes a hydrogen and oxygen sensor that needed calibration for at 
least 6 h in the XFe96 flux analyser. On the day of the experiment, the injection ports of 
the XFe96 flux assay cartridge plate were loaded with different metabolite solutions 
(pH7.4). The cartridge plate was then loaded into the flux analyser. The cells were then 
rinsed once with assay medium pH7.4 before cultured in 200µl assay medium. The cells 
were incubated for 25 min before plate was loaded onto the analyser. The standard 
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protocol included three readings of 3 min each per treatment. Between each reading 
there was a 3 min waiting time. The values were normalised to protein content of the 
cells. 
2.2.4.8 Preparation of metabolite samples for mass spectrometry analysis 
Metabolic profiling by analysing metabolites extracted from cells may provide 
information about the metabolic state of a given cell line. To analyse the metabolites of 
the breast cell line panel, the cells were plated 48 h in 6-well plates prior to the 
metabolite extraction at a density that on the day of extraction the confluency of the cell 
was approximately 80-90%. The media were then aspirated and the cells were quickly 
rinsed twice with 37ºC warm 75mM ammonium carbonate (Sigma-Aldrich) dissolved 
in ddH2O that had been adjusted to pH7.4 by the addition of formic acid (Sigma-
Aldrich). Then the plates with cells were snap-frozen in liquid nitrogen and stored at -
80ºC. The extraction of metabolites was performed in a fume hood. Next, a frozen 6- 
well plate was placed on a heated magnetic stirrer plate that had been preheated to 90ºC. 
Then, 600µl of 80% hot EtOH (preheated to 90ºC) was added to each well of the 6-well 
plate and incubated for 1 min, while the plate was constantly shaken by hand. The cells 
were then scraped and transferred into a 15ml Falcon tube that was placed in a 90ºC 
water bath and incubated for 2 min with a vortex step every 30 sec. Another 600µl of 
90ºC EtOH was added to the plate followed by scraping. The cell suspension was then 
transferred to the same 15ml tube and incubated for another 2 min at 90ºC. The cell 
suspension/ EtOH mixes were spun for 3 min at -10ºC at 3000 x g. The supernatant was 
then transferred into a 1.7ml reaction tube. The pellet was re-extracted and 
homogenised with a syringe/ needle containing 600µl 90ºC EtOH. The homogenate was 
incubated for 1 min at 90ºC before being spun again. The supernatant was added to a 
1.7ml reaction tube with the supernatant collected earlier and stored at -80ºC. Analyses 
were carried out by Dr. Nicola Zamboni’s group at ETH Zurich, Switzerland (Buscher 
et al., 2009). Briefly, extracts were dried with a vacuum centrifuge at 30°C and stored at 
-80°C. Prior to measurement the extracts were resuspended in 100µl Nanopure® water 
(ThermoFisher Scientific). The samples were then injected in an Agilent 6520 Q-TOF 
or an Agilent 6550 iFunnel Q-TOF according to (Fuhrer et al., 2011). 
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2.2.5 Data analysis 
Data are usually presented as mean or median values and the error bars represent either 
the standard deviation (SD) or standard error of the mean (SEM) as described in the 
figure legend. The quantitative data are depicted using GraphPad Prism 5.0 (GraphPad 
software). All experiments have been preformed at least twice independently from each 
other with multiple replicates for each experiment or otherwise indicated.  
The p-values were obtained by using a two-tailed paired/unpaired student t-test. P-
values smaller than 0.05 were considered to be statistically significant.  
For the analysis of the screen the raw data was pre-processed by cellHTS. Z-scores were 
calculated by and normalised on the basis of the median cell number within each plate 
in the screen of one cell line/ condition using cellHTS. The Z-scores of candidate genes 
were defined as those siRNA pools, which had an adjusted Z-score of less than -1.7. Z-
score results were symbol annotated to 231 metabolic genes. The Z-score replicates of 
each cell line under normoxia and hypoxia were combined. The data was then processed 
into an annotated Z-score matrix. This matrix was subjected to unsupervised 
hierarchical clustering based upon Pearson correlation distance measure with a ward-
clustering algorithm. The candidate genes were defined with a Z-score less than -1.7. 
Phenotype and genotype information of breast cell line panel was provided and 
implemented into the R-script. All Z-scores, which separated different 
phenotypes/genotypes as defined by the Mann-Whitney-U test were created and 
displayed in heat maps for each phenotype/genotype under normoxic and hypoxic 
conditions. The heat maps show the significant genes ranked row-wise according to 
their median difference and column-wise ordered for their phenotype/genotype. The 
analysis was performed in R2.9.0 using the script by Dr. Alan Mackay. 
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3 ER-negative/HER2-negative breast cancer cells differ in their 
metabolic phenotype from other subtypes 
3.1 Introduction 
Breast cancer can be classified into different subtypes according to their molecular 
profiles, clinically based upon the expression of predictive markers (i.e. ER, PR and 
HER2) and histological features. There have been numerous studies published 
providing evidence to suggest that these breast cancer subtypes differ in their metabolic 
phenotypes (McCleland et al., 2012; Possemato et al., 2011). For example, using 18F-
FDG-PET imaging of primary breast tumours in female cancer patients showed 
differences in the uptake rate of 18F- FDG, an analogue of glucose, especially in women 
diagnosed with the ER-negative/HER2-negative breast cancer compared to the other 
subtypes (Basu et al., 2008; Tchou et al., 2010).  
 
Alterations of metabolic processes occur during the transformation process from a 
normal to a cancerous cell. This metabolic reprogramming can be influenced by certain 
genetic aberrations such as activating mutations in PIK3CA (Engelman et al., 2006) or 
overexpression/amplification of HER2 (Schafer et al., 2009). Even the selection 
pressure from the microenvironment such as hypoxia or nutrient stress might influence 
the metabolic phenotype of cancer cells. It has been repeatedly observed that solid 
tumours utilise more glucose concurrent with lactate secretion even in the presence of 
oxygen (Gambhir et al., 2001). This hallmark has been termed aerobic glycolysis or 
Warburg effect (Warburg et al., 1927). Although aerobic glycolysis is not as effective in 
energy production as oxidative phosphorylation, cancer cells favour glycolysis over 
oxidative phosphorylation, given that other important metabolic processes branch from 
the glycolytic pathway. These processes are necessary for cells to produce and 
accumulate building blocks such as fatty acids, amino acids and nucleic acids for the 
biosynthesis of lipids, proteins and nucleotides (Vander Heiden et al., 2012). 
 
The molecular heterogeneity of human primary breast cancer (Neve et al., 2006) can be 
recapitulated in-vitro by the use of not a single but a panel of established breast 
epithelial cell lines. Here, a panel of 17 breast epithelial cell lines to account for the 
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heterogeneity of breast cancer was chosen. This panel of cell lines used is characterised 
by distinct gene expression profiles and was established from patients with breast 
tumours of different clinical subtypes, from benign breast lesions (MCF10A, MCF12A) 
and normal breast epithelium (184B5) (Fig 3.1A). These cell lines also showed 
differences in growth patterns and morphologies when grown as two-dimensional (2D) 
monolayers (Fig 3.1B). This, however, was much more prominent when cells were 
grown in 3D cell cultures. It has been shown previously that breast cell lines when 
cultured in 3D extracellular matrix (ECM) cultures adopt either mass, grape-like and 
stellate morphologies (Kenny et al., 2007).  
 
Not only the genetic background of cells has an impact on metabolic reprogramming, 
but also the tumour microenvironment with its nutrient and oxygen gradients. To mimic 
one of these conditions, the breast cell lines used in this study were cultured either 
under normoxic (20% oxygen) or hypoxic (≥0.5% oxygen) conditions. Different 
metabolic assays were then performed to metabolically phenotype the cell lines and to 
determine whether this could be attributed to their receptor status (i.e. ER-
positive/HER2-negative, HER2-positive, ER-negative/HER2-negative and non-
malignant breast cells) and or genetic aberrations (e.g. PTEN loss, PIK3CA mutations). 
 
3.2 Breast cancer cell lines show different dependency on growth factors 
The PI3K/AKT signalling pathway is frequently activated in human cancers, including 
breast cancer. Amplification of genes encoding for receptor tyrosine kinases, such as 
HER2 and EGFR, mutations in PIK3CA, the catalytic subunit p110α of PI3K, and loss 
of PTEN expression lead to an increased activation of PI3K downstream components 
such as AKT (Baselga, 2011). These aberrations facilitate breast cancer cell survival 
and render cells to be less dependent on growth factor stimulation. 
To determine the levels of expression of key components of the PI3K/AKT pathway, 
HER2 and PTEN protein analyses were performed in all 17 breast cell lines included in 
this study (Fig 3.2A). As expected, the HER2-positive breast cancer cell lines SK-BR-3, 
AU-565 and HCC1954 showed high levels of expression of HER2, whereas the EGFR-
amplified MDA-MB-468 showed increased EGFR protein expression levels (Fig 3.2A). 
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Five cell lines had lost expression of PTEN (BT-549, ZR-75-1, MDA-MB-468, HCC38 
and MDA-MB-436) (Fig. 3.2A), which is consistent with previous reports (Neve et al., 
2006; Weigelt et al., 2011).  
To assess whether the PI3K/AKT signalling pathway is activated in the breast cell line 
panel, cells were cultured under full medium, reduced serum and serum-deprived media 
conditions for 24 hours and whole cell lysates were analysed by western blotting. 
Activation of the PI3K/AKT pathway was determined by the ratio of phosphorylated 
AKT over total AKT protein expression levels, quantified using Image J. Under serum-
starved conditions, growth factors in the cell culture medium are reduced leading to a 
decrease in AKT activation. Cells with an activated PI3K/AKT pathway, however, are 
expected to retain high levels of phosphorylated AKT even under serum withdrawal. 
This analysis revealed substantial diversity of AKT activation among the breast cell 
lines studied (Fig 3.2B). Remarkably, some (HCC1954 and T-47D) but not all cell lines 
harbouring activating PIK3CA mutations (Barretina et al., 2012; Weigelt et al., 2011) 
showed elevated AKT activity (MCF7 and BT-20). In contrast, PTEN-deficiency and 
HER2-amplification were associated with increased AKT activation (p=0.0274) (Fig. 
3.2B). The non-malignant breast cell lines were highly sensitive to serum withdrawal 
regarding their AKT activity (Fig 3.2B)  
Taken together, these findings, in line with previous observations (Stemke-Hale et al., 
2008), suggest that activation of the PI3K/AKT pathway, as assessed by AKT 
phosphorylation, is associated with PTEN LOF rather than PIK3CA GOF mutations in 
the breast cell lines studied. Based on the differential activation of AKT observed in 
these cells, one can hypothesise that there may also be different metabolic activities in 
breast cell lines with high vs low levels of AKT activation.  
 
3.3 Glutamine and glucose are crucial for the proliferation of ER-
negative/HER2-negative breast cancer cell lines under hypoxic 
conditions 
Glucose and glutamine are the two main carbon sources available for tumour cells to 
maintain cell growth and proliferation (DeBerardinis et al., 2007). Numerous studies 
have reported the effects of oncogenes and tumour suppressors influencing glycolysis 
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and glutaminolysis in cancer cells (Gaglio et al., 2011; Le et al., 2012; Wise and 
Thompson, 2010; Yuneva et al., 2007). However, cancer cells showed varied glucose 
and glutamine utilisation dependent on the genetic alteration they harboured and/or the 
tumour microenvironment (Yuneva et al., 2012). Under low oxygen conditions, cancer 
cells have been shown to utilise increased amounts of glucose for energy production to 
compensate for the decreased mitochondrial respiration (Semenza, 2010b). Recent 
studies have also implicated a role for glutamine under low oxygen conditions to 
replenish parts of the TCA cycle for fatty acid synthesis (Gaglio et al., 2011; Metallo et 
al., 2012; Soh et al., 2007).  
To determine the substrate dependency of the breast cell lines, cells were deprived of 
glucose, glutamine or both for 72 hours under normoxic and hypoxic conditions. To 
assess differences in cell viability between reduced and depleted glucose and glutamine 
conditions, cell number changes were investigated using normal serum (Fig. 3.3) or 
dialysed serum (Fig 3.4) under both oxygen conditions. The breast cancer cells (Fig 
3.3A-C) cultured in standard serum exhibited no decrease in cell number after 
glutamine withdrawal under normoxic conditions compared to the non-malignant cells 
(Fig 3.3D). However, withdrawal of glucose resulted in reduced cell numbers in all 
breast epithelial cell lines under normoxia (Fig 3.3). Under hypoxic conditions, ER-
positive/HER2-positive breast cancer subtypes became more dependent on glutamine as 
well as glucose. However, the ER-negative/HER2-negative subtype showed no growth 
impairment under hypoxic conditions in the presence of both carbon sources (glucose 
and glutamine) as well as after glutamine deprivation (Fig 3.3C) compared to the other 
breast cancer subtypes and the non-malignant cell lines (Fig 3.3). 
Cell lines cultured with dialysed serum showed a severe impairment in proliferation 
after glutamine withdrawal under normoxic conditions compared to normal serum (Fig 
3.4). Interestingly, glucose withdrawal in the non-malignant cell lines showed better 
survival compared to glutamine depletion under normoxic conditions (Fig 3.4D) Under 
hypoxic conditions, the effect after glutamine depletion was similar to the effects 
observed under normoxia. Of note, the ER-negative/HER2-negative cell lines showed 
only a minor effect under hypoxia when cultured in complete medium (Fig 3.4C). 
While it cannot be ruled out that the effects observed are due to different batches of 
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serum, this finding may indicate that traces of glutamine in the normal serum are 
sufficient to rescue cell proliferation. 
In summary, these results demonstrate that glucose and glutamine dependencies differ 
between breast cell lines. The results of the dialysed serum compared to the normal 
serum suggest that small amounts of glutamine are sufficient to sustain cell proliferation 
of breast cancer cells. In addition, the non-malignant breast cell lines appear to be 
highly sensitive to any perturbations in nutrient and oxygen availability. 
 
3.4 Only ER-negative/HER2-negative breast cancer cells display features 
of the Warburg effect 
Increased glucose utilisation is a feature of aerobic glycolysis in cancer cells, where 
glucose is mainly fermented to lactate even in the presence of oxygen (Warburg, 1956). 
The different dependencies on glucose in the breast cell lines suggest that their glucose 
consumption rate may also differ. 
To test this hypothesis, the panel of breast epithelial cell lines was assessed for the 
phenotype of aerobic glycolysis. To determine glucose uptake and lactate secretion, 
sensitive fluorescent assays were used to measure glucose and lactate levels in the 
supernatant of cultured cells. To control for differences in proliferation, the glucose and 
lactate levels of each culture were normalised to their protein content.  
Under normoxic conditions, the non-malignant cell lines depleted less glucose from the 
media compared to the majority of cancer cell lines. By contrast, only the non-
malignant cell lines displayed significantly higher glucose consumption (p=0.0042) than 
the breast cancer cells under hypoxic conditions (Fig 3.5A). Of note, cell lines with 
increased glucose uptake rates also exhibited enhanced lactate secretion. In general, 
breast cancer cells showed higher levels of lactate secretion as the non-malignant cell 
lines both under normoxia and hypoxia (Fig 3.5B). Surprisingly, the ER-
negative/HER2-negative subgroup showed a more pronounced effect of lactate 
secretion under both oxygen conditions compared to the other cancer cells (p=0.0121), 
while HER2-positive cancer cells only showed a significant difference only under 
hypoxia (Fig 3.5B). 
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Taken together, these data suggests that only the ER-negative/HER2-negative cell lines 
display features of aerobic glycolysis. The non-malignant cell lines exhibit a more 
glycolytic phenotype under oxygen deprivation, which reaches a level similar to that 
observed in the ER-positive/HER2-negative and HER2-positive breast cancer cell lines 
under normoxic conditions. However, no changes in the level of secreted lactate was 
observed, suggesting that the non-malignant cell lines do not possess the capacity to 
export lactate under conditions of low oxygen levels. This could limit their survival 
under hypoxic conditions, which is consistent with the observation of the dramatic 
reduction of cell number in low oxygen of the non-malignant cells. To survive and 
maintain a glycolytic phenotype, cancer cells need to overcome this toxicity, 
particularly under low oxygen conditions. 
 
3.5 ER-negative/HER2-negative breast cancer cell lines show low oxygen 
consumption and reduced mitochondrial oxidative capacity 
Glycolytic cancer cells use pyruvate preferentially for lactate production, which has 
been suggested to result in decreased mitochondrial respiration due to diminished levels 
of pyruvate available for the transport into the mitochondria (Cairns et al., 2011). In fact, 
some cancer cells lines have been described to show HIF1α stabilisation and/or harbour 
genetic alterations affecting genes with mitochondrial function (Semenza, 2010a). 
Together, this results in decreased mitochondrial activity. 
To test the extent to which the breast cell lines use mitochondrial metabolism and 
oxidative phosphorylation, basal oxygen consumption was determined. Mitochondrial 
oxidative capacity was measured in the presence of the uncoupling agent FCCP. FCCP 
is a lipid-soluble acid that disturbs the pH gradient across the mitochondrial membrane, 
which results in disruption of the mitochondrial membrane potential and rapid 
respiration independent of ATP synthesis. Moreover, oligomycin, an inhibitor of 
mitochondrial ATP synthase, was used to block ATP synthesis and abolish ADP-
stimulated respiration in intact mitochondria.  
The non-malignant cell lines displayed high basal oxygen consumption as well as high 
maximal mitochondrial oxidative capacity (Fig 3.6A). Both, the cancer and the non-
malignant breast cell lines responded to oligomycin treatment leading to a reduction in 
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their oxygen consumption. Residual oxygen consumption in the presence of oligomycin 
is caused by proton leakage, which was observed in some of the breast cancer cell lines 
studied (e.g. HCC1954 and SK-BR-3, Fig 3.6A). In general, breast cancer cell lines 
showed lower oxygen consumption rates compared to the highly oxidative non-
malignant cell lines. Remarkably, the majority of ER-negative/HER2-negative breast 
cancer cell lines showed a strong reduction in their basal oxygen consumption (Fig 
3.6B) and a severe impairment in spare mitochondrial capacity (Fig 3.6A) as compared 
to the ER-positive/HER2-negative (p=0.0242), HER2-positive (p=0.0242) and non-
malignant cell lines (p=0.0121).  
Taken together, the highly glycolytic phenotype of ER-negative/HER2-negative cell 
lines in combination with impaired mitochondrial oxidative activity may suggest that 
these cell lines may harbour genetic alterations affecting the TCA cycle and/or the 
electron transport chain.  
 
3.6 ER-negative/HER2-negative breast cancer cells show increased 
survival under hypoxic conditions 
Based on the findings above, one could hypothesise that breast cancer cells with high 
glycolytic flux and low oxygen consumption may be able to survive better under 
hypoxic conditions than those with low glycolytic flux and high oxygen consumption. 
To test this, the impact of hypoxia on proliferation of the 17 breast cell lines was 
investigated. Under hypoxic conditions, the non-malignant cell lines MCF10A, 
MCF12A and 184B5 showed a severe decrease in their proliferation rates compared to 
normoxic conditions (p<0.0001) (Fig. 3.7A). In general, breast cancer cell lines were 
less affected when cultured under hypoxic conditions as similar growth rates compared 
to the normal oxygen conditions were observed (Fig 3.7B). Some cancer cell lines, 
however, in particular HER2-positive cell lines (i.e. SK-BR-3) were sensitive to the 
reduced oxygen conditions and showed decreased proliferation rates. In contrast, ER-
negative/HER2-negative breast cancer cell lines were only marginally affected by 
hypoxia and showed significantly increased proliferation rates under hypoxic conditions 
as compared to the non-malignant cell lines (p=0.0121) (Fig. 3.7B). In fact, ER-
negative/HER2-negative breast cancer cell lines which show features of epithelial to 
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mesenchymal transition, in particular the breast cancer cell lines HS-578T, BT-549, 
MDA-MB-231 and MDA-MB-436 (Bae et al., 1993; Neve et al., 2006), showed the 
highest tolerance to low oxygen conditions. A gene signature of hypoxia has been 
shown to correlate with poor clinical outcome in patients with ER-negative/HER2-
negative breast cancer (Favaro et al., 2011).  
HIF1α is overexpressed in many human cancers including colon, kidney and breast 
malignancies compared to non-malignant tissue samples (Zhong et al., 1999). To further 
investigate the difference in growth observed under hypoxic conditions, the levels of 
HIF1α and HIF2α expression were determined in the different breast cell lines. Western 
blot analysis of HIF1α and HIF2α protein revealed that all cancer cell lines, with the 
exception of SK-BR-3, showed elevated levels of HIF1α under hypoxia compared to 
the non-malignant cell lines (Fig 3.7C). The non-malignant cell lines showed relatively 
low levels of HIF1α expression even under hypoxic conditions. Furthermore, three ER-
negative/HER2-negative breast cancer cell lines displayed HIF1α stabilisation under 
normoxia, MDA-MB-231, HS-578T and BT-549. Given that these cell lines do not 
harbour mutations in VHL (according to the COSMIC database and Broad-Novartis 
Cell Line Encyclopaedia (Barretina et al., 2012)), these findings suggest that other 
genetic alterations may contribute to HIF1α stabilisation in these cells. 
 
To summarise, proliferation in the non-malignant breast cell lines is strongly affected in 
hypoxic conditions, suggesting that they are highly dependent on mitochondrial 
metabolism. The breast cancer cell lines, however, exhibit varied responses to hypoxia. 
Proliferation in the ER-negative/HER2-negative breast cancer cell lines with high levels 
of aerobic glycolysis (chapter 3.4) was found to be affected under low oxygen 
conditions. This might indicate that these ER-negative/HER2-negative cancer cell lines 
already display pseudo-hypoxic characteristics. This is supported by the observation 
that some of these cancer cells lines stabilised HIF1α even in the presence of oxygen.  
 
3.7 Metabolite analysis divides breast cell lines into new subgroups  
The metabolome of a cell/organism comprises all small molecules with low molecular 
weight. The abundance of these molecules or metabolites has been shown to be 
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influenced by the microenvironment and the activity of intracellular enzymes (Oliver, 
2002). The abundance of enzymes as determined by their gene expression levels, CGH, 
or substrate/product balance modifies the metabolic flux (Griffin and Shockcor, 2004). 
Metabolite concentrations can be quantified and changes in metabolites may be used in 
the diagnostic setting (Sreekumar et al., 2009).  
 
Given that the panel of breast epithelial cell lines studied here exhibited differences in 
their metabolic phenotype, it is likely that they also show differences in their 
intracellular metabolite concentrations, hence in their metabolome. To investigate this, 
metabolites were extracted from all cell lines under normoxic and hypoxic conditions 
and their mass and relative abundance was measured by mass spectrometry (in 
collaboration with Dr. Nicola Zamboni, ETH Zurich, Switzerland). In normoxia, 2875 
ions of good quality, meaning good signal-noise ratios, were detected. 320 ions could be 
annotated based on the measured molecular weight and compared to the list of human 
metabolites listed by the Kyoto Encyclopaedia of Genes and Genomes (KEGG) 
(Kanehisa et al., 2012) within a tolerance of 0.001 atomic mass units (amu). Because of 
isomers with identical mass, the 320 ions can be associated to up to 628 compounds. In 
the samples generated under hypoxia, 1539 ions of good quality were detected. After 
KEGG annotation, 202 ions representing 429 compounds were obtained. 
 
To identify cell lines with a similar metabolome, metabolite profiles of all cell lines 
were analysed in an unbiased fashion, using an unsupervised clustering analysis of the 
annotated ions under normoxia (Fig 3.8A) and hypoxia (Fig 3.8B). In general, all 
biological and technical replicates clustered together, confirming the quality of the data. 
An exception were the data of the non-malignant cell line 184B5, which was excluded 
from further analysis due to poor reproducibility between replicates.  
In normoxia, the non-malignant cell lines MCF10A and MCF12A and the ER-
positive/HER2-negative cell line MCF7 displayed a similar metabolome as their results 
clustered together (cluster I) (Fig 3.8A). All remaining 14 breast cancer cell lines 
clustered together in a separate second cluster of the dendrogram (Cluster II). This 
cluster was further divided into 2 branches: The ER-positive/HER2-negative cell line 
ZR-75-1 (IIa) followed by a separate second branch (IIb). The latter one included the 
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ER-positive/HER2-negative cell line T-47D and the HER2-positive cell lines in one 
sub-branch (bi) and the ER-negative/HER2-negative cell lines in a second sub-branch 
(bii) (Fig 3.8A).  
Hierarchical clustering of the metabolomic data from cells grown under hypoxic 
conditions revealed that the ER-positive/HER2-negative cell lines MCF7 and ZR-75-1 
formed a cluster (cluster I) that was distinct from that of the remaining breast epithelial 
cell lines (cluster II) (Fig 3.8B). The second cluster consisted of two sub-clusters: 
cluster IIa consisted of BT-20 that is distinguished from the remaining cell lines (IIb). 
This sub-branch (IIb) could be further divided into the ER-negative/HER2-negative 
non-malignant cell lines, HER2-positive cell line HCC1954 and the other ER-negative 
cell lines (HER2-positive cell lines SK-BR-3 and AU-565 as well as the other six ER-
negative/HER2-negative cell lines including the ER-positive/HER2-negative cell line T-
47D (bi) and MDA-MB-436 as only cell line (bii) (Fig 3.8B).  
These data suggest that ER-negative/HER2-negative breast cancer cell lines may 
harbour a specific hypoxic signature given that they are within one sub-cluster (see Fig 
3.8B). Data from Chi and colleagues stated that ER-negative breast epithelial cell lines 
express a hypoxia response signature on gene expression level that correlated with a 
poorer prognosis (Chi et al., 2006).  
 
To identify certain metabolic process that are significantly enriched in the different 
types of breast epithelial cell lines, a pathway enrichment analysis was performed using 
hypergeometric testing in matrix laboratory (MATLAB). An overview of all the 
metabolic processes is shown in Figure 3.9. Pathway enrichment analysis was 
performed for both oxygen conditions. Two main subgroups of cell lines based on gene 
expression profiling (luminal versus basal) (Neve et al., 2006), the subgroups based on 
different clinical classifiers (ER-positive and HER2-positive versus non-malignant or 
ER-negative/HER2-negative versus non-malignant) and non-malignant versus cancer 
cell lines were compared. 
Under both oxygen conditions, it is obvious that the comparison between the gene 
expression subtypes showed only minor pathway enrichment. This might be explained 
by the importance of posttranslational processes that override gene expression. 
Moreover, fatty acid related metabolic processes displayed no substantial differences, 
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which can be explained by the limited detection of lipid compounds with the method 
used. Under normoxia, most of the enriched pathways are involved in the amino acid 
metabolism such as arginine and proline metabolism (arrow 1), aromatic amino acid 
metabolism (arrow 2), beta alanine metabolism (arrow 3), cyanoamino acid metabolism 
(arrow 4) as well as starch and sucrose metabolism (arrow 5) (Fig 3.9A). Under hypoxia, 
the only enriched pathways involve the metabolism of arginine, proline and aromatic 
amino acids (1,2) (Fig 3.9B). The strongest difference between the different groups was 
observed between cancer and non-malignant cell lines under normoxic conditions and 
ER-negative/HER2-negative versus non-malignant cell lines under hypoxia.  
 
Amino acid metabolism influences metabolic and signalling processes of the cell such 
as arginine regulating nitrite oxide production and proline and serine being part of the 
cellular redox regulation. The differences in the pathway enrichment studies could 
suggest that the non-malignant cells show distinct metabolic features, that are different 
from the cancer cell lines regarding their amino acid metabolism. Tumour progression 
changes the proline and glycine metabolism in breast cancer cells (Richardson et al., 
2008). Furthermore, many cancer cells show increase in glycine metabolism (Jain et al., 
2012). 
 
In conclusion, the metabolome analysis revealed that the metabolite levels under 
normoxic conditions are distinct between breast cancer and non-malignant cell lines. 
Under hypoxic conditions, ER-positive and ER-negative cell lines showed a distinctive 
metabolomic pattern, with the exception of the ER-positive T-47D cells. These findings 
indicate that the non-malignant cell lines may compensate oxygen deprivation through 
changes in their metabolism. The observed changes in activity of certain metabolites in 
ER-negative cell lines also indicate potentially selective dependencies of these cell lines 
for proliferation and survival. It is therefore of great interest to investigate whether 
perturbations of genes involved in these processes differentially affect the cell lines. 
These preliminary results will be further investigated by the group of Dr Nicola 
Zamboni (ETH Zurich, Switzerland). The aim of this work is to identify different 
‘metabo-types’ of breast epithelial cell lines, and to investigate how the ‘metabo-types’ 
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of non-malignant cell lines and cancer cells influence their metabolic activity in 
response to perturbations such as treatment with inhibitors of selected enzymes.  
3.8 Discussion 
Breast cancer is a collection of different diseases that can be defined according to 
histological appearance, molecular and clinical features. The different molecular 
subtypes are predominantly divided by ER status. Molecular gene expression profiling 
demonstrated that ER-positive and ER-negative breast cancer are two different diseases 
(Hu et al., 2006; Perou et al., 2000). This is also recapitulated in their clinical 
classification. ER-positive breast cancers have a better prognosis and OS rates 
compared to ER-negative breast cancer (Fan et al., 2006). Certain genetic alterations are 
more prevalent in one subtype compared to another (Curtis et al., 2012; Shah et al., 
2012).  
Here, it was aimed to investigate the metabolic phenotype of breast cancer cells of 
different genetic composition. To recapitulate this diversity, 17 breast epithelial cell 
lines were chosen for this study. These cell lines harbour frequent genetic alterations 
that are outlined in Figure 3.1. One of the most altered signalling pathway in breast 
cancer is the PI3K/AKT signalling pathway cascade (Baselga, 2011). Therefore to 
assess PI3K activity in these cells we analysed the phosphorylation status - activity - of 
the PI3K effector kinase AKT, as well as the expression of other key components of the 
pathway. It was established that these breast epithelial cell lines differ in their levels of 
AKT activation (pAKT/AKT ratio). Increased AKT activity after growth factor 
withdrawal was associated with loss of PTEN, a negative regulator of the PI3K/AKT 
pathway, and interestingly with amplified HER2, an upstream activator of the 
PI3K/AKT signalling. This has been recently demonstrated by a Cancer Genome Atlas 
Network study, where they examined the relationship between PIK3CA mutation, 
PTEN loss, and activities of certain pathways. Levels of pAKT and pS6 as markers of 
activated PI3K signalling were not increased in PIK3CA-mutated breast cancer 
specimen. Instead, pAKT and pS6 were elevated in basal-like and ERBB2-enriched 
subtypes. This correlated strongly with PTEN loss (CancerGenomeAtlasNetwork, 2012). 
Constitutive HER2 signalling through the activation of downstream kinases, i.e. p110α 
(PIK3CA), have been also mentioned (Stemke-Hale et al., 2008). These and other 
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signalling cascades influence metabolic processes and it is important to determine how 
these genetic aberrations feed into the metabolic phenotypes of cancer cells. Therefore, 
the metabolic phenotype of 17 breast epithelial cell lines was investigated. The 
dependency of the two main carbon sources glutamine and glucose was established, 
demonstrating that all cell lines exhibited to a certain extent glucose and glutamine 
dependency, and that traces of glutamine in glucose-supplemented medium protected 
cell proliferation (see Fig 3.3-3.4). The Warburg effect or aerobic glycolysis was only 
detected in ER-negative/HER2-negative breast cancer cell lines, suggesting that this 
subtype could be more dependent on glycolysis than oxidative phosphorylation, which 
is in line with previous reports (Groheux et al., 2011; Ramanathan et al., 2005), 
explaining the here-observed low mitochondrial oxidative capacities of these cell lines. 
McCleland and colleagues used publically available data from the Broad institute and 
showed that basal-like and ERBB2-enriched cells are not using oxidative 
phosphorylation (McCleland et al., 2012). The high export to lactate was mostly limited 
to the ER-negative cell lines. In agreement with the findings of this study ER-
negative/HER2-negative are the only subtype that displayed the Warburg effect with 
increased glucose utilisation, lactate export and low mitochondrial activity which is 
thought to facilitate their high proliferative capacity. These cells might have adapted 
and optimised their metabolic network to support rapid proliferation.  
Contribution of tumorigenic capacity of cancer cells is also defined by the 
microenvironment. Cancer cells experience oxygen and nutrient fluctuations in different 
areas of their tumour due to the close proximity to blood vessels. Areas of low oxygen 
produce more chemo-resistant cells that are difficult to treat (Horsman et al., 2012).  
The process of adaptation is integral to how cells can survive under these unfavourable 
conditions. This study investigated the survival of breast epithelial cells belonging to 
different subtypes in hypoxia and their ability to handle low oxygen. Here, it was shown 
that non-malignant breast epithelial cells are least able to survive low oxygen, whereas 
most cancer cells showed a degree of adaption, especially the ER-negative/HER2-
negative cell lines. These cells have the best survival under hypoxia (see Fig 3.7) and 
exhibited a pseudo-hypoxic phenotype even under normoxic conditions.  
Central to the survival in hypoxia, is the upregulation of the hypoxic downstream 
effector HIF. Most of the cancer cells showed high expression of HIF1α/HIF2α under 
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hypoxia. Mesenchymal breast cancer exhibited stabilisation of HIF1α/HIF2α even 
under normoxic conditions. Moreover, another possible explanation could be that 
defects in mitochondrial activity lead to an activation of AKT by inhibiting PTEN 
through an increase in NADH levels (Pelicano et al., 2006). Activated AKT signals to 
its downstream target mTORC1, which upregulates HIF (Majumder et al., 2004). 
 
To continue the metabolic characterisation of breast epithelial cell lines, metabolic 
profiling of each cell line under normoxic and hypoxic conditions was assessed. The 
metabolic profiles showed a clear distinction between non-malignant and breast cancer 
cells. Under hypoxia, the ER-negative/HER2-negative breast cancer cell lines had 
metabolite features distinct from the ER-positive/HER2-negative and HER2-positive 
cell lines. In particular, metabolic pathways including amino acid metabolism, were 
enriched in these cells compare to the other subgroups (see Fig 3.9). The neoplastic 
transformation to cancer cells can also change the repertoire of carbon sources and 
amino acids especially glycine and proline are important in tumorigenesis (Jain et al., 
2012; Richardson et al., 2008). 
Although ER-negative/HER2-negative can be further divided into more subclasses, this 
study here suggests that the metabolic phenotype observed unifies the ER-
negative/HER2-negative subtype. However, this might be due to different metabolic 
adaptations caused by the heterogenic genetic composition of these cells that then feed 
into the same biological processes. 
 
A potential limitation of this study is that the intracellular metabolism of these cell lines 
was only investigated under 2D cell culture conditions. As numerous studies have 
shown that 3D culture models create a more physiological environment (Yamada and 
Cukierman, 2007), which may also affect the metabolic features assessed here. 
However, the physiological oxygen environment of breast cancer was recapitulated by 
culturing the cells under low oxygen conditions. 
 
In summary, this study determined that the genotypic and histological diversity of 
breast cell lines mirror metabolic diversity and dependencies. The established clinical 
subtypes show different metabolic features. The ER-positive/HER2-negative cells are 
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more oxidative, while the ER-negative/HER2-negative showed strong aerobic 
glycolysis and a hypoxic phenotype. This suggests that different subtypes can be 
susceptible to different perturbations in the metabolic machinery. Particularly 
interesting are metabolic dependencies of HER2-positive and ER-negative/HER2-
negative breast cancer. These breast cancer subtypes encounter for aggressive diseases 
with poor prognosis in the clinic (Parker et al., 2009). Finding a distinct metabolic 
dependency that could be exploited therapeutically would be of significant interest and 
could display considerable patient benefit.  
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Figure 3-1 Panel of breast epithelial cell lines 
(A) Overview of 17 breast epithelial cells lines consisting of fourteen breast cancer cell lines and three non-
malignant breast epithelial cell lines that were selected for this study. These cell lines can be classified 
according to their genetic alterations (Mutation), gene expression profile (Type) and receptor status 
(Receptor). The data were collected and merged from ATCC, COSMIC database and published data 
(Neve et al., 2006). The cell lines 184B5 and HCC1806 are not classified regarding their gene expression 
profile (nc). (B) Representative pictures of the three non-malignant cell lines 184B5, MCF10A and 
MCF12A, the three ER-positive/HER2-negative breast cancer cell lines ZR-75-1, MCF7 and T-47D, the 
three HER2-positive breast cancer cell lines SK-BR-3, AU-565 and HCC1954, and the eight ER-
negative/HER2-negative breast cancer cell lines HS-578T, MDA-MB-231, MDA-MB-436, BT-549, 
HCC1806, HCC38 including the EGFR overexpressing cell lines MDA-MB-468 and BT-20, are shown. 
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Figure 3-2 Signalling in breast epithelial cell lines 
(A) Seventeen breast epithelial cell lines were seeded in full medium. After 24 hours, whole cell protein 
lysates were harvested and analysed for the stated signalling molecules. (B) Seventeen breast epithelial 
cell lines were seeded in full medium. After 12 hours, cells were washed once with PBS and in medium 
containing 10% FCS, 0.5% FCS and 0.5% BSA. Whole cell protein lysates were analysed for 
phosphorylation of AKT and S6. Cell line names were shortened: H38=HCC38, M10A=MCF10A, M-
468=MDA-MB-468, H1806=HCC1806, H1954=HCC1954, M-231=MDA-MB-231, M12A=MCF12A and M-
436=MDA-MB-436 (C) Quantitative analysis using Image J of pAKT/AKT ratio in 17 breast epithelial cell 
lines. Cell lines were divided according to their PIK3CA and PTEN status. 
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Figure 3-3 Breast cancer cell lines are highly glucose dependent in standard serum conditions 
Seventeen breast epithelial cell lines were seeded in full medium. After 24 hours complete medium was 
changed to medium containing glucose and/or glutamine under normoxic (black symbols) and hypoxic 
conditions (red symbols). Results are shown for the (A) ER-positive/HER2-negative, (B) HER2-positive, 
(C) ER-negative/HER2-negative subtype and the non-malignant cell lines (D). Two independent 
experiments with 3 replicates each were performed and p-values were calculated using the unpaired 
parametric t-test. The mean of each condition is displayed. (**=p ≤0.01; ***=p≤0.001; ****=p≤0.0001) 
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Figure 3-4 Breast epithelial cell lines are glucose and glutamine dependent under dialysed serum 
conditions 
Seventeen breast epithelial cell lines were seeded in full medium. After 24 hours complete medium was 
changed to medium containing dialysed serum with glucose and/or glutamine under normoxic (black 
symbols) and hypoxic conditions (red symbols). Results are shown for the (A) ER-positive/HER2-negative, 
(B) HER2-positive, (C) ER-negative/HER2-negative subtype and the non-malignant cell lines (D). Two 
independent experiments with 3 replicates each were performed and p-values were calculated using the 
unpaired parametric t-test. The mean of each condition is displayed. (*=p-value ≤0.05, **=p-
value≤0.01,***=p-value≤0.001, ****=p-value≤0.0001) 
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Figure 3-5 Glucose uptake and Lactate secretion in different breast cell lines 
Cells from seventeen breast epithelial cell lines were seeded in full medium. After 24 hours medium was 
changed and cells were cultured for a further 48 hours. Then, cells were starved in glucose and glutamine 
free DMEM for 1 hour prior to a further hour of full medium. Medium was then analysed for glucose uptake 
(A) and lactate secretion (B) under normoxic (black) and hypoxic (red) conditions. The raw values were 
normalised to the accumulation of protein content. The mean values of 2 independent experiments with 
three replicates each are displayed. The mean of each condition is displayed and p-values were calculated 
using the unpaired t-test. Parametric comparison was used for the comparison of ER-positive/HER2-
negative, HER2-positive and non-malignant cell lines, whereas the non-parametric MWU test was used for 
the comparison with the ER-negative/HER2-negative cell lines. (*=p≤0.05, **=p≤0.01) 
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Figure 3-6 Oxygen consumption and mitochondrial oxidative capacity in a panel of breast cell lines 
(A) Cell lines were cultured for 48 hours in full medium before oxygen consumption of one million cells was 
determined. Oxygen consumption was measured with BD oxygen biosensor plates (BD Biosciences) for a 
2 hours period. (B) Overview of basal oxygen consumption in different subtypes. Each dot represents 
mean of a representative of 3 experiments performed in triplicate. The error bars display the standard error 
of the mean. (*=p≤0.05) 
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Figure 3-7 ER-negative/HER2-negative breast cancer cells are pseudo-hypoxic 
(A) Cells of seventeen breast epithelial cell lines were seeded in triplicates in 96-well plates, cultured under 
normoxic and hypoxic conditions (O2≤0.5%) for 96 hours. After fixation and staining with DAPI, cell number 
was determined by the Acumen X3. Here shown is the cell number of each breast cell line under hypoxic 
conditions normalised to its normoxic cell number values. (B) Overview of cell number under hypoxia for 
the different subtypes. Three independent experiments were performed and the median of the cell number 
per subgroup is displayed (*=p≤0.05). (C) Cells were seeded for 24 hours under normoxic conditions prior 
to the exposure to hypoxia (O2≤0.5%). Whole cell protein lysates were harvested and analysed for HIF1α 
and HIF2α expression. N=Normoxia, H=Hypoxia. 
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Figure 3-8 Breast epithelial cell lines show differences in their metabolites 
Cells from seventeen breast epithelial cell lines were seeded in 6-well plates in full medium in triplicates. 
After 24 hours, cells were snap frozen in liquid nitrogen. Metabolites were extracted and analysed by mass 
spectrometry. Unsupervised clustering using the euclidean distance and average linkage (UPGMA) 
method of the normalised intensity of the annotated ions of all cell lines under normoxia (A) and under 
hypoxia (B). Colour bars display the affiliation of the cell line with a specific subtype (grey=ER+/HER2-; 
red=HER2; black=ER-/HER2- and white=non-malignant cell lines. Width of the colour bar indicates 
number of samples replicate (1-6), each with 3 independent replicates. 
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Figure 3-9 Subtypes of breast cancer cells show enrichment in amino acid metabolism 
Metabolite data from seventeen breast epithelial cell lines were analysed with MATLAB using a 
hypergeometric test to compute the p-values. Gene pathway enrichment analyses were performed for all 
metabolites under normoxia (A) and hypoxia (B). Heat maps show log10 of p-values indicating that a 
pathway is different between the two groups within the comparison. 
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4 Identification of metabolic enzymes essential for breast cancer cell 
survival by using RNA interference (RNAi)  
1.1 Introduction 
RNA interference (RNAi) is an important endogenous pathway that modulates the 
expression of genes. The generation of small non-coding RNAs involves the processing 
of long double-stranded RNA (dsRNA) molecules into 21-25 nucleotide long dsRNAs 
by the endoribonuclease DICER in the cytoplasm. The ‘guide’-strand, which is a 
template for the mRNA to be repressed, will then be recognised by the RNA induced 
silencing complex (RISC), whereas the ‘non-guide’ or passenger strand is degraded by 
RISC. The RISC complex with the guided strand will then bind to the complementary 
sequence of its target mRNA. The recognition of the target mRNA by the guide-strand 
occurs through the base-pairing model of Watson and Crick. This catalyses the slicing 
or degradation of the target RNA leading to its repression/ablation, which results in a 
LOF phenotype in the cell system used (Hannon, 2002). The recognition of target 
mRNA in the presence of synthetic small-interfering RNA molecules (siRNA) also 
involves RISC (Fig 4.1). 
The discovery of RNAi in the early 1990s has changed the approach of how to study 
gene functions in model organisms such as Drosophila, Caenorhabitis elegans 
(C.elegans) and mammalian cell systems (Fire et al., 1998). Since then, RNAi has been 
utilised as an efficient and effective research tool for the depletion of genes at the 
mRNA level. Today, RNAi is being employed to screen small-scale (e.g. gene family 
networks such as metabolic pathways or kinases) or large-scale gene sets (whole 
genome) in a high-throughput manner. RNAi libraries for mammalian genes are 
commercially available and consist of either siRNAs or vectors expressing short-hairpin 
RNAs (shRNAs) that can be experimentally introduced into different cell systems 
(Carpenter and Sabatini, 2004).  
The screening of RNAi libraries using different cell systems allows for functional 
analysis of the dependencies on certain pathways within cell systems that differ in their 
genetic background or tissue of origin. This technique has led to the identification of 
novel components of various signalling pathways and has increased our understanding 
of how genes affect the viability of cancer cells. Recent RNAi studies integrated data 
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obtained from siRNA/shRNA screens with other datasets such as gene copy number 
changes or gene expression profiles. This has revealed novel insights into the effects of 
single genes within a specific cellular context (Brough et al., 2011; Marcotte et al., 
2012). RNAi screens are highly sensitive to experimental variation and to increase the 
likelihood of identifying biologically relevant candidate genes, RNAi screens need to be 
thoroughly designed and optimised. 
4.1 Optimisation and setup of screen 
To introduce synthetic siRNA oligonucleotides efficiently and effectively into multiple 
cell lines, initial experiments were carried out to optimise RNAi screening conditions. 
Numerous key factors had to be considered during the optimisation process: selection of 
cell lines, optimisation of cell density, choice of transfection reagent, identification of 
the optimal concentration of transfection reagent and targeting siRNA duplexes, 
duration of the assay, the choice of positive and negative controls as well as the 
biological nature of the screen (normoxic and hypoxic conditions).  
4.1.1 Cell number optimisation 
The aim of the siRNA screen of 17 breast epithelial cell lines was to identify metabolic 
genes whose ablation caused marked changes in cell number. Therefore, determining 
the cell density at time of seeding was crucial for detecting changes in cell number at 
the end of the experiment. Given that different cell lines have different growth kinetics 
and conditions, initial cell number seeding experiments for each cell line were carried 
out to define the number of cells to be plated in a well of a 96-well plate, so that at the 
endpoint of the screen (96 hours) a confluency of 80-90% was reached. Each of the 17 
breast cell lines was plated at different cell densities ranging from 1000 up to 6000 cells 
per well of a 96-well plate. After 96 hours, the cells were fixed and two different 
fixation methods (4% PFA or 80% ice-cold EtOH for 12 h at 4ºC) were compared. Cells 
were stained with DAPI and the numbers of nuclei, representative of cell number, were 
detected using the laser imaging scanner Acumen X3 (Fig 4.2A). The different fixation 
methods resulted in comparable cell numbers. However, the quality of the cell cycle 
profile that can be established with the Acumen X3, showed marked differences (Fig 
4.2B). Fixation of cells with 80% EtOH and subsequent DAPI staining resulted in a 
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clear distinction of the different cell cycle phases compared to the 4% PFA fixation. 
Fixation with 80% EtOH was subsequently used for determining the plating cell density 
of all cell lines, and three independent experiments were performed for the 17 cell lines 
(see 2.2.1.7). 
4.1.2 Transfection reagent optimisation 
The delivery of siRNA into cells is normally performed using liposomal reagents 
(Elbashir et al., 2001). The choice of the transfection reagent is crucial for the optimal 
silencing efficiency with minimal toxicity. To achieve optimal transfection, several 
reagents from different suppliers were tested in the chosen panel of breast cell lines. 
The cytoskeleton protein LAMIN A/C was used as a positive control during the 
optimisation procedure (Elbashir et al., 2001). Based on previous experiences by the 
High Throughput Screening (HTS) laboratory (CR UK, LRI), it was decided to perform 
a reverse transient transfection of siRNA duplexes targeting the non-essential gene 
LAMIN A/C. Cells were incubated for a total of 96 hours. To determine the correct 
volume of transfection reagent, two concentrations (1µl/ml and 3µl/ml) of the 23 
different transfection reagents to be tested were used. The knockdown efficiency was 
determined using a fluorescently labelled antibody detecting the amount of LAMIN 
A/C protein in each well. Cell number and LAMIN A/C intensity for all the different 
transfection reagents for each cell line are listed in Appendix Figure 3. 
The transfection reagents RNAiMAX, DharmaFect2, Lullaby and siPORT Amine 
showed the most promising results across the panel of cell lines during the initial tests 
(Fig 4.3A) and were taken forward for a second round to test the toxicity of each 
transfection reagent (Fig 4.3A) and the LAMIN A/C knockdown efficiency (Fig 4.3B). 
Two cell lines are shown to summarise the results. MCF10A cells showed minimal 
reduction in cell number when 1µl/ml transfection reagent was used compared to higher 
doses. However, the knockdown efficiency was only sufficient in Lullaby treated 
samples (60% of LAMIN A/C knockdown). For MDA-MB-468 cells, loss of cell 
number was reduced when increased cell numbers were used. The corresponding 
knockdown efficiency showed that most conditions displayed efficient knockdown of 
60-70%, except for 1µl/ml siPORT Amine.  
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Next, the transfection efficiency was tested by using GAPDH siRNA duplexes in all of 
the cell lines to quantify the knockdown efficiency by immunoblotting (Fig 4.3C). At 
the time these follow-up experiments were performed, RNAiMAX was no longer 
commercially available. Therefore DharmaFect1 was included in the study. Lullaby and 
DharmaFect1 transfection reagents showed repression of GAPDH on protein level 
whereas siPORT Amine knockdown efficiency was lower. Taken together, Lullaby was 
the best transfection reagent across the panel of breast epithelial cell lines tested with 
low toxicity and sufficient delivery of siRNA. All following siRNA transfections were 
carried out using this transfection reagent. 
4.1.3 Transfection controls 
Choosing the right transfection controls are essential for evaluating the efficiency of 
RNAi delivery. Initial experiments were carried out to test if Lullaby shows the desired 
effect using negative and positive controls for the siRNA screen. Negative controls are 
siRNA duplexes that have no homology to the human genome, and should not have any 
effect on cell number. The negative controls used for testing under hypoxic and 
normoxic conditions included mock transfected cells, cells transfected with siRNA 
duplexes chemically modified to impair recognition by the RISC complex (RISCfree) 
and cells transfected with four siRNA duplexes that consist of non-targeting sequences 
(siControl1-4 and siOTP1-4). The positive controls are siRNAs that cause loss of cell 
viability and indicate the efficiency of siRNA transfection such as polo-like-kinase 1 
(PLK1) and ubiquitin B (UBB). PLK1 encodes a regulator of mitosis and its loss results 
in apoptosis (Spankuch-Schmitt et al., 2002). UBB belongs to the ubiquitin family and 
encodes a polyubiquitin precursor. Ubiquitin is essential for the activation of some 
kinases as well as the unfolded protein response, where ubiquitin is a marker for 
degradation of misfolded proteins. Loss of UBB leads to apoptosis (Song et al., 2003). 
In Figure 4.4, all breast cell lines used in this study were reverse transfected with four 
negative and two positive controls. A good differential between the negative and 
positive controls was observed across the cell line panel. The non-malignant cell lines 
as well as the HER2-positive cell lines displayed silencing efficiency that varied on the 
dependent on oxygen conditions. In contrast, the ER-negative/HER2-negative cells 
showed similar silencing efficiency under both oxygen conditions. Overall, the negative 
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controls showed no effect on cell number, whereas the positive controls PLK1 and UBB 
strongly reduced cell number. Taken together, the difference between negative and 
positive controls showed a good margin for identification of potential hits. The 
transfection efficiency between normoxia and hypoxia was also comparable. 
4.1.4 Pilot screen 
To assess the quality of the optimised RNAi screening conditions, a pilot screen was 
implemented in 11 out of the 17 breast cell lines with 12 metabolic genes expected to 
have an effect on cell viability of cancer cells. The chosen genes include those involved 
in lipogenesis such as fatty acid synthase (FASN) (Knowles et al., 2008), mevalonate 
decarboxylase (MVD) (Freed-Pastor et al., 2012), and ATP citrate lyase (ACLY) 
(Hatzivassiliou et al., 2005), as well as genes regulating glycolysis such as PRKAB1, a 
subunit of AMPK, two isoforms of PFK2 (PFKFB3 and PFKFB4) (Ros et al., 2012), 
and an isoform of pyruvate kinase (PKM2) (Christofk et al., 2008a). Moreover, 
signalling components known to be perturbed in breast cancer such as PIK3CA and 
AKT were also chosen. The siRNA for these genes consisted of a pool of four single 
siRNA duplexes. This pool increases the transfection efficiency and minimises the 
likelihood of observing off-target effects (Fig 4.5). All cell lines showed some 
dependencies on a subset of genes. The effect on cell number after the ablation of 
metabolic genes was not as marked as the strong effect of the positive controls. 
However, the effect of some siRNAs targeting metabolic genes on cell number 
compared to the negative control (siControl1-4) was sufficiently strong to be 
distinguished. 
 
In summary, the optimisation and design of the siRNA screen in combination with a 
pilot screen in a panel of breast epithelial cell lines revealed that the conditions are 
suitable for a robust readout. The difference between the negative and positive controls 
demonstrated a good dynamic range to distinguish potential hits for each cell line. The 
pilot screen indicates that silencing of the genes in multiple cell lines can show different 
phenotypes depending on the cell line.  
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4.2 Primary screen 
4.2.1 A functional siRNA screen in breast cancer cell lines 
To determine the contribution of metabolic enzymes, nutrient transporters and 
metabolic regulators to cell proliferation and cell growth in a representative panel of 
breast cancer cell lines, 17 cell lines were chosen for a functional siRNA screen (see Fig 
3.1A). A siRNA library targeting 231 different metabolic genes involved in central 
carbon metabolism was purchased (Fig 4.6A). The siRNAs of this small-screen library 
were distributed over three 96-well plates, where the first two rows were always used 
for the controls (Fig 4.6B). The effect of siRNA transfection on cell growth and survival 
was studied after culturing the cells for 96 hours under normoxic (20% O2) and hypoxic 
(≤0.5% O2) oxygen conditions using a 96-well format. RNAi screens in each cell line 
were performed in triplicate (Fig 4.6C). For efficient reverse transfection and silencing 
conditions, the transfection reagent Lullaby was chosen. Changes in cell number were 
established using the DNA stain DAPI and measured with a microplate cytometer 
(Acumen X3). All RNAi screens were conducted within a three-week period. 
4.2.2 Normalisation and Analysis of the screen data 
Data was collected from all of the 324 96-well plates. The preliminary analysis of the 
siRNA screens performed in this study was carried out by Rebecca Saunders of the HTS 
laboratory (CR UK, LRI) using the Bioconductor software package cellHTS (Boutros et 
al., 2006). Figure 4.7 shows an overview of the analysis flow. 
 
The readings by the Acumen X3 represented the total DAPI fluorescence intensity of a 
given well. The raw data of the cell number derived from the relative fluorescent units 
(RFU) of each well. RFU is defined as the ratio of the total fluorescence intensity of all 
cells divided by the fluorescence intensity of a single cell. Figure 4.8A displays an 
overview of raw cell numbers for all 231 genes targeted by siRNAs and controls in the 
screen. Because every RNAi screen displays variation within itself due to experimental 
variability caused by differences in transfection efficiency, fluctuation in the 
environment or heterogeneity of the cell population (Falschlehner et al., 2010), the raw 
cell number of each well of a 96-well plate had to be plate-normalised. Therefore, the 
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raw data scores of each plate were centred to the plate median per plate excluding the 
negative and positive control values to correct for variations in cell seeding across each 
well of the plate (Fig 4.8B).  
Phenotypes of the same gene in different cells or under different conditions may display 
small dynamic ranges that are difficult to interpret (Falschlehner et al., 2010). Malo and 
colleagues have suggested different types of normalisation for RNAi screens such as 
percentage of negative controls, B-score and Z-score calculations for high-throughput 
screen analyses (Malo et al., 2006). For this study, the Z-score normalisation was 
chosen to identify candidate genes resulting in reduced cell number. The Z-score 
displays the number of standard deviations of a measurement away from the mean of 
the population. A Z-score of zero represents therefore no changes in cell number, 
whereas negative values mean a reduction in cell number. Because a relativly small 
number of siRNA sequences were used in this screen, the Z-score normalisation step 
becomes sensitive towards outliers. To prevent this, the Z-score calculation of replicate 
plates was performed with the median absolute deviation of the population (MAD) 
resulting in the Z-score(MAD) (Chung et al., 2008). For simplicity, Z-score(MAD) will be 
referred to as Z-score in the following sections. In Figure 4.8C, the Z-score 
normalisation of a representative cell line is displayed. An overview of the distribution 
of all replicates of all cell lines is shown in Figure 4.9. 
 
To evaluate if the screen was robust and of good quality, the reproducibility of each 
replicate with the two other replicates of each breast cell line under both oxygen 
conditions was calculated using the Spearman correlation. Generally, a Spearman rho 
value above 0.7 is an indicator of correlation, with 0.8 and higher being considered to 
indicate a very good correlation. Figure 4.10 summarises the correlation analysis. Under 
normoxic conditions, the four cell lines ZR-75-1, SK-BR-3, BT-20 and MDA-MB-231 
showed poor reproducibility with BT-20 being the poorest (rho=0.39±0.068). Five cell 
lines (HCC1954, MDA-MB-468, MDA-MB-436, BT-549 and HCC1806), however, 
showed a correlation of 0.8 and higher. Under hypoxic conditions, only SK-BR-3, BT-
20 and MDA-MB-231 showed less good correlation. 
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In summary, it can be concluded that the screen showed robust results across the 
replicates for the majority of the cell lines used in this study. The cell lines showing less 
robust results were still included in the analysis but the results were treated with 
caution. 
4.2.3 Defining and selection of candidate genes 
There are multiple ways to define and select candidate genes that cause a significant 
reduction in cell number after ablation. The first analysis strategy used unsupervised 
clustering of the data from all cell lines and siRNAs used in the screen to identify 
patterns that showed loss of cell number (Kaufman and Rousseeuw, 1990). The 
different Z-scores of all siRNAs tested for each cell line under normoxic and hypoxic 
conditions were used to generate hierarchical clusters. The siRNA-mediated depletion 
of the metabolic genes showed two distinct clusters: I) reduction in cell number and II) 
increase in cell number (Fig 4.11A). Surprisingly, the hypoxic and normoxic samples of 
each breast cancer cell line were mostly similar to each other and clustered together, 
except for HCC38. In addition, normoxic samples of the non-malignant cell lines 
MCF10A and MCF12A clustered together and away from their respective hypoxic 
samples. In general, there was no correlation with the clinical classification of the 
different breast cancer subtypes in this specific analysis (Fig 4.11A).  
 
To investigate whether the siRNA screens revealed potential patterns for the different 
cell lines under each oxygen condition, the data from each cell line was clustered for the 
normoxic (Fig 4.11B) and hypoxic (Fig 4.11C) conditions. In general, the non-
malignant cell lines built one sub-cluster under both oxygen conditions. Hence, the 
breast cancer cells showed no separation according to their clinical subtypes. Under 
normoxia, two distinct clusters were observed, the EGFR amplified cell lines BT-20 and 
MDA-MB-468 differed from the rest of the cell lines. The second cluster included many 
sub-clusters and it was observed that HCC1954 and ZR-75-1 are not in the same cluster 
as the other cell lines belonging to the HER2-positive or ER-positive/HER2-negative 
subtype, respectively. This was also observed for two cell lines of the ER-
negative/HER2-negative subgroup (MDA-MB-231 and HCC38) that differed from the 
4 remaining triple negative breast cancer cell lines. Under hypoxia, two main clusters 
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were determined. The first cluster distinguished between ZR-75-1 and four other cell 
lines (EGFR-amplified BT-20 and MDA-MB-468 cells, ER-negative/HER2-negative 
cell line MDA-MB-231 and HER2-positive HCC1954 cells). The second cluster 
contained a sub-cluster of the non-malignant cell lines and a sub-cluster consisting of 
the 9 remaining cancer cell lines. 
 
To identify genes that are required for cell viability, a ranking analysis for each cell line 
was performed. This identified the siRNA duplexes with the lowest Z-score, meaning 
the strongest reduction in cell number. For each cell line the Z-scores of all 231 
experimental siRNAs and controls were ranked. Assuming normally distributed Z-
scores (Fig 4.12), a stringent threshold of a Z-score ≤ -1.7 was obtained from the F-
statistics distribution table to identify siRNAs causing significant changes in cell 
number with p≤0.05 (Fig 4.13A). The positive controls were the strongest killers in all 
cell lines, whereas the negative controls lay within the main population of the 
distribution (Fig 4.13). In Table 4.1, the 72 candidate genes across all cell lines under 
normoxic and hypoxic are summarised. These candidate genes are defined as having an 
effect in more than one cell lines or condition.  
 
To identify genes that are differentially required for the survival of cells of a specific 
clinical, genetic or metabolic background, a supervised cluster analysis of the Z-score 
data was carried out. This was performed in collaboration with Dr. Alan Mackay and 
Prof. Jorge Reis-Filho (Institute of Cancer Research, London, UK). Supervised 
hierarchical clustering has been used as a tool for the analysis of microarray data. It is a 
two-step method; at first all genes with a similar behaviour across the cell lines are 
grouped together using a semi-supervised algorithm. Secondly, genes in clusters 
showing a differential expression between a given parameter (e.g. ER or PTEN status) 
are displayed in a heatmap. To test each gene for its significance between the two 
groups defined by a parameter, the Mann-Whitney-U test (MWU) was used. The 
heatmaps in Figure 4.14-4.18 show the siRNAs that exhibit significant differences 
(p≤0.05) for a given parameter between the groups. All significant siRNAs that caused a 
reduction in cell number are shown for the comparison between cancer versus non-
malignant cell lines (Fig 4.14). Under normoxic and hypoxic conditions, the siRNAs 
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with the highest differential were the same. SLC16A3 ablation was more effective in 
cancer cells, while depletion of PMVK was detrimental to the non-malignant cell lines 
(Fig 4.14). Of note, most of the genes that influenced non-malignant cell survival can be 
associated with lipid metabolism.  
 
The candidate genes selective towards the different clinical classification (ER, HER2 
status) are displayed in Fig 4.15. The comparison between ER-negative and ER-positive 
breast cell lines under normoxia revealed strong effects of a gene involved in lipid 
phosphate signalling, PPAP2A, in the ER-negative cell lines. In contrast, OXCT2, 
WBSCR14 and AGXT were mainly important for the ER-positive cell lines (Fig 4.15A). 
Under hypoxic conditions, the depletion of an isoform of malic enzyme, ME2, was 
important for ER-negative cell lines, whereas ER-positive cell lines were dependent on 
the function of TKTL1 and MT-ND4 (Fig 4.15B). For the comparison between HER2-
positive and HER2-negative breast cell lines, SLC16A3 along with PIK3CA and 
PRKAB1 built a strong cluster under normoxia for HER2-positive cell lines (Fig 4.15C). 
Hypoxic conditions however changed most of the genes required for survival (Fig 
4.15D). The ER-negative/HER2-negative candidate genes showed ALDOA as well as 
PPAP2A are essential for the survival of breast cell lines. However, PIK3CA depletion 
was not tolerated by the cell lines expressing ER or with amplified HER2 (Fig 4.15E). 
This is in line with a study that investigated the kinome in a panel of breast epithelial 
cell lines (Brough et al., 2011). The effect of siRNAs on genes important for cell 
survival under hypoxia for ER-positive or HER2-positive cell lines showed only minor 
but still significant differences. GALK2 and ME2 along with c-MYC were essential for 
the survival of ER-negative/HER2-negative breast cell lines (Fig 4.15F).  
When the genetic composition of the three most prevalent mutated genes in breast 
cancer was used for supervised clustering, it was obvious that fewer genes showed 
significant differences (TP53 wt versus mut, PIK3CA wt versus mut and PTEN wt 
versus mut) (Fig 4.16).  
 
However, SLC16A3 and MT-ND3 were important for the survival of the cell lines that 
show high levels of AKT phosphorylation (see Fig 3.2) under normoxic conditions (Fig 
4.17C). Moreover, under normoxic conditions the transcription factor SREBF1 is a 
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candidate gene for cells expressing normal levels of PTEN and showing low AKT 
activity (Fig 4.17A,C). Cell lines that have lost PTEN expression were more sensitive to 
the ablation of H6PD, a gene that encodes the H form of glucose-6-phosphate 
dehydrogenases (Fig 4.17B). Depletion of PIK3CA was detrimental to cell lines with 
high AKT activity under both oxygen conditions (Fig 4.17C,D).  
The supervised cluster analyses for the metabolic parameters glucose uptake, lactate 
secretion and oxygen consumption rate showed that more genes are required under 
hypoxic conditions than normoxic conditions (Fig 4.18). Interestingly, ALDOA, two 
isoforms of ME, GALK2 and SLC16A1 were important for the survival of breast cancer 
cells in hypoxia (Fig 4.18B). In addition, the siRNAs affecting genes important for the 
survival of high lactate secreting cells were similar to the high glucose consuming cells. 
However, another member of the SLC16A family, SLC16A3, and ODC1 were essential 
for high lactate secreting cells (Fig 4.18D). Functional PIK3CA was important for high 
oxygen consuming cells and SOD1 and SLC25A10 were selective to cells with low 
oxygen consumption (Fig 4.18E,F). 
 
In summary, breast epithelial cell lines show differential requirements for metabolic 
enzymes according to their genotype and phenotypic characterisation. However, some 
of these enzymes exhibit differential effects in multiple comparisons or under both 
oxygen conditions.  
4.3 Deconvolution screen 
A known disadvantage of siRNA is that it might affect the physiology of a cell 
independently of the repression of its target gene either by sequence dependent or 
independent off-target effects. Sequence independent off-target effects can be caused by 
a too high dose of siRNA. Sequence specific off-target effects are often due to 
mimicking microRNA or high homology between different siRNAs sequences leading 
to the downregulation of expression of multiple genes. A common method is therefore 
to pool different siRNA duplexes per gene to reduce the possibility of off-target effects.  
 
In order to confirm that the observed loss of cell number is due to the specific effect of 
depleting a given target gene, a deconvolution screen was performed. It is known that 
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the phenotype caused by the pool of four siRNA duplexes is likely to be specific if two 
or more of the single siRNA duplexes show a similar phenotype. Furthermore, the 
knockdown efficiency should correlate with the biological effect. This strategy can be 
used to identify true candidate genes and strengthen the confidence of choosing specific 
genes for follow-up investigations and to elucidate the mechanism of how these genes 
influence breast cancer cell survival.  
Sets of four single siGenome siRNA duplexes were used and each candidate gene was 
deconvoluted individually in combination with the negative controls (siControl1-4) and 
the positive killing control siUBB1 to assure that the transfection conditions were 
efficient. The results for each gene were normalised to the negative controls and the 
siRNA pool results were compared to the siControl1-4 normalised values of a given 
gene in the primary screen. 
Deconvolution of a small number of candidate genes was initially performed and 
assessed on cell number. The most interesting candidate genes from the rank analysis as 
well as candidate genes that showed a differential in the supervised cluster analysis for a 
given parameter (e.g. ER status) were selected. A collection of 16 genes was taken 
forward to test that the loss of cell number was due to silencing of the gene targeted by 
the siRNA (Fig 4.19). For each gene identified as a potential candidate gene, one 
representative sensitive and insensitive cell line was chosen to test the ablation of that 
specific gene. Most of the candidate genes showed a clear distinction between sensitive 
and insensitive cell lines (Fig 4.19). However, siRNAs targeting H6PD or GPX4 failed 
to reproduce the effect observed in the screen (Fig 4.19F,H). The genes PKM2 and 
PFKFB1 were not confirmed as candidate genes, because the sensitivity was opposite to 
the result of the screen data. The resistant cell lines became sensitive after gene ablation, 
while the sensitive cell lines showed no reduction in cell number (Fig 4.19I,K). 
 
To further confirm that the siRNA-mediated effect was specific, deconvolution was also 
performed on mRNA level. The silencing efficiency of each gene was confirmed by 
qPCR after 48 hours of silencing. Some siRNA duplexes showed only minor silencing 
efficiency. However, 10 out of the 14 candidate genes tested were confirmed as true 
targets (Fig 4.20). For ME1 and ME2, only 2 out of 4 siRNA duplexes displayed 
correlation between the effect on cell number and RNA silencing. In contrast, PPAP2A 
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and PPAP2C showed efficient knockdown on mRNA level for all four individual 
siRNA duplexes including the pooled siRNAs (Fig 4.20H,I) but the results showed poor 
correlation with the observed effect on cell number (Fig 4.19M,N).  
4.4 Discussion 
In general, RNAi is a useful tool to analyse the specific genetic dependencies of cells, 
which is pliable to high-throughput technologies for analysing hundreds if not 
thousands of genes at once. The advantage of using RNAi is that the specific genes that 
should be inhibited are known beforehand, and the outcome of silencing can be 
predicted based on their cellular function. However, one of the disadvantages of RNAi 
is that each siRNA duplex can affect the expression of up to 200 genes or more, which 
can cause off-target effects (source: Dharmacon website). To minimise off-target effects 
it is recommended to use siRNA concentrations of less than 50 nM. Off-targets effects 
are often caused by single siRNA sequences and can be identified by repeating the 
experiment using several individual sequences including ones from other distributors. In 
addition, other RNAi constructs such as shRNA (which are comprised of different 
sequence designs and genetic architecture) and small molecular inhibitors can be used 
to recapitulate long-term effects of a gene of interest. 
 
Moreover, the use of transfection reagents may cause unwanted side effects such as 
high toxicity and changes in gene expression profiles. Fedorov and colleagues observed 
that transfection reagents such as Lipofectamine 2000 induced an immune response, 
thereby influencing the transcription of 35 out of 65 genes (Fedorov et al., 2005). 
Therefore, in this study, careful consideration of which reagent and concentration to use 
minimised unwanted effects caused by transfection reagents. Hence, observed 
differences to other published studies might be due to different transfection reagents or 
concentrations of the reagent used and general variation in screen setup and execution. 
 
The plotted frequency of Z-scores presumed a normal distribution scheme, and most 
cell lines showed robust screening replication shown by the Spearman correlation factor 
ρ. This quality control is essential for reducing potential false positive or false negative 
candidate genes or assumptions about screening conditions. Supervised clustering 
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analysis and rank analysis were used for identification of candidate genes, thereby 
combining two different analyses to strengthen the selection process for genes essential 
in breast cancer cell line survival. 
 
In this study, functional cell survival profiles were established for 17 breast epithelial 
cell lines after the abrogation of 231 genes involved in metabolic processes under 
normoxic and hypoxic conditions. This led to the identification of 72 potential 
candidate genes, which significantly impaired survival in at least two cell lines and/or 
conditions. After careful consideration, 16 genes were taken forward for validation. The 
approach of a two-step validation process confirming reduction in mRNA expression 
correlated with reduction in cell number revealed that 10 genes were selectively 
required for cell survival (see Fig 4.19, Fig 4.20). This screen has the potential to 
identify metabolic dependencies of genetically diverse breast epithelial cell lines during 
normal growth conditions and after exposure to hypoxic stress. Most of the essential 
candidate genes have been identified for the ER-negative cell lines (represented in the 
screen by HER2-positive and ER-negative/HER2-negative cell lines). This might be 
explained by the high number of ER-negative cell lines used in this screen (14 cell 
lines) compared to three ER-positive cell lines. However, given that HER2-positive (of 
note, in this study only ER-negative cells with amplified HER2 were used) and ER-
negative/HER2-negative breast cancers show the poorest prognosis for overall survival, 
the screen was biased to identify multiple candidate genes that may be essential for the 
survival of these two subtypes as there is the most need clinically for dependencies that 
could be exploited therapeutically. 
 
In particular, the genes for malic enzyme (ME1, ME2), monocarboxylate transporter 4 
(SLC16A3), transketolase 1 (TKTL1), aldolase A (ALDOA) and two isoforms of 
phosphatidic acid phosphatase (PPAP2A, PPAP2C) were of significant interest. In the 
following chapters, these six genes will be further investigated. 
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Figure 4-1 Overview of the siRNA mechanism 
Schematic overview of the processing of synthetic small-interfering RNAs (siRNA). siRNA is transfected 
into the cell with lipid based transfection reagents. The recognition of siRNA is mediated by the RISC 
complex, which binds the siRNA duplex. The guide strand is used as template for recognition of the target 
mRNA whereas the non-guided strand is degraded. The target mRNA is recognised and bound to the 
guide strand, which induces the degradation of the sequence.  
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Figure 4-2 Optimisation of cell number for high throughput screening 
(A) Growth analysis of MDA-MB-231 cells seeded at the same density, Shown is a representative cell line 
MDA-MB-231. All cell lines were seeded at different densities (1500-5000 cells per well) for 96 hours 
culture. Cell number was determined with the Acumen X3 after fixation with ice-cold 80% EtOH (black line) 
or 4% PFA (red line). (B) Cell cycle profile of a representative cell line after 4% PFA fixation (upper graph) 
and 80% EtOH fixation (lower graph). 
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Figure 4-3 Overview of transfection testing 
(A) Two representative cell lines (MCF10A and MDA-MB-468) were chosen to demonstrate the effect of 4 
transfection reagents on toxicity (left graph) and siRNA delivery (right graph) (B) Immunoblot analysis of 
GAPDH silencing in the two representative cell lines MCF10A and MDA-MB-468. 
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Figure 4-4 Overview of negative and positive controls 
Bar graphs indicating cell number of seventeen breast epithelial cell lines reverse transfected with 4 
negative controls (black bar=normoxia, red bar=hypoxia) and 2 positive controls (white bars) for each 
oxygen condition. (A) 184B5, (B) MCF10A, (C) MCF12A, (D) ZR-75-1, (E) MCF7, (F) T-47D, (G) SK-BR-3, 
(H) AU-565, (I) HCC1954, (J) MDA-MB-468, (K) BT-20, (L) HS-578T, (M) MDA-MB-231, (N) MDA-MB-436, 
(O) BT-549, (P) HCC1806 and (Q) HCC38. 
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Figure 4-5 Summary of pilot screen 
Bar graphs indicating fold change to siControl1-4 transfected cells of eleven breast epithelial cell lines 
reverse transfected with 4 negative controls (black bars), 2 positive controls (white bars) and 12 metabolic 
genes known to be important for cancer cell survival. (A) 184B5, (B) MCF10A, (C) MCF12A, (D) MCF7, (E) 
T-47D, (F) SK-BR-3, (G) MDA-MB-468, (H) BT-20, (I) HS-578T, (J) MDA-MB-231 and (K) BT-549. 
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Figure 4-6 Overview of siRNA screen 
(A) Pie chart of all the siGenome siRNAs targeting genes representing metabolic processes within the 
library. (B) Plate layout of small screen siRNA library distributed over three 96-well plates. (C) Reverse 
transfection of 231 siRNAs (dark grey) including six negative (light grey) or positive (red) controls. Plates 
were divided after reverse transfection to be cultured under normoxic or hypoxic conditions.  
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Figure 4-7 Flow diagram of screen analysis strategy to identify metabolic genes essential for 
survival 
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Figure 4-8 Normalisation and analysis of raw data 
(A) Overview of the raw cell number data of all 237 genes (231 siRNAs and 6 controls) of a representative 
sample. The positive controls siPLK1 and siUBB show low relative fluorescent units (RFU) compared to 
the main population of samples. (B) Overview of the plate normalised data of 237 genes in the screen 
shown here in a representative sample. (C) Z-score(MAD) normalisation of 237 genes in the screen shown 
here in a representative sample. 
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Figure 4-9 Overview of Z-scores of all replicates under both oxygen conditions 
(A) Boxplot of the median Z-scores of all samples in all replicates under normoxic (white) and hypoxic (red) 
conditions across the seventeen breast epithelial cell lines. 
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Figure 4-10 Quality control and reproducibility of siRNA screen 
(A) Example of the reproducibility of data for one cell line/condition. Correlation of two replicates of a 
representative cell line within the screen. (B) Spearman correlation of all replicates under normoxic (left) 
and hypoxic (right) conditions 
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Figure 4-11 Hierarchical cluster analysis of RNAi screen data 
(A) Hierarchical clustering analysis of 231 genes across the cell lines screened under normoxic and 
hypoxic conditions. Cluster I represented loss of cell number, whereas cluster II showed gain of cell 
number. (B) Hierarchical cluster analysis of the data from the experiments performed in normoxia of all cell 
lines. (C) Hierarchical cluster analysis of the data from the experiments performed in hypoxia of all cell 
lines. 
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Figure 4-12 Overview of Z-score frequency in the panel of cell lines. 
(A) Distribution blot of Z-scores frequencies of all 237 genes across the seventeen cell lines under 
normoxic conditions. (B) Distribution blot of Z-scores frequencies of all 237 genes across the seventeen 
cell lines under hypoxic conditions. 
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Figure 4-13 Ranking of Z-scores 
(A) Scatterplot of ranked Z-scores of a representative cell line. A stringent threshold of a Z-score ≤ -1.7 
was applied to identify candidate genes. Red circles indicate positive controls resulting in loss of cell 
number. Black circles represent 231 genes targeted by the siRNAs and black dots represent negative 
controls. (B) Boxplot of positive controls, negative controls and sample Z-scores. Negative Z-scores lay 
within the sample population, whereas the positive controls are showing the strongest negative Z-scores. 
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Table 4-1 Overview of candidate genes 
(A) Overview of the 72 candidate genes with a Z-score(MAD) of less than -1.7 in more than one cell 
line/condition. Indicated in red are the genes taken forward for deconvolution. 
Chapter 4 Results 
 
 165 
 
Figure 4-14 Supervised clustering analysis according to malignancy 
Supervised cluster analysis of Z-scores according to the malignancy status and differential effects between 
non-malignant (non-mal.) and cancer cells under (A) normoxia and (B) hypoxia were identified using the 
Mann-Whitney-U test. Statistically significant effects of siRNAs targeting specific genes are displayed 
(p≤0.05). 
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Figure 4-15 Supervised clustering analysis according to clinical classification 
(A, B) Supervised cluster analysis of Z-scores according to the ER status and differential effects between 
ER-positive and ER-negative breast epithelial cells under (A) normoxia and (B) hypoxia were identified 
using the Mann-Whitney-U test. Statistically significant effects of siRNAs targeting specific genes are 
displayed (p≤0.05). (C, D) Supervised cluster analysis of Z-scores according to the HER2 status and 
differential effects between HER2-positive and HER2-negative breast epithelial cells under (C) normoxia 
and (D) hypoxia were identified using the Mann-Whitney-U test. Statistically significant effects of siRNAs 
targeting specific genes are displayed (p≤0.05). (E, F) Supervised cluster analysis of Z-scores according to 
the ER and HER2 status and differential effects between ER-positive or HER2-positive and ER-
negative/HER2-negative breast epithelial cells under (E) normoxia and (F) hypoxia were identified using 
the Mann-Whitney-U test. Statistically significant effects of siRNAs targeting specific genes are displayed 
(p≤0.05). 
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Figure 4-16 Supervised clustering analysis according to genetic aberrations 
(A, B) Supervised cluster analysis of Z-scores according to the TP53 status and differential effects 
between TP53 mutant (mut) and TP53 wildtype (wt) breast epithelial cells under (A) normoxia and (B) 
hypoxia were identified using the Mann-Whitney-U test. Statistically significant effects of siRNAs targeting 
specific genes are displayed (p≤0.05). (C, D) Supervised cluster analysis of Z-scores according to the 
PIK3CA status and differential effects between PIK3CA mutant (mut) and PIK3CA wildtype (wt) breast 
epithelial cells under (C) normoxia and (D) hypoxia were identified using the Mann-Whitney-U test. 
Statistically significant effects of siRNAs targeting specific genes are displayed (p≤0.05). (E, F) Supervised 
cluster analysis of Z-scores according to the PTEN status and differential effects between PTEN mutant 
(mut) and PTEN breast epithelial cells under (E) normoxia and (F) hypoxia were identified using the Mann-
Whitney-U test. Statistically significant effects of siRNAs targeting specific genes are displayed (p≤0.05). 
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Figure 4-17 Supervised clustering analysis according to signalling 
(A, B) Supervised cluster analysis of Z-scores according to the PTEN expression status and differential 
effects between normal PTEN and lost PTEN expression in the breast epithelial cells under (A) normoxia 
and (B) hypoxia were identified using the Mann-Whitney-U test. Statistically significant effects of siRNAs 
targeting specific genes are displayed (p≤0.05). (C, D) Supervised cluster analysis of Z-scores according 
to the AKT activity status and differential effects between high vs low AKT activity of all breast epithelial 
cells under (C) normoxia and (D) hypoxia were identified using the Mann-Whitney-U test. Statistically 
significant effects of siRNAs targeting specific genes are displayed (p≤0.05). 
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Figure 4-18 Supervised clustering analysis according to metabolic phenotypes 
(A, B) Supervised cluster analysis of Z-scores according to the glucose consumption status and differential 
effects between high vs low glucose consuming breast epithelial cells under (A) normoxia and (B) hypoxia 
were identified using the Mann-Whitney-U test. Statistically significant effects of siRNAs targeting specific 
genes are displayed (p≤0.05). (C, D) Supervised cluster analysis of Z-scores according to the lactate 
secretion status and differential effects between high vs low lactate secreting breast epithelial cells under 
(C) normoxia and (D) hypoxia were identified using the Mann-Whitney-U test. Statistically significant 
effects of siRNAs targeting specific genes are displayed (p≤0.05). (E, F) Supervised cluster analysis of Z-
scores according to the oxygen consumption and differential effects between high vs low oxygen 
consuming breast epithelial cells under (E) normoxia and (F) hypoxia were identified using the Mann-
Whitney-U test. Statistically significant effects of siRNAs targeting specific genes are displayed (p≤0.05). 
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Figure 4-19 Deconvolution of candidate genes on cell number 
Bar graphs of pooled and individual siRNAs targeting a specific genes and its effect on cell number in a 
sensitive (left) and insensitive breast cell line (right). Data was normalised to siControl and siUBB was 
used as a positive control to determine transfection efficiency. Black bars indicate deconvolution under 
normoxia while red bars indicate deconvolution under hypoxia. Following siRNAs were used for 
deconvolution: (A) TKTL1, (B) ME2, (C) ME1, (D) OXCT2, (E) CAD, (F) H6PD, (G) CHPT1, (H) GPX4, (I) 
PFKFB1, (J) G6PD, (K) PKM2, (L) SLC25A10, (M) PPAP2A, (N) PPAP2C, (O) ALDOA, (P) SLC16A3. 
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Figure 4-20 Deconvolution on RNA level 
Bar graphs of pooled and individual siRNAs targeting a specific gene and their effect on mRNA levels in a 
sensitive (left) and insensitive breast cell line (right). Data was normalised to siControl. Following siRNAs 
were used for deconvolution: (A) SLC16A3, (B) ME2, (C) ME1, (D) OXCT2, (E) TKTL1, (F) CAD, (G) 
ALDOA, (H) PPAP2C, (I) PPAP2A, (J) G6PD. 
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5 Monocarboxylate transporter 4 is essential for the survival of ER-
negative breast cancer 
5.1 SLC16A gene family 
Cancer cell metabolism is not only influenced by metabolite concentrations and 
metabolic signalling processes within the cell, but also by the microenvironment. Cells 
exchange signals as well as metabolites with their surroundings to increase proliferation 
and to promote survival. To exchange metabolites, cells have different transporters that 
transport nutrients (such as amino acids and sugars), remove metabolic end products, 
and exchange ions and protons (Ganapathy et al., 2009). 
 
This chapter focuses on the role and function of the human monocarboxylate 
transporters (MCTs). The name MCT derives from their role in carrying molecules with 
one carboxylate group (R-COO-) across membranes. Lactate, pyruvate, ketone bodies 
such as acetoacetate and hydroxybutyrate as well as specific amino acids (e.g. aspartate) 
are known substrates of different MCTs (Halestrap and Meredith, 2004). This family is 
encoded by the solute carrier 16 gene family (SLC16) and is very well conserved. All 
MCTs are predicted to be 12 trans-membrane proteins. Currently fourteen different 
members are known in mammals (Halestrap and Meredith, 2004; Kennedy and 
Dewhirst, 2010). Only four members of the MCT family, MCT1 (SLC16A1), MCT2 
(SLC16A8), MCT3 (SLC16A4) and MCT4 (SLC16A3), facilitate the proton-linked 
symport of monocarboxylates (Halestrap and Price, 1999). The direction of the flux is 
dependent on the concentration gradient of monocarboxylates and protons across the 
membranes. Each MCT1-4 has specific substrates and is affected by different inhibitors. 
Moreover, MCTs show different expression levels across different tissues. These can be 
partially explained by their regulators and co-chaperones, while other regulating 
mechanisms still need to be discovered. MCT1 is constitutively expressed in almost all 
tissues (Garcia et al., 1995) and its main role is to transport lactic acid across the plasma 
membrane (Dimmer et al., 2000). The gene SLC16A1 codes for MCT1 and has been 
suggested to be a direct transcriptional target of c-Myc (Kang et al., 2009). The 
promoter of SLC16A1 contains many CpG islands that are necessary for epigenetic 
regulation through methylation. The methylation of CpG islands might prevent certain 
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transcription factors to bind to the DNA and could thereby suppress the expression of 
MCT1 in certain tissues or under certain metabolic situations (Cross and Bird, 1995). 
MCT1 has been shown to be overexpressed in many cancers (Pinheiro et al., 2010a; 
Pinheiro et al., 2012). It has been demonstrated that MCT1 expression correlates with 
the glycolytic phenotype observed in cancer cells (Birsoy et al., 2012b). 
 
MCT4 is strongly expressed in glycolytic tissue such as the heart and skeletal muscle 
(Bonen, 2001; Juel and Halestrap, 1999). MCT4 is important for lactate export in these 
tissues as it displays lower affinity to lactate compared to MCT1 (Dimmer et al., 2000). 
MCT1 and MCT4 have also been suggested to be part of the coupled metabolism 
between cancer cells (Sonveaux et al., 2008). Other studies have followed 
demonstrating that lactate can be used as an alternative carbon source for cancer cells to 
allow them to proliferate when glucose is scarce (Brooks, 2009; Feron, 2009; Whitaker-
Menezes et al., 2011). The regulation of SLC16A3 is HIF1α dependent and two hypoxic 
response elements (HRE) were found in its promotor (Ullah et al., 2006). Pouyssegur 
and colleagues have demonstrated that both MCT1 and MCT4 are more important for 
pH regulation and tumour growth (Chiche et al., 2010a). 
There are numerous studies suggesting a role for MCT1 and MCT4 in cancer. However, 
conflicting results regarding the transport of lactate or pyruvate by these two MCTs 
have been reported (Bonen, 2001; Dimmer et al., 2000; Garcia et al., 1994; Gerlinger et 
al., 2012; Koukourakis et al., 2006; Sonveaux et al., 2008; Vegran et al., 2011). It has 
also been proposed that MCT4 is not important for cancer cells under normoxic 
conditions as pyruvate is used as a substrate for mitochondrial respiration (Halestrap 
and Wilson, 2012). 
 
MCT1 and MCT4 function in association with the ancillary protein basigin (BSG), a 
member of the immunoglobulin superfamily (Biswas et al., 1995). BSG is necessary for 
trafficking of MCT1 and MCT4 to the plasma membrane and its expression on the 
plasma membrane (Kennedy and Dewhirst, 2010; Kirk et al., 2000; Pinheiro et al., 
2010b). BSG is also implied to be important for tumorigenesis (Davidson et al., 2003; 
Marionnet et al., 2003; Riethdorf et al., 2006) and its depletion has been shown to 
reduce tumour growth (Le Floch et al., 2011; Schneiderhan et al., 2009). 
Chapter 5 Results 
 
 182 
5.2 Ablation of SLC16A3 results in loss of cell viability 
The results of the siRNA screen, showed that depletion of SLC16A3 caused differential 
loss of cell viability under the following criteria: Cell lines with amplified HER2 and 
ER-negative/HER2-negative cell lines are more sensitive towards SLC16A3 ablation 
under both oxygen conditions. Furthermore, most cancer cell lines were highly sensitive 
to the abrogation of SLC16A3 compared to the non-malignant cell lines (Fig 5.1A). 
 
To confirm the screen results, four breast epithelial cell lines were taken forward for 
validation and deconvolution studies. The non-malignant cell line MCF10A and the ER-
negative/HER2-negative cell line MDA-MB-231 were both resistant to siRNA-
mediated abrogation of SLC16A3 (Fig 5.1B,C). In contrast, silencing of SLC16A3 in 
MDA-MB-468 and HCC1954 cells induced substantial loss of cell number. These 
effects were also observed under hypoxic conditions (Fig 5.1D,E). The deconvolution 
of SLC16A3 siRNA sequences revealed the strongest effects with siRNA duplexes #4 
and #5 (see chapter 4, Fig 4.19P, Fig 4.20A).  
To investigate if the reduction in cell number is caused by induction of apoptosis, 
cleaved caspase activity was determined. Indeed, MDA-MB-468 cells (Fig 5.2A) and 
HCC1954 cells (Fig 5.2B) showed significant increases in cleaved caspases 3 and 7 
after depletion of SLC16A3 under normoxic conditions. Interestingly, no induction of 
cleaved caspases was observed in MDA-MB-468 and HCC1954 cells in hypoxia (Fig 
5.2A,B). Furthermore, no increase in caspase activity was found in the non-malignant 
cell line MCF10A (Fig 5.2C) and the cancer cell line MDA-MB-231 (Fig 5.2D) under 
both oxygen conditions. This might suggest a different mechanism that results in the 
observed reduction in cell number. 
To confirm the apoptosis in these cells under normoxic conditions, MCF10A and 
MDA-MB-468 cells were reversed transfected with pooled and individual siRNA 
targeting SLC16A3 and whole cell lysates were analysed for the cleavage of Poly (ADP-
ribose) polymerase (PARP) (Fig 5.2E). MCF10A showed no induction of PARP 
cleavage after depletion of SLC16A3. MDA-MB-468, however, showed elevated levels 
of cleaved PARP in the pooled siRNAs and siRNA duplexes #4 and #5. This correlated 
with the silencing efficiency on RNA (see chapter 4, Fig 4.20A) and protein level (Fig 
5.2E). 
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Given that the culture medium of MCF10A cells is supplemented with growth factors 
and 5% horse serum compared to that of the cancer cell lines grown in 10% standard 
serum, it was assessed if the growth conditions of MCF10A played a protective role 
against SLC16A3 silencing. To test this, MCF10A cells were cultured with the medium 
of the cancer cell lines and the sensitive cell lines HCC1954 and MDA-MB-468 were 
culture under the conditions of the non-malignant cells (Fig 5.3A). Despite the reduced 
proliferation of the cancer cell lines under the growth conditions of non-malignant cells, 
a reduction in cell number was still observed (Fig 5.3A). The non-malignant cell line 
MCF10A showed minor growth impairment in the cancer cell medium after silencing of 
SLC16A3 but not to the same extent as the cancer cells.  
 
In summary, SLC16A3 is selectively important for the survival of ER-negative breast 
cancer cells in-vitro. The cause of reduced cell viability seems to be the induction of 
programmed cell death in normoxia but not in hypoxia. Moreover, it was established 
that the growth factor supplementation of MCF10A is not protecting the cells from 
undergoing cell death after silencing of SLC16A3. 
5.3 SLC16A3 silencing-mediated loss of viability can be rescued using a 
siRNA resistant SLC16A3 construct 
To investigate if the reduced viability after depletion of SLC16A3 can be rescued by re-
expression of the protein, an expression construct for SLC16A3 with a mutated 
sequence within the site that is complementary to the siRNA binding sites (siRNA 
duplexes #4 and #5) was generated. Overexpression of wild-type SLC16A3 only slightly 
diminished the effect of siRNA transfection in HCC1954 and MDA-MB-468 cells. In 
contrast, the siRNA-resistant SLC16A3 mutant prevented the reduction in cell number 
after siRNA transfection (Fig 5.4A). Equal expression of wild-type and mutant 
SLC16A3 was confirmed by immunoblot analysis. 
Taken together, loss of cell viability after depletion of SLC16A3 can be rescued with a 
siRNA resistant construct. 
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5.4 Differential expression of SLC16A3/MCT4 in breast cancer cell lines 
To examine a potential correlation between the observed cell death after SLC16A3 
silencing and the genetic background of the breast epithelial cell lines, RNA and protein 
expression was determined. In Figure 5.5, the expression levels of both mRNA and 
protein revealed differential expression of SLC16A3 across the panel of breast cell lines. 
HER2-positive cell lines expressed higher levels of SLC16A3 on mRNA level compared 
to the ER-positive/HER2-negative and ER-negative/HER2-negative cell lines (Fig 
5.5A). The pattern of SLC16A3 mRNA corresponded to the MCT4 protein expression in 
these cell lines (Fig 5.3B). Of note, the observed phenotype after SLC16A3 depletion 
did not correlate with the RNA or protein expression.  
 
Given that HER2-positive cell lines express high levels of SLC16A3, it was assessed 
whether SLC16A3 expression is regulated by HER2 signalling. Therefore, the sensitive 
HER2-positive cell lines HCC1954 and the ER-negative/HER2-negative cell line 
MDA-MB-468, that overexpresses EGFR and showed very low basal MCT4 expression 
(see Fig 5.5), were exposed to the HER ligands EGF and neuregulin 1β (NRG1β) or the 
dual inhibitor Lapatinib, that targets HER2 and EGFR. HCC1954 cells only showed 
minor induction of MCT4 expression after treatment with high concentrations of EGF 
while treatment with NRG1β had no effect (Fig 5.6A). In contrast, treatment with the 
inhibitor Lapatinib slightly reduced the levels of MCT4 expression (Fig 5.6A). The 
weak induction of MCT4 in HCC1954 cells might be due to the low affinity of HER2 
for ligands and the ligand-independent activation of HER2 in these cells due to 
amplified ERBB2. MDA-MB-468 cells weak MCT4 expression showed weak basal 
MCT4 expression but a stronger increase in MCT4 expression after treatment with 
increasing amounts of EGF. However, NRG1β and Lapatinib did not affect MCT4 
expression in these cells (Fig 5.6B). Of note, NRG1β stimulation of MDA-MB-468 
cells might not trigger ERBB signalling given that NRG1β is not a ligand for EGFR. 
The different levels of inhibition of EGFR/HER2 signalling by Lapatinib in breast 
cancer cells lines has been established and HCC1954 cells are more sensitive towards 
Lapatinib compared to MDA-MB-468 cells (Konecny et al., 2006). 
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To further investigate HER2 signalling in SLC16A3 regulation, MCF10A cells that 
show the highest levels of SLC16A3 expression (see Fig 5.5) and MCF10A cells 
overexpressing ERBB2 (MCF10A-ERBB2) were analysed for SLC16A3 expression 
under normoxic and hypoxic conditions (Fig 5.7). MCF10A-ERBB2 cells were a 
generous gift from Dr. Eyal Gottlieb (Beatson Institute, Glasgow). MCF10A cells 
showed induction of SLC16A3 mRNA after exposure to hypoxia (p<0.0001). However, 
MCF10A-ERBB2 cells had significantly lower SLC16A3 mRNA levels under normoxic 
conditions compared to MCF10A cells (p<0.0001). However, these cells also showed a 
strong induction of SLC16A3 under hypoxia, even though the final levels were slightly 
lower than in MCF10A cells (Fig 5.7A). A similar result was obtained when LDHA 
expression was determined as a positive control for HIF-dependent signalling (Fig 
5.7B). Similar observation was found when looked at the MCT4 expression at protein 
level (Fig 5.7C). 
Next, it was aimed to determine whether SLC16A3 expression is influenced when cells 
are cultured in matrigel for 3D growth. Acini of MCF10A cells with their characteristic 
hollow lumen showed distinct MCT4 expression on the cell membranes that face 
towards the outside of the acinar structure. However, the disorganised structures of 
MCF10A-ERBB2 cells with cell remaining in the lumen displayed stronger staining of 
MCT4, particularly in the cells that are located within the lumen of these structures (Fig 
5.7C). 
 
Taken together, this preliminary data suggests that MCT4 expression is regulated by 
activation of HER/ERBB signalling. To elucidate the mechanism of regulation of 
SLC16A3 by the ERBB family, further experiments are needed. 
 
5.5 Exposure to hypoxia induces SLC16A3/MCT4 expression in some 
breast cancer cells 
It has been shown that SLC16A3 expression can be regulated directly by HIF1α (Ullah 
et al., 2006). To investigate whether its expression changes after exposure to low 
oxygen in the panel of breast epithelial cell lines, SLC16A3 expression in these cell 
lines was determined on RNA and protein level after exposure to low oxygen for 24 
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hours. This revealed that SLC16A3 is strongly upregulated on mRNA (Fig 5.8A) and 
protein level (Fig 5.8B) under hypoxic conditions compared to normoxic conditions in 
most cell lines. However, MCF7, HCC1806 and 184B5 cells lacked the induction of 
SLC16A3 after exposure to hypoxia on RNA and protein levels (Fig 5.8).  
To further determine the role of SLC16A3 and its association to cell survival under 
hypoxia, four cell lines were exposed to hypoxia in a time dependent manner and the 
expression of SLC16A3 was assessed (Fig 5.9). To assure that the observed changes 
correlate with the activation of HIF in hypoxia, VEGFA expression was used as a 
positive control.  
The non-malignant cell line MCF10A, that was insensitive to depletion of SLC16A3, 
showed only a minor increase in SLC16A3 expression, after an initial downregulation 
of SLC16A3 mRNA after 2 hours of hypoxia, while a strong reduction of VEGFA 
expression was observed with prolonged exposure to hypoxia (Fig 5.9A). In contrast, 
the sensitive cell line MDA-MB-468 strongly upregulated SLC16A3 under hypoxia. 
This correlated with VEGFA expression (Fig 5.9B). Analysis of the sensitive cell line 
HCC1954 revealed strong induction of SLC16A3 and VEGFA (Fig 5.9C). 
To determine whether the hypoxic survival of the breast epithelial cell lines is 
predictive for their sensitivity towards SLC16A3 ablation, a Pearson correlation was 
performed (Fig 5.10). A Pearson r factor of 1 indicates a strong positive correlation, 
whereas -1 indicates a negative correlation. Analysis of the Z-scores of each cell line 
with the level of cell survival under hypoxia resulted in a Pearson r factor of -0.45 
indicating that a weak negative linear correlation exists (Fig. 5.10). 
 
In summary, HIF dependent upregulation of SLC16A3 mRNA was observed in MDA-
MB-468 and HCC1954 cells. The insensitive cell line MCF10A however only showed a 
weak induction of SLC16A3 expression. This might partially explain the observed 
insensitivity to SLC16A3 depletion in these cells under hypoxia. Moreover, the 
sensitivity towards SLC16A3 silencing point to a weak correlation with the survival 
under hypoxic conditions of breast cell lines. 
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5.6 SLC16A3 silencing results in decreased intracellular pH 
MCT4 is involved in the transport of monocarboxylates and protons across membranes. 
This requires the presence of its co-chaperone BSG that translocates MCT4 to the 
membrane. The ablation of SLC16A3 might thereby result in changes in the intracellular 
pH (Kirk et al., 2000). To determine whether SLC16A3 depletion influences the pH 
homeostasis in these cells, intracellular pH was measured using the fluorescent probe 
SNARF. MCF10A cells showed no change in intracellular pH under normoxic 
conditions after silencing of SLC16A3 or when BSG was depleted (Fig 5.11A). The cell 
lines HCC1954 and MDA-MB-468, that showed impairment of cell viability after 
abrogation of SLC16A3, exhibited decreased pHi after silencing of SLC16A3 under 
normoxic conditions (Fig 5.11B,C). In addition, HCC1954 cells showed a significant 
decrease in pHi not only in SLC16A3 silenced cells, but also in BSG silenced cells under 
hypoxia (Fig 5.11B). MDA-MB-468 reduced their pHi after SLC16A3 silencing, but 
ablation of BSG did not cause a reduction in pHi (Fig 5.11C). Analysis of pHi in MDA-
MB-231 revealed no changes under normoxic conditions, while an increase in pHi was 
observed after SLC16A3 depletion under hypoxic conditions (Fig 5.11D).  
To investigate if the altered pHi in some of these cells is due to accumulation of lactate, 
intracellular lactate levels were determined in both oxygen conditions (Fig 5.11E-H). 
Analysis of the cells under normoxia showed that there was no increase in intracellular 
lactate. Under hypoxic condition, however, intracellular lactate was increased in BSG 
silenced HCC1954 and MDA-MB468 cells, but not after ablation of SLC16A3 in any of 
the cell lines.  
To further investigate the cause of a reduction in pHi, supernatants of control and 
SLC16A3 silenced MDA-MB-468 cells were analysed by mass spectrometry to assess if 
there are changes in the rates of metabolite import or export after abrogation of 
SLC16A3 (Fig 5.12). In normoxia (Fig 5.12A), the export of lactate, malate, and 
isocitrate/citrate was reduced after ablation of SLC16A3. It should be noted, however, 
that the amount of lactate exported by control cells was 10-times higher compared to the 
amount of citrate/isocitrate. This confirms that MCT4 is involved in the export of 
lactate from these cells. Moreover, cells with silenced SLC16A3 showed increased 
uptake of the amino acids glutamine, isoleucine/leucine, lysine and arginine. Mass 
spectrometry analysis of the supernatants from hypoxic cells showed that SLC16A3 
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silencing caused a strong reduction in lactate and isocitrate/citrate export, suggesting 
that lactate is accumulating in these cells (Fig 5.12B). In contrast, glutamate export 
increased in SLC16A3 silenced MDA-MB-468 cells compared to control transfected 
cells. In addition, besides the decreased import of several amino acids (e.g. glutamine, 
arginine, phenylalanine, lysine), glucose import showed a strong reduction after 
ablation of SLC16A3 under hypoxia (Fig 5.12B). It should be noted, however, that the 
detection of glucose by the technique used here is not very accurate.  
 
To assess whether the export of pyruvate and lactate after SLC16A3 silencing has an 
effect on mitochondrial activity, the oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) was investigated in three cell lines cultured under standard 
medium conditions in normoxia (Fig 5.13). The non-malignant cell line MCF10A 
showed no changes in OCR after depletion of SLC16A3 compared to control transfected, 
accompanied by decreased ECAR levels (Fig 5.13A). In contrast, MDA-MB-468 breast 
cancer cells showed increased OCR but displayed only a minor increase in ECAR levels 
(Fig 5.13B). MDA-MB-231 showed no change in OCR after SLC16A3 depletion 
although the ECAR was increased after silencing of SLC16A3 (Fig 5.13C). 
 
Next, it was aimed to rescue the effect of SLC16A3 silencing on cell number in MDA-
MB-468 and HCC1954 cell lines by perturbation of metabolic processes (Fig 5.14). 
MDA-MB-468 and HCC1954 cells showed a reduction of cell number after treatment 
with 2-DG or glutamine withdrawal, while treatment with dichloroacetate (DCA), an 
inhibitor of PDHK1, or glucose withdrawal only had minor effects under normoxia. 
Silencing of SLC16A3 resulted in a 50% reduction of cell number in DMSO-treated 
cells and this was not enhanced by treatment with 2-DG or glutamine withdrawal (Fig 
5.14A,B). However, in hypoxic cells, treatment with 2-DG in both cell lines or 
withdrawal of glucose in HCC1954 reduced cell number in control transfected cells. 
This was not further enhanced by SLC16A3 silencing in both cell lines after treatment 
with 2-DG (Fig 5.14A,B), suggesting that SLC16A3 ablation targets the metabolic 
pathways also affected by 2-DG treatment. It was surprising that glucose withdrawal of 
SLC16A3 depleted HCC1954 cells had a pronounced effect compared to DMSO treated 
cells after SLC16A3 silencing under hypoxia.  
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Collectively, these results indicate that SLC16A3 influences pH homeostasis by 
affecting lactate transport. Moreover, cancer cells depleted of SLC16A3 seem to import 
more amino acids under normoxic conditions. Under hypoxic conditions, the import of 
several metabolites, including the carbon sources glucose and glutamine was decreased 
after silencing of SLC16A3. It could be hypothesised that this indicates that cells 
respond to SLC16A3 silencing by entering a state of starvation. This has to be further 
investigated. In addition, the fate of lactate in the absence of SLC16A3 needs to be 
elucidated, as no accumulation of intracellular lactate was observed. However the OCR 
and ECAR data suggests that MDA-MB-468 cells indeed try to use their mitochondrial 
activity to cope with increased levels of lactate, pyruvate, aspartate and malate under 
normoxic conditions. 
5.7 Ablation of SLC16A3 increases ROS levels 
To investigate if SLC16A3 affects intracellular ROS, the ROS levels in four cell lines 
following SLC16A3 depletion under normoxic conditions were determined. The non-
malignant cell line MCF10A showed a minor increase in ROS levels (Fig 5.15A), while 
MDA-MB-231 showed no change in ROS levels compared to the control transfected 
MDA-MB-231 cells (Fig 5.15B). In contrast, the sensitive cell line MDA-MB-468 
increased its ROS levels significantly after silencing of SLC16A3compared to the 
control silenced cells (p<0.0001). This was also observed in the second sensitive cell 
line HCC1954 (p=0.004). 
These results indicate that SLC16A3 might be important for the cellular redox balance. 
The sensitive cell line MDA-MB468 increased its OCR after SLC16A3 ablation, while 
ECAR was reduced. This could indicate increased mitochondrial metabolism resulting 
in enhanced production of ROS. In addition, MDA-MB-468 cells showed decreased 
serine uptake and increased levels of glutamine and glutamate uptake, suggesting that 
the serine biosynthesis pathway could be upregulated to compensate for increased ROS 
levels in SLC16A3 depleted cells. However, the mechanism why these cells increase 
ROS after SLC16A3 depletion is still under investigation. 
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5.8 SLC16A3 depletion affects cell viability in an in-vivo like system 
To assess whether SLC16A3 depletion shows similar phenotypes in a more in-vivo like 
situation, 3D cultures and spheroid formation after transient siRNA transfection were 
established and analysed. MDA-MB-468 embedded in matrigel showed that SLC16A3 
silencing affected cell viability, while BSG silencing did not have an effect on cell 
viability (Fig 5.16A). The same was observed for HCC1954 cells (Fig 5.16B). 
Depletion of BSG, however, reduced cell viability in HCC1954. In contrast to the 
sensitive cell lines MDA-MB-468 and HCC1954, 3D cultures of MDA-MB-231 cells 
were not impaired in their viability after silencing of SLC16A3 or BSG (Fig 5.16C). 
These observations were also confirmed by spheroid formation assays (Fig 5.17). 
Clusters of HCC1954 and MDA-MB-468 cells transfected with siSLC16A3 were 
smaller in size compared to control transfected cells (Fig 5.17 A,B). In contrast, MDA-
MB-231 showed no changes in the size or appearance of the 3D cell clusters after 
depletion of SLC16A3 (Fig 5.17C). 
 
Collectively, these findings indicate that SLC16A3 could play a role in the growth of 
breast cancer cell lines in-vivo.  
5.9 Depletion of SLC16A3 using shRNA results in decreased cell viability 
To confirm SLC16A3 as an essential mediator of cell survival in ER-negative cancer 
cells lines (HER2-positive, ER-negative/HER2-negative), four cell lines were taken 
forward for lentiviral infection with TET-pLKO constructs, each containing a different 
shRNA sequence targeting SLC16A3. The expression of these shRNAs is under the 
control of the Tet-operator and can be induced by doxycycline administration.  
First, silencing efficiency of the different shRNAs was tested. Effective silencing on 
RNA and protein expression upon doxycycline treatment was observed in all four cell 
lines with at least one sequence (Fig 5.18).  
 
To establish if shRNA-mediated silencing also affects cell viability, colony assays were 
carried out. The sensitive cell line MDA-MB-468 and the insensitive cell line MDA-
MB-231, both expressing shRNAs targeting SLC16A3, were cultured for 10 days in the 
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presence or absence of doxycyline (Fig 5.19). Loss of cell viability was observed in 
doxycycline treated MDA-MB-468 cells containing shRNA sequences #74 and #88 
compared to their untreated counterparts (Fig 5.19A) and this was confirmed by 
quantified measurements (Fig 5.19B). In contrast, MDA-MB-231 cells displayed no 
effect in all samples treated with doxycycline compared to the non-doxycyline treated 
samples and no significant effect of silencing of SLC16A3/MCT4 was observed (Fig 
5.19B, D).  
 
To investigate the cause of the reduction in cell viability, the metabolic state of the cells 
was investigated. To do this, the acute effect of glucose and glutamine on oxygen 
consumption was investigated using the Seahorse Bioanalyser (Fig 5.20). Cells were 
initially depleted of glucose and glutamine and basic OCR was determined. Both 
metabolites were then sequentially injected into the plate and changes in OCR over the 
baseline were recorded. After titration of glucose into the glucose- and glutamine-
depleted medium, MDA-MB-468 cells (either expressing a scrambled shRNA or in the 
absence of doxycycline) displayed a decrease in oxygen consumption after injection of 
glucose (Fig 5.20). Ablation of SLC16A3 by doxycycline administration reduced the 
ability of the cells to decrease their OCR following glucose injection. This effect was 
even more pronounced when glutamine was subsequently injected into the now 
glucose-containing medium (Fig 5.20A). In contrast, the insensitive cell line MDA-MB-
231 showed a small increase in OCR after glucose or glutamine injection and this was 
not affected by depletion of SLC16A3 (Fig 5.20B). 
 
In summary, these results suggest that the ablation of SLC16A3 leads to decreased long-
term viability only in sensitive breast cancer cell lines. Furthermore, in sensitive cell 
lines depletion of SLC16A3 prevents cell from reducing their OCR in the presence of 
glucose. Increased mitochondrial metabolism in the absence of SLC16A3 could cause 
enhanced oxidative stress and cell death.  
5.10 SLC16A3 is important for tumour formation and progression in-vivo 
Given that silencing with shRNA promotes long-term silencing compared to siRNA, 
and to further characterise SLC16A3 as a regulator of cell survival in a more in-vivo like 
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situation, spheroid formation assays were performed over a period of 12 days with 
MDA-MB-231 and MDA-MB-468 cells containing shRNA sequence #88 (Fig 5.21A). 
Immunohistochemical analysis was performed on spheroid sections to show diminished 
MCT4 expression after doxycycline treatment. Staining for active caspase 3 was used to 
detect apoptotic cells. Transduced MDA-MB-468 cells formed spheroids with a 
necrotic inner core shown by the hematoxylin and eosin staining. Moreover, the 
expression of MCT4 was mainly located in an area between the outer cell layers and the 
necrotic core. In this area, MCT4 showed stronger staining on the plasma membrane 
(Fig 5.21A). The staining of cleaved caspase correlated with MCT4 expression in 
untreated cells. Depletion of SLC16A3 reduced spheroid size and expression of MCT4 
in the inner core and only weak staining was detected on the plasma membranes of the 
spheroid cells. Moreover, it appeared that the cleaved caspase staining was not as 
pronounced compared to the untreated sample (Fig 5.21A). The spheroids of MDA-
MB-468 were phenotypically different from those of MDA-MB-231 cells with no 
defined necrotic core (Fig 5.21B). In addition, light patches were distributed within the 
spheroid. The detection of MCT4 in the control cells displayed strong membranous 
staining especially in the cells at the border between the spheroid and the medium. In 
contrast, the inner core showed more cytoplasmic staining of MCT4. The light patches 
were negative for MCT4 staining. There was only weak staining for cleaved caspase 
with no distinct pattern. After doxycyline induced silencing of SLC16A3, it was noted 
that the spheroids were larger and this is mainly due to an increase in size of the lighter 
patches. There was also a clear reduction in MCT4 expression visible and no cleaved 
caspase staining of any distinct area. 
 
To establish whether SLC16A3 is important for tumour growth, cells of the sensitive 
breast cancer cell line MDA-MB-468 transduced with the shRNA construct #88 were 
orthotopically injected into the mammary fat pad of 8-week old female immuno-
compromised mice (nu/nu). After initial tumour formation (10 days post-injection) mice 
were separated and one cohort was given doxycycline in their diet to initiate the 
depletion of SLC16A3 whereas the other cohort was kept on a standard diet. Tumours of 
the mice in the different cohorts were measured twice per week and tumour volume was 
calculated with the ellipsoidal volume formula: ½ x length x (width)2. After 65 days, 
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depletion of SLC16A3 showed a strong impairment of tumour growth in the 
doxycycline treated mice compared to the cohort on a standard diet. However, at the 
time of this thesis being written, this experiment was still ongoing (Fig 5.21C). 
To further determine a potential link between tumour growth and SLC16A3, different 
slides from a MMTV-PyMT transgenic mouse model (Guy et al., 1992) (provided by Dr. 
Erik Sahai) were probed for MCT4 expression. The expression of MCT4 in normal 
tissue was low and increased with the grade of neoplastic transformation (Fig 5.22). 
Remarkably, the expression of MCT4 in the mouse carcinoma was very distinct. In the 
adenocarcinoma/early carcinoma tissues, MCT4 expression was observed in tumour 
cells as well as in the surrounding fibroblasts. The carcinoma stage exhibited strong 
MCT4 expression in cancer cells on the border of the tumour with the stroma (Fig 5.22). 
This raises the interesting hypothesis that MCT4 expression could be important for the 
exchange of metabolites between the tumour and the stroma.  
 
Taken together, SLC16A3 expression is essential for tumour growth in breast cancer 
cells. Ablation of SLC16A3 impaired spheroid growth in MDA-MB-468 cells and 
reduced tumour formation of MDA-MB-468 cells in an orthotopic mouse model. The 
expression of MCT4 also correlated with tumour progression in a MMTV-PyMT mouse 
model. Moreover, breast cancer cell lines show a distinct response to SLC16A3 
depletion, suggesting that some breast cancer cells (e.g. MDA-MB-231) are not 
dependent on the function of SLC16A3.  
5.11 SLC16A3 expression is upregulated in human breast cancer 
To evaluate if SLC16A3 might be important for the biology of breast cancer, expression 
of its mRNA in breast cancer tumour specimen was assessed using the publically 
available platform Oncomine (Rhodes et al., 2004) (Fig 5.23). The TCGA dataset 
showed elevated expression of SLC16A3 in invasive carcinomas of the breast (Fig 
5.23A). A similar observation was found in the datasets of Zhao et al (Fig 5.23B) and 
Richardson et al (Fig 5.23C). Moreover, SLC16A3 expression differed between the 
normal and tumour stroma (Fig 5.23D). This might indicate the coupled metabolism 
between stroma and tumour cells (Brooks, 2007; Sonveaux et al., 2008). SLC16A3 
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expression was also found to be a predictor for the recurrence of breast cancer in the 
study by Finak et al (Fig 5.23E). 
Moreover, a tissue microarray of 75 breast specimen in duplicates was used to examine 
if the clinically defined subtypes show differential expression of MCT4 (Fig 5.24). The 
different staining intensities were determined by two different pathologists (Prof. 
Gordon Stamp, Dr. Daniel N. Rodrigues). Normal tissue cores showed low expression 
of MCT4 protein, whereas breast cancer cores showed higher expression. HER2-
positive breast cancer cores showed higher staining intensity in the tumour cells 
compared to the ER-positive/HER2-negative and ER-negative/HER2-negative subtypes 
(Fig 5.24A).  
Interestingly, GOBO, a online portal for gene expression data, can be used to find 
correlations between gene expression and breast cancer outcome (Ringner et al., 2011) 
showed that the overall survival (OS) of HER2-positive breast cancers is dependent on 
the expression levels of SLC16A3 (Fig 5.24B). HER2-positive tumours with high 
expression of SLC16A3 had an OS of 30-35% after 5 years whereas HER2-positive 
cancers with low or medium SLC16A3 expression showed an OS of 70% after 5 years 
of diagnosis (Fig 5.24B). 
 
Taken together, the data from Oncomine and GOBO as well as the TMA analysis 
support a role of SLC16A3/MCT4 in HER2-positive breast cancer. However, the 
regulation of SLC16A3 by the HER2 signalling axis and the molecular mechanisms 
underlying the dependence of these tumours on this transporter still needs to be 
elucidated. 
5.12 Discussion 
Patients with ER-negative breast cancer including HER2-positive and ER-
negative/HER2-negative subtypes show the worst overall survival (Owens et al., 2004; 
Slamon et al., 1987). This is due to the lack of personalised therapeutics in ER-
negative/HER2-negative breast cancer, highly aggressive tumours accompanied by high 
incidences of recurrence or the development of resistance against systemic therapy (Fan 
et al., 2006). In this chapter, the monocarboxylate transporter MCT4 was identified to 
be important for cancer cell survival of ER-negative breast cancers. Depletion of 
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SLC16A3 using siRNA and shRNA demonstrated reduced cell viability in-vitro and in-
vivo. This is primarily due to apoptosis supported by increased activity of effector-
caspases and enhanced PARP cleavage that was observed after SLC16A3 silencing 
under normoxic conditions. Interestingly, the cause of reduced cell viability and 
induction of cell death under hypoxia appeared to be different to that in normoxia as no 
activation of caspases was observed. This could indicate that the abrogation of 
SLC16A3 induces necrotic cell death in hypoxic cells, potentially via metabolic 
catastrophe. This hypothesis is supported by the impaired lactate export and decrease in 
intracellular pH found after SLC16A3 depletion. Reduced import of amino acids and 
glucose was also observed. Interestingly, this study showed that citrate and malate 
export are also influenced as a consequence of SLC16A3 depletion, suggesting that 
perturbing the activity of discrete nodes could have wide-ranging effects on the 
metabolic network. 
Using a commercially available tissue microarray, different invasive ductal carcinomas 
were probed for MCT4 expression and higher staining intensity for HER2-positive 
tumours was revealed. This is in line with increased expression of MCT4 in the HER2-
positive cell lines used in this study. A similar observation by Whitaker-Menezes and 
colleagues showed that 14 patients with HER2-positive breast cancer had increased 
SLC16A3 levels and this is associated with decreased OS (Whitaker-Menezes et al., 
2011). This is further supported by the results from the GOBO analysis, that showed a 
statistically significant reduction in overall survival in HER2-positive tumours with 
high SLC16A3 expression compared to normal/low expression tumours (see 5.24). 
However, there are other studies indicating that SLC16A3/MCT4 expression is not 
preferentially higher in HER2-positive tumours (McCleland et al., 2012; Pinheiro et al., 
2010a).  
Recent studies also demonstrated that another monocarboxylate transporter is important 
for the survival of ER-negative/HER2-negative and basal-like breast cancers (Pinheiro 
et al., 2010a). MCT1 expression has been shown to correlate with high glucose 
consumption and glycolytic activity in cancer cells (Birsoy et al., 2012a). Another study 
linked MCT1 to LDHB, an enzyme important for survival of breast cancer cells, 
arguing that these enzymes are co-upregulated (McCleland et al., 2012; Porporato et al., 
2011). However, this study also included MCT4 expression showing an inverse 
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correlation to high LDHB expression. This might indicate that LDHA and MCT4 
function together (Hussien and Brooks, 2011). Both enzymes are upregulated by HIF1α 
and are important for lactate production and secretion. Moreover, numerous studies 
demonstrated co-localisation between LDHA, MCT4, HIF1α and other glycolytic 
enzymes (e.g GLUT1) in breast tumours (Rademakers et al., 2011). 
New interesting data from Sonveaux and colleagues propose a coupled metabolism of 
different cells within tumours, suggesting that metabolites are exchanged between 
glycolytic and oxidative cells within a tumour (Sonveaux et al., 2008). It is possible that 
some tumour cells that are highly dependent on glucose express high levels of MCT1 to 
facilitate the export of pyruvate/lactate, which can then be used by highly glycolytic 
cells to generate energy and biomass.  
Interestingly, cells depleted of SLC16A3 showed a higher rate of glutamine and amino 
acid uptake. However, this was restricted to normoxic conditions. In hypoxia, glutamine 
uptake was reduced after SLC16A3 depletion. It has been shown that LDHA as well as 
glutamine are important for cell survival under hypoxia (Fantin et al., 2006; Wise et al., 
2008). To postulate a connection between MCT4 and glutamine metabolism needs 
further investigation. Surprisingly, only a weak dependency of breast cell lines on 
MCT1 in different oxygen conditions was observed (cells with high glucose uptake). 
Moreover, the panel of cell lines displayed no sensitivity to an MCT1 inhibitor 
(unpublished observation). This suggests that the dependency of cancer cells on 
different monocarboxylate transporters could be complex and might dependent on 
specific conditions, such as metabolite composition of the medium. However, the effect 
of SLC16A3 depletion on tumour growth clearly demonstrates that this transporter is 
required under physiological nutrient conditions. This confirms that the importance of 
the MCT family of proteins as a whole is unquestionable. 
Immunohistochemistry data from MMTV-PyMT suggests that increased expression of 
MCT4 correlates with tumour progression. Both the early stages of the mouse tumour 
progression model and the normal tissue cores of the human TMA showed low or 
absent expression of MCT4. Several studies have indicated MCT4 to be important for 
higher-grade tumours or proposed a role for MCT4 in cell invasion and metastasis 
(Chiche et al., 2012; Gallagher et al., 2009; Parks et al., 2011). A study in ccRCC cell 
lines and expression data from ccRCC tumours showed a strong link between MCT4 
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expression and dependency to hypoxia/HIF as these cells lack functional VHL 
(Gerlinger et al., 2012). Here, it is shown that cell lines sensitive to SLC16A3 depletion 
strongly upregulate its expression after exposure to low oxygen. Hypoxia also causes 
extracellular acidosis and this feature of the tumour microenvironment can promote 
cancer cell invasion and metastasis formation. It will be interesting to investigate 
whether MCT4 is also involved in the metastasis formation in the breast cancer cells 
used here. 
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Figure 5-1 SLC16A3 important for most breast cancer cells 
(A) Supervised cluster analysis identified SLC16A3 as a candidate gene for cell lines negative for hormone 
receptor expression. (*=p≤0.05, ***=p≤0.001). (B-E) MCF10A, HCC1954, MDA-MB-468 and MDA-MB-231 
cells were reverse transfected with siRNA targeting SLC16A3. 96 hours post-transfection, cells were 
stained with DAPI and analysed for cell number under normoxic (black bars) and hypoxic conditions (red 
bars). Values show mean and SD of two independent experiments with three independent replicates each. 
  
Chapter 5 Results 
 
 199 
 
Figure 5-2 SLC16A3 silencing induces apoptosis only under normoxic conditions 
Four breast epithelial breast cell lines MCF10A (A,), HCC1954 (B), MDA-MB-468 (C), and MDA-MB-231 
(D) were reverse transfected with siRNA targeting SLC16A3 and cultured under normoxic (black bars) and 
hypoxic conditions (red bars). (A-D) 96 hours post-transfection, cells were analysed for caspase activity. 
Results were normalised to protein content. Values show mean and SD of two independent experiments 
with three independent replicates each (***=p≤0.001, ****=p≤0.0001) (E) Three days post-transfection, 
whole cell lysates of MCF10A and MDA-MB-468 cells were harvested and analysed for PARP cleavage 
and MCT4 expression.  
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Figure 5-3 Growth factors in MCF10A medium are not protective after depletion of SLC16A3 
The sensitive cell lines HCC1954 and MDA-MB-468 (A) and the non-malignant insensitive MCF10A cell 
line (B) were reverse transfected with siControl or siSLC16A3 and cultured for 12 hours, before being 
placed in the indicated medium conditions. Cell number was determined by DAPI staining. Values show 
mean and SD of three independent replicates 
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Figure 5-4 Overexpression of mutant SLC16A3 constructs rescue siRNA mediated reduction in cell 
number 
The sensitive cell lines MDA-MB-468 and HCC1954 expressing empty vector (pBABE EV), wildtype 
SLC16A3 (pBABE SLC16A3 wt) or mutant SLC16A3 (pBABE SLC16A3 mut) were reverse transfected 
with siControl or siSLC16A3 duplexes #4 and #5, and cultured for 96 hours, before cell number was 
assessed. Whole protein lysates of the cells 72 post-transfection were harvested and analysed for MCT4 
expression. Values show mean and SD of a single experiment performed with three independent 
replicates. Unpaired t-test was used for significance calculation (**=p≤0.01, ***=p≤0.001). Constructs were 
generated with the help of Beatrice Griffiths. 
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Figure 5-5 Differential expression of SLC16A3/MCT4 in breast epithelial cell lines 
Breast epithelial cell lines were seeded 24 hours prior to harvesting whole cell lysates for protein and RNA 
analyses. (A+B) Expression of SLC16A3 was determined by (A) qPCR on mRNA level and (B) for protein 
expression. Unpaired t-test was used to determine p-values. Values in (A) show mean and SD of two 
independent experiments with two biological replicates each (**=p≤0.01, ***=p0.001, ****=p≤0.0001). 
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Figure 5-6 Influence of HER signalling on MCT4 expression  
HER2-positive cell lines HCC1954 and EGFR-amplified/ER-negative/HER2-negative MDA-MB-468 were 
seeded 24 hours prior to treatment with different ligands (EGF and NRG1β) or the dual HER2 and EGFR 
inhibitor Lapatinib for 24 hours before whole cell lysates were harvested and used for protein analyses. (A) 
Expression of MCT4 and β-actin in HCC1954 lysates was determined by immunoblot and quantified using 
ImageJ. (B) Expression of MCT4 and β-actin of HCC1954 lysates was determined by immunoblot and 
quantified using ImageJ. This experiment has been performed once. 
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Figure 5-7 ERBB2 overexpression in MCF10A cells alters SLC16A3/MCT4 expression  
The non-malignant MCF10A breast epithelial cells and ERBB2-overexpressing MCF10A cells were 
seeded in 2D for 12 hours prior to exposure to hypoxia for further 24 hours. Whole cell lysates were 
harvested for protein and RNA analyses. Expression of SLC16A3 (A) and LDHA (B) was determined by 
qPCR on mRNA level. Values show mean and SD of two independent experiments with two biological 
replicates each. Unpaired t-test was used to determine p-values. (*=p≤0.05, **=p≤0.01, ***=p0.001, 
****=p≤0.0001). (C) Expression of MCT4 and β-actin were determined by immunoblot. (D) Non-malignant 
MCF10A breast epithelial cells and ERBB2-overexpressing MCF10A cells were embedded in matrigel for 
3D culture for 15 days. Cells were then fixed and stained according to a protocol provided by Prof. Joan 
Brugge (Harvard Medical School, Boston, MA, USA) and immuno-fluorescent staining of MCT4 and DAPI 
was assessed by confocal microscopy. Images show a series of confocal sections along the z-axis. 
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Figure 5-8 SLC16A3/MCT4 upregulation under hypoxic conditions 
(A) Cells of breast epithelial cell lines were seeded for 24 hours before exposure to hypoxia for further 24 
hours. Whole cell lysates were harvested for total RNA and analysed for SLC16A3 and β-actin expression 
by qPCR. Graph shows SLC16A3 mRNA levels normalised to β-actin from cells under normoxic (black 
bars) and hypoxic (red bars) conditions. Values show mean and SD of one independent experiment with 
two biological replicates each. (B) Cells of breast epithelial cell lines were seeded for 24 hours before 
exposure to hypoxia for further 24 hours. Whole cell lysates were harvested for protein analysis of HIF1α, 
HIF2α, MCT4 and β-actin expression for cells cultured in normoxia (N) and hypoxia (H).  
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Figure 5-9 Induction of SLC16A3 in hypoxia 
MCF10A cells (A), HCC1954 cells (B) and MDA-MB-468 cells (C) were seeded 12 hours prior to being 
placed in hypoxia for 0-24 hours. Whole cell lysates were harvested for RNA analyses. Expression of 
SLC16A3 and β-actin was determined by qPCR. Values show mean and SD of an independent 
experiment with two biological replicates each. 
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Figure 5-10 Cell viability of breast cell line panel in hypoxia shows weak correlation with sensitivity 
towards SLC16A3 silencing 
Data from Figure 3.7 was used for the Pearson correlation with data from Figure 5.1. 
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Figure 5-11 Depletion of SLC16A3 decreases intracellular pH levels 
Four breast epithelial breast cell lines MCF10A (A,E), HCC1954 (B,F), MDA-MB-468 (C,G), and MDA-MB-
231 (D,H) were reverse transfected with siRNA targeting SLC16A3 and cultured under normoxic (black 
bars) and hypoxic conditions (red bars). (A-D) Three days post-transfection, cells were loaded with 
SNARF-4F, trypsinised and analysed by FACS to determine the intracellular pH. Displayed is the mean 
and standard deviation of 2 independent experiments with two independent replicates. (E-F) Three days 
post-transfection, cells were trypsinised and counted. Of each cell line, 0.5x106 cells were lysed with 
ddH2O before intracellular lactate levels were determined using the Biovision lactate detection kit. 
Displayed is the mean and standard deviation of 2 independent experiments with three biological 
replicates. Unpaired t-test was used for significance calculations. (*=p≤0.05, **=p≤0.01, ****=p≤0.0001).  
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Figure 5-12 Analysis of metabolite import and export in MDA-MB-468 after SLC16A3 ablation 
MDA-MB-468 cells were reverse transfected with control and SLC16A3 siRNA in triplicate and cultured for 
70 hours. Cells were placed in normoxia or hypoxia. Medium was collected at equal time points over a 
period of 24 hours and used to determine metabolite levels using mass spectrometry (Sebastien Dubuis, 
ETH, Zurich, Switzerland). The slope of the change in concentration for each metabolite over time was 
calculated to generate import/export rates and normalised to control transfected cells. Values shown 
represent the log2-transformed fold change in import/export rate for each metabolite in normoxic (A) and 
hypoxic (B) cells. 
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Figure 5-13 OCR and ECAR are influenced by SLC16A3 abrogation 
Three breast epithelial cell lines MCF10A (A), MDA-MB-468 (B), and MDA-MB-231 (C) were reverse 
transfected with siRNA targeting SLC16A3 or controls. Two days post-transfection, cells were trypsinised, 
counted and seeded into Seahorse analysis plates. Basal OCR and ECAR were assessed. Values show 
mean and SD of one independent experiment with five independent replicates each.  
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Figure 5-14 Metabolic dependency of the effect of SLC16A3 depletion on cell viability  
The sensitive breast cancer cell lines MDA-MB-468 (A) and HCC1954 (B) were reverse transfected with 
siRNA targeting SLC16A3 or controls and cultured under normoxic and hypoxic conditions. Twelve hours 
post-transfection, cells were treated with different inhibitors or depleted of either glucose or glutamine. 96 
hours post-transfection, cells were stained with DAPI and analysed for cell number. Cell number was 
normalised to siControl-transfected cells. Values show mean and SEM of six independent experiments 
with one biological replicate each. Unpaired t-test was used (*=p≤0.05, **=p≤0.01, ***=p≤0.001, 
****=p≤0.0001) 
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Figure 5-15 ROS levels increase in SLC16A3 depleted cells 
The breast cell lines MCF10A (A), MDA-MB-231 (B), MDA-MB-468 (C) and HCC1954 (D) were reverse 
transfected with siRNA targeting SLC16A3 or controls and cultured under normoxic conditions. 72 hours 
post-transfection, cells were treated with H2DCFDA and its incorporation was measured by FACS. Mean 
fluorescence intensity was normalised to that of siControl transfected cells. Values show mean and SEM 
of three independent experiments with two independent replicates each. Unpaired t-test was used to 
determine significance. (**=p≤0.01, ****=p≤0.0001) 
 
Chapter 5 Results 
 
 216 
 
Figure 5-16 Matrigel cultures of breast cells show reduced cell viability after SLC16A3 silencing 
The breast cell lines MDA-MB-468 (A) HCC1954 (B) and MDA-MB-231 were reverse transfected with 
siRNA targeting SLC16A3, BSG or controls and cultured under normoxic conditions. 12 hours post-
transfection, cells were trypsinised, counted and embedded on matrigel. The cell viability of cultured cells 
was assessed with CellTiterBlue assay. Mean fluorescence was normalised to siControl-transfected cells. 
Values show mean and SEM of three independent experiments with two independent replicates each. 
Unpaired t-test was used to determine significance (**=p≤0.01, ****=p≤0.0001) 
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Figure 5-17 Spheroid formation of breast cells shows reduction in size after SLC16A3 silencing 
The breast cell lines MDA-MB-468 (A), HCC1954 (B) and MDA-MB-231 (C) were reverse transfected with 
siRNA targeting SLC16A3 or controls and cultured under normoxic conditions. 12 hours post-transfection, 
cells were trypsinised, counted and incubated with 2% matrigel before centrifugation to initiate spheroid 
formation. Representative images of spheroids were assessed to determine size and pixel number was 
quantified with Adobe Photoshop. Mean pixel number of six different spheroids per condition was 
normalised to spheroids formed by siControl-transfected cells. Unpaired t-test was used to determine 
significance. (****=p≤0.0001) 
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Figure 5-18 SLC16A3/MCT4 depletion with shRNA reduces cell viability 
The breast cell lines MDA-MB-468 (A), MDA-MB-231 (B), HCC1954 (C), and MCF10A (D) were 
transduced with lentiviruses expressing two different shRNA sequences targeting SLC16A3 (#74 and #88) 
or scrambled control. 12 hours after seeding, cells were treated with doxycycline (dox) or EtOH. Whole cell 
lysates for total RNA (day 4) and protein (day 6) were harvested and analysed for SLC16A3/MCT4 and β-
actin expression. Values show mean and SEM of three independent experiments with two biological 
replicates each. Unpaired t-test was used to determine significance. (*=p≤0.05, **=p≤0.01) 
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Figure 5-19 Cell viability is reduced in MDA-MB-468 after shRNA-mediated depletion of SLC16A3 
The breast cell lines MDA-MB-468 (A) and MDA-MB-231 that have been transduced with two different 
shRNA targeting SLC16A3 (#74 and #88) or scrambled control were seeded at a density of 10,000 cells 
per well in a 12-well plate. 12 hours after seeding, cells were either treated with doxycycline (dox) or EtOH. 
Cell viability was assessed with crystal violet dye at day 10. Representative Images are shown (B) 
Quantification of staining shown in A. Values show mean and SEM of six independent experiments with 
three biological replicates each. Unpaired t-test was used to determine significance. (****=p≤0.0001) 
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Figure 5-20 SLC16A3 ablation influences OCR  
The breast cell lines MDA-MB-468 (A) and MDA-MB-231 (B) that have been transduced with two different 
shRNA targeting SLC16A3 (#74 and #88) or scrambled control were seeded at a density of 0.15x106 cells 
in a 6-well plate. 12 hours after seeding, cells were treated with either doxycycline (dox) or EtOH. On day 
6, cells were trypsinised, counted and plated in Seahorse analysis plates. The following day, cells were 
deprived of glucose and glutamine for 30 minutes before being placed in Seahorse Bioanalyzer. After 
measuring the baseline OCR of the cells, 10mM glucose was injected and OCR was measured three 
times. After this, 2mM glutamine was injected and OCR was measured again three times. Baseline OCR 
(after glucose and glutamine starvation) was set at 100. All measurements were performed with 6 
replicates. Unpaired t-test was used to determine significance. (**=p≤0.01***=p≤0.001) 
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Figure 5-21 SLC16A3 depletion impairs tumour growth in-vivo 
The breast cell lines MDA-MB-468 (A) and MDA-MB-231 (B) that have been transduced with lentiviruses 
expressing shRNA targeting SLC16A3 (#88) were incubated with 2% matrigel before centrifugation to 
initiate spheroid formation and seeded at a density of 0.1x104 cells per well in a low-attachment 96-well 
plate. 12 hours after seeding, spheroids were either treated with doxycycline (dox) or EtOH. At day 12, 
spheroids were collected, fixed and processed for H&E and immunohistochemical staining of MCT4 and 
cleaved caspase 3. Representative images of spheroids are shown here. (C) 1.5x106 cells of the breast 
cell line MDA-MB-468 transduced with a lentivirus expressing shRNA targeting SLC16A3 (TET-pLKO 
SLC16A3 #88) were mixed with with 10% matrigel and injected orthotopically into the mammary fat pad of 
8-week old immuno-compromised mice (nu/nu). After tumour initiation (day 10), mice were divided into two 
cohorts (4 mice in each cohort): one on standard diet while the other cohort was on a doxycycline 
supplemented diet (0.2g/kg doxycycline in food pellets). Tumours were measured twice per week and 
growth analysis is plotted here. (*=p≤0.05) 
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Figure 5-22 MCT4 expression correlates with tumour progression in a MMTV-PyMT mouse model 
Two slices of the four different stages that develop during MMTV-PyMT tumorigenesis were probed with 
MCT4 according to the staining protocol that was established for the TMA. Here are shown representative 
pictures of the four different stages at different magnifications. 
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Figure 5-23 SLC16A3 expression in human breast cancer 
Oncomine was analysed for studies that included SLC16A3 expression. The search was based on 
SLC16A3 being significantly different between normal and cancer tissue (A-C), cancer vs stroma (D) and 
recurrence (E). 
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Figure 5-24 SLC16A3 staining in human HER2-positive breast tumours 
(A) TMA purchased from BioMax was stained for MCT4 expression and analysed according to the staining 
intensity. Examples of the different staining intensities are displayed here (from absent 0 to high 3). (B) 
GOBO analysis of overall survival in HER2-positive tumour samples according to SLC16A3 expression.  
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6 Follow up of metabolic genes that are selectively required for the 
viability of specific subgroups of breast cancer cells 
This chapter focuses on preliminary results of six other metabolic enzymes that have 
been identified by the rank analyses and supervised clustering (see chapter 4). The 
validated candidate genes were chosen because they occurred in multiple comparisons 
or of special interest because of isoform specificity in breast cancer subtypes. The ER-
positive breast cancer cell lines harbouring PIK3CA mutations are sensitive to the 
ablation of TKTL1 (see Fig 4.19, whereas ER-negative cell lines showed dependency on 
PPAP2A, ME2 and ALDOA (see Fig 4.19. The supervised clustering analyses for 
metabolic parameters (e.g. high glucose utilisation versus low glucose utilisation) 
identified PPAP2C and ME1 as important genes for cell survival (see Fig 4.19. 
6.1 Malic enzyme ablation result in loss of cell number in ER-negative 
breast cancer cells  
Malic enzymes (ME) belong to the family of oxidative decarboxylases. They are highly 
conserved across different species. The different isoforms of malic enzyme have 
cofactor specificity and can be also distinguished by their location within the cell. Malic 
enzyme 1 (ME1) is a NADP+ dependent cytosolic enzyme, whereas malic enzyme 2 
(ME2) and malic enzyme 3 (ME3) are located in the mitochondria and utilise NAD+. 
Cytoplasmic malate is converted into pyruvate via ME1. This reaction produces 
cytosolic NADPH, which is important for the overall NADPH pool. Pyruvate can then 
re-enter the mitochondria to generate acetyl-CoA via oxidative decarboxylation 
(MacDonald, 1995). Malate is normally generated in the mitochondria as part of the 
TCA cycle. The malate-citrate shuttle can transport citrate out of the mitochondria and 
then further convert it to malate, which can be used for NADPH and pyruvate 
production (Farfari et al., 2000). Mitochondrial malate can be converted into 
mitochondrial pyruvate by ME2. This might allow cells to become independent of 
glucose-derived pyruvate. Other malate consuming enzymes are malate dehydrogenases 
(MDH1, MDH2) that play roles in oxaloacetate production and the malate-aspartate 
shuttle. So far, very little is known about the role of malic enzymes in cancer.  
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6.1.1 Differential expression of malic enzyme 1 and 2 in breast epithelial cell lines 
Supervised clustering analysis demonstrated that silencing of ME1 and ME2 is 
detrimental to the survival of some breast cell lines. The comparison of high and low 
glucose consuming cell lines showed that abrogation for ME1 is necessary for high 
glucose consuming cell lines under hypoxic conditions (Fig 6.1A). By comparing the 
different subtypes of breast cancer based on ER expression, ME2 silencing showed a 
stronger effect in the ER-negative subgroup under hypoxic conditions compared to 
normoxic conditions (Fig 6.1B).  
Because the silencing of these two isoforms of malic enzyme showed an effect on cell 
viability (see chapter 4, Fig 4.18B, C), the silencing efficiency was determined for both 
enzymes after depletion. The silencing efficiency on protein level after depletion of 
ME1 was good for the siRNA pool as well as each individual sequence in high glucose 
consuming BT-549 cells and low glucose consuming ER-positive/HER2-negative 
MCF7 cells. However, the low glucose consuming HER2-positive cell line SK-BR-3 
showed only minor silencing efficiency after ME1 depletion (Fig 6.1C). Comparing the 
reduction of mRNA with that of protein levels revealed that all four single siRNA 
duplexes deplete ME1 protein expression but only two sequences silence on mRNA 
level in BT-549 cells (see chapter 4, Fig 4.19C). 
After silencing of ME2, a good reduction in protein levels was observed in all three cell 
lines except for the siRNA oligo #3 in ER-negative/HER2-negative BT-549, ER-
positive/HER2-negative MCF7 and HER2-positive SK-BR-3. Of note, MCF7 siControl 
sample under hypoxia was not blotted correctly onto the membrane due to an air bubble 
(Fig 6.1D). The protein expression after ME2 depletion did correlate mostly with the 
RNA profile except for oligo #3 (Fig 4.19B). 
 
To determine the overall expression of both enzymes in the panel of breast epithelial 
cell lines, expression on mRNA and protein levels were analysed (Fig 6.2). It was 
observed that the HER2-positive cell lines expressed higher levels of ME1 compared to 
the other subgroups (Fig 6.2A). This was also observed on protein level (Fig 6.2B). 
ME2 expression was also higher in the HER2-positive subgroup mainly due to 
HCC1954 and also in the non-malignant cell lines compared to the ER-positive/HER2-
negative and ER-negative/HER2-negative subgroups (Fig 6.2C,D). Of note, ME2 
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mRNA levels were low in BT-549 cells, but their protein expression was high. This 
might indicate post-transcriptional regulation in these cell lines. 
 
6.1.2 Decrease in cell number after ME1 silencing is due to apoptosis 
To further investigate the reduction in cell number after silencing of ME1 or ME2, 
caspase activity was determined. In the high glucose consuming cell line BT-549 that is 
sensitive towards ME1 depletion, activity of caspases 3 and 7 was observed after ME1 
silencing using ME1 pooled siRNA oligos, or sequences #2 and #3 under normoxic and 
hypoxic conditions (Fig 6.3A). In contrast, neither MCF7 nor SK-BR-3 that both 
displayed low glucose consumption showed an induction of apoptosis (Fig 6.3B-C). 
Ablation of ME2 under normoxic conditions induced no increase in caspase activity 
when the pool of four siRNA duplexes was used. However, ME2 siRNA duplexes #2 
and #4 caused a small increase in cleaved caspases 3 and 7 in two of the three cell lines 
(Fig 6.4). Under hypoxic conditions, only the ER-negative/HER2-negative cell line BT-
549 showed increased caspase activity after transfection of ME2 siRNA pool or in each 
of the four individual siRNA duplexes (Fig 6.4A).  
Taken together, ME1 as well as ME2 ablation causes cells to undergo apoptosis.  
 
6.1.3 Effect of malic enzyme ablation on cellular redox balance 
Given that ME1 functions in the cytoplasm to generate NADPH, which is important for 
glutathione-mediated redox homeostasis, treatment with ROS scavengers was used to 
investigate whether loss of cell viability after ME1 depletion is caused by oxidative 
damage. To demonstrate whether ROS accumulation is compromising cell viability, two 
ROS scavengers, N-acetylcysteine (NAC) and 4-hydroxy-TEMPO (TEMPO), were 
therefore tested for their effect on caspase activity (Fig 6.5). Increasing amounts of the 
anti-oxidant TEMPO diminished the effect of ME1 depletion on cell viability in BT-549 
cells (Fig 6.5A), but not in MCF7 and SK-BR-3 cells as no increase in caspase activity 
following ME1 depletion was observed (Fig 6.5C,E). In contrast, the second antioxidant 
NAC showed no effect on reducing caspase activity after silencing of ME1 in any of 
these cell lines (Fig 6.5B,D and F). This might be explained by the different 
mechanisms of these ROS scavengers. TEMPO is a ROS scavenger that mimics 
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superoxide dismutase 2 (Sledzinski et al., 1995), whereas NAC is a precursor of L-
cysteine and glutathione (Ziment, 1988).  
 
Because of the effect on cell viability after TEMPO treatment, the ROS levels in all 
three cell lines following ME1 depletion under both oxygen conditions were determined. 
BT-549 cells showed elevated ROS levels under hypoxic conditions (Fig 6.6A). No 
increased ROS levels were detected in MCF7 and SK-BR-3 cells (Fig 6.6B,C). 
To evaluate if TEMPO reduces ROS levels, BT-549 cells were cultured under hypoxic 
conditions and treated with 2 µM TEMPO every 24 h before detecting ROS levels (Fig 
6.7). Indeed, BT-549 showed a reduction in ROS levels when treated with TEMPO after 
ME1 ablation.  
These preliminary experiments indicate that ME1 is important for cellular redox balance. 
However, it could be argued that the minor increase in ROS levels might not be 
sufficient to influence cell survival. An explanation for this could be that the cell death 
is due to other forms of oxidative damage that were not investigated here. This study 
only used H2DCFDA for the detection of ROS. Moreover, the impairment of cell 
viability might be a result of cumulative ROS over time, rather than an acute effect. 
 
6.1.4 Ablation of ME2 influences the NAD+/NADH ratio 
ME2 is important to generate NADH in the mitochondria for oxidation to produce 
energy via the electron transport chain. Since ME2 is a NAD+-dependent enzyme, it was 
investigated whether siRNA-mediated depletion of ME2 might cause an increase in the 
NAD+/NADH ratio. NAD+/NADH levels were determined in two independent 
experiments in the three representative cell lines. Silencing of ME2 in BT-549 cells 
resulted in a significant increase of NAD+/NADH compared to control-transfected cells 
(Fig 6.8A). This increase was absent or not significant in SK-BR-3 and MCF7 cells (Fig 
6.8B,C). The increased NAD+ levels affected the overall ratio of NAD+/NADH in the 
sensitive cell line and might therefore influence other metabolic processes that depend 
on NADH. 
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6.1.5 Ablation of ME1 and ME2 causes changes in intracellular metabolite levels 
The flux of metabolites through enzymatic reactions is regulated by the activity of the 
enzyme, but also by the availability of the substrate and the concentration of the product. 
Ablation of an enzyme might lead to a depletion of the product and an accumulation of 
the substrate. To assess whether ablation of ME1 and ME2 causes altered metabolite 
levels, intracellular metabolites were extracted and analysed by mass spectrometry. 
Unsupervised clustering of the significant fold changes (log2) are displayed in Figure 
6.9. Overall, the cluster analysis distinguished two main sub-clusters across the cell 
lines after depletion of ME1 or ME2 compared to the controls. The first cluster 
contained intracellular metabolites that show no clear effect or are downregulated, while 
the second cluster included metabolites that are upregulated in ME1 and ME2 silenced 
cells compared to the controls. Surprisingly, the three metabolites in this cluster are all 
associated with the TCA cycle. Depletion of ME2 showed an effect on malate, 
fumarate, and aspartate in all cell lines under both oxygen conditions. However, ME1 
silencing only affected these metabolites in BT-549 cells under hypoxia. SK-BR-3 cells 
displayed only a minor increase in these metabolites compared to BT-549 (Fig 6.9). 
 
Collectively, this preliminary data indicate that ME1 is necessary for cellular redox 
homeostasis in high glucose consuming cells such as BT-549, but not for the low 
glucose consuming cell lines. This might lead to growth inhibition via the accumulation 
of ROS. The ablation of ME1 affected metabolite levels only under hypoxic conditions, 
which could suggest impaired cell viability due to increased accumulation of malate, 
fumarate and aspartate. Interestingly, ME2 was required for ER-negative/HER2-
negative cell lines. Abrogation of ME2 caused increased NAD+/NADH levels in BT-
549 cells, but all cell lines showed elevated levels of three TCA cycle metabolites. This 
might suggest that mitochondrial metabolism plays a role in the response to ME2 
silencing. Further experiments are required to understand the role of ME1 and ME2 in 
these breast cancer cell lines. 
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6.2 ER-driven breast cancer cells harbouring a PIK3CA mutation are 
sensitive to TKTL1 ablation 
Multiple metabolic processes are involved to secure the demand in biomolecules for 
proliferating cancer cells including the pentose phosphate pathway (PPP). In 
mammalian cells, the PPP reactions take place in the cytoplasm. There are two main 
forms of the PPP: the oxidative and the non-oxidative pathway. The oxidative pathway 
generates approximately two thirds of all NADPH available in a cell. NADPH acts as a 
reducing power required for biosynthetic reactions such as lipogenesis and is also 
important to maintain the cellular redox balance. The non-oxidative process is 
responsible for the generation of pentoses and hexosamines, which are fundamental 
building blocks for aromatic amino acids and nucleotides. 
 
Transketolase-like 1, an enzyme involved in the non-oxidative PPP, is a homodimer 
encoded by the TKTL1 gene. It drives the conversion of sedoheptulose-7-phosphate and 
D-glyceraldehyde-3-phosphate to D-ribose-5-phosphate and D-xylulose-5-phosphate. 
This reaction connects the glycolytic pathway with the PPP. Previous work has shown 
that TKTL1 is overexpressed in lung, breast and gastrointestinal cancers (Foldi et al., 
2007; Kayser et al., 2011; Langbein et al., 2006). The ablation of TKTL1 led to decrease 
cell viability in cancer cells (Xu et al., 2009; Yuan et al., 2010). However there are 
contradictory studies about the role of TKTL1 and its influence on metabolic processes 
such as glycolysis (Mayer et al., 2010; Sun et al., 2010). In addition, mutated forms of 
TKTL1 have been discovered with a potential role in cancer (Coy et al., 2005).  
 
The supervised clustering analysis of the screen data revealed that the ER-positive 
breast cancer cells MCF7 and T-47D are more sensitive to TKTL1 silencing as both cell 
lines carry a PIK3CA mutation. Based on the screen data it was particularly interesting 
to investigate the role of TKTL1 under hypoxia. To confirm whether TKTL1 is 
selectively required for the survival of ER-expressing breast cancer cells harbouring a 
PIK3CA mutation under hypoxic conditions, the ER-positive/HER2-negative cell lines 
MCF7 and T-47D and the ER-negative/HER2-negative cell line BT-20, which also 
harbours a PIK3CA mutation, were used to deconvolute the four single siRNA duplexes 
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for TKTL1. The samples were analysed for knockdown efficiency on mRNA level as 
well as loss of cell number under normoxia and hypoxia (see chapter 4, Fig 18.A, Fig 
4.19E). Indeed, MCF7 and T-47D showed a reduction in cell number under hypoxia 
whereas BT-20 showed no loss of viability despite effective knockdown on mRNA 
level. This suggests that expression of ER is important for the sensitivity to TKTL1 
silencing. 
Given that ER-positive/HER2-negative breast cancers are mostly driven by the 
expression of ESR1 and estrogen regulated genes, it was aimed to elucidate the 
contribution of ESR1 and estrogen regarding the TKTL1 dependency in these cell lines. 
At first, ESR1, the gene encoding the estrogen receptor was ablated using siRNA. 
Silencing of ESR1 in MCF7 and T-47D cells under normoxic and hypoxic conditions 
caused a reduction in cell number by 25-30% in MCF7 and T-47D cells. BT-20 cells 
showed only a minor response to TKTL1 silencing. There was no additive effect of co-
silencing TKTL1 and ESR1 they both genes affect the same pathway. This might 
propose that TKTL1 is downstream of ER. 
To investigate this possibility, TKTL1 expression in the ER-positive/HER2-negative cell 
lines MCF7 and T-47D was determined by using an antagonist of estrogen, 4-hydroxy-
tamoxifen, that inhibits the transcriptional activity of ER and promotes its proteasomal 
degradation (Osborne and McGuire, 1979). Treatment with 4-hydroxy-tamoxifen 
caused a reduction in TKTL1 mRNA expression in MCF7 and T-47D under hypoxia, 
but not under normoxia (Fig 6.11). To further assess if TKTL1 expression is dependent 
on ER, MCF7 and T-47D were treated with the ER ligand 17β-estradiol. In MCF7 cells, 
treatment with 17β-estradiol, which downregulates ERα through ligand-mediated 
proteasomal degradation (Fan et al., 2004), led to the downregulation of TKTL1 
expression on mRNA level (Fig 6.11B). However, the response to 17β-estradiol in T-
47D was not conclusive (Fig 6.11D). Further experiments are needed to determine if 
TKTL1 is regulated by an ER-dependent mechanism and to elucidate the role of TKTL1 
in ER-positive breast cancer cells. 
 
Collectively, these findings indicate that TKTL1 is a candidate gene for ER-positive 
breast cancer cell lines harbouring a PIK3CA mutation. TKTL1 expression was 
repressed by treatment with the estrogen antagonist 4-hydroxy-tamoxifen. Moreover, 
Chapter 6 Results 
 
 233 
TKTL1 expression was decreased after 17β−estradiol stimulation. However, TKTL1 
was not among the genes identified to contain an estrogen response element (ERE) in 
their promotors (Carroll et al., 2006). This might suggest a more complex mechanism 
rather than a direct regulation.  
 
It should be noted that the ER-positive cell lines that are sensitive to TKTL1 ablation 
also harboured PIK3CA mutations. ZR-75-1 cells belonging to the ER-positive/HER2-
negative subtype but do not carry a PIK3CA mutation were insensitive to TKTL1 
silencing. It is therefore possible that PIK3CA and ER act in combination to induce the 
observed phenotype.  
6.3 Aldolase A 
Altered glycolytic flux is one hallmark of cancer metabolism and metabolic enzymes 
involved in glycolysis are upregulated in many different cancer types. One of these is 
Aldolase A, which converts 6-carbon-metabolites (F-1,6-BP, F-1-P or sedoheptulose-
1,7-phosphate) into the 3-carbon-molecules dihydroxyacetonphosphate and glycerate-3-
phosphate. 
 
There are three different genes coding for aldolases (A, B, and C) in mammals. The 
expression of aldolase isoforms varies across different tissues. ALDOA is constitutively 
expressed in most tissues, ALDOB is expressed mainly in hepatic, renal and small 
intestinal tissue (Lebherz and Rutter, 1969) whereas ALDOC is found in smooth muscle 
tissue and the brain (Baron et al., 1969) (Penhoet et al., 1969)  
Aldolase A has been identified as a direct transcriptional target of HIF1α. Moreover its 
substrate F-1,6-BP shares its binding to ALDOA with a inositol-3-phosphate (IP3) 
binding site (Koppitz et al., 1986).  
 
Studies in saccharomyces cerevisae demonstrated that mutants in ALDOA show severe 
growth defects and are not viable (Giaever et al., 2002). Moreover, ALDOA is 
overexpressed in malignant tumours (Tomonaga et al., 2004; Tsunematsu et al., 1968).  
Interestingly, human aldolases have also been linked to be involved in other cellular 
functions that are distinct from its role in metabolism (‘moonlighting’) (Waingeh et al., 
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2006). Aldolase has been shown to interact with actin in-vitro and in-vivo independent 
from its metabolic function (Wang et al., 1996; Wang et al., 1997).  
 
6.3.1 Aldolase A is important for the survival of ER-negative/HER2-negative cell 
lines under hypoxic conditions 
One of the candidate genes identified through supervised clustering analysis using ER 
and HER2 as a parameter was Aldolase A (see chapter 4). Depletion of ALDOA was 
selectively detrimental to ER-negative/HER2-negative cell lines under normoxia and 
hypoxia (Fig 6.12A). 
 
To confirm the effect of ALDOA ablation in these cells, the non-malignant cell line 
MCF12A, the HER2-positive cell line SK-BR-3 and the ER-negative/HER2-negative 
cell lines MDA-MB-231 were used to test different siRNA sequences targeting ALDOA. 
ALDOA protein levels were substantially reduced after siRNA transfection in MCF12A 
and MDA-MB-231 cells, while SK-BR-3 cells only showed minor effects. To confirm 
the on-target effect of ALDOA siRNA, ALDOA siRNA duplexes from another provider 
were used and similar results were obtained (Fig 6.12B). 
 
To investigate if the expression of ALDOA across the panel of breast epithelial cell 
lines caused the different levels of reduction in protein, RNA and protein expression 
was determined (Fig 6.13). Interestingly, overexpression of ALDOA was observed in the 
ER-negative/HER2-negative and non-malignant cell lines compared to the other 
subtypes (Fig 6.13A). However, the protein expression profile did not correlate with the 
mRNA expression levels, raising the possibility of post-transcriptional regulation (Fig 
6.13B).  
Because ALDOA has been identified as a HIF1α target (Duvel et al., 2010), all breast 
cell lines were cultured under normoxic and hypoxic conditions to investigate if 
ALDOA is induced under hypoxia. Indeed, preliminary results show that 16 out of 17 
breast epithelial cell lines upregulated ALDOA expression under low oxygen conditions. 
However, HCC38 did not show this induction (Fig 6.12C). Further studies are required 
to confirm this finding. 
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In summary, ALDOA was identified as a candidate gene that was selectively required 
for the survival of ER-negative/HER2-negative cell lines. Deconvolution confirmed that 
3 out of 4 siRNA duplexes show this effect. ER-positive/HER2-negative and HER2-
positive cell lines were less sensitive to the depletion of ALDOA despite efficient 
knockdown of expression. These findings suggest that ALDOA inhibition could 
potentially target only ER-negative/HER2-negative cell lines. However, the mechanism 
by which ALDOA supports cell viability still needs to be elucidated. 
  
Chapter 6 Results 
 
 236 
6.4 Lipid phosphate phosphatases 
Lipid phosphate phosphatases (LPPs) belong to the phosphatase super family. These 
integral membrane proteins are dephosphorylating various lipid phosphates such as 
sphingosine-1-phosphate (S-1-P), ceramide-1-phosphate and phosphatic acid (PA). 
LPPs regulate lipid components that can act as signalling molecules. They generate 
active second messenger signalling molecules (e.g. ceramide, sphingosine and 
diacylglycerol) that affect cell proliferation, migration and cell survival (Roberts and 
Morris, 2000; Sciorra and Morris, 2002).  
 
There are three different isoforms of LPP (Waggoner et al., 1999). Each isoform is 
encoded by a separate gene: PPAP2A encodes LPP1 (Kai et al., 1996), PPAP2B codes 
for LPP3 and PPAP2C codes for LPP2 (Brindley et al., 2002). The three isoforms have 
different substrate specificity and are expressed in a tissue specific manner. LPP1 and 
LPP3 are constitutively expressed in most tissues. These two isoforms show high 
affinity towards PA and lysophosphatic acid (LPA), whereas LPP2 shows higher 
affinity towards S-1-P. LPP2 expression has been shown to be restricted to brain, 
placenta and pancreatic tissue (Pyne et al., 2004).  
 
The effect of ablation of LPPs has been demonstrated in different studies. Deletion of 
LPP3 mice is embryonic lethal (Escalante-Alcalde et al., 2003). In contrast, mice 
deficient for LPP2 are viable and fertile and show no abnormal phenotype (Zhang et al., 
2000). The role of LPP1 during development has not been elucidated. However, LPP1 
expression in transgenic mice resulted in a different phenotype. These mice are smaller 
and show abnormal fur growth (Yue et al., 2004).  
It is has been proposed that some LPP isoforms may play a role in cancer. A study by 
Imai and colleagues showed that overexpression of LPP3 reduces growth of ovarian 
cancer cells (Imai et al., 2000). Moreover, LPP1 is involved in platelet-derived growth 
factor (PDGF) mediated induction of cell migration in mouse embryo fibroblasts (Long 
et al., 2006) and has been shown to affect ERK signalling and cell division (Jasinska et 
al., 1999). 
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6.4.1 Lipid phosphate phosphatases 1 and 2 are necessary for the survival of 
breast cancer cells 
PPAP2A and PPAP2C have been identified as candidate genes in the siRNA screen (see 
chapter 4) in breast cell lines under normoxic and hypoxic conditions. Sensitivity to 
PPAP2A depletion was more prevalent in the ER-negative/HER2-negative subtype 
under normoxia (Fig 6.14A). In contrast, resistance towards PPAP2A ablation was 
observe in the ER-positive/HER2-negative cell lines under normoxic conditions (see 
chapter 4, Fig 4.14C). Silencing of PPAP2C showed a stronger effect in high oxygen 
consuming cells (mostly ER-positive and HER2-positive cell lines) compared to low 
oxygen consuming cell lines (mostly ER-negative/HER2-negative cancer cell lines) 
under hypoxic conditions (Fig 6.14B). 
 
To test if PPAP2A and PPAP2C are differentially expressed across the breast epithelial 
cell lines, mRNA levels were analysed. PPAP2A and PPAP2C display strong 
differences in their expression across the cell line panel. However, the cancer cell lines 
BT-549, MDA-MB-468, MDA-MB-231, HCC1806, T-47D and HCC38 show high 
levels of PPAP2A mRNA (Fig 6.14C). PPAP2C expression was low across all cell lines 
except for HCC38 (Fig 6.14D). 
 
6.4.2 Loss of cell number after PPAP2A or PPAP2C silencing is accompanied by 
PARP cleavage 
Next, it was aimed to elucidate if the decrease in cell number is due to apoptosis. 
Therefore, whole protein lysates were analysed for cleaved PARP. The abrogation of 
PPAP2A induced PARP cleavage only in the ER-negative/HER2-negative cell line BT-
549, but not in the non-malignant cell line MCF12A and the ER-positive/HER2-
negative cell line MCF7. It should be noted that BT-549 cells show minor levels of 
PARP cleavage even in the mock or siControl transfected samples (Fig 6.15).  
Interestingly, reduction of cell number after PPAP2C silencing correlated with 
induction of cleaved PARP as BT-549 and MCF7, the two cell lines sensitive to 
PPAP2C ablation, show increased PARP cleavage (Fig 6.15). 
 
This preliminary data indicates that PPAP2A might be important for the survival of 
some ER-negative/HER2-negative cell lines and PPAP2C for high oxygen consuming 
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cells. This is in line with a study from Flanagan and colleagues suggesting PPAP2C to 
be a putative therapeutic target in cancer (Flanagan et al., 2009). However, further 
studies are needed to investigate the mechanism by which PPAP2A and PPAP2C 
support cancer cell growth and survival, and how the differential sensitivity of some 
cancer cell lines is determined.  
 
6.4.3 Discussion 
 
This study aimed to identify discreet metabolic dependencies by ablation of metabolic 
enzymes that are necessary for the survival of distinct subgroups of breast cancer cell 
lines. By using the siRNA screen (see chapter 4), 7 genes have been taken forward for 
further evaluation. It was found that two isoforms of malic enzyme (ME) play an 
important role in distinct subgroups of breast epithelial cell lines. ME1 and ME2 were 
validated and it was found that these isoform are highly expressed in HER2-positive 
cells compared to other cell lines within the panel. ME1 was selectively required for the 
survival of cell lines with high glucose uptake, while ME2 was mainly important for the 
survival of ER-negative cell lines (HER2-positive and ER-negative/HER2-negative) but 
was also found in several other comparisons. The preliminary results show that ablation 
of ME1 in BT-549 results in increased caspase activity, suggesting that the cell death in 
response to ME1 ablation involves apoptosis. ME1 is one of the enzymes that contribute 
to the cellular NADPH pool. This is important for biosynthetic processes and for 
sequestering of ROS, including mitochondrial superoxide. Indeed, induction of ROS 
levels after ME1 silencing was rescued when cells were supplemented with the ROS 
scavenger TEMPOL, a mimetic of mitochondrial superoxide dismutase, inhibiting the 
induction of apoptosis, supporting cell survival.  
 
In this study, it was also postulated that depletion of ME2 could be important for the 
survival of different cancer subgroups. It was found that ME2 is selectively required for 
ER-negative, ER-negative/HER2-negative and high glucose consuming cell lines. 
However, the mechanism by which ME2 contributes to cell viability is likely to be 
different to that of ME1, given that ME2 is a NAD+-dependent enzyme compared to the 
NADP+- dependent ME1. Furthermore, both enzymes have different localisation within 
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the cell with ME1 being cytoplasmic while ME2 is localised to the mitochondria. 
Interestingly, depletion of ME2 in BT-549 cells increased the cellular NAD+/NADH 
ratio, confirming its enzymatic function.  
When publicly available datasets of breast cancer were studied (i.e. Oncomine) no 
significant overexpression of either ME1 or ME2 was found (either between the 
differing subgroups or cancer to non-cancer samples). This might suggest that the 
activity of these enzymes is more important than their mRNA expression levels. It 
would be of great interest to investigate the effect of ME1 or ME2 silencing over a 
longer period of time using shRNA to determine their role in long-term cell survival and 
to study their contribution to tumour cell growth in an in-vivo setting (i.e. xenograft). 
Although not much is known about the different isoforms of malic enzyme in cancer, it 
would be of significant interest to determine if these enzymes can compensate for each 
other.  
 
The siRNA screen used was biased towards hormone receptor negative breast cancer 
cell lines (ER-negative/HER2-negative), as breast tumours from this subtype (triple 
negative) are generally difficult to treat and have the least favourable clinical outcome.  
 
While many studies have addressed the role of glycolytic enzymes in cancer, few 
studies have investigated the dependency of cancer cells on the activity of the PPP. The 
siRNA screen identified enzymes of this pathway that were selectively required for the 
survival of ER-positive/HER2-negative breast cancer cells. Of particular interest is 
TKTL1, an isoform of transketolase, which is part of the non-oxidative arm of the PPP. 
TKTL1 was selectively required for the survival under hypoxia of ER-positive/HER2-
negative breast cancer cells harbouring a PIK3CA mutation. Although the molecular 
mechanism by which TKTL1 supports cell survival still needs to be elucidated, it can be 
hypothesised that TKTL1 depletion could result in reduced levels of glyceraldehyde-3-
phosphate and F-6-P, which are required to maintain glycolytic flux and provide 
intermediates for lipid synthesis during cell growth. TKTL1 depletion might also lead to 
a reduction in cellular pyruvate that is necessary for biosynthetic processes and energy 
production. It is also notable that the non-oxidative PPP is necessary for the synthesis of 
ribose-5-phosphate required for nucleotide biosynthesis (Tong et al., 2009).  
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It would be of great interest to investigate other breast cell lines derived from ER-
positive breast cancer to see if they exhibit a similar dependency on TKTL1, given that 
over two thirds of diagnosed breast cancer patients in the UK present with ER-positive 
disease. Moreover, other cancer types such as ovarian and endometrial cancers are also 
driven by estrogen and could show similar dependencies. Many of these gynaecological 
cancers also harbour PIK3CA mutations, and TKTL1 might also play a role in these 
cancers (Krockenberger et al., 2007). Previous immunohistochemical studies have 
found a correlation between AKT expression and TKTL1 levels (Volker et al., 2008). 
 
The glycolytic enzyme ALDOA was identified to be selectively required for ER-
negative/HER2-negative cell lines. ALDOA is known to be a downstream target of 
mTOR/HIF signalling. Given that the ER-negative/HER2-negative cell lines display 
high proliferative capacity compared to the other breast cancer subtypes, it might be 
expected that these cell lines are highly dependent on ALDOA expression. ALDOA may 
be important to maintain the flux from 6-carbon- to 3-carbon-metabolites within the 
glycolytic process. Depletion of ALDOA may therefore arrest cells as not enough 
metabolic intermediates are generated to support rapid proliferation. This hypothesis 
has to be further investigated. 
 
Other interesting candidate genes were the two isoforms of an enzyme involved in lipid 
signalling. The lipid phosphate phosphatase PPAP2A was selectively required for 
viability of ER-negative cell lines in normoxia, while PPAP2C was selectively required 
for cell lines that show high oxygen consumption. These enzymes are important for the 
generation of specific lipid species (i.e. DAG), which are important in the activation of 
second messenger signalling molecules, such as PKC family members, that are known 
to be activated in cancers and promote tumour progression. Perturbation of the 
downstream signalling of these signalling intermediates might prevent the 
communication between extracellular stimuli and intracellular signalling cascades. 
Moreover, lipid biosynthesis, membrane fluidity and architecture might be altered 
resulting in cells not having enough lipids for proliferation. This is very speculative, and 
investigating the effect of PPAP2A/C isoforms on processes such as ER-stress, which is 
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activated when lipid synthesis is disrupted, would be of significant interest, although 
this requires further study. 
 
In summary, the siRNA screen revealed a number of different metabolic dependencies 
in breast cancer cell lines. Further work is needed to elucidate the molecular 
mechanisms by which these enzymes support the viability of cells within the different 
clinical, genetic and phenotypic subtypes of breast cancer.  
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Figure 6-1 Malic enzyme 1 and malic enzyme 2 are detrimental to the ER-negative breast cell lines 
(A) Supervised cluster analysis identified ME1 as a candidate gene for cell lines exhibiting high glucose 
utilisation under hypoxia. (**=p≤0.01). (B) Supervised cluster analysis identified ME2 as a candidate gene 
for ER-negative cell lines under hypoxia. (*=p≤0.05). (C) Whole protein lysates were harvested after siRNA 
transfection of ME1 in these cell lines for 72 hours and analysed for ME1 and β−actin. (D) Whole protein 
lysates were harvested after siRNA transfection of ME2 in these cell lines for 72 hours and analysed for 
ME2 and β−actin. 
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Figure 6-2 Differential expression of ME 1 and ME2 in breast epithelial cell lines 
Breast epithelial cell lines were seeded 24 hours prior harvesting whole cell lysates for protein and RNA 
analyses. (A+B) Expression of ME1 was determined by (A) qPCR on mRNA level and (B) for protein 
expression. (C+D) Expression of ME2 was determined by (C) qPCR on mRNA level and (D) for protein 
expression. LC is the control lysate to cross-compare immunoblots. Actin is shown as loading control. 
(*=p≤0.05, ***=p≤0.001, ****=p≤0.0001) 
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Figure 6-3 Loss of cell number after ME1 ablation is due to apoptosis 
(A) BT-549, (B) SK-BR-3 and (C) MCF7 cells were reverse transfected with non-targeting siControls, 
pooled or individual siRNAs targeting ME1. siUBB was used the positive control. Cells were cultured in a 
96-well format under normoxic or hypoxic conditions. After 96 hours of culture, cells and supernatants 
were analysed for the activity of caspases 3 and 7 using an enzymatic fluorescent assay. This assay was 
incubated 1.5 hours prior to measurement. Values were normalised to protein content (cell mass). Data 
shown is based on two independent experiments each done in triplicates. P-values were calculated using 
the unpaired t-test (*=p≤0.05, **=p≤0.01, ***=p≤0.001). 
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Figure 6-4 Loss of cell number after ME2 silencing leads to apoptosis 
(A) BT-549, (B) SK-BR-3 and (C) MCF7 cells were reverse transfected with non-targeting siControls, 
pooled or individual siRNAs targeting ME2. siUBB was used the positive control. Cells were cultured in a 
96-well format under normoxic or hypoxic conditions. After 96 hours of culture, cells and supernatants 
were analysed for the activity of caspases 3 and 7 using an enzymatic fluorescent assay. This assay was 
incubated 1.5 hours prior to measurement. Values were normalised to protein content (cell mass). Data 
shown is based on two independent experiments each done in triplicates. P-values were calculated using 
the unpaired t-test (*=p≤0.05, **=p≤0.01, ***=p≤0.001). 
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Figure 6-5 ROS scavenger diminish effect of cleaved caspase activity 
(A) BT-549 cells, (B) SK-BR-3 and (C) MCF7 cells were reverse transfected with siRNA targeting ME1 or 
the non-targeting siControl in a 96-well format and cultured under normoxic conditions. The indicated 
doses of NAC and TEMPOL were added repeatedly at 12, 24, 48 and 72 hours after transfection. After 96 
hours of culture, cells and supernatants were analysed for the activity of caspases 3 and 7 using an 
enzymatic fluorescent dye. Apo-one was incubated 1.5 hours prior to its measurement and normalised to 
protein content (cell mass). Data shown here is based on one experiment done in triplicates. P-values 
were calculated using the unpaired t-test (*=p≤0.05, **=p≤0.01). 
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Figure 6-6 ME1 abrogation increases ROS levels in BT-549 under hypoxia 
(A) BT-549 cells, (B) SK-BR-3 and (C) MCF7 were reverse transfected with siRNA targeting ME1 or the 
non-targeting siControl and cultured under normoxic and hypoxic conditions. After 72 hours the 
incorporation of H2DCFDA was measured by using FACS. H2O2 was added 1 hour before starting of the 
H2DCFDA incorporation as a positive control for determining ROS levels 
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Figure 6-7 ROS scavenger rescues effect after ME1 depletion 
BT-549 cells were reverse transfected with siRNA targeting ME1 or the non-targeting siControl and 
cultured under hypoxic conditions. The indicated doses of NAC and TEMPOL were added repeatedly at 
12, 24 and 48 hours after transfection before the incorporation of H2DCFDA was measured 72 hours post-
transfection. H2O2 was added 1 hour before starting the H2DCFDA incorporation as a positive control. Data 
shown here represent one experiment performed in triplicates. P-values were calculated using the 
unpaired t-test (*=p≤0.05, **=p≤0.01). 
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Figure 6-8 NAD+/NADH levels are affected after ME2 silencing  
(A) BT-549, (B) SK-BR-3 and (C) MCF7 cells were transiently transfected with ME2 siRNA or siControl 
and cultured for 72 hours under normoxic conditions. 0.2x106 cells per condition were used for analysis of 
the NAD+/NADH ratio. Data shown represents two independent experiments performed in duplicates 
Significance was calculated with unpaired t-test (*=p≤0.05). 
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Figure 6-9 Perturbation of ME1 or ME2 results in significant changes in succinate, fumarate and 
malate levels 
Cells of MCF7, SK-BR-3 and BT-549 cells were transiently transfected with ME1, ME2 siRNA or siControls 
in 6-well plates in triplicate. Cells were then cultured under normoxic and hypoxic conditions for 72 hours. 
Cells were then snap frozen in liquid nitrogen prior to metabolite extraction and analysed by mass 
spectrometry. Here shown is the log2 fold change of significant intracellular metabolite levels in log2 ME1 
ablated and ME2 ablated samples that have been normalised to siControl. 
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Figure 6-10 TKTL1 silencing is detrimental in ER-positive breast cancer cells under hypoxia 
(A) Supervised cluster analysis identified TKTL1 as a candidate gene for ER-positive/HER2-negative cell 
lines under normoxic and hypoxic conditions (*=p≤0.05). (B) ER-positive cell lines MCF7, T-47D and the 
ER-negative cell line BT-20 were transiently transfected with ESR1 or TKTL1 alone, or in combination 
under normoxic (black bars) and hypoxic conditions (red bars). Cells were analysed after 96 hours culture 
for changes in cell number. Data shown here are from two independent experiments. Unpaired t-test was 
used for testing significance. (*=p≤0.05, **=p≤0.01, ***=p≤0.001, ****=p≤0.0001) 
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Figure 6-11 TKTL1 is potentially regulated by the ER signalling 
MCF7 and T-47D were cultured under normoxic and hypoxic condition in phenol red free DMEM/F12 
supplemented with 10% charcoal-treated FCS 24 hours prior treatment with (A+C) 4-hydroxy-tamoxifen 
and (B+D) 17β-estradiol for 24 and 48 hours. Cell lysates were harvested for total RNA. Expression of 
TKTL1 on mRNA level was analysed by qPCR and normalised to β−actin. Data from two independent 
experiments are shown. (*=p≤0.05, **=p≤0.01) 
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Figure 6-12 ALDOA is important for the survival of ER-negative breast cancer cell lines under 
hypoxia 
(A) Supervised cluster analysis identified ALDOA as a candidate gene for ER-negative/HER2-negative cell 
lines under normoxic and hypoxic conditions (*=p≤0.05, **=p≤0.01). (B) Effects of ALDOA silencing with 
different siRNA sequences. Cells were reverse transfected with ALDOA siRNA and harvested for whole 
cell protein lysates after 72 hours and analysed for ALDOA and β-actin. 
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Figure 6-13 ALDOA expression is more prevalent in ER-negative breast cancer cells 
Expression of ALDOA in the panel of 17 breast epithelial cell lines. (A) Cells were seeded for 24 hours 
before total RNA was extracted and analysed for ALDOA and β-actin by qPCR. (B) Cells of breast 
epithelial cell lines were seeded for 24 hours before whole cell lysates for protein were harvested and 
analysed for ALDOA and β-actin. (C) Cells were seeded for 24 hours before exposure to hypoxia for 24 
hours. Whole cell lysates were harvested for total RNA and mRNA was then analysed for ALDOA and β-
actin by qPCR. Normoxia (black bars) Hypoxia (red bars). 
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Figure 6-14 PPAP2A and PPAP2C are important for survival of breast cell lines 
(A) Supervised cluster analysis identified PPAP2A as a candidate gene for ER-negative/HER2-negative 
cell lines under normoxic conditions. (*=p≤0.05). (B) Supervised cluster analysis identified PPAP2C as a 
candidate gene for supporting the survival of cell lines exhibiting high oxygen consumption under hypoxia. 
(*=p≤0.05). (C) Cells were seeded for 24 hours before total RNA was extracted. mRNA was then analysed 
for PPAP2A and PPAP2C and β-actin by qPCR. 
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Figure 6-15 PPAP2A and PPAP2C silencing results in PARP cleavage 
(A) Cells of the above breast epithelial cell lines were reverse transfected with PPAP2A or PPAP2C siRNA 
and cultured for 72 hours before being harvested for protein analyses. Supernatant as well as whole cell 
lysates were collected and analysed for PARP cleavage. AKT is shown as loading control. 
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7 Discussion 
7.1 Cancer metabolism 
Cancer is defined as a collection of complex and heterogeneous diseases depending on 
the tissue origin and the specific genetic repertoire of each tumour. Nevertheless, 
distinct phenotypic characteristics have been described that encompass the broad nature 
of cancer (Hanahan and Weinberg, 2011). One hallmark has been the rewired 
metabolism of cancer cells (Cantor and Sabatini, 2012). Within the last couple of years, 
the field of cellular metabolism in cancer was revived substantially. The initial finding 
of aerobic glycolysis was by Otto Warburg, who showed that cancer cells display 
increased glucose uptake, which is predominantly being converted into lactate even in 
the presence of oxygen. Nowadays, it is established that glucose dependency is one 
aspect of cancer cell metabolism. Experimental models of tumour progression in-vitro 
and in-vivo have shown that with increased transformation the cells become more 
reliant on glycolysis rather than mitochondrial respiration for energy production 
(Ramanathan et al., 2005). Glucose consumption studies in an in-vivo mammary mouse 
model have also monitored increased glucose uptake with FDG-PET during tumour 
progression from an in-situ ductal carcinoma to invasive carcinomas (Abbey et al., 
2004). 
 
However, it becomes more and more obvious, that this was just the tip of the iceberg 
given that genetic reprogramming of the metabolism by oncogenes and tumour 
suppressors, communication with the microenvironment to cope with limited supplies 
of oxygen and nutrient, homeostasis of pH and cellular redox potential all need to work 
together to facilitate the proliferative capacity of tumour cells (Cantor and Sabatini, 
2012; Vander Heiden et al., 2009). Not only are these processes highly complex, it is 
now established that cancer cell metabolism differs between different tissues in which 
tumours arise in and this is linked to the effects of the genetic alterations that drive these 
tumours (Yuneva et al., 2012). In-vivo analysis with stable isotope labelling in mice also 
illustrated site-specific cancer cell metabolism (Marin-Valencia et al., 2012). 
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This study aimed to elucidate the metabolic capacity of a panel of breast epithelial cell 
lines and to understand whether their dependency on specific metabolic processes could 
be exploited. Nowadays, breast cancer is a more generic term of different diseases that 
show distinct histopathological, molecular and clinical features. Despite the numerous 
subtypes, the main classification it is often referred to as ER-positive or ER-negative 
breast cancer, as gene expression studies have shown that ER-negative and ER-positive 
breast cancers show substantial differences leading to the conclusion that these 
represent different diseases (Perou et al., 2000; Sorlie et al., 2001). 
 
Clinically, breast cancer is differentiated by the expression of hormone receptors, 
receptor tyrosine kinase HER2 and tumours that lack the expression of these receptors. 
The development of molecular therapies such as endocrine therapy and inhibition of 
HER2 by targeted therapies, such as Tamoxifen for ER-positive and Trastuzumab and 
Lapatinib for HER2-positive breast cancer patients, have translated into improved 
overall survival. In contrast, patients who have breast tumours that do not display the 
expression of these extracellular receptors (ER-negative/HER2-negative) have to date 
only limited therapeutic options and their disease is treated with agents such as 
Anthracyclines that perturb DNA synthesis, which are less efficacious and toxic to all 
highly proliferative cells, not just cancer cells.  
7.2 Metabolic classification of breast cancer 
In chapter 3 it was established that the metabolism in different breast cancer cell lines 
shows distinct features. It was demonstrated that the ER-negative/HER2-negative 
subtype of highly proliferative breast cancer cells exhibit high aerobic glycolysis. 
Interestingly, these breast cancer cells also showed low mitochondrial activity and 
pseudo-hypoxic features. This has been recently confirmed by a study with multiple 
breast cancer cell lines which investigated the role of an isoform of LDH in cancer cell 
survival (McCleland et al., 2012). Altered mitochondrial metabolism can influence 
tumour growth. Silencing of the mitochondrial genes MRPL28 and MRPL12 that are 
involved in mitochondrial activity resulted in increased glycolysis and enhanced tumour 
growth (Chen et al., 2009). Moreover, genetic alterations that impaired mitochondrial 
respiration induce NADH levels and suppressed PTEN function leading to increased 
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AKT activity (Pelicano et al., 2006). The activation of AKT has been demonstrated to 
shift cell metabolism towards biosynthetic processes (Bauer et al., 2005; Hatzivassiliou 
et al., 2005). In chapter 3, it was also shown that high AKT activity correlates with 
PTEN and HER2 status in these cell lines. Therefore, it can be hypothesised that cancer 
cells harbouring loss of PTEN or amplified HER2 depend on lipogenesis as AKT 
signals through mTORC1 and induces the transcription factor SREBP1 (Duvel et al., 
2010; Porstmann et al., 2008). This might have clinical relevance for ER-
negative/HER2-negative tumours as they could benefit from dual inhibitors of 
mTORC1/AKT signalling, compounds that impede SREBP activity or the use of agents 
that inhibit lipid synthesis. 
 
The ER-positive/HER2-negative and HER2-positive cell lines were similar to each 
other when glucose utilisation and lactate secretion was investigated. Moreover, these 
cell lines displayed an oxidative phenotype compared to the ER-negative/HER2-
negative subtype. This was somewhat surprising as these subtypes differ in their clinical 
parameters including overall survival and aggressiveness. 
 
The results of the work described in chapter 3 also shows that breast epithelial cells 
displayed specific dependencies on glucose and glutamine, demonstrating that the non-
malignant cell lines were highly sensitive towards growth factor, glucose and glutamine 
withdrawal. Cancer cells were more resistant to growth factor or nutrient withdrawal. 
However, how starvation affects the metabolic processes and which metabolites are 
utilised for which process in these cells needs further investigation. 
 
To further characterise the differences in metabolism, metabolite analyses were carried 
out shown in chapter 3. ER-negative/HER2-negative cells were distinct from most other 
cell type with significant differences in amino acid metabolism when compared to the 
other subtypes. Previous studies analysed the metabolite repertoire of cancer cells under 
normoxic conditions (Jain et al., 2012; Sreekumar et al., 2009) and identified certain 
metabolites such as sarcosine and glycine as markers for tumorigenesis. These studies 
also determined that glucose utilisation correlates with the export of lactate. Not only 
lactate was secreted but also other metabolites (e.g. malate, isocitrate/citrate and 
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pyruvate) were also incompletely catabolised and secreted into the culture medium. 
Increased consumption of amino acids was also noticed in the cancer cells studied here. 
To better characterise amino acid metabolism in ER-negative/HER2-negative cells, 
tracing of isotope-labelled amino acids to evaluate their contribution to biochemical 
processes would be of great interest. Moreover, investigating whether ablation of 
specific amino acid transporters cause decreased cell viability or how amino acid 
starvation impact breast cancer survival are all interesting question remaining open as 
this study here did not focus on amino acid transporter in detail. Metabolite profiling 
within this study provides a foundation for the future studies.  
7.3 Functional studies 
Global siRNA and shRNA screens have been used successfully to identify drivers of 
tumorigenesis in multiple cell lines. (Toyoshima et al., 2012; Zuber et al., 2011). Small-
scale siRNA screens targeting the kinome or metabolic processes have shown to be 
valid approaches to identify particular dependencies (Brough et al., 2011; Possemato et 
al., 2011; Ros et al., 2012). Moreover, targeted siRNA screens performed using 2D 
cultures which recapitulate a component of the tumour microenvironment, such as low 
serum, have been validated in-vivo and shown to have a striking effect on tumour 
growth (Possemato et al., 2011; Ros et al., 2012). 
 
In the present study, a functional analysis using RNAi across 17 breast epithelial cell 
lines under normoxic and hypoxic conditions was performed. A small-scale siRNA 
library of 231 pooled siRNA duplexes targeting genes associated to metabolic processes 
was used. This has led to the identification of metabolic dependencies, which can be 
categorised according to the established breast cancer subtypes (chapter 4). 
The optimisation process that was undertaken was important for reducing non-
specific/off-target effects. A non-biased approach to screen transfection reagents for 
low toxicity and good siRNA delivery was performed. The screening conditions under 
hypoxia were used to recapitulate a feature of solid breast tumours, which can be found 
in-vivo that is associated with poor prognosis and decreased survival in patients. In 
chapter 4, a workflow for the identification of candidate genes was followed. Spearman 
analysis suggested robust screening data in most of the breast epithelial cells as the 
Chapter 7 Discussion 
 
 267 
controls behaved as expected and the replicates were similar to each other in most cases. 
Different analysis strategies were used to identify candidate genes, and, initially, genes 
that showed effects in more than two cell lines/ conditions were identified. Among these 
candidates were genes previously identified or mentioned in relation to cancer 
metabolism. ODC1 was predicted to be important in cancer cells (Hayes et al., 2006). 
Interestingly, some genes identified here were also found in other screens such as 
PIK3CA (Brough et al., 2011; Iorns et al., 2009), PFKFB1 (Iorns et al., 2009) and 
SLC16A3 (Possemato et al., 2011) suggesting reliable screening results in these cells. 
Moreover, non-malignant cells also displayed metabolic dependencies that were distinct 
from those of cancer cells (e.g. PDP2), indicating that cancer cells have specifically 
adapted their metabolism. However, it should be noted that the non-malignant cell lines 
were also highly proliferative under the 2D culture conditions used here. This is in 
contrast to the normal cells within living tissues as these are mostly in a differentiated 
state. 
The difficulty of modelling normal cells within an in-vitro system is a common 
experimental problem. However, 3D cultures of these cells better mimic the behaviour 
of different cell types in-vivo. 
7.4 Candidate genes 
In chapter 5, the role of the monocarboxylate transporter 4 (MCT4), which has been 
found to disturb pH homeostasis of ER-negative breast cancer cells, is described. It was 
demonstrated that cells after ablation of MCT4 increase their mitochondrial activity to 
compensate for reduced export of lactate. This might have detrimental effects if these 
cancer cells are normally not using their mitochondria. One of the main drivers of 
aggressive cancer phenotypes is acidosis (Gatenby et al., 2007). Therefore MCT4 might 
be an interesting candidate to be exploited therapeutically. The observations in chapter 3 
showed that most of the ER-negative cells are highly glycolytic and display 
pseudohypoxic features. This supports the role of MCT4 as an important lactate 
transporter in breast cancer suggested in chapter 5. This was confirmed by the analysis 
of metabolites of the supernatant. However, previous studies have suggested that MCT4 
is not important under normoxic conditions and that both MCT1 and MCT4 have to be 
inhibited to reduce cell viability (Le Floch et al., 2011). This is in contrast to the 
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findings described in this thesis as it is demonstrated that SLC16A3 is also important for 
HER2-positive breast cancer cells under normoxia. Moreover, silencing of SLC16A3 
alone was sufficient to impair cell growth. This was further supported by the in-vivo-
like analyses indicating that inhibition of MCT4 might be sufficient to prevent 
proliferation and survival in some cancer cells. Perturbing lactate metabolism via 
inhibition of MCT resulted in cell death (necrosis) in a study by Colen and colleagues 
that investigated highly glycolytic glioblastoma cells and the role of lactate in 
supporting their survival (Colen et al., 2011). This study also showed reduced survival 
of matrigel cultures when lactate secretion was impaired. Another isoform, MCT1, was 
identified for highly glycolytic cells, but the differential was quite weak and not further 
followed up. 
 
HER2-positive breast cancer tissue showed stronger immunohistological staining for 
MCT4. MCT1, which has been shown to be upregulated in basal-like and ER-
negative/HER2-negative breast cancer cells, was used as positive control. In fact, the 
same staining protocol previously established by Pinheiro et al was used for this 
analysis (Pinheiro et al., 2010a). However, MCT1 expression was found not to be 
increased in ER-negative/HER2-negative breast cancer tissues (data not shown). This 
might be due to different fixation methods of the tumour material and differences in 
antigen retrieval. Therefore, larger studies are needed to evaluate the significance of 
different MCT expression levels across different breast cancer subtypes.  
 
In summary, it is still not known why some cancer cells depend on MCT1, MCT4 or 
both transporters. MCT1 has been shown recently to be involved in the coupled 
metabolism between cancer cells (Sonveaux et al., 2008). This study suggested that 
MCT1 takes up lactate that is secreted from cancer cells that express MCT4. Moreover, 
MCT1 has been implicated to be important for cells with mutant p53 under hypoxia as 
MCT1 is upregulated in a p53-dependent way to adapt to metabolic needs (Boidot et al., 
2012). Together with the work described here, these findings delineate that highly 
glycolytic cancer cells may be able to use either MCT1 or MCT4 for exporting lactate. 
However, the relative importance of these two transporters may depend on the genetic 
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background of the cancer cell and their relative position within the tumour 
microenvironment.  
 
It can also be hypothesised that cancer cells with increased lactate secretion have less 
pyruvate available for mitochondrial metabolism. Hypoxia and HIF activation can 
rewire mitochondrial metabolism and induce aerobic glycolysis by the induction of 
PDHK, PKM2, LDHA and SLC16A3. This might suggest a network of different 
enzymes and transporters supporting one specific process: induction of glycolysis and 
enhanced export of lactate. In contrast, MCT1 has been suggested to work together with 
LDHB, which would support lactate import that is then converted to pyruvate via 
LDHB (Hussien and Brooks, 2011; McCleland et al., 2012). However, the relative use 
of different transporters and the direction of metabolite flux need further investigation. 
 
Lactate export from cancer cells might also be important for modification of the tumour 
microenvironment as inhibition of proton and lactate transport affect the pH 
homeostasis. Given that some enzymes such as MMPs and cathepsins need a more 
acidic environment to function (Hirschhaeuser et al., 2011), the ablation of MCTs 
would cause a more alkaline extracellular pH. Moreover, MCTs have also been 
implicated as targets in immunosuppression (Murray et al., 2005; Vegran et al., 2011). 
As the microenvironment contributes to the metabolic heterogeneity of cancer cells 
(Almendro et al., 2012; Marusyk et al., 2012), the interference of metabolic processes 
that influence the microenvironment might be highly important. 
 
It could be argued that with the here presented data the importance of MCT4 in ER-
negative breast cancers is underlined but whether in-vivo MCT1 or MCT4 is responsible 
for facilitating cancer progression needs further investigation, however the importance 
of the MCT family of proteins is irrefutable, and the work in this thesis contributes 
strongly to this statement. 
 
As well as SLC16A3, the screen also identified other metabolic enzymes that were 
found to be important mainly for ER-negative breast cell lines. ALDOA, a direct 
downstream target of mTORC1 (Duvel et al., 2010), has been suggested to have a 
Chapter 7 Discussion 
 
 270 
similar role as PKM2 in cancer as it is important for the provision of glycolytic 
intermediates for cell growth (Mazurek et al., 2002).  
 
Moreover, malic enzymes 1 and 2 have also been identified as important enzyme for 
cancer cell survival. ME2 was mainly important for ER-negative cell lines, whereas 
ME1 was selectively required for highly glycolytic cells. The roles of ME isoforms in 
cancer have not been studied extensively. While several reviews have predicted a role 
of malic enzyme in cancer cells, this has previously not been supported by experimental 
evidence. A study by Vander Heiden suggested that NADP+-dependent ME1 should be 
a promising enzyme for the targeting of cancer because glutamine catabolism to 
pyruvate or lactate could generate NADPH via this enzyme (Vander Heiden et al., 
2009). The induction of glutaminolysis by Myc allows the cancer cells to generate 
additional NADPH for nucleotide and fatty acid synthesis. Therefore the regulation of 
NADPH production in rapidly proliferating cancer cells is crucial for biomass 
production (Wise et al., 2008). The modulation of abundant pyruvate in glutamine 
dependent cancer cells via ablation of ME1 might be important. These studies all imply 
that ME are good candidates that could be exploited for cancer therapy (Deberardinis et 
al., 2008; Wise et al., 2008). Furthermore, a study has demonstrated that ME1 is a target 
of the transcription factor SREBP1 (Amemiya-Kudo et al., 2002). It is postulated that 
cancer cells with high SREBP activity display higher ME1 expression. Regulation of 
SREBP by upstream signalling components such as AKT, mTORC1 and HIF might 
therefore also influence ME1 levels. 
Interestingly, ME2 was important for ER-negative/HER2-negative breast cancer cells 
that have exhibited low oxygen consumption and mitochondrial capacity in the 
metabolic characterisation described in chapter 3. It could be postulated that these cells 
depend on glutaminolysis, as they cannot completely rely on glucose-derived pyruvate. 
Therefore, pyruvate generated from malate might give these cells a survival benefit. 
Perturbation of this reaction is not compensated by pyruvate produced by ME1 and/or 
glucose. However, whether isoform compensation as shown by Mueller and colleagues 
(Muller et al., 2012) might play a role in breast cancer cells needs to be further 
investigated. 
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7.5 Hypoxia 
Beside acidosis, hypoxia is considered to be the second main driver of aggressive and 
advanced diseases. Breast cancers exhibit a median pO2 of 10 mm HG with an overall 
hypoxia coverage of 25% with less than ≤2.5mm HG (Ward et al., 2013). Therefore, it 
has been proposed that detection of hypoxia would be a good tool for patient selection 
(Vaupel et al., 2007). A third of all breast cancers display hypoxic areas with an oxygen 
concentration below 0.3%. In 40-50% of all primary and locally advanced breast 
cancers, hypoxic heterogeneity within the tumour has been observed (Ward et al., 2013). 
This heterogeneity is due to leaky tumour blood vessels and insufficiently vascularised 
areas of the tumour. This is not favourable, as breast cancers with hypoxic areas that are 
below 1% in oxygen display resistance to radiation in 30-40% of all patient cases 
evaluated. 
Moreover, oxygen is also required for non-mitochondrial processes, including fatty acid 
desaturation. However, even under hypoxic conditions, some amount of oxygen is still 
available (Evans et al., 2001). The extent of hypoxia is crucial for the metabolic 
consequences for the tumour cells. Moderate hypoxia might cause a decrease in 
proliferation (Hockel and Vaupel, 2001a, b), while a severe form of hypoxia, anoxia, is 
more detrimental to the cells and can lead to necrotic cell death (Papandreou et al., 
2005). 
The activity of HIF regulates mitochondrial metabolism to allow cells to maintain their 
proliferative capacity (Kim et al., 2006; Papandreou et al., 2006; Zhang et al., 2007a). 
Most cancer cells retain active mitochondrial metabolism and only a small percentage 
of human tumours carry genetic alterations that completely impair mitochondrial 
activity. Genetic mutations in mitochondrial DNA have been identified in multiple 
cancers (e.g. prostate and ovarian cancer) (Brandon et al., 2006; Liu et al., 2001; Petros 
et al., 2005). Additionally, previous studies have shown mutations in metabolic 
enzymes that lead to the stabilisation of HIF (Gottlieb and Tomlinson, 2005). However, 
genetic alterations of SDH or FH were not observed in the CCLE data of the breast 
epithelial cell lines used in the study, suggesting that variations in the mitochondrial 
activity are caused by different mechanisms.  
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Most breast cancers belong to the ER–positive/HER2-negative subtype (approximately 
70%), and patients are successfully treated with endocrine therapy of different SERM. 
The RNAi screen described here was biased towards breast cancer cell lines that are 
representative of the subtype that is difficult to treat (i.e. ER-negative cell lines). 
However, a candidate gene for ER-positive/HER2-negative cell lines harbouring mutant 
PIK3CA, was identified under hypoxic conditions. ER is an important driver of tumour 
growth and potential perturbations of ER-mediated metabolic signalling by targeting 
TKTL1 might reveal novel insights into ER/PIK3CA signalling in general. As discussed 
in chapter 3, ER-positive/HER2-negative cells display a more oxidative phenotype than 
the ER-negative cells. Therefore, it could be postulated that these cells when exposed to 
hypoxia, become more dependent on non-oxidative processes such as the non-oxidative 
PPP. The hypoxic response evaluated by Hedenfalk and colleagues in three breast cell 
lines (MCF7, T-47D and MDA-MB-468) demonstrated that the same biological 
processes can be affected by hypoxia although through different genes (Hedenfalk et al., 
2005). HIF suppresses oxidative PPP, but increases activity of PKM2 and transketolases, 
to compensate for unavailability of oxidative PPP. When TKTL1 is lost under hypoxia, 
cells might not cope well with an impaired non-oxidative PPP (Tong et al., 2009). All 
reactions within non-oxidative PPP are reversible, but under hypoxia the rewiring to 
other metabolic pathways might be limited (Schenk et al., 1998) and the main source of 
ribulose-5-phosphate synthesis in tumour cells might not be available ((Boros et al., 
2000; Cascante et al., 2000). TKTL1 has been reported to be overexpressed in metastatic 
tumours and its inhibition has led to death (Coy et al., 2005) (Zhang et al., 2007b). 
Another possibility could also be that TKTL1 was found as a hypoxia-specific candidate 
gene as hypoxia downregulates ERα and ERβ due to repression of transcription and 
proteasomal degradation. However, the data shown in chapter 6 suggests ER-mediated 
signalling and decrease of ER activity by 4-hydroxy tamoxifen and 17β-estradiol causes 
downregulation of TKTL1. 
 
Hypoxia and HIF repress MCT1 expression but increase MCT4 (Ullah et al., 2006). 
Under hypoxic condition, all cancer cells were sensitive to SLC16A3 ablation as shown 
in chapter 5. The cell lines displaying MCT4 sensitivity showed a strong induction of it 
expression following hypoxia compared to the non-malignant cell line MCF10A. 
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Moreover, the overexpression of ERBB2 can induce HIF1α and stabilise it (Semenza, 
2002), suggesting a potential mechanism for the MCT4-dependency of HER2-positive 
cells under normoxia. It has also been shown by next-generation sequencing that some 
ER-negative cell lines and tumours can harbour specific HER2 mutations, which could 
explain the dependency on MCT4 of some of the HER2-negative cell lines and extend 
the potential of MCT4 as a target for cancer treatment. 
 
It has been shown that cancers can also depend on the activity of genes that are not 
themselves oncogenes. The activity of these genes is required to maintain the oncogenic 
state. Only a few metabolic enzymes have so far been found to harbour mutations or 
amplifications in tumours. Nonetheless, metabolic enzymes are regulated by oncogenic 
signalling cascades and could be a rate-limiting factor in the respective signalling 
pathway. Targeting the activity of these enzymes could block the growth and survival of 
cancer cells harbouring oncogenic activations within this pathway. 
 
As demonstrated in this thesis, the use of small-scale siRNA screens is an effective 
approach to discover novel cancer vulnerabilities. The unbiased approach of testing 
multiple cell lines that recapitulate the genetic diversity in breast cancer in small-scale 
screening experiments has brought forward 7 candidate genes. These seem to be mostly 
required for the survival of ER-negative breast cancer cell lines for which no suitable 
targeted therapy strategy has been developed yet. Monocarboxylate transporters, malic 
enzymes and PPAP2A are promising candidates for further investigations into their 
roles in the biology of HER2-positive and ER-negative/HER2-negative breast cancers, 
while the dependency of cancer cells on TKTL1, ME1 and PPAP2C was defined by 
their respective metabolic features, a concept that may become available through 
advanced diagnostics and requires further study. 
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7.6 Concluding remarks and future outlook 
The continuous work and progress of scientists and clinicians in understanding the 
biology of cancer has improved the overall survival of cancer patients. Today’s 
knowledge of the sequence of the human genome, RNA interference and next 
generation sequencing technology has provided extensive knowledge of the genetic 
landscape of cancer and the role of individual genes. The observed high- and low-
frequency of genetic alterations influence the signalling cascades in these tumour cells. 
As signalling and metabolism are directly linked, it would be of great interest to unravel 
metabolic dependencies that allow the perturbation of the rewired signalling of these 
tumour cells. This should selectively impair their ability to fulfil the requirements for 
rapid proliferation. The complexity of rewired metabolism and signalling in cancer cells 
is even further extended by tumour heterogeneity. This reinforces the need for a better 
understanding of the underlying genetic and biochemical processes that support cancer 
development, tumour progression and recurrence as well as therapy resistance. 
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8 Appendix 
8.1 Plasmid map
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8.2 Dharmacon siGenome library 
Table 4: siRNA oligonucleotides used in this study 
Gene 
Symbol  Gene Id Plate Well Pool Number Duplex Number Sequence 
HK1 3098 1 A03 MU-006820-01 D-006820-01 GGAAGGAGAUGAAGAAUGG 
         D-006820-03 GAAGUUACCUGUGGGAUUC          D-006820-04 GCACAACAAUGCCGUGGUU           D-006820-05 GACCGAGAAUGGUGACUUC 
HK2 3099 1 A04 MU-006735-01 D-006735-05 GCGGAUGUGUAUCAAUAUG 
         D-006735-02 GAAGUUGGCCUCAUUGUUG          D-006735-03 GCAGAAGGUUGACCAGUAU           D-006735-04 CAAGCUACAUCCUCACUUU 
GCK 2645 1 A05 MU-010819-01 D-010819-05 CCACGAUGAUCUCCUGCUA 
         D-010819-01 GCAAGCAGAUCUACAACAU          D-010819-02 GCUCAUAGGUGGCAAGUAC           D-010819-04 GCACGAAGACAUCGAUAAG 
PKLR 5313 1 A06 MU-006780-01 D-006780-01 GUGAAGAGGUUUGAUGAAA 
         D-006780-02 GGGCAAGCCUGUUGUCUGU          D-006780-03 GUGGAGAGCUUUGCAGGUU           D-006780-04 GAAGGACACGGCAUCAAGA 
PKM2 5315 1 A07 MU-006781-02 D-006781-05 GCAUUGAGAUUCCUGCAGA 
         D-006781-01 GAAAGAACAUCAAGAUUAU          D-006781-02 UUAGGAAGGUCCUGGGAGA           D-006781-03 GCAAGAAGGGUGUGAACCU 
PC 5091 1 A08 MU-008950-02 D-008950-01 GAAAGCAGAUGAAGCCUAU 
         D-008950-03 GAGCUGAUGUGGUGGAUGU          D-008950-18 GGAUAAUGCUUCCGCCUUC           D-008950-19 UCUCUGAGCGAGCGGACUU 
PDHA1 5160 1 A09 MU-010329-02 D-010329-02 GCUCUAGCCUGUAAGUAUA 
         D-010329-04 GCUCACGGCUUUACUUUCA          D-010329-05 AAGCAGAUCAGCUGUAUAA           D-010329-06 AAUAAUCGCUAUGGAAUGG 
PDHA2 5161 1 A10 MU-023925-01 D-023925-01 UAAGAGGGAUCCUAUAAUA 
         D-023925-02 GAUGAGAUCUGUUUGACUU          D-023925-03 GCAGAUAGCCGAAGCUUUC           D-023925-04 GCUCAUGGUGUGUGCUAUA 
PDHB 5162 1 A11 MU-008803-01 D-008803-01 CAAAUCAUCUUGUAACUGU 
         D-008803-02 GGUCAAAGACAUCAUAUUU          D-008803-03 GAAAGGCAAGGAACACAUA           D-008803-04 GAGAAUGAAUUGAUGUAUG 
DLD 1738 1 A12 MU-009509-01 D-009509-04 GUACAAAGUUGGGAAAUUC 
         D-009509-01 GAAGUUCGCUUGAAUUUAG          D-009509-02 UAUUAAAGCUGCCCAGUUA          D-009509-03 CAAUGGAUAUGGAAAGAUA DLAT 1737 1 B03 MU-008490-00 D-008490-01 GCACAGCGAUUAAUGCAAU 
         D-008490-02 CAACCGAAGUAACAGAUUU          D-008490-03 GGAUUGAUCUUACACAAGU           D-008490-04 GUACGGAAAGAACUUAAUA 
ACACA 31 1 B04 MU-004551-02 D-004551-01 GAAAGCAGGUCAACUAUGA 
         D-004551-03 CAGCAAACCUGGAUUCUGA          D-004551-04 GCAGAUGACUUCCCUAAUC           D-004551-09 GCAAUUAGAUUCGUUGUCA 
LDHA 3939 1 B05 MU-008201-01 D-008201-01 GGAGAAAGCCGUCUUAAUU 
         D-008201-02 GGCAAAGACUAUAAUGUAA          D-008201-03 GAAGAGGCCCGUUUGAAGA           D-008201-04 CUACGUGGCUUGGAAGAUA 
LDHB 3945 1 B06 MU-009779-01 D-009779-01 GAAAGUCUCUGGCUGAUGA 
         D-009779-02 GGAAGGAAGUGCAUAAGAU          D-009779-03 GAACUGACAAUGAUAGUGA           D-009779-04 CAUGGGAGCUUAUUUCUUC 
LDHC 3948 1 B07 MU-008759-02 D-008759-01 GGAUUUGGCUGAUGAACUU 
         D-008759-03 GUUAAGGGAUUAUAUGGAA          D-008759-04 GGAAUGGUGUCUCAGAUGU           D-008759-05 CGUAAUGUGGCUAUAAUGA 
 
Appendix 
 
 278 
 
Gene 
Symbol Gene Id Plate Well Pool Number Duplex Number Sequence 
CS 1431 1 B08 MU-009334-01 D-009334-01 GCAAAGAUCUACCGAAAUC 
         D-009334-03 GGACUGGUCUCACAAUUUC 
         D-009334-04 GCAAAGCUACCUUGUGUUG 
          D-009334-17 GGAAGACUGAUCCGCGAUA 
ACLY 47 1 B09 MU--004915-00 D-004915-01 CCAACGAGCUCAACAAUAU 
         D-004915-02 GACCAAAGAUGGAGUCUAU          D-004915-03 UCAACGAGCUGGCAAACUA           D-004915-04 CCACUCCUCUGCUCGAUUA 
G6PD 2539 1 B10 MU-008181-02 D-008181-05 UGACCUACGGCAACAGAUA 
         D-008181-01 GAGAGUGGGUUUCCAGUAU          D-008181-02 CAACAUCGCCUGCGUUAUC           D-008181-03 CGUGAGGCCUGGCGUAUUU 
FASN 2194 1 B11 MU-003954-04 D-003954-01 GAGCGUAUCUGUGAGAAAC 
         D-003954-03 UGACAUCGUCCAUUCGUUU          D-003954-04 CCAUGGAGCGUAUCUGUGA           D-003954-08 GCAACUCACGCUCCGGAAA 
CHKA 1119 1 B12 MU-006704-01 D-006704-01 GAAUUAAGUUUGCCAGAUA 
         D-006704-02 CAGAUGAGGUCCUGUAAUA          D-006704-03 GAGCAAACAUCCGGAAGUA           D-006704-04 GAAUACAGCAGUUACAAUU 
CHKB 1120 1 C03 MU-006705-00 D-006705-01 GGAAUGGCCUUUCUACAAA 
         D-006705-02 GUGAGUGGGUUUAUGAUUA          D-006705-03 CCACGAAGAUGGCGCAAUU          D-006705-04 CAUAGAAUUUGGUUACUUG HMGCS1 3157 1 C04 MU-009808-01 D-009808-01 GAAGACACCUACUUUGAUA 
          D-009808-04 GAUAUUAACUCUCUUUGCA 
          D-009808-17 GCCAAAUGUACUCGAAUGA 
          D-009808-18 CAGAGACAAUCAUCGACAA 
HMGCS2 3158 1 C05 MU-010179-01 D-010179-01 AAACUGACCUGGAGAAGUA 
         D-010179-02 ACACAAACCAGCUUAUAUA          D-010179-03 AGAGAGCAAUUCUACCAUA           D-010179-04 GGGCAUAGAUACCACCAAU 
HMGCR 3156 1 C06 MU-009811-02 D-009811-03 UGAAGAAUGUCUACAGAUA 
         D-009811-04 CCAGAAAUGUGAUUCAGUA          D-009811-06 GAGCAGUGACAUUAUAAUU           D-009811-19 GAUGGAAACUCAUGAGCGU 
SLC2A4 6517 1 C07 MU-007517-02 D-007517-01 CAGAUAGGCUCCGAAGAUG 
         D-007517-02 GCAUGGGUUUCCAGUAUGU          D-007517-03 UCAACCAACUGGCCAUUGU           D-007517-05 ACAGAUAGGCUCCGAAGAU 
SLC2A1 6513 1 C08 MU-007509-01 D-007509-02 CCAAGAGUGUGCUAAAGAA 
         D-007509-03 CAUCGUGGCUGAACUCUUC          D-007509-04 GAGCAUCGUGGCCAUCUUU           D-007509-05 GUAUGUGGGUGAAGUGUCA 
SREBF1 6720 1 C09 MU-006891-01 D-006891-01 UGACUUCCCUGGCCUAUUU 
         D-006891-02 ACAUUGAGCUCCUCUCUUG          D-006891-03 GCGCACUGCUGUCCACAAA           D-006891-04 ACACAGACGUGCUCAUGGA 
SREBF2 6721 1 C10 MU-009549-00 D-009549-01 GAGCGGAGCUGGUCUGUGA 
         D-009549-02 GAAGAGAGCUGUGAAUUCU          D-009549-03 GCACAAGUCUGGCGUUCUG           D-009549-04 AAACUCAGCUGCAACAACA 
PRKAA1 5562 1 C11 MU-005027-02 D-005027-01 CAAAGUCGACCAAAUGAUA 
         D-005027-02 GUAGAGCAAUCAAACAAUU          D-005027-03 GACAAGCACUUACUCCAAA           D-005027-05 ACAAUUGGAUUAUGAAUGG 
PRKAA2 5563 1 C12 MU-005361-02 D-005361-02 GUACCUACGUUAUUUAAGA 
         D-005361-03 GGAAGGUAGUGAAUGCAUA          D-005361-04 GACAGAAGAUUCGCAGUUU           D-005361-05 ACAGAAGAUUCGCAGUUUA 
HIF1A 3091 1 D03 MU-004018-05 D-004018-01 GGACACAGAUUUAGACUUG 
         D-004018-06 UCACCAAAGUUGAAUCAGA          D-004018-03 GAUGGAAGCACUAGACAAA           D-004018-05 CGUGUUAUCUGUCGCUUUG 
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AKT2 208 1 D05 MU-003001-02 D-003001-05 GUACUUCGAUGAUGAAUUU 
         D-003001-06 GCAAAGAGGGCAUCAGUGA          D-003001-07 GGGCUAAAGUGACCAUGAA           D-003001-08 GCAGAAUGCCAGCUGAUGA 
AKT3 10000 1 D06 MU-003002-02 D-003002-09 GAAAGAUUGUGUACCGUGA 
         D-003002-10 GGACUACUGUUAUAGAGAG          D-003002-11 UGAGACAGAUACUAGAUAU           D-003002-12 GCUCAUUCAUAGGAUAUAA 
ILVBL 10994 1 D07 MU-009658-02 D-009658-03 UGACUGCGGUGAAGAAUGC 
         D-009658-20 CCUGGUAUUUAGAGAAUUA          D-009658-21 CGUCAAUCGUAAUCGGGAA           D-009658-22 GCUACAGCCUCAUCGAAUU 
PHGDH 26227 1 D08 MU-009518-01 D-009518-01 GAACAUCCCUGAAGAAUGC 
         D-009518-02 GAACUCACUUGUGGAAUGA          D-009518-03 GGAAAGACCCUGGGAAUUC           D-009518-04 GGAAGGGCAUCUUGGUUAU 
MDH1 4190 1 D09 MU-009264-00 D-009264-01 CAAAGGAACUGACAGAAGA 
         D-009264-02 CAUCAAGGCUCGAAAACUA          D-009264-03 GUUGAAGGUCUCCCUAUUA           D-009264-04 AAGGUGAAAUUGCAAGGAA 
MDH2 4191 1 D10 MU-008439-00 D-008439-01 CCAGAACAAUGCUAAAGUA 
         D-008439-02 CAACACCAAUGCCACGAUU          D-008439-03 CAAGAAGCAUGGAGUGUAC           D-008439-04 CCUGAAAGGUUGUGAUGUG 
GPD1 2819 1 D11 MU-008782-01 D-008782-02 AGAAAGAGUUGCUGAAUGG 
         D-008782-04 GAUCGUGGGUGGCAAUGCA          D-008782-17 AGAUGAUAGCCUUCGCCAA           D-008782-18 CCCAUCAGUUCAUCGGCAA 
GPD2 2820 1 D12 MU-009843-02 D-009843-01 UGAAUGAAGUGCGUAAUUA 
         D-009843-02 GAACCUGGCCUAUGUUAAA          D-009843-03 GAUAUGAUUUCACGUCGUA           D-009843-05 GAGAGUGGCCUUAUUACUA 
PRPS1 5631 1 E03 MU-006784-00 D-006784-01 GCAAAUAUGCUAUCUGUAG 
         D-006784-02 UGGAGGAACUGCACUAUUG          D-006784-03 GUGAUUGACAUCUCUAUGA           D-006784-04 CCAUGCAGCUGACAAACUU 
PRPS2 5634 1 E04 MU-004877-02 D-004877-05 GAUCUUGGCCGAAGCAAUC 
         D-004877-01 AUACAGGGAUUCUUUGAUA          D-004877-03 CAAAGUGUAUGCUAUCCUU           D-004877-04 CAGAGUAACUGCCGUGAUC 
PPAT 5471 1 E05 MU-006003-01 D-006003-01 GAAAUGGUCUGGAAUGUUU 
         D-006003-02 GGUAAAUGCUGCUCGAUUA          D-006003-03 GGGAAUGGGUCUUGUAAAU           D-006003-05 GAAUGGGUCUUGUAAAUCA 
UMPS 7372 1 E06 MU-009828-01 D-009828-02 GAACUAAGCGUCUUGUAGA 
         D-009828-04 GAAGACUCAUGUAGAUAUU          D-009828-17 AUUUCUGGCUCCCGAGUAA           D-009828-18 UGAUAUUUGAAGACCGGAA 
SLC1A5 6510 1 E07 MU-007429-01 D-007429-02 GGAUGUGGGUUUACUCUUU 
         D-007429-03 GUUCUGGUCUCCUGGAUCA          D-007429-17 GAGAGGAAUAUCACCGGAA           D-007429-18 CAGUCAACCUCCCGGUCGA 
SLC7A5 8140 1 E08 MU-004953-01 D-004953-01 GAUCCCAACUUCUCAUUUG 
         D-004953-03 UGACCAACCUGGCCUACUU          D-004953-17 GUGAACUGCUACAGCGUGA           D-004953-18 UGAAAACUCUGGUACGAAU 
PFKL 5211 1 E09 MU-006822-00 D-006822-01 UGAAGAUGCUGGCACAAUA 
         D-006822-02 GCACAAUACCGCAUCAGUA          D-006822-03 CACAAUACCGCAUCAGUAU           D-006822-04 UGCUGAAGAUGCUGGCACA 
GAPDH 2597 1 E10 MU-004253-02 D-004253-01 CAACGGAUUUGGUCGUAUU 
         D-004253-03 GACCUCAACUACAUGGUUU          D-004253-04 UGGUUUACAUGUUCCAAUA           D-004253-05 GUCAACGGAUUUGGUCGUA 
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GAPDS 26330 1 E11 MU-009671-01 D-009671-01 CAAGGGAAGUGUGGAAUUC 
         D-009671-02 GGACAACCAUGAGAUCUCU          D-009671-03 UGGUGUACAUGUUUAAGUA           D-009671-04 CCAUGAACAUUGUGAGCAA 
PGK1 5230 1 E12 MU-006767-01 D-006767-05 GAAGCGGGUCGUUAUGAGA 
         D-006767-01 CAAAAUUGAUGAUCCAUUA          D-006767-02 UUGAUGAUCCAUUAAGUAA           D-006767-04 GCACAGCAUCUCAGCUCAU 
PGK2 5232 1 F03 MU-006768-02 D-006768-05 GGAAUGGGCCGUUAGGAGU 
         D-006768-02 GCAGACAAGAUCCAACUUA          D-006768-03 CAAGAUCCCUCUGGAAAGA           D-006768-04 UGACAAAUAUUCCUUAGCA 
ENO1 2023 1 F04 MU-004034-02 D-004034-03 CAAACUGAUGAUCGAGAUG 
         D-004034-04 AAUGAUAAGACUCGCUAUA          D-004034-01 GAACGUCACAGAACAAGAG           D-004034-02 GAUAAGACUCGCUAUAUGG 
IDH1 3417 1 F05 MU-008296-00 D-008294-03 GUACAUAACUUUGAAGAAG 
         D-008294-04 CAAGAUAAGUCAAUUGAAG          D-008294-01 GAGCAAAGCUUGAUAACAA           D-008294-02 GGACUUGGCUGCUUGCAUU 
IDH2 3418 1 F06 MU-004013-00 D-004013-01 CAAGAACUAUGACGGAGAU 
         D-004013-02 GCGCCACUAUGCCGACAAA          D-004013-03 AACGAGCACUUCCUGAACA           D-004013-04 GACAUCCAGCUAAAGUAUU 
OGDH 4967 1 F07 MU-009679-02 D-009679-03 GCUAGGACAUUUCAACAGA 
         D-009679-05 CAGACAAACUUGGGUUCUA          D-009679-18 UCUAGAAGGCUGCGAGGUA           D-009679-19 CUGAUGAGGGCUCCGGAGA 
SDHA 6389 1 F08 MU-009398-02 D-009398-01 GAGGGAGGCAUUCUCAUUA 
         D-009398-03 CGAAGGACCUGGCGUCUAG          D-009398-04 UGAGAAAGAUCACGUCUAC           D-009398-14 CGAAAGGUUUAUGGAGCGA 
SDHB 6390 1 F09 MU-011773-02 D-011773-01 GGUAUUGGAUGCUUUAAUC 
         D-011773-02 GAACAUCAAUGGAGGCAAC          D-011773-19 GUGAGAAACUGGACGGGCU           D-011773-20 GCUACUGGUGGAACGGAGA 
SDHC 6391 1 F10 MU-011385-01 D-011385-17 GGGCUUAGAUAGAAAGUCU 
         D-011385-18 AGUUAAAGCUGUGGGUCGA          D-011385-19 GAAAAGAAGUGACGCAUGU           D-011385-20 UCGAAGUAAUGUACCCUUU 
SDHD 6392 1 F11 MU-006305-00 D-006305-01 GGACCGACCUAUCCCAGAA 
         D-006305-02 GCUUUGCUAUUUCAACUAU          D-006305-03 ACUUUCAGCUUUAACCUUU           D-006305-04 CAGACCUGCUCAUAUCUCA 
FH 2271 1 F12 MU-009512-00 D-009512-01 GAUCUACGAUGAACUUUAA 
         D-009512-02 UCAACAAGCUGAUGAAUGA          D-009512-03 GCACAGAUCAUCAAGAUUG           D-009512-04 AGCCAGAGCUCAAAUGAUA 
CHPT1 56994 1 G03 MU-009775-02 D-009775-01 GAACUUAUCCUGACUGGUU 
         D-009775-06 UUUCAGGCAUGUUGAGAUU          D-009775-19 GCGCUCAUUGGCAGACUUA           D-009775-20 CUUCAUUUGAUAUGGUGAU 
MVK 4598 1 G04 MU-006749-00 D-006749-01 UGGAAGAGCUCAUUGACAU 
         D-006749-02 ACACCAAAGUCCCUCGCAA          D-006749-03 GCUCAAGUUCCCAGAGAUC           D-006749-04 ACCAAAGUCCCUCGCAAUA 
PMVK 10654 1 G05 MU-006782-01 D-006782-01 UUUAUCCGCUCCAGACUUU 
         D-006782-02 CGAGAACCAUGGAGUUGAA          D-006782-03 GCGAAACCCUGCCAUAUCC           D-006782-04 AAUGUGGCCUGGACAACUU 
MVD 4597 1 G06 MU-006748-00 D-006748-01 GACCGGAUUUGGCUGAAUG 
         D-006748-02 ACAUCGCGGUCAUCAAGUA          D-006748-03 GCCCAUCUCUUACCUCAAU           D-006748-04 CAGCAUCGCUCGGCAAGUG 
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FDPS 2224 1 G07 MU-008632-02 D-008632-01 GACCAGAAUUCAGAUGUUU 
         D-008632-02 CAGCAGUGUUCUUGCAAUA          D-008632-05 GAAGACAGUUACAGCCACA           D-008632-06 GGGUGAAGGCGCUAUAUGA 
GGPS1 9453 1 G08 MU-016477-02 D-016477-03 CAAAUUAGGGAUGAUUAUG 
         D-016477-04 UAAAACCGCUACUUAAUAC          D-016477-20 GGGACAAGGCCUAGAUAUU           D-016477-21 CCAAUUGGGAAGCGGAAAA 
LSS 4047 1 G09 MU-008624-00 D-008624-01 GGACUGCGCUCAACUAUGU 
         D-008624-02 GCAGAAGGCUCAUGAGUUC          D-008624-03 GAAGCUGUAUGAACACAUU           D-008624-04 UGCAGGCGCUUAAGUAUUU 
DHCR7 1717 1 G10 MU-020182-01 D-020182-01 GGCCAAGACUCCACCUAUA 
         D-020182-02 GAACAAGUAUCAGAUCAAC          D-020182-03 CAUCAUGGCUUGUGACCAG           D-020182-04 GCCCAGCUCUAUACCUUGU 
PRKAG2 51422 1 G11 MU-009693-01 D-009693-02 GCAAUAAGCUGGAAAUACU 
         D-009693-03 CCACAACAUUGCCUUCAUA          D-009693-17 CGGAGUGACCGCCGUGAAU           D-009693-18 CCACAGAUUGCCCGUUAUU 
PRKAG3 53632 1 G12 MU-009859-01 D-009859-01 UCUAUGAGAUUGAACAACA 
         D-009859-02 GGGAAGUGAUCGACAGGAU          D-009859-03 ACAAACGCCUGCUCAAGUU           D-009859-05 GCUCCAAGCUAGUCAUCUU 
PRKAB1 5564 1 H03 MU-007675-00 D-007675-01 CAGAAGCCACAAUAACUUU 
         D-007675-02 CAACAACUGGAGUAAACUU          D-007675-03 UGUCUGAGCUGUCCAGUUC           D-007675-04 GGAAGGAGAGCAUCAGUAC 
PRKAB2 5565 1 H04 MU-007672-00 D-007672-01 GUUCGAUGCUUUAAAGUUA 
         D-007672-02 UAAGAGCCAUAAUGACUUU          D-007672-03 GCAAGGAGGUCUUCAUCUC           D-007672-04 GCACCAAGAUUCCACUGAU 
PRKAG1 5571 1 H05 MU-009056-01 D-009056-01 GGACAUCUACUCCAAGUUU 
         D-009056-02 GAUGCUGUCUCUUCAUUAA          D-009056-03 CAACAUCGAUCACAUUACU           D-009056-04 GUGUAUACUUCCUUCAUGA 
EPAS1 2034 1 H06 MU-004814-01 D-004814-05 ACACAUCUUUGGAUAACGA 
         D-004814-02 GCAAAUGUACCCAAUGAUA          D-004814-03 GAGCGGGACUUCUUCAUGA           D-004814-04 AGACGGAGGUGUUCUAUGA 
MT-ND1 4535 1 H07 n.a. D-012827-01 UAACCUCCCUGUUCUUAUG 
         D-012827-02 UGAUUUAUCUCCACACUAG          D-012827-03 CUAAUAAGUGGCUCCUUUA           D-012827-04 CCGAAUACACAAACAUUAU 
MT-ND2 4536 1 H08 n.a. D-012828-01 GCGCUAAGCUCGCACUGAU 
         D-012828-02 UAACCAAUACUACCAAUCA          D-012828-03 CAAUAUACUCUCCGGACAA           D-012828-04 CCAUAUCUAACAACGUAAA 
MT-ND3 4537 1 H09 n.a. D-012829-01 CAACUAACCUGCCACUAAU 
         D-012829-02 CCGCGUCCCUUUCUCCAUA          D-012829-03 CUUAGUAGCUAUUACCUUC           D-012829-04 CAACUCAACGGCUACAUAG 
MT-ND4 4538 1 H10 n.a. D-012830-01 CUAGGCGGCUAUGGUAUAA 
         D-012830-02 GACCUAAAAUCGCUCAUUG          D-012830-03 GAGCCAAUAACUUAAUAUG           D-012830-04 UAACCACGUUCUCCUGAUC 
MT-ND5 4540 1 H11 n.a. D-012831-01 UGAGAGGGCGUAGGAAUUA 
         D-012831-02 GCCUAUAGCACUCGAAUAA          D-012831-03 CUAGGACUCAUAAUAGUUA           D-012831-04 CUACUCCACUCAAGCACUA 
MT-ND6 4541 1 H12 n.a. D-012832-01 GGUCGGGUGUGUUAUUAUU 
         D-012832-02 GAAUGAUGGUUGUCUUUGG          D-012832-03 CGAUGGCUAUUGAGGAGUA           D-012832-04 GAUUAUGGGCGUUGAUUAG 
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GALK1 2584 2 A03 M-007728-01 D-007728-03 GACCAGUUCAUCUCACUUA 
         D-007728-04 GCGCCAAUGUGAAGAAGUG          D-007728-05 GGGAACACACGGACUACAA           D-007728-06 GAGCCAAGGUGCUGUGCUU 
GALK2 2585 2 A04 M-006725-00 D-006725-01 GCUAAUAACAUCCAGAUUG 
         D-006725-02 GCACAACUAUUUCUUAUGU          D-006725-03 GGAAAUAUCCCACCAAGUU           D-006725-04 GGACCAGUCUAUAUCAUUU 
GALT 2592 2 A05 M-010327-00 D-010327-01 AAACAAAGGUGCCAUGAUG 
         D-010327-02 GAUCUAGCCUCCAUCAUGA          D-010327-03 GAUCUCAGCAGGCCUAUAA           D-010327-04 GCAAACGACCAUCAGCAUA 
PGM1 5236 2 A06 M-010925-00 D-010925-01 CGAAUCGUCUUCCGACUGA 
         D-010925-02 GUACAUCGAUAGCUAUGAG          D-010925-03 CGACUGAAGAUCCGUAUUG           D-010925-04 GGAAAUUGUGGAUUCGGUA 
PGM3 5238 2 A07 M-013912-00 D-013912-01 GAGGUCAAUUCCAUGAUUA 
         D-013912-02 GGAUUUAGGUGCUAUUACA          D-013912-03 GGGCAAACUCAAUCAUUUA           D-013912-04 GACAAGAUAGCAACGUUAA 
GLUD1 2746 2 A08 M-004032-02 D-004032-01 GCAACCAUGUGCUGAGUCU 
         D-004032-02 UAAAUCAUGUCAGCUAUGG          D-004032-05 CAAUGAAGCUUCUUACAUG           D-004032-19 GAAAUUAAGGUUAGCGGAU 
GLUD2 2747 2 A09 M-009067-02 D-009067-01 CAAUGAAGCUUCUUACAUG 
         D-009067-04 GGACGCAUCUCUGCUACUG          D-009067-05 CAAGGGAGGUAUCCGUUAC           D-009067-18 CUUUAUUGGUCCUGGCGUU 
HK3 3101 2 A10 M-006736-00 D-006736-01 GGAAUGCGAUGUCUCCUUA 
         D-006736-02 GCAGUUGACUCGUGUCUGA          D-006736-03 GACAGGAGCACCCUCAUUU           D-006736-04 UCACGUUCCUGCAGUCAGA 
GPI 2821 2 A11 M-004900-01 D-004900-01 GGAAAUACAUCACCAAAUC 
         D-004900-03 CAACCAAAGUGAAGGAGUU          D-004900-04 GAUGAUACCCUGUGACUUC           D-004900-05 UCACGACGCUUCUACCAAU 
PFKM 5213 2 A12 M-006765-01 D-006765-01 UCAAGAAUCUGGUGGUUAA 
         D-006765-03 GAUCAUGGAAAUUGUAGAU          D-006765-04 CAGAAGACAUCAAGAAUCU           D-006765-05 GGAUAUGACACCCGGGUUA 
PFKP 5214 2 B03 M-010253-01 D-010253-01 GAAAUCGGCUGGACAGAUG 
         D-010253-02 CAACGUAGCUGUCAUCAAC          D-010253-03 GAAGAGAUCGCCACACAGA           D-010253-05 GGAACGGCCAGAUCGAUAA 
PFKFB1 5207 2 B04 M-006761-01 D-006761-01 UAAAGAGAAUUGAGUGCUA 
         D-006761-03 UAAUGACCCUGGCAUAAUU          D-006761-04 GCUAUGAGGUCAACUACCA           D-006761-17 UACCAGAGAACGACGGUCA 
PFKFB2 5208 2 B05 M-006762-02 D-006762-01 GAACUUUGCUGAACAGAAU 
         D-006762-02 GAACAGAGAGAACGUGAUG          D-006762-03 CCAAUAUUCUGGAGGUUAA           D-006762-18 CGGCAUGGAGAAAGCGAGU 
PFKFB3 5209 2 B06 M-006763-01 D-006763-01 GGACCUAACCCGCUCAUGA 
         D-006763-02 GAGGAUCAGUUGCUAUGAA          D-006763-03 AAAGCUACCUGGCGAAAGA           D-006763-17 ACAAGUACUAUUACCGCUA 
PFKFB4 5210 2 B07 M-006764-01 D-006764-01 GAGCGACCAUCUUUAAUUU 
         D-006764-02 GAAAUGACCUACGAGGAAA          D-006764-04 CAUCGUAUAUUACCUCAUG           D-006764-17 GGGACAGGCCUCAGAACGU 
ALDOA 226 2 B08 M-010376-01 D-010376-02 GGACAAAUGGCGAGACUAC 
         D-010376-03 UUGAAGCGCUGCCAGUAUG          D-010376-04 GGCGUUGUGUGCUGAAGAU           D-010376-05 UGACAUCGCUCACCGCAUC 
 
 
Appendix 
 
 283 
Gene 
Symbol Gene Id Plate Well Pool Number Duplex Number Sequence 
ALDOB 229 2 B09 M-010990-01 D-010990-01 CCAAAGCCCUGGAAACUAA 
         D-010990-02 GGACAUGCCUGCACCAAGA          D-010990-04 GAAGAAGGAGCUCUCAGAA           D-010990-05 CCAAAGGACAGUAUGUUCA 
ALDOC 230 2 B10 M-012697-01 D-012697-01 GAAAGAUGAUAAUGGUGUU 
         D-012697-02 GCGCUUACCUUCUCCUAUG          D-012697-03 GCACAGUCACUCUACAUUG           D-012697-04 AAACGUUGUCAGUAUGUUA 
TPI1 7167 2 B11 M-009776-02 D-009776-01 GCAAGGUCGUCCUGGCCUA 
         D-009776-02 GCUCAGAGCACCCGUAUCA          D-009776-05 AGAGAGAAGGCAUGUCUUU           D-009776-06 GAUCAAAGACUGCGGAGCC 
PGAM4 441531 2 B12 M-034271-00 D-034271-13 GCACAGGUUCUCAGUCUAA 
         D-034271-14 CCUCAUACCAAUAUAGGAU          D-034271-15 CAUGCUAAGCCACGACCAA           D-034271-16 CAGAAGAGAGUGAUCCGGA 
PGAM1 5223 2 C03 M-008883-01 D-008883-02 GGACAAGAACUUGAAGCCU 
         D-008883-03 CCAUGCAGUUUCUGGGGGA          D-008883-04 UGAAGAGACGGUGCGCAAA           D-008883-05 GGUCUAACCGGUCUCAAUA 
PGAM2 5224 2 C04 M-008712-02 D-008712-01 GAUCAAGGCCGGCAAGCGA 
         D-008712-03 CCAAGAUGGAGUUUGACAU          D-008712-18 UGUCAGACCAGGCGAUCAU           D-008712-19 GGAUGUCAGACCAGGCGAU 
BPGM 669 2 C05 M-008917-02 D-008917-02 GAAAGCUCCUGGCGUCUAA 
         D-008917-03 GGAAUAAGGAGAACCGUUU          D-008917-04 GGAGGAAGCUCGGAACUGU           D-008917-18 CAACUGCCACGGUCGGAAA 
ENO2 2026 2 C06 M-009777-01 D-009777-04 CUGAACGUCUGGCUAAAUA 
         D-009777-17 GGACAUAACUUCCGUAAUC          D-009777-18 CCACUGAUCCUUCCCGAUA           D-009777-19 CCUCAGAGUUUUAUCGUGA 
ENO3 2027 2 C07 M-009718-02 D-009718-02 CUAUGAGGCUCUGGAACUA 
         D-009718-03 GGGUGAACAUCCAGAUUGU          D-009718-04 GCAAUGGGAAGUACGAUCU           D-009718-05 CGGAGCGUCUGGCCAAAUA 
LDHAL6A 160287 2 C08 M-008760-01 D-008760-01 GGAGAAACACGCCUUGAUU 
         D-008760-02 CCAGAUAUAGGAACUGAUA          D-008760-03 GGAGUGGUGUGAACAUUGC           D-008760-04 GAAGAGGAGGCCAUUCAUC 
LDHAL6B 92483 2 C09 M-008908-02 D-008908-01 UGGAAUAGAUGAAGAAGUA 
         D-008908-03 AGUAAGGUCUCCAUCAUAG          D-008908-04 GACGAUGGAUCUUCAACAU           D-008908-17 GAGUGAGCUUAUUGAGCGU 
PDK3 5165 2 C10 M-005021-02 D-005021-02 GUUGGUAUAUGCAGAGUUU 
         D-005021-03 UAAGAUCAGUGACCUAGGU          D-005021-05 CGGGAGAGAUAAUGCAUGU           D-005021-06 GUUCAGAGUUGGUAUAUGC 
PDK4 5166 2 C11 M-019425-02 D-019425-01 AAAGAAGACCUUACCAUUA 
         D-019425-02 GAAAUAGACACCAUAAUGU          D-019425-03 CGACAAGAAUUGCCUGUGA           D-019425-04 GACCGCCUCUUUAGUUAUA 
PDP1 54704 2 C12 M-008718-00 D-008718-01 CGACUGAUAUUGAUGUUAA 
         D-008718-02 GAACUGAGCAGGAUCUAUG          D-008718-03 GCAUCCAAAUUGUACUUUA           D-008718-04 GCAAGUUGGUGAUCCUAAU 
PDP2 57546 2 D03 M-022572-00 D-022572-01 CAACAGAGGAAGAUGAUUU 
         D-022572-02 GCAAACCAAUGGACUGAUG          D-022572-03 GGAACAGCAUUGCCACAUU           D-022572-04 GAAGAAGCAUUAAUGUACU 
ACO1 48 2 D04 M-010037-00 D-010037-01 GCAAACAGGUCGUGAUGAA 
         D-010037-02 GAACAUAGAAGUGCCAUUU          D-010037-03 GUAGGAAUGUUUCGAGAUU           D-010037-04 GAGAUUCGGUAACAACUGA 
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ACO2 50 2 D05 M-009566-00 D-009566-01 CAAUCUAGCUGAUGAAUUC 
         D-009566-02 CCACUUCCGUGUUCCCUUA          D-009566-03 GCAGUGCCCUCAACAGAAU           D-009566-04 GGACGGCUAUGCACAGAUC 
LOC441996 441996 2 D06 M-035153-01 D-035153-09 CAGGCAAGGAUGGCAAGAA 
         D-035153-10 GGUCAGUUGCACAGAAAGG          D-035153-11 GCAGGAGAAGAACAUAAUU           D-035153-12 GCAGAUCCGUGCCUCCAUU 
IDH3A 3419 2 D07 M-008753-00 D-008753-01 GCAGAAAGCUGUAAAGAUA 
         D-008753-02 GAACGUCACUGCCAUUCAA          D-008753-03 GGAAAGAGCUUGACAAAAG           D-008753-04 GCUAAAGAGUCCAUGGAUA 
IDH3B 3420 2 D08 M-009596-00 D-009596-01 UGAAGAAGGUGAUCAAAGU 
         D-009596-02 GCAUCUUAAUCUUGAGUAU          D-009596-03 GCAGUGGGCAGGAAUAUAG           D-009596-04 UUGAGACAAUGAUCAUAGA 
IDH3G 3421 2 D09 M-009361-00 D-009361-01 GCAAGAGUAUCGCCAAUAA 
         D-009361-02 GGACAUAGACAUCCUCAUU          D-009361-03 GCACGUGAGUUCCAAUGCU           D-009361-04 GAACACAGAGGGCGAGUAC 
DLST 1743 2 D10 M-009941-02 D-009941-01 GCAGGAAGGUUGUCAUUAA 
         D-009941-02 GCAGAGAGGCUGUGACUUU          D-009941-05 GAUGAGGGCUCGGCACAAA           D-009941-19 CAAAAUCAAGGCAGCGGUA 
LOC283398 283398 2 D11 M-026908-01 D-026908-01 UAAAGGAAGCUCAAGUAUA 
         D-026908-02 CAAAUUACGAAGCUGUAUA          D-026908-03 GGACGACAAAUCAGAGAAU           D-026908-04 ACUAGAAACUUCCAGUCAA 
SUCLG2 8801 2 D12 M-008918-01 D-008918-01 AAAGGAAGCUCAAGUAUAU 
         D-008918-02 AAAUGAAGCUGCCAAAUAU          D-008918-04 GGACUAGAUGGGAACAUUG           D-008918-17 GGUACAAUCUAGCGACAAA 
SUCLG1 8802 2 E03 M-008677-01 D-008677-01 GAAAUUCCCUUGGUUGUGU 
         D-008677-02 AGAGAAUGCUGCAGAAUUU          D-008677-03 GGGCUUACCUGUCUUUAAU           D-008677-04 GAUCUGGCACCCUGACUUA 
SUCLA2 8803 2 E04 M-008237-00 D-008237-01 GCAAAGGAAUCUCUCACUA 
         D-008237-02 GGAUGAAGCUGCUAGAAUG          D-008237-03 UCAAGGUCCUGUAUUAAUA           D-008237-04 GGGAAGUUCUGGAUUGUUU 
GOT1 2805 2 E05 M-011673-01 D-011673-01 GAGCAUAUCGCACGGAUGA 
         D-011673-02 UUAAAGACAUUCGGUCCUA          D-011673-03 UAGCCUAAAUCACGAGUAU           D-011673-17 GAACAGGUGCACUUCGAAU 
GOT2 2806 2 E06 M-011674-02 D-011674-01 GCAUGCAGCUACAAGGUUA 
         D-011674-03 AACAUGGGCUUAUAUGGUG          D-011674-04 CUUGAAGAGUGGCCGGUUU           D-011674-18 UGAGAAACAGCACACGUUA 
SLC25A11 8402 2 E07 M-007470-00 D-007470-01 GGACUCAGGCUACUUCUCU 
         D-007470-02 GGGAUGGGAGCUACAGUUU          D-007470-03 CAGAACAUGCGGAUGAUUG           D-007470-04 UCUAUACCGUGCUGUUUGA 
GPD1L 23171 2 E08 M-008514-01 D-008514-01 GGAAGACCAUUGAAGAGUU 
         D-008514-02 GGCUGAAGCUCAUUUCUGA          D-008514-03 GUUGCCAUGUCAAAUCUUA           D-008514-04 GCAGACCAGUUCAAGAGAU 
ME3 10873 2 E09 M-008499-01 D-008499-01 CAACAAUGCUGAAUUCUUG 
         D-008499-02 ACAAAUACCGUAACAAGUA          D-008499-03 GGAGCCACCUGAACCAUGA           D-008499-04 CUAAAGGGCUCAUUGUCAA 
GLUL 2752 2 E10 M-008228-01 D-008228-01 GCACGUGUCUUCUCAAUGA 
         D-008228-02 GAAGAAGGGUUACUUUGAA          D-008228-03 GCACACCUGUAAACGGAUA           D-008228-04 CAUGAAACCUCCAACAUCA 
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GPT 2875 2 E11 M-031622-00 D-031622-01 GAAGAAGCCUUUCACCGAG 
         D-031622-02 GAACAUGGACGCUGCAGUG          D-031622-03 GCGCAGUGCAGGUGGAUUA           D-031622-04 CCGAGCAGGUCUUCAAUGA 
GPT2 84706 2 E12 M-004173-02 D-004173-01 UCAAAUGGCUCCAGACAUG 
         D-004173-03 GUGAAAGACUUCCACAUCA          D-004173-04 UCAAGAAGGUGCUGUACGA           D-004173-18 GUGAAAAGGUUAAAUCGUA 
DDO 8528 2 F03 M-009311-01 D-009311-02 CAGCACGGAUUGCAGUUGU 
         D-009311-03 UCAGAGAAACCUUUAAUCA          D-009311-17 GGACCUAUGCAGAUUUAUA           D-009311-18 GGUGUAACAUGUAAGCUGA 
AGXT 189 2 F04 M-008925-01 D-008925-01 GGAGAGACAUCGUCAGCUA 
         D-008925-02 GCAAGGAUAUGUACCAGAU          D-008925-04 UAGACCACUUCGACAUUGA           D-008925-05 GGUCAUCUCUGGCUCGGGA 
AGXT2 64902 2 F05 M-009818-00 D-009818-01 GGAAAGAAGAGCUAAGUAA 
         D-009818-02 GGACCUACAUGUUACUAAA          D-009818-03 GGAAGCAGAUACCUGGAUU           D-009818-04 CAUAACCACUCCAGAGAUU 
PSAT1 29968 2 F06 M-010398-02 D-010398-21 UUUAAGAGUGCCAGGCGAA 
         D-010398-22 GAGAAUCUUGUGCGGGAAU          D-010398-23 GCGCAAAUGAGACGGUGCA           D-010398-24 GGACUAUAAAUAUCGUUCA 
CAD 790 2 F07 M-009471-01 D-009471-01 GAGGGUCUCUUCUUAAGUA 
         D-009471-17 GGAAGGAGAUUGAGUACGA          D-009471-18 CCAACAGAUAAGCGGAUUU           D-009471-19 AUUAAGACUCCACGGGUAU 
ODC1 4953 2 F08 M-006668-00 D-006668-01 GAGCAGACCUUUAUGUAUU 
         D-006668-02 CGAAAGAGCUAAAUAUCGA          D-006668-03 GAAGUUGAGUUGAUGAAAG           D-006668-04 GAAGAGAUCACCGGCGUAA 
SHMT1 6470 2 F09 M-004617-00 D-004617-01 GAGCUGGCAUGAUCUUCUA 
         D-004617-02 GGAGAACGCACGCCUCUUC          D-004617-03 CCUAGGCUCUUGCUUAAAU           D-004617-04 UACGGAAGAUUGCAGAUGA 
SHMT2 6472 2 F10 M-004906-01 D-004906-01 GGAGAUCCCUUACACAUUU 
         D-004906-02 GGUCAGGGCUCAUCUUCUA          D-004906-03 GGACAGUGAUCCUGAGAUG           D-004906-04 AAACUGGCCUCAUUGACUA 
TKT 7086 2 F11 M-004734-01 D-004734-01 GAAAAUGCCAUCAUCUAUA 
         D-004734-03 GAACUAGCCGCCAAUACAA          D-004734-04 CUGCCGAACUGCUGAAGAA           D-004734-05 GGAACUAGCCGCCAAUACA 
TKTL1 8277 2 F12 M-004736-01 D-004736-01 GCAAGUACCGCUCUAAUUU 
         D-004736-02 GGAAUUCCCUUCGCUGUUU          D-004736-03 GCAGAAAGUUGGCAUGCAA           D-004736-04 GGAAUUAGUGCCAGACAUA 
DKFZP 84076 2 G03 M-004735-01 D-004735-01 CGACAGAGCAUGCUAUUUA 
434L1717        D-004735-02 GUGAAUUGCUGGAUAUGUU          D-004735-03 GAUAAAGUCACAGUAAUUG           D-004735-04 GUAAUUGGAGCUGGAGUUA 
PGLS 25796 2 G04 M-020023-00 D-020023-01 GAUUGUGGCUCCCAUCAGU 
         D-020023-02 CACACUACCUGUCCUGAAU          D-020023-03 GCAAGGCAGCUGUUCUGAA           D-020023-04 CGGCUGAGGACUACGCCAA 
H6PD 9563 2 G05 M-004692-01 D-004692-01 CCGAGGAGCUGAUCUCUAA 
         D-004692-02 GCAGCCCUCUGUCCGAUUA          D-004692-03 GGACAUGUCUCCAUAAUCC           D-004692-04 GGGCUACGCUCGGAUCUUG 
PGD 5226 2 G06 M-008371-00 D-008371-01 GAUCAUCUCUUACGCUCAA 
         D-008371-02 UAAUAGGACUGUCUCCAAA          D-008371-03 GAAAUCACAGCCAAUAUUC           D-008371-04 GAAAUUGGUACCAUUGUUG 
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RPIA 22934 2 G07 M-016428-01 D-016428-01 GGAAGUGGUUCUACAAUUG 
         D-016428-02 GCGAAUAGCUGAAAGGGUG          D-016428-03 GCUAGUCGCUUCAUCGUGA           D-016428-04 CAAAUGGAGUGAAGUGAAU 
PRPS1L1 221823 2 G08 M-006804-00 D-006804-01 GCAAAUAUGCUCUCUAUAG 
         D-006804-02 GAAAUCAACGACAGUCUAA          D-006804-03 CAACACUGCAUGCUUUGAA           D-006804-04 CAACCAGAGUUUAUGCUAU 
GPAM 57678 2 G09 M-009946-01 D-009946-01 GGAAAGAUGUUCUCUAUAG 
         D-009946-02 GAUAAUACCUGUUGGAAUC          D-009946-03 GUUCAUAGAUCCCAUAUUG           D-009946-04 AGAAAGAAAUGUUGCAGUA 
AGPAT1 10554 2 G10 M-003810-01 D-003810-01 AUGAAGAUCUUGCGUCUAA 
         D-003810-03 CGUGGCGCCUUCCAUCUUG          D-003810-04 UCGAGAACAUGAAGAUCUU           D-003810-05 UCAAAUACCUGUACGGGAU 
AGPAT2 10555 2 G11 M-003811-02 D-003811-01 GUGCGAAGCUUCAAGUACU 
         D-003811-03 GCCGGACGGUGGAGAACAU          D-003811-21 CGGCCGAGUUCUACGCCAA           D-003811-22 GCGCUGUGCUUCACGGUGU 
AGPAT6 137964 2 G12 M-010300-00 D-010300-01 GAAAUUGGAGCCACAGUUU 
        D-010300-02 UUAAGGAGUUCAUGAGUAA          D-010300-03 GAACCUGCAUCAAUAAUAC           D-010300-04 GAGAAGAACCACCAGCUUU 
UNQ1849 253558 2 H03 M-010307-00 D-010307-01 GGAAUUGCCUGAUGCGAUA 
         D-010307-02 UCGAAGACAUGAUUGAUUA          D-010307-03 GCCUAUAUCUUCAUUCAUA           D-010307-04 GAAAGAAGUGUCAUUAUCA 
AGPAT3 56894 2 H04 M-008620-00 D-008620-01 GCUCCAAGGUCCUCGCUAA 
         D-008620-02 GGGAGCAGCUUCCUUUGGA          D-008620-03 UCCAGGAGAUAUAUAAUCA           D-008620-04 GCAGCUGUCUAUGAUGUAA 
AGPAT4 56895 2 H05 M-009283-01 D-009283-01 AGAAAGAGCUGGCCUAUGU 
         D-009283-02 GGAGUUCGAUGGAUGAUUG          D-009283-03 GCACACGGUUCACGGAGAA           D-009283-04 AAAUGUAGUUUCAGCUGUA 
PPAP2A 8611 2 H06 M-019098-01 D-019098-01 GAGGAGGACUCUCAUACAA 
         D-019098-03 CUACAUAUGUCGAGGGAAU          D-019098-04 CAACAACUGGGAAUCACUA           D-019098-17 CUGUAUAUGUAUCGGAUUU 
PPAP2C 8612 2 H07 M-011500-00 D-011500-01 UGACAGACCUGGCCAAGUA 
         D-011500-02 GCACGACUCUGUUGGAAGU 
         D-011500-03 GCUCGGACUUCAACAACUA 
          D-011500-04 CCGCGUGUCUGAUUACAAA 
PPAP2B 8613 2 H08 M-017312-01 D-017312-01 GGGACUGUCUCGCGUAUCA 
         D-017312-02 UCUAUUACCUGAAGAAGUC 
         D-017312-03 CAGUUCACCUUGAUCAUGA 
          D-017312-05 GGAAUUCUACCGGAUCUAU 
PCYT1A 5130 2 H09 M-008642-01 D-008642-01 GGAGAGGGUUGACAAAGUA 
         D-008642-02 UGAAACAUAUGCUGAAAGA 
         D-008642-04 GGAGAAGUCCCGAGAAUUC 
          D-008642-17 UGUGAGAGUUUAUGCCGAU 
PCYT1B 9468 2 H10 M-009611-01 D-009611-02 GGACAUCAUUACCAGAAUU 
         D-009611-03 AAAGAGCCAUGAUCUAAUU 
         D-009611-17 GGAAAUAACUAAUGCCUAU 
          D-009611-18 CUUAGUCACCUGUGCGAAA 
PLD1 5337 2 H11 M-009413-00 D-009413-01 UAACUGAGCUUAUCUAUGU 
         D-009413-02 GAAGAACAAUUCCUUGGUA 
         D-009413-03 GAAGAUUACUUGACAAAGA 
          D-009413-04 GGUAAUCAGUGGAUAAAUU 
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PLD2 5338 2 H12 M-005064-01 D-005064-01 GGACAACCAAGAAGAAAUA 
         D-005064-02 GGACCGGCCUUUCGAAGAU 
         D-005064-03 GACCUGCACUACCGACUGA 
          D-005064-04 CAGCAUGGCGGGACUAUAU 
ACAS2L 84532 3 A03 M-008549-00 D-008549-01 CCACCAAGAUCGCCAAAUA 
         D-008549-02 GAUCGGAGCUGUCCACACA 
         D-008549-03 GAAGAUCAAUCAGUUCUAU 
          D-008549-04 UGAGGAAGAUCAUCACUAG 
ACAS2 55902 3 A04 M-010396-00 D-010396-01 GAGAAGGGUUUCCCAGUAA 
         D-010396-02 GAGACAACCUACUUUAAGA 
         D-010396-03 CCACAACCUUCAAGUAUGU 
          D-010396-04 GCACCUGGCUUGCCUAAAA 
ACACB 32 3 A05 M-004759-02 D-004759-01 GAACAUCCCUGCACAGAAA 
         D-004759-05 CCACAAAGGAUUUAAAUAC 
         D-004759-18 GAACUUAACCGGAUGCGUA 
          D-004759-19 AGAUACAUGAUCACGGAUA 
MT 27349 3 A06 M-014204-01 D-014204-01 GAAGAAUUCCUCUAAGUUU 
         D-014204-02 UAAAGGCAGUCGACAUUAA 
         D-014204-04 AGACGAUGCAUGCCAUAUA 
          D-014204-17 GCUGGCCGCUGUCGAGAAA 
THEDC1 55301 3 A07 M-004796-01 D-004796-01 GGGCAGAUCUGAACAUUGU 
         D-004796-02 GGAUAAACCAUUUGCAUUU 
         D-004796-04 CCAAGGAAUUUGUGAAACA 
          D-004796-17 GGAUCCUGCGAACGAGAAA 
FLJ20604 54995 3 A08 M-031860-00 D-031860-01 GGAGACUCAUUUAGAUUUA 
         D-031860-02 GGUCAGCAUUCGAUAUAAA 
         D-031860-03 GCAAUUGGCAUGGGAAUGA 
          D-031860-04 UCUCAACUAUGUUCCACUA 
ELOVL6 79071 3 A09 M-008861-01 D-008861-01 CAAUGGACCUGUCAGCAAA 
         D-008861-02 GGUCGGCACCUAAUGAAUA 
         D-008861-03 CGAACUAGGAGAUACAAUA 
          D-008861-17 GGGUGUAUAUCUAGAACGA 
SCD 6319 3 A10 M-005061-01 D-005061-02 GAUAUGCUGUGGUGCUUAA 
         D-005061-04 AGAAUGAUGUCUAUGAAUG 
         D-005061-05 CGACAUUCGCCCUGAUAUA 
          D-005061-06 GGAGUACGCUAGACUUGUC 
SCD5 79966 3 A11 M-008416-03 D-008416-03 CAUAUUGGGUGGCUGUUUG 
         D-008416-20 AGAACAUCGUCUGGAGGAA 
         D-008416-21 GAGAAAGCUUGACGUCACU 
          D-008416-22 CAGAAUGACAUCUUCGAGU 
ACAT1 38 3 A12 M-009408-00 D-009408-01 GAAAUGAACAGGACGCUUA 
         D-009408-02 GGGUAAAGCUUGAAGAUUU 
         D-009408-03 GCAAAGAAGCUGAAUAUUG 
          D-009408-04 GCGAAGAGGCUCAAUGUUA 
ACAT2 39 3 B03 M-010001-01 D-010001-01 UCACUUGGCUUACUUGAGA 
         D-010001-02 GGAAUUCCCUACUCUGUUC 
         D-010001-03 GAAGCCAUGUCCAAGCUAA 
          D-010001-04 GCAUCUGGCUGUCGAAUUC 
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AACS 65985 3 B04 M-009458-01 D-009458-02 CGAAAGGAAUCGCAGAUGU 
         D-009458-04 GGCAAGAAGUGGCUUUGUU 
         D-009458-17 CGUAUACGCUCAACGGCAA 
          D-009458-18 GGAACGAUGAGAACGGCAA 
IDI1 3422 3 B05 M-009357-00 D-009357-01 GAACAUUGAGAAAGGAUUA 
         D-009357-02 GAGGAAGAAUGUAACUUUG 
         D-009357-03 UAAGAUAACGCCAUGGUUU 
          D-009357-04 UAAAUGGUGGGAUAACUUA 
IDI2 91734 3 B06 M-008463-00 D-008463-01 GUAGUAGCCACCCAUUAUA 
         D-008463-02 GGAAUUGCCAUCUGAACGA 
         D-008463-03 UGGAGGAAAUGCUGAUUGU 
          D-008463-04 UCACGUUUCCUGGGUAUUU 
FDFT1 2222 3 B07 M-009442-02 D-009442-01 GGAAGAGAUUUAUCAUAGA 
         D-009442-03 GGACAAGUACUGCCACUAU 
         D-009442-04 CCACUUUGGCUGCCUGUUA 
          D-009442-05 GUUUGGAGCAGGUAUGUUA 
SQLE 6713 3 B08 M-009646-01 D-009646-04 UAUUGAAGGUGUUGUGUUA 
         D-009646-17 UUUCAAACUUGGUGGCGAA 
         D-009646-18 CAAACUUGGUGGCGAAUGU 
          D-009646-19 GAGAUACAGUGGAAGGUCU 
CYP51A1 1595 3 B09 M-009215-01 D-009215-01 CAGCAUACAUCCUCAACUA 
         D-009215-02 CCACUAUGCUUCGUUUAUA 
         D-009215-03 GAAGGGAGUUGCAUACGAU 
          D-009215-17 GGUAGGGAAUAAUCGAACA 
NSDHL 50814 3 B10 M-008448-00 D-008448-01 UGACAGGCCUCAAUUAUGA 
         D-008448-02 GCCAAGAGAUGCACAGUGA 
         D-008448-03 GAUAUGCUGUCAAUGUAUU 
          D-008448-04 GCAGUUAGCGAGCCAAUGA 
HSD17B7 51478 3 B11 M-008140-02 D-008140-02 GAAGAUGGACCUAGAUGAA 
         D-008140-03 GGAAUUCUGCCUCCGUUUA 
         D-008140-18 CAAUAUUGCUACUUCGCUU 
          D-008140-19 GCAUUCACUUUGACACCAU 
EBP 10682 3 B12 M-012282-01 D-012282-01 GAAAGAGUAUGCCAAGGGA 
         D-012282-03 GCCGAUACAUCCUGGGUGA 
         D-012282-04 ACGAAGACCUGCUUGGAGA 
          D-012282-17 CCCACAGUUUGGAGGGACA 
SC5DL 6309 3 C03 M-009745-01 D-009745-01 CAAAUUACAUGAUGACCUA 
         D-009745-02 GAAGAUUCCUACUCCAUUU 
         D-009745-03 GGAAGGGACCGCUCAGUUA 
          D-009745-04 GUGCAACACUGAGCUAUUA 
DHCR24 1718 3 C04 M-010222-01 D-010222-01 CAACACAUCUGCACUGCUU 
         D-010222-02 GAAAUGAGGCAGAGCUCUA 
         D-010222-03 GGAGUACAUUCCCUUGAGA 
          D-010222-04 CAUCAUCCCUGCCAAGAAG 
SOD1 6647 3 C05 M-008364-01 D-008364-05 UCGUUUGGCUUGUGGUGUA 
         D-008364-06 ACAAAGAUGGUGUGGCCGA 
         D-008364-07 GUGCAGGGCAUCAUCAAUU 
          D-008364-08 UUAAUCCUCUAUCCAGAAA 
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SOD2 6648 3 C06 M-009784-02 D-009784-03 AAAGAUACAUGGCUUGCAA 
         D-009784-04 GUAAUCAACUGGGAGAAUG 
         D-009784-19 ACCAGGAGGCGUUGGCCAA 
          D-009784-20 GGAUUGAUGUGUGGGAGCA 
SOD3 6649 3 C07 M-009741-01 D-009741-01 GCGCCAAGCUCGACGCCUU 
         D-009741-02 ACGCCAAGGUCACGGAGAU 
         D-009741-03 GCGGAGUGGAUCCGAGACA 
          D-009741-04 AAGAAGCGGCGGCGCGAGA 
CAT 847 3 C08 M-010021-01 D-010021-01 CACAUGACAUUACCAAAUA 
         D-010021-02 GGAAUCCAGUUAAUUACUU 
         D-010021-03 GAGCACAGCAUCCAAUAUU 
          D-010021-04 GGACAUCGCCACAUGAAUG 
GPX6 257202 3 C09 M-019309-00 D-019309-01 GCAAGCACGUCCUGUUUGU 
         D-019309-02 GCAGUUCAAUACCCACUAG 
         D-019309-03 GCGAGGAGUACAUCCAAUU 
          D-019309-04 AUAGGAAGGUGGAUUGCAA 
GPX1 2876 3 C10 M-008982-00 D-008982-01 GCAAGGUACUACUUAUCGA 
         D-008982-02 UGAAUUCCCUCAAGUACGU 
         D-008982-03 GGAGAACGCCAAGAACGAA 
          D-008982-04 GCAACCAGUUUGGGCAUCA 
GPX2 2877 3 C11 M-011675-00 D-011675-01 GAACGAGCAUCCUGUCUUC 
         D-011675-02 GAAGGUAGAUUUCAAUACG 
         D-011675-03 CAGGAGAACUGUCAGAAUG 
          D-011675-04 GCAGGGCCGUGCUGAUUGA 
GPX3 2878 3 C12 M-006485-01 D-006485-01 GUACGGAGCCCUCACCAUU 
         D-006485-02 GGAUGUCAAUGGAGAGAAA 
         D-006485-03 AGGAAGAGCUUGCACCAUU 
          D-006485-04 GAGGCUUUGUCCCUAAUUU 
GPX4 2879 3 D03 M-011676-01 D-011676-01 CAACGUGGCCUCCCAGUGA 
         D-011676-03 GUAACGAAGAGAUCAAAGA 
         D-011676-04 CGUCAAAUUCGAUAUGUUC 
          D-011676-17 GCUGCGUGGUGAAGCGCUA 
GPX5 2880 3 D04 M-009445-01 D-009445-03 GCAAGCACAUCCUCUUCGU 
         D-009445-04 UGGCGUACUUGAAGCAAUU 
         D-009445-17 AGGCCAUCGCACUUAAUAA 
          D-009445-18 GGGAGGAUUUGUACCUAGU 
GPX7 2882 3 D05 M-009875-01 D-009875-01 GAAGCGAGAAGACUUAUAA 
         D-009875-02 ACAAGGAGAUUGAGAGCUU 
         D-009875-03 GCACCUACAGUGUCUCAUU 
          D-009875-04 GGACUUCUACGACUUCAAG 
SCO2 9997 3 D06 M-011987-01 D-011987-01 GCAGAUCGGCUGAGCAGAU 
         D-011987-02 GAACAGAAGCCCUGCGCCA 
         D-011987-03 GAACCCGGCUGCUGAUCAC 
          D-011987-04 ACAGUUACCGCGUGUACUA 
ATPIF1 93974 3 D07 M-017220-00 D-017220-01 AAGAAGAAAUCGUUCAUCA 
         D-017220-02 AGAGAGAGCAGGCUGAAGA 
         D-017220-03 GCCAUAAGCAGAAGAUCAA 
          D-017220-04 GGGCGUGAGGACCAUGCAA 
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COX4I1 1327 3 D08 M-011625-00 D-011625-01 UGUACGAGCUCAUGAAAGU 
         D-011625-02 GCAGAAGCACUAUGUGUAC 
         D-011625-03 CGAGUUGUAUCGCAUUAAG 
          D-011625-04 CCAAGUGGGACUACGAAAA 
COX4I2 84701 3 D09 M-013590-00 D-013590-01 GCACAGAACUCAACGCUGA 
         D-013590-02 UCGCAGCUCUGGUGAUUUG 
         D-013590-03 GCAGCGGGUCUACGUAUUU 
          D-013590-04 GAUGAACCGUCGCUCCAAU 
COX5A 9377 3 D10 M-011940-00 D-011940-01 GAACUUAGACCAACUUUAA 
         D-011940-02 ACACACUUGUUACCUAUGA 
         D-011940-03 GCAUGCAGACGGUUAAAUG 
          D-011940-04 GAUAUAGAUGCCUGGGAAU 
C12ORF5 57103 3 D11 M-020597-01 D-020597-01 AAUCACAGCUCUAAAGUUA 
         D-020597-02 GAUAUGACGGUAAAGUAUG 
         D-020597-03 GAAAUACGGGGUUGUAGAA 
          D-020597-04 GAGUCACGGUGCUUACAUG 
OXCT1 5019 3 D12 M-004045-00 D-004045-01 GAACGACAGUACUUAUCUG 
         D-004045-02 UUAUGUACAUCGCCUUAUA 
         D-004045-03 UGUGUCAACCGCAUUAUUA 
          D-004045-04 UCAACCGCAUUAUUACUGA 
OXCT2 64064 3 E03 M-013881-00 D-013881-01 UUAUGUAGAUCGCGUGAUA 
         D-013881-02 CCAAGAUCAUGGAGAAAUG 
         D-013881-03 ACGCGCAGCUCUGGAAUUU 
          D-013881-04 GCGCUUAACGAUCCUGAAA 
SLC16A7 9194 3 E04 M-007409-01 D-007409-01 GGAUUUAACUGGAGAAUAU 
         D-007409-02 GAUAGCAGGAGGCUUAUUA 
         D-007409-04 CAGCAAAUAUUCCACACUA 
          D-007409-17 CGGAAGAUGUUAACGUCAA 
SLC16A3 9123 3 E05 M-005126-03 D-005126-03 GGCAACUUCUUCUGCAUUA 
         D-005126-04 CGACCCACGUCUACAUGUA 
         D-005126-05 CAUGGUGGCUGCGUCCUUU 
          D-005126-06 GCUCACCUCCUCCCUGAUU 
SLC16A8 23539 3 E06 M-007410-01 D-007410-02 GCACGUCCCGUAUCUGUUC 
         D-007410-03 CCAAAGCCGUGAGCGUCUU 
         D-007410-04 UGUACGCCGUCACCAAGUU 
          D-007410-17 CUGCCUGCGUUGUGCUAAA 
SLC16A4 9122 3 E07 M-007406-00 D-007406-01 GACAGGAGCCCUUAUAUUA 
         D-007406-02 GAAACACACUGCCAUGAGA 
         D-007406-03 GAAGAAAGUGAUAAGGUUA 
          D-007406-04 UGACAUACUUGGAGAGAAA 
TALDO1 6888 3 E08 M-008996-02 D-008996-01 GAGCAGAAAUACUAAAGAA 
         D-008996-02 CAGCACAGAUGCCCGCUUA 
         D-008996-05 CACAAGAGGACCAGAUUAA 
          D-008996-18 CCACAGAAGUAGACGCAAG 
RPE 6120 3 E09 M-012767-00 D-012767-01 GGGCUAAUCAGAUAGAUAU 
         D-012767-02 GAGCUAACAUGAUUGUGUC 
         D-012767-03 GUUCCCAUCUUUGGAUAUA 
          D-012767-04 CCAUAAAUGUGCAGAGGCA 
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GFPT1 2673 3 E10 M-008833-01 D-008833-02 GGACGAGGCUAUCAUUAUG 
         D-008833-03 UGAAACGGCUGCCUGAUUU 
         D-008833-17 GAGCAUGGAUGACGAAAUU 
          D-008833-18 CAUGCAAGAAAGACGCAAA 
GFPT2 9945 3 E11 M-010390-01 D-010390-01 UCGCCAAGCUGAUUAAAUA 
         D-010390-03 GAUCAUCCGUGGCUUGAGA 
         D-010390-04 AGACAAAGGCAACGAAUUU 
          D-010390-17 CGAUGGGAAUAAUCACGAA 
GNPNAT1 64841 3 E12 M-005239-01 D-005239-02 CGGCAACUCUGAUUAUAGA 
         D-005239-03 CUACAUGUGUCGGAGGUUU 
         D-005239-04 GUACUGCUGACUUAAAUAG 
          D-005239-17 GGAUUACAUAUGUCGGCUA 
UAP1 6675 3 F03 M-017160-01 D-017160-01 GAACAAAGUUUCUAUGGCU 
         D-017160-02 UGAGAGAUGUUGUCAAUGU 
         D-017160-03 CUACUACGUUUCUGGAAUG 
          D-017160-04 ACCCAAGGACAGUUAAUUA 
OGT 8473 3 F04 M-019111-00 D-019111-01 GCAGUUCGCUUGUAUCGUA 
         D-019111-02 CGACAUGCAUUGCGUCUCA 
         D-019111-03 GAUUAAGCCUGUUGAAGUC 
          D-019111-04 CCGAGAAAUUGGCUUAUAU 
PGM1 5236 3 F05 M-010925-00 D-010925-01 CGAAUCGUCUUCCGACUGA 
         D-010925-02 GUACAUCGAUAGCUAUGAG 
         D-010925-03 CGACUGAAGAUCCGUAUUG 
          D-010925-04 GGAAAUUGUGGAUUCGGUA 
PGM3 5238 3 F06 M-013912-00 D-013912-01 GAGGUCAAUUCCAUGAUUA 
         D-013912-02 GGAUUUAGGUGCUAUUACA 
         D-013912-03 GGGCAAACUCAAUCAUUUA 
          D-013912-04 GACAAGAUAGCAACGUUAA 
WBSCR14 51085 3 F07 MU-009253-00 D-009253-01 GACACUCUCUUCACCAUGAUU 
         D-009253-02 ACAAGUGGCGCAUCUACUAUU 
         D-009253-03 GGGCACAUCUACCAGUAUCUU 
          D-009253-04 GCCCAUGCCUUCAAACUUCUU 
SLC25A10 1468 3 F08 MU-007469-00 D-007469-01 GCAGACAGAUGACCUACUCUU 
         D-007469-02 GUACCUCUCUGACAACAUCUU 
         D-007469-03 CCGCGUAGCUCGUGAAGAGUU 
          D-007469-04 CUGAAGACUCGCCUGAUGUU 
ME1 4199 3 F09 MU-009348-02 D-009348-02 CAUCUGACAUUGAGAAAUU 
         D-009348-03 AGUAAGAGGUUCUGAAUAU 
         D-009348-19 CCUUGCAGCUCUUCGAAUA 
          D-009348-05 GGUAAAUUGGCUCUAUAUA 
ME2 4200 3 F10 MU-009461-00 D-009461-01 GAAGAAGCAUAUACACUUAUU 
         D-009461-02 UGAAAGGCCUGUAAUAUUUUU 
         D-009461-03 GAACAUGGCGGAGUGAAUAUU 
          D-009461-04 GAAACGAGAUCGCACACAAUU 
GLS 2744 3 F11 MU-004548-00 D-004548-01 AGACAUGGUUGGUAUAUUAUU 
         D-004548-02 UGAAUAAGAUGGCUGGUAAUU 
         D-004548-03 GGUGGUUUCUGCCCAAUUAUU 
          D-004548-04 GAAUAACACUCCCAUGGAUUU 
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GLS2 27165 3 F12 MU-012500-00 D-012500-01 UCAAACUGCUUCAAGAUUAUU 
         D-012500-02 GAACUUAGAAAGCAUGGUAUU 
         D-012500-03 CAAGUGGCCUGCGCUACAAUU 
          D-012500-04 GCCAUCGGCUAUUAUCUCAUU 
PIK3CA 5290 3 G03 MU-003018-03 D-003018-07 GGACAACUGUUUCAUAUAG 
         D-003018-08 GCCAGUACCUCAUGGAUUA 
         D-003018-24 CUUGAAGAGUGUCGAAUUA 
          D-003018-25 GCUUGAAGAGUGUCGAAUU 
MYLCD 23417 3 G04 MU-009626--01 D-009626-01 GGAAUGAACUCUUUACAGA 
         D-009626-02 GAACAUCCUCCAUCAGAAA 
         D-009626-03 UGAAAGGAAUGCUCUCAGA 
          D-009626-04 UCAACUGGAUGGCGGAUGU 
IRS1 3667 3 G08 MU-003015-01 D-003015-05 AAAGAGGUCUGGCAAGUGA 
         D-003015-06 GAACCUGAUUGGUAUCUAC 
         D-003015-07 CCACGGCGAUCUAGUGCUU 
          D-003015-08 GUCAGUCUGUCGUCCAGUA 
PTEN 5728 3 G12 MU-003023-01 D-003023-05 GUGAAGAUCUUGACCAAUGUU 
         D-003023-06 GAUCAGCAUACACAAAUUAUU 
         D-003023-07 GGCGCUAUGUGUAUUAUUAUU 
          D-003023-08 GUAUAGAGCGUGCAGAUAAUU 
MYC 4609 3 H03 MU-003282-07 D-003282-14 AACGUUAGCUUCACCAACA 
         D-003282-15 GGAACUAUGACCUCGACUA 
         D-003282-16 GAACACACAACGUCUUGGA 
          D-003282-35 CUACCAGGCUGCGCGCAAA 
RPTOR 57521 3 H04 MU-004107-00 D-004107-01 GAAACCAUCGGUGCAAAUUUU 
         D-004107-02 AGAAGGGCAUUACGAGAUUUU 
         D-004107-03 UGGAGAAGCGUGUCAGAUAUU 
          D-004107-04 GCCCGUCGAUCUUCGUCUAUU 
RICTOR 253260 3 H05 MU-016984-01 D-016984-01 UCAACGAGCUCACAUAUGAUU 
         D-016984-02 GUACGAAGACUACUUUAUUUU 
         D-016984-03 UGACCGAUCUGGACCCAUAUU 
          D-016984-04 GUACUUGGGCUCAUAGCUAUU 
SLC16A1 6566 3 H06 MU-007402-02 D-007402-01 GCAGUAUCCUGGUGAAUAA 
         D-007402-02 AGAGGAAGCUUUCUAAUUC 
         D-007402-05 GGUAAUUGGAGCUUUCAUU 
          D-007402-18 GCCAAUAAGACCUCGAAUU 
SLC25A1 6576 3 H07 MU-007468-01 D-007468-01 CCAUAGUGUUUGUCAUCUA 
         D-007468-02 GCCUGGAGGCGCACAAAUA 
         D-007468-05 GCGCACAAAUACCGGAACA 
          D-007468-06 UGAAGCUGCUCAACAAAGU 
PDK1 5163 3 H08 MU-005019-00 D-005019-01 GGAAGUCCAUCUCAUCGAAUU 
         D-005019-02 GGAACACCAUGCCAACAGAUU 
         D-005019-03 GAUCAGAAACCGACACAAUUU 
          D-005019-04 GAUCAGUGAAUGCUUGUGAUU 
PDK2 5164 3 H09 MU-005020-00 D-005020-01 CAAAGAUGCCUACGACAUGUU 
         D-005020-02 GCACGGAGCCCAAGAACACUU 
         D-005020-03 GCUCCUGUGUGACAAGUAUUU 
          D-005020-04 CCAGCACACCCUCAUCUUUUU 
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CPT1a 1374 3 H10 MU-009749-02 D-009749-01 GAGAGAACCUCAUCAAUUU 
         D-009749-02 GAAGAAGGAUACAGAAGUG 
         D-009749-05 GGACAGCUACGCCAAAUCU 
          D-009749-18 UGACAACGAUGUACGCCAA 
CPT1b 1375 3 H11 MU-010266-01 D-010266-04 CAAGUAACUAUGUGAGUGA 
         D-010266-17 GAUCAUGUAUCGCCGUAAA 
         D-010266-18 GGACUGAGACUGUGCGUUC 
          D-010266-19 CAUGAUUGCAGGCGAGAAC 
AKT1 207 3 H12 MU-003000-03 D-003000-05 GACAAGGACGGGCACAUUA 
AKT2 208     MU-003001-02 D-003000-07 GCUACUUCCUCCUCAAGAA 
AKT3 209     MU-003002-02 D-003000-08 GACCGCCUCUGCUUUGUCA 
          D-003000-22 GGCAGCACGUGUACGAGAA 
         D-003001-05 GUACUUCGAUGAUGAAUUU 
         D-003001-07 GGGCUAAAGUGACCAUGAA 
         D-003001-08 GCAGAAUGCCAGCUGAUGA 
         D-003001-21 GAGUAGAAUAAUCGUCUUU 
         D-003002-09 GAAAGAUUGUGUACCGUGAUU 
          D-003002-10 GGACUACUGUUAUAGAGAGUU 
          D-003002-11 UGAGACAGAUACUAGAUAUUU 
          D-003002-12 GCUCAUUCAUAGGAUAUAAUU 
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